ࡱ>      %` bjbj"x"x @@)4TQhPgbNbxxx-//////$LhpS"@b"Sxx#xx--z1x DjL 20b*$y $$$Ս L6,2kSS9Xbggj$ggj Aims to provide a simple, empirical approach to the treatment of common infections to promote the safe, effective and economic use of antibiotics to minimise the emergence of bacterial resistance in the community Principles of Treatment This guidance is based on the best available evidence but professional judgement should be used and patients should be involved in the decision. A dose and duration of treatment for adults is usually suggested, but may need modification for age, weight and renal function. In severe or recurrent cases consider a larger dose or longer course. Lower threshold for antibiotic use in immunocompromised or those with multiple morbidities; consider culture and seek advice. Prescribe an antibiotic only when there is likely to be a clear clinical benefit. Consider a no, or delayed, antibiotic strategy for acute self-limiting upper respiratory tract infections 1 Limit prescribing over the telephone to exceptional cases. Avoid broad spectrum antibiotics (eg co-amoxiclav, quinolones and cephalosporins) when narrow spectrum antibiotics remain effective, as they increase risk of Clostridium difficile, MRSA and resistant UTIs. Do not extrapolate antibiotics across classes e.g. recommendations for a first generation cephalosporin (e.g. cefalexin) cannot be extrapolated to a second generation (e.g. cefuroxime); similarly co-amoxiclav is not a substitute for amoxicillin. There are very few indications in community care where a combination of two or more systemic antibiotics would be evidence-based Avoid use of topical antibiotics (especially those agents also available as systemic preparations, e.g. fusidic acid). In pregnancy AVOID tetracyclines, aminoglycosides, quinolones, high dose metronidazole (e"2 g). Short-term use of nitrofurantoin (at term - theoretical risk of neonatal haemolysis) is unlikely to cause problems to the foetus. Trimethoprim also unlikely to cause problems unless poor dietary folate intake or taking another folate antagonist such as antiepileptic. Where a best guess therapy has failed or special circumstances exist, microbiological advice can be obtained from ** 25454528 or 25456401 **  ILLNESSCOMMENTSDRUGDOSEDURATION OF TXUPPER RESPIRATORY TRACT INFECTIONS1Influenza1-3 Annual vaccination is essential for all those at risk of influenza. For otherwise healthy adults antivirals are not recommended. Treat at risk patients, ONLY within 48 hours of onset & when influenza is circulating in the community or in a care home where influenza is likely. At risk: 65 years or over, chronic respiratory disease (including COPD and asthma) significant cardiovascular disease (not hypertension), immunocompromised, diabetes mellitus, chronic neurological, renal or liver disease. Use 5 days treatment with oseltamivir 75mg BD or if there is resistance to oseltamivir use 5 days zanamivir 10mg BD (2 inhalations by diskhaler). There is no evidence that antibiotics given prophylactically reduce the incidence of post-influenza pneumonia. Acute Sore Throat1-10 Avoid antibiotics as 90% resolve in 7 days without, and pain only reduced by 16 hours Use Pharyngitis score to assess likelihood of Group A streptococcal infection. 10  Empiric treatment or delayed prescription: Penicillin V 500mg TDS for 10 days Cefalexin 500mg TDS for 5 days (can also be used in previous history of mild (rash only) or uncertain penicillin allergy: Severe confirmed penicillin allergy: Clarithromycin 500mg BD for 10 days Acute Otitis Media 1-11 (child doses) Optimise analgesia 2,3 Avoid antibiotics as 60% are better in 24 hours without: they only reduce pain at 2 days (NNT15) and do not prevent deafness 4 Consider antibiotics if fever e"39oC and or evidence of systemic toxicity use antibiotics. < 2yrs especially if bilateral All ages with otorrhoea 6 amoxicillin 8 Penicillin Allergy: clarithromycin Child doses 80mg/kg/day in 3 doses (max. 3g daily) 10 body-weight under 8kg, 7.5mg/kg BD; 811kg, 62.5mg BD; 1219kg, 125mg BD; 2029kg, 187.5mg BD; 3040kg, 250mg BD 5 days 5 daysAcute Otitis Externa 1-4 Pseudomonas aeruginosaFirst use aural toilet (if available) & analgesia Cure rates similar at 7 days for topical acetic acid or antibiotic +/- steroid 1 If cellulitis or disease extending outside ear canal, start oral antibiotics and refer 2 Acute diffuse OE (e.g. swimming/ immersion related)First Line: acetic acid 2% Second Line: framycetin with dexamethasone ciprofloxacin 1 spray TDS 3 drops TDS 500mg BD7 days 7 days min to 14 days maxRhinosinusitis Acute 1-10 Chronic Avoid antibiotics as 80% resolve in 14 days without, and they only offer marginal benefit after 7 days Use adequate analgesia Consider 3-day delayed prescription Immediate antibiotic treatment indicated when purulent nasal discharge and systemic symptoms are present In persistent infection use an agent with anti-anaerobic activity e.g. co-amoxiclav Amoxicillin or doxycycline co-amoxiclav 500mg TDS (1g if severe) 200mg stat/100mg BD 625mg TDS 7 days 7 days 7 daysORAL INFECTIONSDental abscess Emergency antibiotic may be considered if dental assessment is unavailable and patient has: - facial swelling - severe infection (e.g. fever, lymphadenopathy) - immunocompromised - diabetes mellitus Early dental referral is essential Amoxicillin or metronidazole 500mg TDS 500mg TDS  LOWER RESPIRATORY TRACT INFECTIONSNote: Low doses of penicillins are more likely to select out resistance1, Do not use ciprofloxacin as first line due to poor pneumococcal activity. Reserve all quinolones (including levofloxacin) for proven resistant organisms. Acute cough, bronchitis 1-6 Antibiotic little benefit if no co-morbidity Symptom resolution can take 3 weeks. Consider 7-14 day delayed antibiotic with symptomatic advice,Amoxicillin or doxycycline (delayed prescription)500mg TDS 200mg stat/100mg BD5 days 5 daysAcute exacerbation of COPD1-3 Treat exacerbations promptly with antibiotics if purulent sputum and increased shortness of breath and/or increased sputum volume Risk factors for antibiotic resistant organisms include co-morbid disease, severe COPD, frequent exacerbations, antibiotics in last 3 months 2amoxicillin or doxycycline If resistance risk factors: co-amoxiclav or doxycycline500mg TDS 200mg stat/100mg BD 625mg TDS or 1 g BD 200mg stat/100mg BD5 days 5 days 5 daysCommunity-acquired pneumonia1-3 5 - 7 days ILLNESSCOMMENTSDRUGDOSEDURATION OF TXURINARY TRACT INFECTIONSNOTES: People >65years: do not treat asymptomatic bacteriuria; it is common but is not associated with increased morbidity 1 Catheter in situ: antibiotics will not eradicate asymptomatic bacteriuria; only treat if systemically unwell or pyelonephritis likely 2 Do not use prophylactic antibiotics for catheter changes unless history of catheter-change-associated UTI 3Lower UTI in men & women (no fever or flank pain) 1-16 Women with severe/e" 3 symptoms: treat Women with mild/ d"2 symptoms: use dipstick to guide treatment. Nitrite & blood/leucocytes has 92% positive predictive value ; -ve nitrite, leucocytes, and blood has a 76% NPV Men: send pre-treatment MSU OR if symptoms mild/non-specific, use  ve nitrite and leucocytes to exclude UTI. In catheterised patients cloudy or foul smelling urine is not an indication for antibiotic treatmentIf pH d"7: Nitrofurantoin If pH >7: co-amoxiclav 50mg -100mg QDS 625mg TDSWomen 3 days 1 Men 7 days Second line: perform culture in all treatment failures 1 Amoxicillin resistance is common; only use if susceptible 13 Community multi-resistant HYPERLINK "http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/1191942126367/"Extended-spectrum Beta-lactamase E. coli are increasing: consider referral for IV treatment in hospitalUTI in pregnancy 1-16 Send MSU for culture & sensitivity and start empirical antibiotics Short-term use of nitrofurantoin in pregnancy is unlikely to cause problems to the foetus First line: nitrofurantoin if susceptible amoxicillin Second line or last trimester: cefalexin50-100mg QDS 500mg TDS 500mg TDSNOT at Term or during breast feeding! All for 7 days UTI in children 1-2 Child <2 years: refer urgently for assessment Child e" 2 years: use positive nitrite and WBC to start antibiotics. Send pre-treatment MSU for all. Lower UTI: co-amoxiclav Second line: cefuroxime  15mg/kg/dose TDS 10-15mg/kg/dose BD Lower UTI 3 days Upper UTI 710daysRecurrent UTI in women 1-3 e" 3 UTIs/year Post-coital prophylaxis or standby antibiotic Nightly: reduces UTIs but adverse effects nitrofurantoin 50mg STAT Post coital stat (off-label) Prophylaxis OD at night ILLNESSCOMMENTSDRUGDOSEDURATION OF TXSUSPECTED MENINGOCOCCAL DISEASE Meningococcal septicaemia (not meningitis) HYPERLINK "http://www.hpa.org.uk/cdph/issues/CDPHVol5/no3/Meningococcal_Guidelines.pdf"Transfer all patients to hospital immediately. Only consider antibiotic treatment in presence of: non-blanching rash AND fever AND signs of sepsis AND time permits: unless H/O serious penicillin hypersensitivity i.e. history of difficulty breathing, collapse, loss of consciousness. Benzylpenicillin IV/IM <1 yr: 300mg 1-9 yrs: 600mg 10 - 17yrs: 1200mg e"18 yrs: 2400mg (give IM ONLY if vein cannot be found)Prevention of secondary cases of meningitis in the community: Only prescribed by Public Health Doctor.  ILLNESSCOMMENTSDRUGDOSEDURATION OF TXGASTRO-INTESTINAL TRACT INFECTIONSEradication of Helicobacter pylori 1-10 Symptomatic relapse Consider test and treat in persistent uninvestigated dyspepsia Do not offer eradication for GORD Do not use clarithromycin or metronidazole if used in the past year for any infection Specialist referral advisedFirst line Proton pump inhibitor (PPI) PLUS clarithromycin PLUS amoxicillin  BD 500mg BD 1g BD Note clarithromycin XL not to be used All for 7days 1,9 Infectious diarrhoea 1-4Refer previously healthy children with acute painful or bloody diarrhoea to exclude E. coli 0157 infection.1 Antibiotic therapy not indicated unless systemically unwell, even if Salmonella is cultured. 2 If systemically unwell and Campylobacter suspected (e.g. undercooked meat and abdominal pain), consider clarithromycin 250500mg BD for 57days if treated early.3Threadworms1 Treat all household contacts at the same time PLUS advise hygiene measures for 2weeks (hand hygiene, pants at night, morning shower) PLUS wash sleepwear, bed linen, dust, and vacuum on day one >6 months: mebendazole (off-label if <2yrs) 3-6months: refer to hospital100mg stat  ILLNESSCOMMENTSDRUGDOSEDURATION OF TXGENITAL TRACT INFECTIONSSTI screening1-2People with risk factors should be screened for chlamydia, gonorrhoea, HIV, syphilis. Refer individual and partners to GU clinic. Risk factors: < 25y, no condom use, recent (<12mth)/frequent change of partner, symptomatic partnerVaginal candidiasis1-5 All topical and oral azoles give 75% cure In pregnancy: avoid oral azole and use intravaginal treatment for 7 days clotrimazole or oral fluconazole clotrimazole or miconazole 2% cream500mg pess or 1% cream 150mg orally 100mg pessary at night 5g intravaginally BD stat stat 6nights 7 days Bacterial vaginosis1-5Oral metronidazole (MTZ) is as effective as topical treatment but is cheaper. Treating partners does not reduce relapse oral MTZ 1 or MTZ 0.75% vag gel 400mg TDS 5g applicatorful at night7 days + 5 nights Trichomoniasis1-4 Treat partners and refer to GU clinic In pregnancy or breastfeeding: Consider clotrimazole for symptom relief (not cure) if MTZ declined metronidazole (MTZ) clotrimazole 400mg BD 100mg pessary at night5-7 days 6 nights Pelvic Inflammatory Disease 1-5 Refer woman & contacts to GU clinic Always culture for gonorrhoea & chlamydia Cefpodoxime proxetil PLUS metronidazole PLUS doxycycline 100mg OD + 400mg TDS + 100mg BD stat 14 days 14 days Acute prostatitis 1-2 Send MSU for culture and start antibiotics. 4-wk course may prevent chronic prostatitis Quinolones achieve higher prostate levels ciprofloxacin 2nd line: co-trimoxazole 500mg BD 960mg BD28 days 28 days  SKIN INFECTIONSSKIN TOPICAL TREATMENTORAL TREATMENTCOMMENTSAcne vulgarisBenzoyl peroxideMinocycline 100mg BDTopical antibiotic preparations are best avoided. If use they should only be reserved for patients who cannot tolerate oral antibiotics such as minocycline.Burns: small & superficial (infected)Hydrogen peroxide 1% cream or Silver sulfadiazine 1% creamNot applicableMupirocin should be avoided to prevent the development of resistance in Staph. aureus Carbuncles Not indicatedOral flucloxacillin 500mg QDS or Cefalexin 500mg QDS Use clindamycin or macrolide in documented penicillin hypersensitivityCellulitis1-4 Not indicatedOral flucloxacillin 500mg QDS or Cefalexin 500mg QDSUse clindamycin or macrolide in documented penicillin hypersensitivity. If febrile and systemically ill, admit for IV treatment.HordeolumRemove offending eyelash in external hordeolum.In severe cases: Oral flucloxacillin 500mg QDS or Cefalexin 500mg QDS Use clindamycin or macrolide in documented penicillin hypersensitivityDecubitus ulcers with fever & cellulitisNot indicatedOral co-amoxiclav 625mg TDSUse ciproflaxacin + metronidazole in documented penicillin hypersensitivityErysipelasNot indicatedAmoxicillin 1g TDS, or Cefalexin 500mg QDSUse clindamycin or macrolide in documented penicillin hypersensitivityErythrasma Hydrogen peroxide 1% creamCombine with oral macrolide or tetracycline for 2 weeks in severe casesFolliculitis - localisedHydrogen peroxide 1% cream or Silver sulfadiazine creamIf unresponsive, bacteriological and mycological investigations are needed to rule out the possibility of MRSA, nasal carriage of Staph. aureus, and Gram-negative bacterial and fungal aetiologies. Hot-tub folliculitis caused by Pseudomonas aeruginosa usually resolves without treatmentFolliculitis - extensiveNot indicatedOral flucloxacillin 500mg QDS or Cefalexin 500mg QDS for 10 daysUse macrolide or clindamycin in documented penicillin hypersensitivity. If unresponsive, bacteriological and mycological investigations are needed to rule out the possibility of MRSA, nasal carriage of Staph. aureus, and Gram-negative bacterial and fungal aetiologies. Furunculosis Not indicatedIn severe cases: Oral flucloxacillin 500mg QDS or Cefalexin 500mg QDSUse clindamycin or macrolide in documented penicillin hypersensitivitySKIN TOPICAL TREATMENTORAL TREATMENTCOMMENTSImpetigo - localised & non-bullous 1-5Hydrogen peroxide 1% cream or Silver sulfadiazine cream or retapamulin (not licensed in infants under 9 months of age)Mupirocin should be avoided due to known MRSA prevalence and further repercussions of resistance.Impetigo - widespread or bullous1-5Not indicatedIn severe cases: Oral flucloxacillin 500mg QDS or Cefalexin 500mg QDSUse clindamycin or macrolide in documented penicillin hypersensitivityInsect bitesNot indicatedNot indicated Unless pus is present, insect bites are invariably an allergic reaction, even when blistered. Use topical steroids and/or oral antihistamines. Intertrigo Clotrimazole 1% cream 1% hydrocortisone hydrogen peroxide 1% creamLeg ulcers 1-3 (superficial) Not indicatedUsually not indicatedTOPICAL ANTIBIOTICS (ESPECIALLY MUPIROCIN) SHOULD BE AVOIDED. Ulcers are always colonized. Antibiotics do not improve healing unless active infection with cellulitis is present in which case use oral amoxicillin/clavulanic acid (ciprofloxacin + metronidazole in documented penicillin hypersensitivity)Paronychia & pulp-space infection Not indicated; drainage essentialOral flucloxacillin 500mg QDS or Cefalexin 500mg QDSUse clindamycin or macrolide in documented penicillin hypersensitivity.Infected eczema1-2Chlorhexidine-cetrimide cream or Silver sulfadiazine 1% cream or Hydrogen peroxide 1% creamIn moderate to severe cases, oral antibiotics plus nasal screening and decontamination should be undertaken under specialist advice.Rosacea 1% metronidazole creamCombine with oral tetracycline or a macrolide in more severe casesMalodorous, ulcerating, fungating, malignant tumours of the skin 1% metronidazole cream Treatment is only a palliative measure to combat malodour. If severe, supplement with oral metronidazole by po / rectal administration, at the lower dose, to prevent dose-related gastro-intestinal effects Wounds lacero-contused and abrasions: minor & infected Chlorhexidine-cetrimide cream or Silver sulphadiazine creamMupirocin should be avoided due to relevance of resistance. If cellulitis >0.5cm is present, use oral flucloxacillin or cefalexin (clindamycin or macrolide in documented penicillin hypersensitivity)Hidradenitis suppurativa Not indicatedChoice of systemic therapy according to aetiological agentSKIN TOPICAL TREATMENTORAL TREATMENTCOMMENTSBites1-7 Human: Cat or dog: Thorough irrigation is important Assess risk of tetanus, HIV, hepatitis B&C Antibiotic prophylaxis is advised Give prophylaxis if 3 cat bite/puncture wound; bite to hand, foot, face, joint, tendon, ligament; immunocompromized/ diabetic/ asplenic/ cirrhotic Assess risk of tetanus Prophylaxis or treatment: co-amoxiclav If penicillin allergic: metronidazole PLUS doxycycline (cat/dog/human) or metronidazole PLUS clarithromycin (human bite) AND review at 24&48hrs 625mg TDS 200-400mg TDS 100mg BD 200-400mg TDS 250-500mg BD  All for 7 days Scabies1-4 Treat all home & sexual contacts within 24h Treat whole body from ear/chin downwards and under nails. If under 2/elderly, also face/scalp permethrin If allergy: malathion 5% cream 0.5% aqueous liquid2 applications 1week apart Fungal infection skin Terbinafine is fungicidal, so treatment time shorter than with fungistatic imidazoles If candida possible, use clotrimazole If intractable: send skin scrapings If infection confirmed, use oral terbinafine/itraconazole Scalp: discuss with specialistTopical clotrimazole TDS 1-2 wks after healing (i.e. 4-6wks) Fungal infection 1-6 fingernail or toenail Take nail clippings: start therapy only if infection is confirmed by laboratory Terbinafine is more effective than azoles Liver reactions rare with oral antifungals If candida or non-dermatophyte infection confirmed, use oral itraconazole For children, seek specialist advice Superficial only amorolfine 0.25% nail lacquer First line: terbinafine Second line: itraconazole  1-2x/weekly fingers Toes (nails) 250mg OD fingers toes(nails) 200mg BD Fingers/ toes (nails)6 months 12 months 6 12 weeks 3 6 months 7 days monthly 2 courses 3 coursesVaricella1-11 zoster/ chicken pox & Herpes zoster/ shingles Pregnant/immunocompromised/neonate: seek urgent specialist advice Chicken pox:IF started <24h of rash & >14y or severe pain or dense/oral rash or 2o household case or steroids or smoker consider aciclovir Shingles: treat if >50 yrs and within 72 hrs of rash (PHN rare if <50yrs); or if active ophthalmic or Ramsey Hunt or eczema.If indicated: aciclovir  800mg five times a day  7 days Cold sores1-4Cold sores resolve after 710d without treatment. Topical antivirals applied prodromally reduce duration by 12-24hrs Skin abscessImportant to drain before attempting treatmentFlucloxacillin500mg QDS7 daysEYE INFECTIONS Conjunctivitis1-6 Treat if severe, as most viral or self-limiting. Bacterial conjunctivitis is usually unilateral and also self-limiting; it is characterised by red eye with mucopurulent, not watery, discharge; 65% resolve on placebo by day fiveIf severe: gentamicin 0.3% 2 hourly for 2days then 4hourly All for 48 hours after resolution  UPPER RESPIRATORY TRACT INFECTIONS NICE 69: National Institute for Health and Clinical Excellence. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. 2008. (Clinical guideline 69). A no antibiotic prescribing strategy or a delayed antibiotic prescribing strategy should be negotiated for patients with the following conditions: acute otitis media, acute sore throat, common cold, acute rhinosinusitis, acute cough/acute bronchitis. Depending on patient preference and clinical assessment of severity, patients in the following specific subgroups can also be considered for immediate antibiotics in addition to the reasonable options of a no antibiotic strategy or a delayed prescribing strategy: bilateral acute otitis media in children under two years, acute otitis media in children with otorrhoea. acute sore throat/acute tonsillitis when three or four of the Centor criteria are present. For all antibiotic prescribing strategies, patients should be given advice about the usual natural history of the illness, including the average total length of the illness (before and after seeing the doctor): acute otitis media: 4days; acute sore throat/acute pharyngitis/acute tonsillitis: 1 week; common cold: 1weeks; acute rhinosinusitis: 2weeks; acute cough/acute bronchitis: 3 weeks. Advice should also be given about managing symptoms, including fever (particularly analgesics and antipyretics). When the delayed antibiotic prescribing strategy is adopted, patients should be offered the following: reassurance that antibiotics are not needed immediately because they are likely to make little difference to symptoms and may have side effects advice about using the delayed prescription if symptoms are not starting to settle in accordance with the expected course of the illness or if a significant worsening of symptoms occurs advice about re-consulting if there is a significant worsening of symptoms despite using the delayed prescription. A delayed prescription with instructions can either be given to the patient or left at an agreed location to be collected at a later date. A. Influenza National Institute for Health and Clinical Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of NICE technology appraisal guidance 58) HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/TA168quickrefguide.pdf"http://www.nice.org.uk/nicemedia/pdf/TA168quickrefguide.pdf Accessed 05.08.10 Oseltamivir resistance in European influenza viruses. Health Protection Agency 2008. HYPERLINK "http://www.hpa.org.uk/webw/HPAweb&HPAwebPrinterFriendly/HPAweb_C/1204186172107?p=1204186170287"http://www.hpa.org.uk/webw/HPAweb&HPAwebPrinterFriendly/HPAweb_C/1204186172107?p=1204186170287 Accessed 05.08.10 Turner D, Wailoo A, Nicholson K , Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment 2003;7(35):iii-iv, xi-xiii, 1-170. Sore Throat NICE 69: National Institute for Health and Clinical Excellence. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. 2008. (Clinical guideline 69) RATIONALE: Acute Sore Throat: NICE 69 includes 3 trials that use a delayed-antibiotic strategy for treating Acute Sore Throat. Two USA studies used a 2-day-delayed antibiotic and the UK primary care study used a 3-day-delayed antibiotic. Spinks A, Glasziou PP, Del Mar C. Antibiotics for sore throat. Cochrane Database of systematic reviews 2006, Issue 4.Art. No CD000023.DOI:10.1002/14651858.CD000023.pub3. (Review content up to date 24 November 2008). RATIONALE: This meta-analysis includes 27 RCTs and 2,835 cases of sore throat. Without antibiotics 40% of sore throats resolve in 3 days and 90% in 7 days. Antibiotics do confer a marginal benefit: To resolve one sore throat at 3 days the NNT is 6 and at 7 days the NNT is 21. However, absolute benefits are modest, especially as the Number Needed to Harm for antibiotic use in respiratory infections is about 15. Centor RM, Whitherspoon JM, Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. Med Decision Making 1981;1:239-46. RATIONALE: Centor Criteria: History of fever; absence of cough; tender anterior cervical lymphadenopathy and tonsillar exudates. A low Centor score (0-2) has a high negative predictive value (80%) and indicates low chance of Group A Beta Haemolytic Streptococci (GABHS). A Centor score of 3-or-4 suggests the chance of GABHS is 40%. If a patient is unwell with a Centor score of 3-or-4 then the chance of developing Quinsy is 1:60. Peterson I, Johnson AM, Islam A, Duckworth G, Livermore DM, Hayward AC. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 2007;335:982-4. RATIONALE: This UK retrospective cohort study looked at the extent to which antibiotics prevent serious suppurative complications of self-limiting upper respiratory tract infections. To prevent an episode of Quinsy the NNT of acute sore throat with antibiotics is >4000. This supports the recommendation that in the UK antibiotics should not be used to prevent suppurative complications of acute sore throat. Most patients with Quinsy develop the condition rapidly and dont present first with an acute sore throat. Kagan, B. Ampicillin Rash. Western Journal of Medicine 1977;126(4):333-335 RATIONALE: Amoxicillin should be avoided in the treatment of acute sore throat due to the high risk of developing a rash, when the Epstein Barr virus is present. Lan AJ, Colford JM, Colford JMJ. The impact of dosing frequency on the efficacy of 10 day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis. Pediatr 2000;105(2):E19. RATIONALE: This meta-analysis provides the evidence that BD dosing with phenoxymethylpenicillin is as effective as QDS in treating GABHS. Expert opinion is that phenoxymethylpenicillin should be dosed QDS for severe infections in order to optimise the therapeutic drug concentrations. Schartz RH, Wientzen RL Jr, Predreira F, Feroli EJ, Mella GW, Guandolo VL. Penicillin V for group A streptococcal pharyngotonsillitis. A randomized trial of seven vs ten days therapy. JAMA 1981 Oct 16;246(16):1790-5 RATIONALE: The best evidence for a 10 day course of penicillin comes from the early trials using the parenteral form. This RCT demonstrates that a 10 day course of oral phenoxymethylpenicillin is better than 7 days for resolution of symptoms and eradication of GABHS. Altamimi S, Khali A, Khalaiwa KA, Milner R, Pusic MV, Al Othman MA. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children. Cochrane Database of systematic reviews 2009, Issue 1. Art No.: CD004872. DOI: 10/1002/14651858.CD004872.pub2. RATIONALE: This recent meta-analysis shows short-course (including 5 days Clarithromycin) broad-spectrum antibiotics are as efficacious as 10-day-penicillin for sore throat symptom treatment and GABHS eradication. 10-day-phenoxymethylpenicillin remains the treatment of choice. Evidence suggests the use of broader spectrum antibiotics will drive the emergence of bacterial resistance; increase the risk of developing Clostridium difficile Associated Disease; and are associated with more adverse drug reactions. 5-days-clarithromycin should be reserved for those with true penicillin allergy. McIsaac WJ, Kellner JD, Aufricht P, Vanjaka A, Low DE. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA. 2004 Apr 7;291(13):1587-95. Additional references: Howie JGR, Foggo BA. Antibiotics, sore throats and rheumatic fever. BJGP 1985;35:223-224. RATIONALE: This Scottish retrospective study confirms the low incidence of Rheumatic Fever in the UK, (0.6 per 100,000 children per year). It would take 12 working GP life times to see one case of Rheumatic Fever. The risk of developing Rheumatic Fever was not reduced in this study by treating sore throats with antibiotics. This supports the recommendation that in the UK antibiotics should not be used to prevent non-suppurative complications of acute sore throat. Taylor JL, Howie JGR. Antibiotics, sore throat and acute nephritis. BJGP 1983;33:783-86. RATIONALE: This study shows that Glomerulonephritis is a rare condition, (2.1 per 100,000 children per year) and that treating acute sore throat with antibiotics doesnt prevent it occurring. Acute Otitis Media NICE 69: National Institute for Health and Clinical Excellence. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. 2008. (Clinical guideline 69) RATIONALE: Acute Otitis Media: NICE 69 includes 3 trials that use a delayed-antibiotic strategy for treating AOM. Two USA studies used a 2-day-delayed antibiotic and the UK primary care study used a 3-day-delayed antibiotic. Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavey J. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001;322:336-42 RATIONALE: This RCT makes two important observations: that parents tend to underestimate the amount of analgesia theyve administered and that when recommending a no-antibiotic strategy it is all the more important to optimise analgesia. Bertin L, Pons G, dAthis P, Duhamel JF, Mauelonde C, Lasfargues G, Guillot M, Marsac A, Debregeas B, Olive G. A randomized, doubleblind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Fundam Clin Pharmacol 1996;10(4):387-92 RATIONALE: This small RCT is probably the best trial evidence we have specifically for analgesia use in AOM. Both Paracetamol and Ibuprofen showed a non-significant trend towards effective analgesia compared with placebo. Note that all children were also treated with an antibiotic. Sanders S, Glasziou PP, Del Mar C, Rovers MM. Antibiotics for acute otitis media in children. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No.:CD000219.DOI:10.1002/14651858.CD00021 9pub2. (Content up to date 08.11.08) RATIONALE: Most (66%) of children are better in 24 hours and antibiotics have no effect. 80% of children are better in 2-to-7 days and antibiotics have a small effect (symptoms reduced by 16 hours), (RR 0.72; 95% CI 0.62 to 0.83). Antibiotics did not reduce tympanometry (deafness), perforation or recurrence. Vomiting, diarrhoea or rash was more common in children taking antibiotics (RR 1.37; 95% CI 1.09 to 1.76) with a Number Needed to Harm of 16. Rovers MM, Glasziou P, Appleman CL, Burke P, McCormick DP, Damoiseaux RA, Little P, Le Saux N, Hoes AW. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: a meta-analysis of individual patient data. Pediatrics 2007;119(3):579-85 RATIONALE: The risk of prolonged illness was 2 times higher for children <2years with bilateral AOM than for children with unilateral AOM. For this sub-group parents should be advised that symptoms may persist for up to 7 days, and they should optimise analgesia use. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, Gaboury I, Little P, Hoes AW. Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006;368:1429-1435 RATIONALE: Note this is sub-analysis of data. In children <2 years old with bilateral AOM, 30% on antibiotics and 55% of controls had pain and/or fever at 3 to 7 days (RD -25%; 95% CI: -36, -14) and the NNT was 4 in children with otorrhoea, 24% on antibiotics and 60% of controls had pain and/or fever at 3 to 7 days (RD-36%; 95% CI: -53, -19) and the NNT was 3. Thompson PL, Gilbert RE, Long PF, Saxena S, Sharland M, Wong IC. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the United Kingdom general practice research database. Pediatrics 2009;123(2):424-30 RATIONALE: Antibiotics halved the risk of mastoiditis, but GPs would have to treat 4831 episodes of AOM to prevent one episode of mastoiditis. Although mastoiditis is a serious illness, most children make an uncomplicated recovery after mastoidectomy or IV antibiotics, (Incidence mastoiditis 0.15 per 1000 child years). Takata GI, Chan LS, Shekelle P, et al. Evidence assessment of management of acute otitis media: The role of antibiotics in treatment of uncomplicated acute otitis media. Pediatrics 2001;108:239-247 RATIONALE: Pooled analyses did not show any difference in efficacy between comparisons of penicillin, ampicillin, amoxicillin (2 or 3 times daily; standard or high dose), amoxicillin-clavulanate, cefaclor, cefixime, ceftriaxone, azithromycin and trimethoprim. Macrolides concentrate intracellularly and so are less active against the extracellular H influenzae. Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA. Trends on otitis media treatment failure and relapse. Pediatrics 2008;121(4):674-9. RATIONALE: High-dose amoxicillin treatment did not reduce the risk of individual infections resulting in adverse outcomes. Kozyrskyj AL, Hildes Ripstein GF, Longstaffe SE, et al. Short-course antibiotics for acute otitis media. Cochrane Database Syst Rev 2000;(2):CD001095. RATIONALE: This review found that 5 days of antibiotic treatment was as effective as 10 days in otherwise healthy children with uncomplicated AOM. Acute Otitis Externa Kaushik V, Malik T, Saeed SR. Interventions for acute otitis externa. Cochrane Database of Systematic Reviews 2010, Issue1. Art. No.:CD004740. DOI: 10.1002/14651858.CD004740.pub2. RATIONALE: The best evidence we have to date. Includes 19 low quality RCTs only two of which are from primary care, and therefore probably included more severe or chronic cases. One big downside for primary care is that over half of the trials involved ear cleaning. The meta-analysis demonstrates topical treatments alone are adequate for treating most cases of AOE. Acetic acid was as effective and comparable to antibiotic/steroid for the first 7 days, but inferior after this point. It is important to instruct patients to use drops for at least one week, and to continue for up to 14 days if symptoms persist. Rosenfeld RM, Brown L, Cannon R, Dolor RJ, Ganiats TG, Hannley M, Kokemueller P, Marcy M, Roland PS, Shiffman RN, Stinnett SS, Witsell DL, Singer M, Wasserman JM. Clinical Practice Guideline: Acute Otitis Externa. Otolaryngology Head and Neck Surgery 2006;134(Suppl 4):S4-S23 RATIONALE: Up to 40% of patients with AOE receive oral antibiotics unnecessarily. The oral antibiotics in the trails were often inactive against P aeruginosa (incidence 36%) and S aureus (incidence 21%). Topical antibiotics such as neomycin have a broader spectrum of activity. When using topical antibiotics in this situation bacterial resistance is far less of a concern as the high concentration of the drug in the ear canal will generally eradicate all susceptible organisms, plus those with marginal resistance. Malignant Otitis Externa is an aggressive infection that affects the immunocompromised and elderly that requires prompt admission. Facial Nerve paralysis may be an early sign. GPs should refer severe cases, characterised by unremitting pain, cranial nerve deficits, perforated tympanic membrane or history of previous ear surgery. Abelardo E, Pope L, Rajkumar K, Greenwood R, Nunez DA. A double-blind randomised clinical trial of the treatment of otitis externa using topical steroid alone versus topical steroid-antibiotic therapy. European Archives of Oto-rhino-laryngology: 2009;266(1):41-5 RATIONALE: A hospital outpatient RCT showing superiority of topical steroid-antibiotic therapy. The Cochrane Review 2010 also stated that the evidence for steroid-only drops is very limited and as yet not robust enough to allow us to reach a conclusion or provide recommendations. NEOMYCIN SULPHATE with CORTICOSTEROID is suggested as topical antibiotic + steroid as it contains an antibiotic that is not used orally, Neomycin is active against Pseudomonas and Staphylococci the most common bacterial causes, plus there is the choice of four agents: Betnesol-N; Otomize; Otosporin and Predsol-N. Acute Rhinosinusitis NICE 69: National Institute for Health and Clinical Excellence. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. 2008. (Clinical guideline 69). Although there are no specific studies looking at delayed antibiotics for acute rhinosinusitis, NICE 69 recommends the same approach as for the other self limiting respiratory tract infections. The 7-day delay is recommended as systematic review shows no benefit of antibiotics in rhinosinusitis within the first 7 days. Young J, De Sutter A, Merenstein D, van Essen GA, Kaiser L, Varonen H, Williamson I, Bucher HC. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet. 2008;371:908-914 RATIONALE: This meta-analysis included 2.547 pts from 9 Placebo-controlled trials. This primary care meta-analysis showed that 15 people would have to be given antibiotics before an additional patient was cured. The Odds Ratio of treatment effect for antibiotics relative to placebo was 1.37 (95% CI 1.13 to 1.66). A further sub-group analysis showed that those patients with purulent discharge were more likely to benefit from antibiotics with a NNT of 8. There was no additional benefit of antibiotics for: older patients; more severe symptoms or longer duration of symptoms. Ahovuo-Saloranta A, Borisenko OV, Kovanen N, Varonene H, Rautakorpi UM, Williams Jr JW, Makela M. Antibiotics for acute maxillary sinusitis. Cochrane Database of Systematic Reviews 2008, Issue 2.Art. No.: CD000243. DOI:10.1002/14651858.CD000243.pub2. (Last assessed as up-to-date 28 May 2007) RATIONALE: This is a big clinical review (57 studies), that contained 6 placebo controlled trials.5 of these were in primary care and involved 631 patients. There was a slight statistical difference in favour of antibiotics compared with placebo (RR 0.66; 95%CI 0.65 to 0.84). Note cure/improvement rate was high in placebo group (80%) compared with the treatment group (90%). Antibiotics have a small treatment effect in patients with uncomplicated acute rhinosinusitis, in a primary care setting, for more than seven days. Ah-See KW, Evans AS. Sinusitis and its management. BMJ 2007:334:358-61 RATIONALE: Adequate analgesia is becoming recognised as the first-line management for acute rhinosinusitis. Robust evidence for this is limited, as it is for analgesia use in general. This is partly due to the widespread accepted efficacy and tolerability of analgesics, that such research isnt deemed necessary. We have to make do with the consensus expert opinion. Thomas M, Yawn B, Price D, Lund V, Mullol J, Fokkens W. EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 a summary. Primary Care Respiratory Journal2008;17(2):79-89. RATIONALE: This primary care guideline states that: Acute rhinosinusitis is an inflammatory condition that may be diagnosed on the basis of acute symptoms of nasal blockage, obstruction, congestion with or without facial pain or reduced smell; many episodes are self-limiting, but where symptoms persist or increase after 5 days, topical steroids may be considered to reduce the inflammatory reaction. Bartlett JG, Gorbach SL. Anaerobic infections of the head and neck. Otolaryngol Clin North Am 1976;9:655-78. RATIONALE: Anaerobes are an unusual finding in acute upper respiratory infections such as acute rhinosinusitis and acute otitis media, but are increasingly found in chronic disease. Co-amoxiclav is active against many anaerobes as well as S. pneumoniae and H. influenzae. De Ferranti SD, Lonnidis JPA, Lau J, Anniger WV, Barza M. Are amoxicillin and folate inhibitors as effective as other antibiotics for acute sinusitis? BMJ1998;317:632-7 RATIONALE: On current evidence, no one class of antibacterial is more likely than another to cure patients with sinusitis. Hansen JG, Schmidt H, Grinsted P. Randomised double-blind, placebo controlled trial of penicillin V in the treatment of acute maxillary sinusitis in adults in general practice. Scan J Prim Health Care2000;18:44-47. RATIONALE: This primary care study (133 patients) demonstrates that Penicillin V is more effective than placebo in the treatment of acute maxillary sinusitis, but only where there is pronounced pain. Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomised trials. British Journal of Clinical Pharmacology2009;67(2):161-71 RATIONALE: there was no difference in the comparison of short-course (3-7 days) with long-course treatment (6-10 days). The pragmatic interpretation of this meta-analysis is that a 7 day course is optimal. In severe sinusitis a 1g dose may be considered to ensure bactericidal concentrations of amoxicillin in the sinuses. Lower concentrations may encourage the stepwise form of resistance that occurs with pneumococci. Additional reference: Hansen JG, Hojbjerg T, Rosborg J. Symptoms and signs in culture proven acute maxillary sinusitis in general practice population. APMIS 2009;117(10):724-9 RATIONALE: We dont yet have robust diagnostic criteria for those patients with acute rhinosinusitis that would most benefit from antibiotics. This primary care prospective cohort study of 174 patients shows: Fever >38 degrees; maxillary toothache and raised ESR were associated with S. pneumoniae and H. influenzae positive rhinosinusitis. LOWER RESPIRATORY TRACT INFECTIONS Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, Schabert T, Torres A, can der Jeijden G, Werheij TJM. Guidelines for the management of adult lower respiratory tract infection. Eur Respir J 2005;26:1138-80. HYPERLINK "http://www.erj.ersjournals.com/contents-by-date.0.shtml"http://www.erj.ersjournals.com/contents-by-date.0.shtml (Accessed 3rd January 2010). Appendices 1, 2 and 3 give a detailed account of the definitions of LRTI, the microbiological aetiologies of LRTI unspecified, community acquired pneumonia, exacerbations of COPD and bronchiectasis and the pharmacodynamic/pharmacokinetic properties of the antibiotics used to treat them. Strep. Pneumoniae remains the most commonly isolated pathogen in all of the above except in bronchiectasis. The infective agents causing exacerbations of COPD differ according to the severity of the underlying condition suggesting that more broad spectrum antibiotics are indicated in patients with severe COPD (FEV1< 50%). Antibiotic classes are discussed with reference to their mode of action in terms of time dependent or concentration dependent effect, their tissue penetration and whether they exert a post antibiotic effect. Other factors such as bioavailability are also considered. Acute bronchitis NICE Clinical Guideline 69. Respiratory Tract Infections - antibiotic prescribing for self-limiting respiratory tract infections in adults and children in primary care. July 2008. Describes strategies for limiting antibiotic prescribing in self-limiting infections and advises in which circumstances antibiotics should be considered. A no antibiotic or a delayed antibiotic prescribing strategy should be agreed for patients with acute cough/chronic bronchitis. In the 2 RCTs included in the review, the delay was 7-14 days from symptom onset and antibiotic therapy. Patients should be advised that resolution of symptoms can take up to 3 weeks and that antibiotic therapy will make little difference to their symptoms and may result in side effects. Patients should also be advised to seek a clinical review if condition worsens or becomes prolonged. The evidence behind these statements is primarily from the studies referred to below. Fahey T, Smucny J, Becker L, Glazier R. Antibiotics for acute bronchitis. In: The Cochrane Library, 2006, Issue 4. Chichester, UK: John Wiley & Sons, Ltd HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000245/pdf_fs.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000245/pdf_fs.html Accessed 05.08.10. Systematic review of nine studies (4 in primary care). Studies in primary care showed antibiotics reduced symptoms of cough and feeling ill by less than one day in an illness lasting several weeks in total. Chronic cough due to acute bronchitis. Chest. 2006;129:95S-103S. Clinical guidelines on managing cough associated with acute bronchitis. Large body of evidence including meta-analyses and systematic reviews does not support routine antibiotic use . Wark P. Bronchitis (acute). In: Clinical Evidence. London. BMJ Publishing Group. 2008;07:1508-1534 Discusses the evidence to support self care and limiting antibiotic prescriptions. Systematic review of 13 RCTs found that antibiotics only modestly improved outcomes compared with placebo. Francis N et al. Effect of using an interactive booklet about childhood respiratory tract infections in primary care consultations on reconsulting and antibiotic prescribing: a cluster randomised controlled trial. BMJ, 2009;339:2885 Utilising an information booklet during primary care consultations for children with RTIs significantly decreased antibiotic use (absolute risk reduction 21.3% (95%CI, 13.7-28.9 p<0.001). Reconsultation occurred in 12.9% of children in intervention group and 16.2% in control group(absolute risk reduction 3.3%, no statistical difference). There was no detriment noted to patient satisfaction in the intervention group. Treatment of acute bronchitis available in Clinical Knowledge Summaries website: HYPERLINK "http://www.cks.library.nhs.uk/search?&page=1&q=sore%20throat%20acute&site=0"http://www.cks.library.nhs.uk/search?&page=1&q=sore%20throat%20acute&site=0 Accessed 05.08.10. COPD Anthonisen MD, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med 1987;106:196-204. Describes the cardinal signs of an infective exacerbation of COPD and the evidence for commencing antibiotics. Randomised double blinded cross-over trial showed a significant benefit from using antibiotics. Success rate with antibiotic therapy 68% vs 55% with placebo. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. Management of exacerbations. Updated December 2009. Discusses the aetiology, pathophysiology and evidence based therapeutic management of COPD. Antibiotic therapy is stratified according to severity of disease. S. pneumoniae, H. influenzae, M. catarrhalis remain the predominant pathogens in mild disease. Chronic obstructive pulmonary disease. Management of COPD in adults in primary and secondary care. NICE Clinical Guideline 12 February 2004. HYPERLINK "http://guidance.nice.org.uk/CG101"http://guidance.nice.org.uk/CG101 Accessed 05.08.10. A meta analysis of nine trials found a small but statistically significant effect favouring antibiotics over placebo in patients with exacerbations of COPD. Effect size 0.22 (95% CI, 0.1 to 0.34).Four studies assessed whether there was a relationship between severity of exacerbation and the effectiveness of antibiotic use. Three of these studies suggest that the worse the COPD severity of exacerbation (lung function impairment (FEV1, PEFR), purulence of sputum) then the greater the degree of benefit from antibiotics. Community-acquired pneumonia BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2009;64 (Suppl III):III 1-55 Updated guideline on the management of CAP includes diagnosis, severity assessment, ,microbiological profile and therapeutic management in both the community and hospital. Assessing severity using CRB65 scores in addition to clinical judgement allows patients to be stratified according to increasing risk of mortality. (score 0, mortality risk 1.2%; score 1. 5.3%; score 2. 12.2%; scores 3-4, up to 33%).Patients with a CRB65 score e"1 are deemed to have moderately severe CAP and should be assessed with a view to hospital admission. Patients with moderately severe CAP should receive antibiotics which also cover atypical organisms. Loeb M. Community-acquired pneumonia. In: Clinical Evidence. London BMJ Publishing Group. 2008;07:1503-1516. (Accessed 6th January 2010. While there is no direct information about the benefits of antibiotics in the treatment of CAP in the community, there is consensus they are beneficial. No one regime has shown superiority over another. van der Poll T, Opal S. Pathogenesis, treatment and prevention of pneumococcal pneumonia. Lancet. 2009;374:1543-1556. Detailed review of pneumococcal pneumonia, the most common cause of CAP. Includes discussion of clinical features, risk factors and rationale for high dose penicillins to overcome resistance.. MENINGITIS NICE. Bacterial meningitis and meningococcal septicaemia. National Collaborating Centre for Womens and Childrens health 2009. HYPERLINK "http://guidance.nice.org.uk/CG102/Guidance"http://guidance.nice.org.uk/CG102/Guidance Accessed 05.08.10. Expert opinion is that in children or young people with suspected bacterial meningitis or meningococcal septicaemia, transfer to hospital is the priority, and that intravenous benzylpenicillin should be given at the earliest opportunity, either in primary or secondary care. The NICE guideline development group recommended benzylpenicillin because it is the most frequently used antibiotic in primary care and they found no evidence to recommend an alternative antibiotic. Although the scope of this guideline is for children, it seems reasonable to extrapolate the advice to older age groups. SIGN. Management of invasive meningococcal disease in children and young people. Scottish Intercollegiate Guidelines Network. 2008 HYPERLINK "http://www.sign.ac.uk/guidelines/fulltext/102/index.html"http://www.sign.ac.uk/guidelines/fulltext/102/index.html Accessed 05.08.10. Expert opinion is that parenteral antibiotics (either benzylpenicillin or cefotaxime) should be administered in children as soon as invasive meningococcal disease is suspected, and not delayed pending investigations/ URINARY TRACT INFECTIONS Notes Abrutyn E, Mossey J, Berlin JA, Boscia J, Levison M, Pitsakis P, Kaye D. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Int Med 1994;120(10):827-33. A cohort study and a controlled trial found that bacteriuria was not an independent risk factor for mortality in elderly women without catheters, and that its treatment did not lower the mortality rate. Grabe M, Bishop MC, Bjerkland-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou, J, Tenke, P, Wagenlehner F. Guidelines on Urological Infections. European Association of Urology 2009: 1-110. Asymptomatic bacteriuria is seldom associated with adverse outcomes in people with indwelling catheters. Treatment of bacteriuria causes harms: increased short-term frequency of symptomatic infection, and re-infection with organisms of increased antimicrobial resistance. NICE. Infection control. Prevention of healthcare-associated infections in primary and community care. The National Collaborating Centre for Nursing and Supportive Care and the Thames Valley University. 2003 HYPERLINK "http://guidance.nice.org.uk/CG2"http://guidance.nice.org.uk/CG2 Accessed 05.08.10. This guideline originally stated that prophylactic antibiotics were also indicated for people with heart valve lesions, septal defects, patent ductus, or prosthetic valves. However, NICE state that this recommendation has been superseded by their 2008 guideline on prophylaxis of endocarditis, which states that prophylactic antibiotics are no longer required for people with those conditions requiring a catheter change. Uncomplicated UTI SIGN. Management of suspected bacterial urinary tract infection in adults: a national clinical guideline. Scottish Intercollegiate Guidelines Network. 2006 http://www.sign.ac.uk/guidelines/fulltext/88/index.html Accessed 05.08.10. Diagnosis in women: expert consensus is that it is reasonable to start empirical antibiotics in women with symptoms of UTI without urine dipstick or urine culture. Diagnosis in men: a urine sample is recommended because UTI in men is generally regarded as complicated (it results from an anatomic or functional abnormality) and there are no studies on the predictive values of dipstick testing in men. Duration of treatment for men: there is no evidence to guide duration of treatment; expert consensus is that 7 days of antibiotics should be used because men are likely to have a complicating factor. Second line treatment: resistance is increasing to all antibiotics used to treat UTI. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no. 91: Treatment of urinary tract infections in non-pregnant women. Obstetrics and Gynecology 2008;111(3):785-794. Diagnosis in women: expert consensus is that it is reasonable to start empirical antibiotics in women with symptoms of UTI without urine culture. Little P, Turner S, Rumsby K., Warner G, Moore M, Lowes JA, Smith H, Hawke C, Turner D, Leydon GM, Arscott A, Mullee M. Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technology Assessment 2009;13(19):1-96. In women with uncomplicated UTI, the negative predictive value when nitrite, leucocytes, and blood are ALL negative was 76%. The positive predictive value for having nitrite and EITHER blood or leucocytes was 92%. Grabe M, Bishop MC, Bjerkland-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou, J, Tenke, P, Wagenlehner F. Guidelines on Urological Infections. European Association of Urology 2009: 1-110. Diagnosis in men: a urine sample is recommended because UTI in men is generally regarded as complicated (it results from an anatomic or functional abnormality) and there are no studies on the predictive values of dipstick testing in men. Duration of treatment for men: there is no evidence to guide duration of treatment; expert consensus is that 7 days of antibiotics should be used because men are likely to have a complicating factor. Although use of dipstick testing has not been well studied in men, it seems reasonable to extrapolate results from studies of dipstick testing in women with suspected UTI to men with only mild symptoms of UTI as contamination is likely to be lower. Gossius G and Vorland L. The treatment of acute dysuria-frequency syndrome in adult women: Double-blind, randomized comparison of three-day vs ten-day trimethoprim therapy. Current Therapeutic Research, Clinical & Experimental 1985;37: 34-42. Two-weeks after completion of treatment, 94% of women using a 3-day course of trimethoprim achieved bacteriological cure compared with 97% of those using a 10-day course of trimethoprim (n =135). Christiaens TCM, De Meyere M, Verschcragen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Brit J Gen Pract 2002;52:729-34. This small (n = 78) double-blind RCT found that nitrofurantoin 100mg qds for 3 days was more effective than placebo (NNT = 4.4, 95% CI 2.3 to 79). The HPA and the Association of Medical Microbiologists recommend trimethoprim and nitrofurantoin as first-line empirical treatment for uncomplicated UTI in women and men because they are narrow-spectrum antibiotics that cover the most prevalent pathogens. Broad spectrum antibiotics (e.g. co-amoxiclav, pivmecillinam, quinolones and cephalosporins) should be avoided when narrow spectrum antibiotics remain effective, as they increase risk of Clostridium difficile, MRSA and resistant UTIs. Several guidelines recommend that nitrofurantoin should not be used to treat UTI in men. This is on the grounds that it can be difficult to exclude the possibility of prostatitis, and that nitrofurantoin is not present in therapeutic concentrations in prostatic secretions. However, these recommendations refer to UTI with fever or other signs of acute prostatitis, and neither guideline expressed concern that acute prostatitis would be likely in men with symptoms of lower UTI and without fever and other symptoms of prostatitis. MeReC Bulletin. Modified-release preparations. 2000;11(4). Modified- release preparations can be used to reduce dosing frequency. Reduced dosing frequency (e.g. from four times a day to twice a day) improves compliance. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother 1994;33(Suppl A):121-9. This non-blinded RCT (n = 538) found that nitrofurantoin MR had equivalent clinical cure rates to co-trimoxazole, and trimethoprim. The rate of gastrointestinal adverse effects was similar between groups (7-8%). Falagas, M.E., Kotsantis, I.K., Vouloumanou, E.K. and Rafailidis, P.I. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. Journal of Infection 2009;58(2):91-102. Clinical cure for antibiotics compared with placebo: OR4.67 (95%CI 2.34 to 9.35; fourRCTs, n=1062). Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Review. The Cochrane Library 2006, Issue 2. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004682/pdf_fs.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004682/pdf_fs.html Accessed 05.08.10. No difference in outcome between 3 day, 5 day or 10 day antibiotic treatment course for uncomplicated UTI in women (RR 1.06; 95% CI 0.88 to 1.28; 32 trials, n = 9605). Newell A, Bunting P, Anson K, Fox E. Multicentre audit of the treatment of uncomplicated urinary tract infection in South Thames. International Journal of STD & AIDS 2005;16:74-77. This audit of urine samples taken at presentation found that 43.3% of isolates were resistant to amoxicillin, 22.6% were resistant to trimethoprim, and 10.3% were resistant to nitrofurantoin. DTB. Risks of extended-spectrum beta-lactamases. Drug and Therapeutics Bulletin 2008;46(3):21-24. Extended spectrum beta-lactamases (ESBLs) are able to hydrolyse antibiotics that were designed to resist the action of older beta-lactamases. These organisms may be resistant to most antibiotics commonly used to treat UTI, such as trimethoprim, ciprofloxacin, co-amoxiclav, and all cephalosporins. Most ESBL-producing E coli are sensitive to nitrofurantoin. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. European Urology 2008;54:1164-1175. In all countries, susceptibility rate to E. coli above 90% (p < 0.0001) was found only for fosfomycin, mecillinam, and nitrofurantoin. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50. Ninety seven per cent of ESBL-producing E coli isolates and 81% of Klebsiella pneumonia ESBL-producing isolates were susceptible to fosfomycin. Fosfomycin is not available commercially as a licensed product in the UK. Currently the only means of obtaining fosfomycin is to order from a specials supplier. There will be a delay in obtaining the product in the community setting and careful consideration needs to be given when prescribing and supplying to patients who may need treatment more urgently. Brands: These include - MONURIL (Zambon Italy; Netherlands) and MONUROL (Pharmazam Spain USA, Hong Kong). Advice to patient: As there is a delay in obtaining fosfomycin in the community, the patient should be advised to consult GP if symptoms worsen whilst awaiting supply. Nutritional interactions: Food intake can slow down the absorption of fosfomycin with, as a result, lower concentrations in the urine. Fosfomycin should, therefore, be administered while fasting or 2 or 3 hours before meals. UTI in pregnancy SIGN. Management of suspected bacterial urinary tract infection in adults: a national clinical guideline. Scottish Intercollegiate Guidelines Network. 2006 http://www.sign.ac.uk/guidelines/fulltext/88/index.html Accessed 05.08.10. MSU should be performed routinely at the first antenatal visit. If bacteriuria is reported, it should be confirmed with a second MSU. Dipstick testing is not sufficiently sensitive to be used for screening for bacteriuria in pregnant women. UKTIS. The treatment of infections in pregnancy. The UK Teratology Information Service. 2008. (Tel: 0844 892 0909, HYPERLINK "http://www.toxbase.org"www.toxbase.org ) Accessed 05.08.10. Amoxicillin and cefalexin: The available data suggest that neither penicillins nor cephalosporins are associated with an increased risk of congenital malformations when used during pregnancy. Nitrofurantoin: significant placental transfer of nitrofurantoin does not occur. Nitrofurantoin has not been associated with an increased risk of congenital malformations. Nitrofurantoin has been associated with haemolysis in people with glucose-6-phosphate dyhydrogenase (G6PD) deficiency. However, the risk seems very small because placental transfer is so low. There is only one reported case of haemolytic anaemia in a newborn whose mother was treated at term with nitrofurantoin. Trimethoprim: trimethoprim is a folate antagonist. Folate supplementation during the first trimester reduces the risk of neural tube defects in offspring of pregnant women treated with trimethoprim. In women with normal folate status, who are well nourished, trimethoprim is unlikely to cause folate deficiency. However, it should not be used by women with established folate deficiency or low dietary folate intake, or by women taking other folate antagonists (e.g. antiepileptic drugs or proguanil). Ruxton CHS and Derbyshire E. Womens diet quality in the UK. Nutrition Bulletin 2010;35:126-137. Data from the National Diet and Nutrition Surveys show that womens dietary intake of iron, vitamin D, calcium and folate remain below recommended levels. The Health Protection Agency and the British Society for Antimicrobial Chemotherapy recommend that cefalexin is reserved for third-line use for the treatment of a UTI in a pregnant woman. Cefalexin has a good safety record in pregnancy. However, because it is a broad-spectrum antibiotic, it increases the risk of Clostridium difficile, and there have been recent reports of C difficile in pregnant women. Rouphael NG, ODonnell JA, Bhatnagar J, Lewis F, Polgreen PM, Beekman S, Guarner J, Killgore GE, Koffman B, Campbell J, Zaki SR, McDonald LC Clostridium difficile-associated diarrhoea: an emerging threat to pregnant women. Am J Obs Gynaecol 2008;198:e1-635.e6 In this series of 10 cases, most were associated with antibiotic use. Seven of the women were admitted to intensive care. Three infants were stillborn and 3 women died. Grabe M, Bishop MC, Bjerkland-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou, J, Tenke, P, Wagenlehner F. Guidelines on Urological Infections. European Association of Urology 2009: 1-110. Expert consensus is that 7 days of antibiotics should be used to treat urinary tract infections during pregnancy. Children National collaborating centre for womens and childrens health. NICE clinical guideline. Urinary tract infection in children. Diagnosis, treatment and long-term management. HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG54fullguideline.pdf"http://www.nice.org.uk/nicemedia/pdf/CG54fullguideline.pdf Accessed 05.08.10. Diagnosis and referral: expert opinion is that children under the age of 3 months with suspected UTI should be admitted; that imaging during the acute episode is only needed for atypical UTI or for children under the age of 6 months with UTI. Choice of antibiotics for lower UTI: NICE identified 3 RCTs comparing trimethoprim to other antibiotics for UTI in children, and one systematic review comparing short and long course of antibiotics for UTI in children that included studies assessing trimethoprim, nitrofurantoin and amoxicillin. The NICE guideline development group recommend trimethoprim, nitrofurantoin, amoxicillin, or cefalexin for empirical treatment of lower UTI in children. Duration of antibiotics for lower UTI: one systematic review found no difference in efficacy between short-courses (2-4 days) and longer courses (7-14 days) of antibiotics in children with lower UTI. Upper UTI: one systematic review combined two studies of co-amoxiclav treatment for 10-14 days compared with IV antibiotic treatment. No difference in efficacy was found. Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis. Cochrane Database of Systematic Reviews 2007. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003772/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003772/frame.html Accessed 05.08.10. Twenty three studies (3407 children) were eligible for inclusion. No significant differences were found in persistent kidney damage at six to 12 months (824 children: RR 0.80, 95% CI 0.50 to 1.26) or in duration of fever (808 children: MD 2.05, 95% CI -0.84 to 4.94) between oral antibiotic therapy (10 to 14 days of cefixime, ceftibuten or co-amoxiclav) and IV therapy (3 days) followed by oral therapy (10 days). Recurrent UTI in non-pregnant women Albert X, Huertas I, Pereir I, Sanflix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database of Systematic Reviews 2004, Issue 3, HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001209/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001209/frame.html Accessed 05.08.10. Nightly prophylaxis: pooled data from 19 RCTs of poor methodological quality calculated an NNT of 1.85 for nightly prophylaxis for 612months. But adverse effects do occur and 30% of women did not adhere to treatment. Benefit lost as soon as prophylaxis stops. Post-coital antibiotics: one study of post-coital ciprofloxacin compared with ciprofloxacin prophylaxis found no significant difference between regimens on the rate of UTIs. Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo- controlled trial. JAMA 1990;264(6):702-706. This small (n = 27) RCT found that the relative risk of symptomatic recurrence was lower with post-coital co-trimoxazole (RR 0.15, 95% CI 0.04 to 0.58). Adverse event rates were low and not significantly different between antibiotic and placebo. Grabe M, Bishop MC, Bjerkland-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou, J, Tenke, P, Wagenlehner F. Guidelines on Urological Infections. European Association of Urology 2009: 1-110. Standby antibiotics: expert opinion, based on one open prospective trial, is that standby antibiotics may be suitable if the rate of recurrences is not too common. Post-coital antibiotics: expert opinion is that the same antibiotics and same doses as for nightly prophylaxis can be used as a stat dose for post-coital prophylaxis of UTI. GASTRO-INTESTINAL TRACT INFECTIONS Eradication of Helicobacter pylori NICE. Dyspepsia: managing dyspepsia in adults in primary care. National Institute for Health and Clinical Excellence. August 2004 HYPERLINK "http://www.nice.org.uk/nicemedia/pdf/CG017fullguideline.pdf"www.nice.org.uk/nicemedia/pdf/CG017fullguideline.pdf Accessed 05.08.10. NICE give guidance on when to consider H pylori test and treat in primary care. First-line H pylori eradication: NICE recommend a twice daily full-dose PPI plus clarithromycin 250mg bd and metronidazole 400mg bd, or a PPI plus clarithromycin 500mg bd plus amoxicillin 1g bd. Second-line H pylori eradication: NICE recommend that a regimen is used that does not include the antibiotics given previously. Duration of treatment: although 14-day triple therapy gives almost a 10% higher eradication rate, the absolute benefit of H pylori therapy is modest in NUD and undiagnosed dyspepsia and the longer duration of therapy does not appear cost effective. In patients with PUD increasing the course to 14 days also gives a nearly 10% higher eradication rate, but does not appear cost effective. MALToma: expert opinion is that for MALT lymphoma, the increased efficacy of a 14-day regimen will reduce the need for chemotherapy and/or gastric resection. Malfertheiner P, Megraud F, OMorain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuiper EJ, The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. MALToma: sixty two percent of patients with low grad gastric MALT lymphoma have complete remission after H pylori eradication within 12 months. Second-line treatment: bismuth-based quadruple therapy is a preferred option. Moayyedi P, Soo S, Deeks JJ, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Eradication of Helicobacter pylori for non-ulcer dyspepsia. The Cochrane library 2006. Issue 2 HYPERLINK "http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002096/frame.html"http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002096/frame.html Accessed 05.08.10. Pooled data from 17 RCTS (n = 3566) found there was a 10% relative risk reduction in dyspepsia symptoms in people with non-ulcer dyspepsia randomized to receive H pylori eradication (95% CI 6% to 14%) compared to placebo. The NNT to cure one case of dyspepsia was 14 (95% CI 10 to 25). Delaney BC, Qume M, Moayyedi P, Logan RFA, Ford AC, Elliott C, McNulty C, Wilson S, Hobbs FDR. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-654. At 12months, there were no significant differences in QALYs, costs, or dyspeptic symptoms between the group assigned to initial H pylori test and treat and the group assigned to initial acid suppression (n = 699). Fischbach L and Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-357. Pooled data found that the efficacy of a PPI + clarithromycin + metronidazole was reduced more by resistance to clarithromycin than by resistance to metronidazole. Metronidazole resistance reduced efficacy by 18% while clarithromycin resistance was estimated to reduce efficacy by 35%. Clarithromycin resistance reduced the efficacy of a PPI + clarithromycin + amoxicillin by 66%. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010;340:c2096 Individuals prescribed an antibiotic in primary care for a respiratory or urinary infection develop bacterial resistance to that antibiotic. The effect is greatest in the month immediately after treatment but may persist for up to 12 months. Luther J, Higgins PDR, Schoenfield PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73. Pooled data from 9 RCTs (n = 1679) found that eradication rates were comparable between clarithromycin triple therapy (77%) and bismuth-containing quadruple therapy (78%). Most trials of 7-10days duration. The Health Protection Agency recommends that oxytetracycline is not substituted for tetracycline hydrochloride as part of the quadruple therapy regimen. Oxytetracycline is thought to have different mucus penetration properties to tetracycline hydrochloride. In addition, the treatment studies have been done with tetracycline hydrochloride. If third line treatment is required, clinicians may also consider changing the PPI to rabeprazole, as it has a different metabolism to the other PPIs, which may be metabolised rapidly in some patients, causing treatment failure. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Annals Internal Medicine 2007; 147: 553-562. Pooled data found that extending the course of triple therapy from 7 to 14 days increased eradication rates only by about 5% (no statistically significant difference). The authors concluded that this is unlikely to be a clinically useful difference. British National Formulary. 58th Edition. 2009. London: BMJ Group and RPS Publishing. Second-line therapy: expert opinion is that a 14-day course of quadruple therapy consisting of a PPI + bismuth + metronidazole + tetracycline can be used for eradication failure. Infectious diarrhoea The Griffin Report. Report of the Independent Investigation Committee June 2010. Review of the major outbreak of E. coli O157 in Surrey, 2009 An evaluation of the outbreak and its management, with a consideration of the regulatory framework and control of risks relating to open farms. 2010 HYPERLINK "http://www.griffininvestigation.org.uk"www.griffininvestigation.org.uk Accessed 05.08.10. Farthing M, Feldman R, Finch R, Fox R, Leen C, Mandal B, Moss P, Nathwani D, Nye F, Percival A, Read R, Ritchie L, Todd WT, Wood M. The management of infective gastroenteritis in adults. A consensus statement by the British Society for the Study of Infection. J Infect 1996;33:143-52. Empirical treatment for patients well enough to be managed in primary care is not recommended because the majority of illnesses seen in the community do not have an identifiable bacterial cause. In addition, an RCT of quinolones as empiric therapy found no benefit in patients whose stool cultures were negative. The Health Protection Agency and Association of Medical Microbiologists recommend that, if campylobacter is strongly suspected as the cause of diarrhoea, consider empirical treatment with clarithromycin. Quinolones are not recommended because there is increasing resistance of campylobacter to quinolones, and broad spectrum antibiotics such as quinolones are not recommended for empirical therapy because they are associated with an increased risk of Clostridium difficile, MRSA, and resistant UTIs. E coli 0157 Independent Investigation Committee. Review of the major outbreak of E coli 0157 in Surrey, 2009. HYPERLINK "http://www.griffininvestigation.org.uk/"http://www.griffininvestigation.org.uk/ Accessed 05.08.10. The Griffin report recommends that E coli 0157 should be suspected in any child presenting with bloody diarrhoea. Threadworm CKS (2007) Threadworm. Clinical Knowledge Summaries. HYPERLINK "http://www.cks.nhs.uk/search?&page=1&q=threadworm&site=0"http://www.cks.nhs.uk/search?&page=1&q=threadworm&site=0 Accessed 05.08.10. There is only limited evidence regarding the two products licensed for the treatment of threadworm in the UK. Mebendazole is recommended first line based on expert opinion and its relatively better safety profile compared with piperazine. Piperazine is licensed only from 3 months of age, and although the BNF recommends off-label use of mebendazole for children aged 6 months and over, it does not recommend it for infants under 6 months of age. Expert opinion is that strict hygiene methods for 6 weeks can be used as an alternative treatment in those who cannot take mebendazole or piperazine. This is based on the life cycle of the threadworm (adults survive for about 6weeks) and the long viability of eggs (up to 2weeks). GENITAL TRACT INFECTIONS STI screening National Chlamydia Screening Programme HYPERLINK "http://www.chlamydiascreening.nhs.uk/ps/index.html"http://www.chlamydiascreening.nhs.uk/ps/index.html Accessed 05.08.10. BASHH and MedFASH. Standards for the management of sexually transmitted infections (STIs). British Association of Sexual Health and HIV and the Medical Foundation for AIDs and Sexual Health. 2010. HYPERLINK "http://www.medfash.org.uk"www.medfash.org.uk Accessed 05.08.10. Vaginal Candidiasis Nurbhai M, Grimshaw J, Watson M, Bond CM, Mollison JA, Ludbrook A. Oral versus intravaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews 2007, Issue 4. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002845/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002845/frame.html Accessed 05.08.10. No statistically significant differences were observed in clinical cure rates of antifungals administered by the oral or the intravaginal route. At short-term follow-up, 74% cure was achieved with oral treatment and 73% cure with intra-vaginal treatment (OR 0.94, 95% CI 0.75 to 1.17). UKTIS. Use of fluconazole in pregnancy. The UK Teratology Information Service. 2008. (Tel: 0844 892 0909, HYPERLINK "http://www.toxbase.org"www.toxbase.org) Accessed 05.08.10. Data on the outcomes of over 1,700 pregnancies exposed to low-dose fluconazole (150mg stat) show no increased incidence of spontaneous abortions, malformations, or patterns of defects. However, there may be an increased risk of malformations associated with high-dose chronic therapy (>400mg/day). First-line treatment of candidal infection in pregnancy should be with an imidazole. However, fluconazole (150mg stat) may be a suitable second-line treatment if clotrimazole is ineffective. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews 2001, Issue 4. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000225/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000225/frame.html Accessed 05.08.10. This Cochrane review found that topical imidazole appears more effective than nystatin at treating vaginal candidiasis in pregnancy. In addition, treatment for only four days was less effective than treatment for seven days (OR 11.7, 95% CI 4.21 to 29.15). Schaefer C, Peters P, Miller RK. Drugs during pregnancy and lactation: treatment options and risk assessment. Academic Press 2007. Clotrimazole and miconazole are the topical antifungals of choice during pregnancy. There is no evidence of an increased risk of spontaneous abortions or malformations with use of clotrimazole or miconazole during pregnancy. The Health Protection Agency and the Association of Medical Microbiologists recommend 6 nights treatment with clotrimazole 100mg pessaries during pregnancy because this is the quantity in one original pack of clotrimazole 100mg pessaries. Bacterial vaginosis Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical implications for therapy. Clin Infect Dis 1999;28(suppl 1):S57-S65. Pooled data from five RCTs found no significant difference between cucmulative cure rates 5-10days after finishing treatment for metronidazole 400mg BD for 7 days (86%), intravaginal metronidazole 5g BD for 5 days (81%) or intravaginal clindamycin 5g at night for 7 days (85%). McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database of Systematic Reviews 2007, Issue 1. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000262/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000262/frame.html Accessed 05.08.10. Pooled data from 10 RCTs indicated that both oral and intravaginal antibiotics are effective at eradicating bacterial vaginosis in pregnant women. Oral antibiotics compared with placebo (seven trials, n = 3244) OR0.15, 95% CI 0.13 to 0.17. Intravaginal antibiotics compared with placebo (three trials, n = 1113) OR0.27, 95% CI 0.21 to 0.35. Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical implications for therapy. Clin Infect Dis 1995;20(Suppl 1):S72-S79. The 2g single dose is less effective than the 7-day course at 4-week follow up. When data from studies that only directly compared the two dose regimens were pooled, the cumulative cure rates 3-4weeks after completion of treatment were 62% for the single-dose regimen and 82% for the 7-day regimen (p < 0.005). UKTIS. Use of metronidazole in pregnancy. The UK Teratology Information Service. 2008. (Tel: 0844 892 0909, HYPERLINK "http://www.toxbase.org"www.toxbase.org) Accesses 05.08.10. The available data (almost exclusively based on oral treatment) does not indicate an increased risk of adverse fetal effects associated with metronidazole use during pregnancy. The manufacturer advises avoidance of the 2g stat regimen during pregnancy. BASHH. National guideline for the management of bacterial vaginosis. British Association for Sexual Health and HIV. 2006. HYPERLINK "http://www.bashh.org/documents/62/62.pdf"http://www.bashh.org/documents/62/62.pdf Accessed 05.08.10. No reduction in relapse rate was reported from two studies in which male partners of women with BV were treated with metronidazole, tinidazole, or clindamycin. Trichomoniasis BASHH. UK National Guideline on the Management of Trichomonas vaginalis. British Association for Sexual Health and HIV. 2007. HYPERLINK "http://www.bashh.org/documents/87/87.pdf"http://www.bashh.org/documents/87/87.pdf Accessed 05.08.10. Treatment of partners: the recommendation to also treat partners for trichomoniasis, irrespective of the results of investigations is based on two prospective RCTs. UKTIS. Use of metronidazole in pregnancy. The UK Teratology Information Service. 2008. (Tel: 0844 892 0909, HYPERLINK "http://www.toxbase.org"www.toxbase.org) Accessed 05.08.10. The available data (almost exclusively based on oral treatment) does not indicate an increased risk of adverse fetal effects associated with metronidazole use during pregnancy. The manufacturer advises avoidance of the 2g stat regimen during pregnancy. Du Bouchet I, Spence MR, Rein MF, Danzig MR, McCormack WM. Multicentre comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulphanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997;24:156-160. In this randomized, open-label trial (n = 168) clotrimazole vaginal tablets were not found to effectively eradicate trichomoniasis. However, a reduction in symptoms was reported. The numbers of patients who had positive cultures after treatment were 40/45 (88.9%) in the clotrimazole group, 35/43 (81.4%) in the AVC suppository group, and 9/45 (20%) in the metronidazole group (P < 0.001). Forna F, Gulmezoglu MU. Interventions for treating trichomoniasis in women. Cochrane Database of Systematic Reviews. 2003. Issue 2. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000218/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000218/frame.html Accessed 05.08.10. Pooled data from two RCTs (n = 294) found an 88% cure rate in women treated with metronidazole 2g stat compared with a 92% cure rate in women treated with metronidazole for 5 or 7days. Relative risk of no parasitological cure 1.12, 95% CI 0.58 to 2.16. Pelvic Inflammatory Disease RCOG. Management of Acute Pelvic Inflammatory Disease. Green Top Guideline No.32. Royal College of Obstetricians & Gynaecologists. 2008. HYPERLINK "http://www.rcog.org.uk/womens-health/clinical-guidance/acute-pelvic-inflammatory-disease-pid"http://www.rcog.org.uk/womens-health/clinical-guidance/acute-pelvic-inflammatory-disease-pid Accessed 05.08.10. Recommended regimens: the recommended regimens are broad spectrum to cover N. gonorrhoea, C. trachomatis, and anaerobes. For outpatient management, either ofloxacin plus metronidazole for 14 days, or a stat dose of IM cefuroxime plus metronidazole and doxycycline for 14 days are recommended. Broad-spectrum treatment is warranted in PID because of the consequences of untreated infection (ectopic pregnancy, infertility, pelvic pain). Cefoxitin has a better evidence base for the treatment of PID than ceftriaxone, but it is not readily available in the UK. Ceftriaxone is therefore recommended. Although the combination of doxycycline and metronidazole (without IM ceftriaxone) has previously been used in the UK to treat PID, there are no clinical trials that adequately assess its effectiveness and its use is not recommended. BASH. UK National Guideline for the management of PID. British Association for Sexual Health and HIV. 2005. HYPERLINK "http://www.bashh.org/documents/118/118.pdf"http://www.bashh.org/documents/118/118.pdf Accessed 05.08.10. Recommended regimens: the recommended regimens for outpatient management are either ofloxacin plus metronidazole for 14 days, or a stat dose of IM cefuroxime plus metronidazole and doxycycline for 14 days. Ofloxacin should be avoided in women who are at high risk of gonococcal PID, because of increasing quinolone resistance in the UK. Treatment of partners: partners should be screened for gonorrhoea and chlamydia. GRASP Steering Group. GRASP 2008 report: trends in antimicrobial resistant gonorrhoea. Health Protection Agency. 2009. HYPERLINK "http://www.hpa.org.uk/servlet/Satellite?c=Page&childpagename=HPAweb%2FPage%2FHPAwebAutoListName&cid=1153999752025&p=1153999752025&pagename=HPAwebWrapper&searchmode=simple&searchterm=grasp"http://www.hpa.org.uk/servlet/Satellite?c=Page&childpagename=HPAweb%2FPage%2FHPAwebAutoListName&cid=1153999752025&p=1153999752025&pagename=HPAwebWrapper&searchmode=simple&searchterm=grasp Accessed 05.08.10. Ciprofloxacin resistance is now endemic in England and Wales, accounting for 28% of all gonorrhoea isolates tested in 2008. Meads C, Knight T, Hyde C and Wilson J. The clinical effectiveness and cost-effectiveness of antibiotic regimens for pelvic inflammatory disease. West Midlands Health Technology Assessment group. 2004. HYPERLINK "http://www.rep.bham.ac.uk"www.rep.bham.ac.uk Accessed 05.08.10. This systematic review identified 34 trials of antibiotic treatment for PID. Most studies were small, open-label, and of poor methodological study. One small trial was found that compared oral ofloxacin plus metronidazole with clindamycin plus gentamicin. The cure rate was 15/15 for ofloxacin plus metronidazole plus 17/18 for clindamycin plus gentamicin. The systematic review found one trial of ceftriaxone plus doxyxcyline was found, two trials of cefoxitin plus probenecid and doxycycline, and three trials of cefoxitin plus doxycycline compared to other antibiotics. Meta-analysis of these six studies found no difference in cure rates between IM cephalosporin plus doxycycline and the comparator antibiotics. The Health Protection Agency and the Association of Medical Microbiologists recommend that, for practical issues of administration in primary care, a stat dose of oral cefixime 400mg can be substituted for IM ceftriaxone. A stat dose of oral cefixime is one of the treatment options recommended by the WHO (HYPERLINK "http://www.who.int"www.who.int , the CDC (HYPERLINK "http://www.cdc.gov"www.cdc.gov), and CKS (HYPERLINK "http://www.cks.nhs.uk"www.cks.nhs.uk) for the treatment of gonorrhoea. All accessed 05.08.10. Acute prostatitis BASHH. UK National Guidelines for the Management of Prostatitis. British Association for Sexual Health and HIV. 2008. MSU for all men: acute prostatitis is a severe illness. It is important that an MSU is sent for culture and sensitivities to ensure that an appropriate antibiotic is used. Treatment regimens: there are no randomized controlled trials of quinolones or trimethoprim for the treatment of prostatitis. Expert opinion is that, for men with acute prostatitis who are suitable for oral antibiotic treatment, ciprofloxacin 500mg BD for 28 days or ofloxacin 200mg BD for 28 days will provide sufficient levels within the prostate gland. Expert opinion is that trimethoprim 200mg BD for 28 days is a suitable alternative for men who are intolerant or allergic to quinolones. Duration of treatment: the optimum duration of treatment is unknown. Expert opinion is that a 4-week course of antibiotics is required to reduce the risk of developing chronic bacterial prostatitis. Micromedex. Drugdex drug evaluations. Thompson Healthcare. 2009. Trimethoprim reaches good concentrations in prostatic tissue (peak prostate concentration was reported to be 2.3 mcg/g 280minutes after an oral dose compared with serum levels of 2.2mcg/mL at 125minutes after an oral dose). Ciprofloxacin reaches high concentrations in prostatic fluid, often exceeding serum levels (at 2 to 4hours following oral administration, prostatic fluid levels ranged from 0.02 to 5.5 mcg/mL compared with serum levels of 1 to 2.5mcg/mL. Ofloxacin also reaches high concentrations in prostatic fluid (at 1 to 4 hours following oral administration prostatic guide levels ranged from 3.22 to 4.25mcg/g. SKIN INFECTIONS Cellulitis CREST Guidelines on the management of cellulitis in adults. Clinical Resource Efficiency Support Team. 2005. HYPERLINK "http://www.crestni.org.uk"www.crestni.org.uk Accessed 05.08.10. Expert consensus is that people who have no signs of systemic toxicity and no uncontrolled co-morbidities can usually be managed on an outpatient basis with oral antibiotics. Flucloxacillin 500mg QDS (or clarithromycin 500mg BD for those with penicillin allergy) are suitable oral antibiotics because they cover staphylococci and streptococci, the most commonly implicated pathogens. Clindamycin 300mg QDS is also recommended as a further alternative for people with penicillin allergy. Most cases of uncomplicated cellulitis can be treated successfully with 1-2weeks of treatment. Jones, G.R. Principles and practice of antibiotic therapy for cellulitis. CPD Journal Acute Medicine. 2002;1(2):44-49. Oral agents will be as effective as intravenous agents for cellulitis if they can maintain the free antibiotic level above the MIC of the pathogen for more than 40% of the dose interval. Flucloxacillin 500mg, clarithromycin 500mg and clindamycin 300mg are suitable oral doses. Morris AD. Cellulitis and erysipelas. Clinical Evidence. 2007. London. BMJ Publishing Group. This systematic review found no RCTs of antibiotics compared with placebo of sufficient quality for inclusion. Although 11 RCTs were identified that compared antibiotic treatments, these studies were small and only powered to demonstrate equivalence, not superiority, between antibiotics. Two RCTs using intravenous flucloxacillin were found, but none using oral flucloxacillin. Oral azithromycin was compared with erythromycin, flucloxacillin, and cefalexin in three RCTs. Oral co-amoxiclav was compared with fleroxacin (available in Germany) in one sub-group analysis. Fischer RG and Benjamin DK Jr. Facial cellulitis in childhood: a changing spectrum. Southern Medical Journal. 2002;95: 672-674. Buccal cellulitis is commonly due to Haemophilus influenzae infection, although rates are decreasing following the Hib immunization programme. The Health Protection Agency and the Association of Medical Microbiologists recommends co-amoxiclav for empirical treatment of facial cellulitis because it is broader spectrum than flucloxacillin and also covers H. influenzae. Impetigo The Health Protection Agency and the Association of Medical Microbiologists recommend that topical antibiotics are reserved only for treatment of very localised lesions because fusidic acid is an antibiotic that is also used systemically. There are concerns that widespread use of topical fusidic acid will lead to increased resistance, rendering systemic fusidic acid (used for severe staphylococcal infections such as osteomyelitis or systemic MRSA) ineffective. If a topical antibiotic is used, a short course (such as 5 days) reduces exposure and the risk of resistance. Since few agents are effective against MRSA, mupirocin should be reserved for such cases. The Health Protection Agency and the Association of Medical Microbiologists recommend flucloxacillin for first-line treatment of impetigo because it is a narrow-spectrum antibiotic that is effective against Gram-positive organisms, including beta-lactamase producing Staphylococcus aureus, and it demonstrates suitable pharmacokinetics, with good diffusion into skin and soft tissues. Clarithromycin is recommended for people with penicillin allergy because it is also active against most staphylococcal and streptococcal species. Koning S, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler C, van der Wouden JC. Interventions for impetigo. Cochrane Database of Systematic Reviews. 2003. Issue 2. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003261/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003261/frame.html Accessed 05.08.10. Many RCTs identified by this Cochrane review were of poor methodological quality. Pooled data from four RCTs found no difference in cure rates between topical mupirocin and topical fusidic acid (OR 1.22, 95% CI 0.69 to 2.16). Most RCTs that compared topical compared with oral antibiotics used mupirocin. However, mupirocin is reserved for MRSA and should not be used first-line for impetigo. Topical fusidic acid was significantly better than oral erythromycin in one study, but no difference was seen between fusidic acid and oral cefuroxime in a different arm of the same study. Topical bacitracin was significantly worse than oral cefalexin in one small study, but there was no difference between bacitracin and erythromycin or penicillin in two other studies. The results of one non-blinded RCT suggested that topical fusidic acid was more effective than topical hydrogen peroxide, but this did not quite reach statistical significance. The Health Protection Agency and the Association of Medical Microbiologists recommend that topical retapamulin or Polymixin are reserved for use in areas where there are rising rates of resistance to fusidic acid. Polymixin (contains bacitracin) has less robust RCT evidence than fusidic acid. Although topical retapamulin has been demonstrated to be non-inferior to topical fusidic acid for the treatment of impetigo in one randomized controlled trial, it is more expensive and there are less safety data available (it is a black triangle drug). Denton M, OConnell B, Bernard P, Jarlier V, Williams Z, Santerre Henriksen A. The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK, and Ireland. J Antimicrob Chemother 2008;61:586-588. Of S. aureus isolates from the UK, only 75.6% were susceptible to fusidic acid. A diagnosis of impetigo was associated with reduced fusidic acid susceptibility. Leg ulcer OMeara S, Al-Khurdi D, Ovington LG. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database of Systematic Reviews. 2010. Issue 1. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003557/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003557/frame.html Accessed 05.08.10. Most studies identified by this Cochrane review were of poor methodological quality. Use of antibiotics did not promote healing compared to placebo in four trials of people with leg ulcers without visible signs of infection. RCN The nursing management of patients with venous leg ulcers. Recommendations. Royal College of Nursing. 2006 HYPERLINK "http://www.rcn.org.uk/development/practice/clinicalguidelines/venous_leg_ulcers"http://www.rcn.org.uk/development/practice/clinicalguidelines/venous_leg_ulcers Accessed 05.08.10. Expert consensus is that swabbing (and so by definition antibiotic therapy) is unnecessary unless there is evidence of clinical infection such as inflammation, redness, or cellulitis; increased pain; purulent exudates; rapid deterioration of the ulcer; pyrexia; or foul odour. Health Protection Agency. Investigation of skin and superficial wound swabs. National Standard Method BSOP 11 Issue 3. http://www.hpa-standardmethods.org.uk/pdf_sops.asp. Accessed 05.08.10. Wound swabs should be taken from clinically infected ulcers before starting antibiotics. Taking swabs after starting antibiotics may affect the swab results. Sensitivity results can help guide the appropriate use of further antibiotics if the infection is not clinically improving on empirical treatment. Eczema Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database of Systematic Reviews. 2008. Issue 3. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003871/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003871/frame.html Accessed 05.08.10. Most RCTs identified by this Cochrane review were of small, of poor quality and heterogeneous. Oral antibiotics were not associated with benefit in two small trials of people with eczema without visible signs of infection (n = 66). Adding antibiotics to topical steroids reduced the numbers of S aureus in 4 trials (n = 302) but not in a further 9 trials (n = 677). National Collaborating Centre for Women's and Children's Health (2007) Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years (full NICE guideline). National Institute for Health and Clinical Excellence. HYPERLINK "http://www.nice.org.uk"www.nice.org.uk Accessed 05.08.10. In view of the lack of robust trial evidence, the GDGs view was that flucloxacillin should normally be the first-line treatment for active S aureus and streptococcal infection because it is active against both. Erythromycin or clarithromycin should be used when there is local resistance to flucloxacillin and in children with a penicillin allergy because it is as effective as cephalosporins and less costly. It is the view of the GDG that topical antibiotics, including those combined with topical corticosteroids, should be used to treat localised overt infection only, and for no longer than two weeks. Bites (human or animal) Health Protection Agency. Guidelines for the management of human bite injuries. Guidance for healthcare professionals on dealing with injuries where teeth break the skin. Health Protection Agency North West 2007. HYPERLINK "http://www.hpa.org.uk"www.hpa.org.uk Accessed 05.08.10. Gives guidance on initial wound assessment, wound care, and assessment of risk of tetanus and blood-borne viruses. CKS. Bites human and animal. Clinical Knowledge Summaries. 2007. HYPERLINK "http://www.cks.nhs.uk/bites_human_and_animal"http://www.cks.nhs.uk/bites_human_and_animal Accessed 05.08.10. Expert opinion is that prophylaxis for animal bites is not required unless bite to the hand, foot, and face; puncture wounds; all cat bites; wounds requiring surgical debridement; wounds involving joints, tendons, ligaments, or suspected fractures; wounds that have undergone primary closure; wounds to people who are at risk of serious wound infection (e.g. those who are diabetic, cirrhotic, asplenic, immunosuppressed, people with a prosthetic valve or a prosthetic joint). Medeiros I, Saconat H. Antibiotic prophylaxis for mammalian bites. Cochrane Database of Systematic Reviews, 2001 Issue 2 HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001738/pdf_fs.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001738/pdf_fs.html Accessed 05.08.10. Human bites: only one trial (n = 48) analyzed human bites, and the infection rate in the antibiotic group (0%) was significantly lower than the infection rate in the control group (47%); OR 0.02, 95% CI 0.00 to 0.33. Dog bites: pooled results from six RCTs (n = 463) found that the infection rate was not reduced after the use of prophylactic antibiotics (4%) compared with the control group (5.5%); OR 0.74, 95% CI 0.30 to 1.8). Cat bites: one small study (n = 11) reported a lower infection rate in the treatment group who received prophylactic antibiotics (0%) compared with the control group (67%). First-line antibiotic. The Health Protection Agency and the Association of Medical Microbiologists recommend co-amoxiclav for treatment or prophylaxis of human or animal bites because it is a broad-spectrum antibiotic that is effective against the most commonly isolated organisms from human bites (alpha- and beta-haemolytic streptococci, S. aureus, S. epidermis, corynebacteria, and E. corrodens) and animal bites ( such as Pasteurella [57% of dog bites and 75% of cat bites], streptococci, staphylococci, moraxella, neisseria, and anaerobes). First-line antibiotics in penicillin allergy for animal bites. The Health Protection Agency and the Association of Medical Microbiologists recommend metronidazole PLUS doxycycline for adults with penicillin allergy who require treatment or prophylaxis of an animal bite. Doxycycline has activity against pasturella species (the most common pathogen), staphylococci and streptococci. Metronidazole is included to cover anaerobes. Macrolides are not recommended for animal bites because they do not adequately cover pasturella. Seek specialist advice for children under the age of 12 years (doxycycline contraindicated). First-line antibiotics in penicillin allergy for human bites. The Health Protection Agency and the Association of Medical Microbiologists recommend metronidazole plus either doxycycline or clarithromycin for adults and children with penicillin allergy who require treatment or prophylaxis of a human bite. Both doxycycline and clarithromycin are active against staphylococci and streptococci (the most common pathogens). Metronidazole is included to cover anaerobes. Doxycycline, but not clarithromycin is active against Eikenella species, which is also a common pathogen isolated from human mouths. The Health Protection Agency and the Association of Medical Microbiologists recommend that people with penicillin allergy are reassessed at 24 and 48 hours after starting a course of antibiotic treatment because the recommended regimen covers the majority, but not all, of the likely pathogens from an animal or human bite. Scabies HPA. The management of scabies in the community. Health Protection Agency North West. 2005. HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947308867"http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947308867 Accessed 05.08.10. Treatment of all contacts: expert opinion is that the index case and all members of the household and sexual contacts should be treated within 24 hours of one another, even in the absence of symptoms, to reduce the risk of re-infestation. Two treatments, 7 days apart: expert opinion is that two treatment sessions are needed to treat scabies effectively. ABPI Medicines Compendium. Lyclear Dermal Cream. Datapharm Communications Ltd. 2008. HYPERLINK "http://www.medicines.org.uk/EMC/medicine/10439/SPC/Lyclear+Dermal+Cream/"http://www.medicines.org.uk/EMC/medicine/10439/SPC/Lyclear+Dermal+Cream/ Accessed 05.08.10. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database of Systematic Reviews. 2007. Issue 3 HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000320/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000320/frame.html Accessed 05.08.10. Permethrin: topical permethrin appeared more effective than oral ivermectin, topical crotamiton, and topical lindane. The greatest body of evidence is for topical permethrin compared with lindane (n = 735, five RCTs: RR 0.32, 95% CI 0.13 to 0.75). Malathion: no RCTs were found that evaluated the efficacy of malathion for the treatment of scabies. Malathion has only been evaluated in uncontrolled studies. Dermatophyte infection skin ABPI Medicines Compendium. Lamisil AT 1% cream. 2009. Datapharm Communications Ltd. HYPERLINK "http://www.medicines.org.uk/EMC/searchresults.aspx?term=Lamisil&searchtype=QuickSearch"http://www.medicines.org.uk/EMC/searchresults.aspx?term=Lamisil&searchtype=QuickSearch Accessed 05.08.10. Terbinafine cream is not licensed for the treatment of Candida infection. HPA and the Association of Medical Microbiologists. Fungal skin & nail infections: diagnosis & laboratory investigation. Quick reference guide for primary care for consultation and local adaptation. 2009 HYPERLINK "http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726"http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1240294785726 Accessed 05.08.10. The recommendation to send skin scrapings to confirm the diagnosis before starting oral treatment is based on expert opinion and clinical experience. Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, Tyrrell W, Russel I. Oral treatments for fungal infection of the foot. Cochrane Database of Systematic Reviews. 2002. Issue 2 HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003584/frame.html"www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003584/frame.html Accessed 05.08.10. Terbinafine: one RCT (n=41) found that oral terbinafine, 250mg a day for 6weeks, was more effective than placebo for treating athletes foot. At 8weeks, 65%of the terbinafine group were cured, compared with none of the placebo group (relative risk [RR] of cure with terbinafine25, 95%CI 2 to 384). Itraconazole: one RCT (n=77)found that oral itraconazole, 400mg a day for 1week, was more effective than placebo. At 9weeks, 55%of the itraconazole group were cured compared with 8%of the placebo group (RR of cure with itraconazole7, 95%CI 2 to 20). Terbinafine vs itraconazole: Pooled data from three RCTs (n=222) found no difference in cure rates between oral terbinafine 250mg a day for 2weeks (76% cured), and itraconazole 100mg a day for 4weeks (71% cured); risk difference 5%, 95%CI 6 to +27 Crawford F and Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database of Systematic Reviews 2007. Issue 3. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001434/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001434/frame.html Accessed 05.08.10. Terbinafine and imidazoles: pooled data (8 RCTs; n = 962) found little difference between allylamines (e.g. terbinafine for 1-2 weeks) and imidazoles (for 4-6 weeks) at 2 weeks after baseline. But at 6weeks after baseline, there was a relative reduction in treatment failure with allylamines compared with imidazoles (RR 0.63, 95% CI 0.42 to 0.94). Treatment with an imidazole for 4-6weeks reduced the risk of treatment failure by 60% compared with placebo at 6-weeks (Risk Ratio 0.40, 95% CI 0.35 to 0.46; n = 1235). Treatment with an allylamine for 1-4weeks reduced the risk of treatment failure by 67% compared with placebo at 6weeks (Risk Ratio 0.33, 95% CI 0.24 to 0.44; n = 1116) Undecanoates: this systematic review identified two RCTs of undecanoates compared with placebo (n = 283). There was a 71% relative reduction in the risk of treatment failure at 6 weeks with 4 weeks treatment with undecanoates compared with placebo (Risk Ratio 0.29, 95% CI 0.12 to 0.70). Dermatophyte infection - nail Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Brit J Dermatol 2003;148:402410. Confirmation of diagnosis: only 50% of cases of nail dystrophy are fungal, and it is not easy to identify these clinically. The length of treatment needed (6-12months) is too long for a trial of therapy. Chung CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007;120:791-798. Pooled data from about 20,000 participants found that both continuous and pulse therapy with terbinafine, itraconazole, or fluconazole were well tolerated. The risk of having asymptomatic raised liver transaminases was less than 2% for all treatments. The risk of having raised liver transaminases that required treatment discontinuation with continuous treatment ranged from 0.11% (itraconazole 100mg/day) to 1.22% (fluconazole 50mg/day). The risk with pulse treatment ranged from 0.39% (itraconazole 400mg/day) to 0.85% (fluconazole 300-450mg/week). CKS. Fungal nail infection (onychomycosis) Clinical Knowledge Summaries 2009. HYPERLINK "http://www.cks.nhs.uk/fungal_nail_infection"http://www.cks.nhs.uk/fungal_nail_infection Accessed 05.08.10. Non-dermatophyte nail infection: there is limited evidence that both terbinafine and itraconazole are effective. Candidal nail infection: there is evidence that itraconazole is effective for candidal nail infection. There is weak evidence that terbinafine is also effective. Specialist advice for children: this is because fungal nail infection is rare in children, and the preferred treatments are not licensed for use in children. The HPA Mycology Reference Laboratory recommends itraconazole for non-dermatophyte infections because although some of the infecting organisms are not particularly susceptible to this agent in vitro, it does reach high concentrations in nail tissue. It can be given as a pulse therapy regimen rather than continuous treatment. Reinel, D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology. 1992;184(Suppl 1): 21-24. One RCT (n = 456) without a placebo control found that 46% of those randomized to amorolfine applied once a week for 6 months achieved mycological cure of dermatophyte infection compared with 54% of those who applied topical amorolfine twice a week. Crawford F & Ferrari J. Fungal toenail infections. In Clinical Evidence Concise. London. BMJ Publishing Group. 2006; 15: 561-63 Terbinafine vs itraconazole: one systematic review pooled data from two randomized controlled trials (n = 501). At 1-year follow-up, the cure rate following 12 weeks of treatment was greater for people with dermatophyte onychomycosis treated with oral terbinafine 250mg once a day (69%) compared with oral itraconazole 200mg daily (48%). Absolute risk reduction 21%, 95% CI 13% to 29%. Pulsed vs continuous itraconazole: four small RCTs were identified that found no statistically significant difference between continuous and pulsed itraconazole for dermatophyte onychomycosis. Chickenpox/shingles DH. Immunisation against infectious diseases The Green book. Chapter 34. Varicella. Department of Health 2006. HYPERLINK "http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_4097254"http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_4097254 Accessed 05.08.10. Pregnant women are at greater risk of varicella pneumonia, and there is a risk to the fetus of congenital varicella syndrome if exposure occurs during the first 20weeks of pregnancy, and severe disease in the neonate if varicella is contracted a week before delivery. Neonates and immunocompromised individuals are at greater risk of disseminated or haemorrhagic varicella. Urgent specialist assessment is needed for all neonates, pregnant women, or immunocompromised individuals with varicella to assess the need for varicella immunoglobulin and antiviral treatment. Klassen TP and Hartling L. Aciclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database of Systematic Reviews. 2005. Issue 4. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002980/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002980/frame.html Accessed 05.08.10. Pooled data from three studies who enrolled participants within 24hours of rash onset found that aciclovir was associated with a small reduction in the number of days with fever (-1.1, 95% CI -1.3 to -0.9) and in reducing the maximum number of lesions. Results were less supportive of a reduction in the number of days of itching. There were no differences in complication rates between those treated with aciclovir or placebo. Swingler G. Chicken Pox. In: Clinical Evidence Concise. London. BMJ Publishing Group. 2006;15:267-79. One systematic review was identified that found one RCT (n = 148 adults) which compared early versus late administration of acyclovir 800mg five times a day compared with placebo. It found that aciclovir given within 24 hours of the onset of rash significantly reduced the maximum number of lesions (P < 0.01) and the time to full crusting of lesions (P = 0.001) compared with placebo. It found no significant difference in time to full crusting of lesions if aciclovir was given 2472 hours after the rash (P > 0.2). The Health Protection Agency recommends that treatment with aciclovir should be considered (if it can be started within 24 hours of the rash) in those with severe chickenpox (including secondary cases) and in those at increased risk of complications (adults and adolescents aged 14 years and over, smokers, people on steroids). Hope-Simpson RE. Postherpetic neuralgia. Brit J Gen Pract 1975;25:571-75. Study showing that incidence of post-herpetic neuralgia in a general practice population increases with age and is much more common in over 60 year olds. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valciclovir on prolonged pain. J Infect Dis 1998;127(Suppl 1);S81-S84. A study of two databases (n = 1076) found no difference in time to complete resolution of zoster-associated pain whether treatment was started within 48 hours or between 48 and 72 hours of the onset of cutaneous herpes zoster. Acyclovir HR 2.2, 95% CI1.03 to 4.71. Valaciclovir HR 1.40, 95% CI 1.04 to 1.87. Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials. Clin Inf Dis 1996;22:341-7. Meta-analysis of four RCTs (n = 691) found greatest benefit in those aged over 50years, in whom pain resolved twice as fast with acyclovir compared with placebo. Oral acyclovir also reduced the incidence of post herpetic neuralgia pain. International Herpes Management Forum. Improving the management of varicella, herpes zoster, and zoster-associated pain. 2002. HYPERLINK "http://www.ihmf.org"www.ihmf.org Accessed 05.08.10. Antiviral treatment is recommended for ophthalmic shingles to prevent the potentially sight-threatening complications than can occur following herpes zoster involving the trigeminal nerve. Aciclovir, famciclovir, and valaciclovir have all been shown to reduce the complications of ophthalmic shingles in RCTs. Dworkin RH, Johnson JW, Bruer J et al. Recommendations for the management of Herpes Zoster. Clin Infect Dis 2007;44(Suppl 1):S1-S26. Expert opinion is that treatment of shingles should be considered for non-truncal involvement, people with moderate or severe pain, or those with moderate or severe rash. Evidence from RCTs supports treatment for all those over 50years to prevent the incidence of post-herpetic neuralgia. Beutner KR, Friedman DJ, Forszpaniak C, Anderson PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother1995;39:1546-1553. This randomized double-blind controlled trial (n = 1141) in people aged 50years and over within 72 hours of onset of herpes zoster found that valaciclovir 1g three times a day for 7 or 14 days reduced the time to resolution of pain compared with acyclovir 800mg five times a day for 7 days. Median time to cessation of pain was 38 days for valaciclovir for 7 days compared with 51 days for acyclovir (p = 0.001), and was 44 days for valaciclovir for 14 days. Shen MC, Lin HH, Lee SS, Chen YS, Chiang PC, Liu YC. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004;37:75-81. In this small study (n = 55), famciclovir and acyclovir were comparable in healing of lesions and cessation of acute-phase pain. Cold sores Sprurance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for the treatment of herpes labialis: results of two randomized, double-blind, vehicle-controlled, multicentre clinical trials. Antimicrob Agents Chemother 2002;46:2238-2243. Aciclovir 5% cream reduced the mean duration and pain of an episode by about half a day. Sprurance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, double-blind, multicentre, placebo-controlled trial. JAMA 1997;277:1374-1379. Penciclovir 1% cream reduced the mean duration of cold sores by 0.7days. Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Sprurance SL. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002;133:303-309. Penciclovir reduced the mean duration of cold sores by 1 day. Arduino PG and Porter SR. Oral and perioral herpes simplex type 1 (HSV-I) infection: review of its management. Oral Dis 2006;12(3):254-70 Prophylaxis with oral antivirals may be of use for those with frequent, severe episodes, predictable triggers e.g. sunlight or for immunocompromised individuals (i.e. at higher risk of complications). Seek specialist advice if long-term prophylaxis is being considered. EYE INFECTIONS Conjunctivitis Sheikh A and Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database of Systematic Reviews 2006. Issue 2. HYPERLINK "http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001211/frame.html"http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001211/frame.html Accessed 05.08.10. Meta-analysis of five RCTs (n = 1034) found that antibiotics (one trial each of ocular polymixin plus bacitracin, ciprofloxacin, norfloxacin, fusidic acid, and chloramphenicol) reduce early clinical remission rates (Risk Ratio on days 2 to 5 1.24, 95% CI 1.05 to 1.45). Clinical remission rates compared with placebo are lower if remission is assessed later (Risk Ratio on days 6 to 10 1.11, 95% CI 1.02 to 1.21). However, most cases resolve spontaneously, with clinical remission being achieved in 65% (95% CI 59 to 70%) by days 2 to 5 in those receiving placebo. ~  E c g ~ Z ͼۯۖcQ?#h |hi1b7CJOJQJ^JaJ#h |hi1bCJH*OJQJ^JaJ9h |hi1bB* CJOJQJ^JaJmH nH phPsH tH *h6kdCJOJQJ^JaJmH nH sH tH 0h |hi1bCJOJQJ^JaJmH nH sH tH h |hi1bOJQJ^J h |hlZ=CJOJQJ^JaJhi1bCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ&h |hi1b5CJOJQJ\^JaJS E  tu  !$IfgdlZ= & F !$If & F$If  & F$If $IfgdlZ=  & F$If$IfZ o p[oqstuvͿۀۀraTG:h |hi1bOJQJ^Jh |hlZ=OJQJ^JhlZ=hi1bOJQJ^J h |h |CJOJQJ^JaJh |CJOJQJ^JaJh6kdCJOJQJ^JaJ h |h|wCJOJQJ^JaJ#h|wh|w>*CJOJQJ^JaJh|wCJOJQJ^JaJh CJOJQJ^JaJhi1bCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ&h |hi1b6CJOJQJ]^JaJuv{}|ztkkkk $$Ifa$$If W$^ukd$$Ifl4L0**     0*44 laf4p v{|}GK\мНkVA3h |CJOJQJ^JaJ)h |hi1bB* CJOJQJ^JaJph)h |hi1bB*CJOJQJ^JaJph2h |hi1b5B*CJH*OJQJ\^JaJph/h |hi1b5B*CJOJQJ\^JaJph#h |hi1bCJH*OJQJ^JaJh |hi1bOJQJ^J&h |hi1b5CJOJQJ\^JaJ h |hi1bCJOJQJ^JaJhlZ= hlZ=5\&h |hlZ=5CJOJQJ\^JaJkd$$IflrLU6$0*j 2&&&&&0*44 lap2&&&&&ef{{{{{$Ifwkd$$Ifl4L0**  &0*44 laf4p &$If\t?AB`abdeoqǵǣǵܕǃq[qF9h |hi1bOJQJ^J(h|wh|wCJOJQJ^JaJmH sH +h|wh|w5CJOJQJ^JaJmH sH "h|wCJOJQJ^JaJmH sH "hi1bCJOJQJ^JaJmH sH hCJOJQJ^JaJ"h_.CJOJQJ^JaJmH sH "hKLiCJOJQJ^JaJmH sH (h |hi1bCJOJQJ^JaJmH sH  h |hi1bCJOJQJ^JaJ#h |hi1b5CJOJQJ^JaJGi^VVKKVV <$IfgdX<$If <$IfgdXkd$$Ifl40L0*E% 0*44 laf4p%Fﺨq\N@Nh#CJOJQJ^JaJhCJOJQJ^JaJ)jyhXhw^CJOJQJU^JaJ hXhXCJOJQJ^JaJ#h |hXCJOJQJ\^JaJ&h |hX5CJOJQJ\^JaJ#hWr/hWr/6CJOJQJ^JaJhXCJOJQJ^JaJ#hQY5CJH*OJQJ\^JaJ)h |hQY5CJH*OJQJ\^JaJ h |hXCJOJQJ^JaJhryss$If~kd$$Ifl40L0*E%0*44 laf4yt&u<$If g01Sp丧p^J8J^#h |hi1bCJOJQJ\^JaJ&h |hi1b5CJOJQJ\^JaJ#h |hi1b5CJOJQJ^JaJ&h |hi1b6CJOJQJ]^JaJ&h |hi1b6CJOJQJ]^JaJhQYCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJh |hXOJQJ^J hhCJOJQJ^JaJh#CJOJQJ^JaJhCJOJQJ^JaJh CJOJQJ^JaJpqrz 6ѵѵ߆udRd>&hlZ=hi1b6CJOJQJ]^JaJ#hlZ=hi1bCJH*OJQJ^JaJ hlZ=hi1bCJOJQJ^JaJ hKd-hi1bCJOJQJ^JaJhQYCJH*OJQJ^JaJ#hX/hX/CJH*OJQJ^JaJhX/CJOJQJ^JaJhHKCJOJQJ^JaJhfCJOJQJ^JaJhhCJOJQJ^JaJ h |hi1bCJOJQJ^JaJhKd-CJH*OJQJ^JaJz 8VXp  $<$Ifa$$If <$Ifgdy<$If & F! i$If^`igdKd- & F! i$If^`i & F1 r<$If^`rgdf6VXpr,.CEXZ]^opɵtbtbtbtbtbtQ?#h |hi1bCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ"hKLiCJOJQJ^JaJmH sH (hlZ=hlZ=CJOJQJ^JaJmH sH )hQY56CJH*OJQJ\]^JaJ,hlZ=hi1b56CJOJQJ\]^JaJ&hX/56CJOJQJ\]^JaJ)hlZ=hi1b5CJOJQJ\]^JaJ hlZ=hi1bCJOJQJ^JaJ hlZ=hlZ=CJOJQJ^JaJ4K^_fghip<$If$If pqKCCCCCC<$Ifkd.$$Ifl4rLU$0*jq0*44 laf4pq'()޺zeM<-hi1bCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ/h |hi1b;B*CJH*OJQJ^JaJph)hQY;B*CJH*OJQJ^JaJph)h |hi1bB*CJOJQJ^JaJph+hh_.6CJOJQJ^JaJmHsH(hh_.CJOJQJ^JaJmHsH(hhi1bCJOJQJ^JaJmHsHhQYCJH*OJQJ^JaJ(hhi1bCJOJQJ^JaJmHsHh |hi1bOJQJ^J )*+,-.7 $<$Ifa$<$If$If <<$If<$If)*-./0467Xνίt]OOO> h |hhCJOJQJ^JaJhhCJOJQJ^JaJ,h |hi1b56CJOJQJ\]^JaJ h |hX/CJOJQJ^JaJh5CJOJQJ^JaJhi1bCJOJQJ^JaJh?CJOJQJ^JaJhlCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ#h |hi1b6CJOJQJ^JaJ#h |hX/CJH*OJQJ^JaJhX/CJOJQJ^JaJ7>?YZ3kd$$Ifl4rLU$0*jq0*44 laf4x$If<$If,$IfXYZhinos +>Rϳϓm[G&h |hs5CJH*OJQJ^JaJ#h |hs5CJOJQJ^JaJ#h |hsCJOJQJ\^JaJ&h |hs5CJOJQJ\^JaJ h |hsCJOJQJ^JaJhQYCJH*OJQJ^JaJhQYCJOJQJ^JaJhsCJOJQJ^JaJ h |hsCJOJQJ^JaJh |hi1bOJQJ^J#h |hi1bCJH*OJQJ^JaJZituvwxyz{)* ($IfgdEZ $IfgdEZ <<$IfgdEZ <$IfgdEZ <$IfgdEZRSp  $'3456GHKνΝ܌wePeP(huhsCJOJQJ^JaJmH sH "hsCJOJQJ^JaJmH sH (hlhsCJOJQJ^JaJmH sH  hs6CJOJQJ]^JaJ#h |hs6CJOJQJ^JaJhQYCJOJQJ^JaJ hVhsCJOJQJ^JaJhsCJOJQJ^JaJ h |hsCJOJQJ^JaJ#h |hsCJH*OJQJ^JaJ   &56JKLMWXYZabcdkl <$IfgdEZ $IfgdEZ ($IfgdEZKMWZ`dimtuy]^˺˺˺k˺Z˺˺˺˺I hlZ=hsCJOJQJ^JaJ h |hsCJOJQJ^JaJ,h |hs9B*CJOJQJ^JaJph,h |hs9B*CJOJQJ^JaJph&hs9B*CJOJQJ^JaJphh |hsOJQJ^J h |hsCJOJQJ^JaJhsCJOJQJ^JaJ(h |hsCJOJQJ^JaJmHsH"hsCJOJQJ^JaJmHsHlmtu=4 $IfgdEZkd$$Ifl4rLU$0*jq0*44 laf4ytEZ <$IfgdEZ6J^ypggggg\\ x$IfgdEZ $IfgdEZ $IfgdEZ x$IfgdEZzkd$$Ifl4L0**  &0*44 laf4p &ytEZ  x$Ifgds x$IfgdEZ $IfgdEZ пЇzcL?Lh |hi1bOJQJ^J,h |hi1b9B*CJOJQJ^JaJph,h |hi1b9B*CJOJQJ^JaJphh |hsOJQJ^J h |hsCJOJQJ^JaJ"hsCJOJQJ^JaJmHsH(hlZ=hsCJOJQJ^JaJmHsH hlZ=hsCJOJQJ^JaJhsCJOJQJ^JaJ#hlZ=hs6CJOJQJ^JaJhs6CJOJQJ^JaJKE$Ifkdo$$IflrLU$0*jq0*44 laytEZ $IfwkdI$$Ifl4L0**  &0*44 laf4p &' ) - 0 B E ԺԟԊpcR=R.RhQYCJH*OJQJ^JaJ)h |hi1bB* CJOJQJ^JaJph h |hi1bCJOJQJ^JaJh |hi1bOJQJ^J2h |hi1b59B*CJOJQJ\^JaJph)hs6B*CJOJQJ]^JaJph5h |hi1b56B*CJOJQJ\]^JaJph2h |hi1b6B*CJH*OJQJ]^JaJph/h |hi1b6B*CJOJQJ]^JaJph&h |hi1b5CJOJQJ\^JaJ !A!!!!!!!{pggg $IfgdlZ= x$IfgdlZ=x$If$If$Ifx$Ifhkd$$Ifl4L0**0*44 laf4 !!}!~!!!!!!!!!!!!!!޻xjYD2D"hKLiCJOJQJ^JaJmHsH(hlZ=hi1bCJOJQJ^JaJmHsH hlZ=hlCJOJQJ^JaJhlCJOJQJ^JaJhi1bCJOJQJ^JaJ#hlZ=hlZ=6CJOJQJ^JaJ#hlZ=hi1b6CJOJQJ^JaJ hlZ=hi1bCJOJQJ^JaJ hlZ=hlZ=CJOJQJ^JaJ#h |hi1bCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ!!!!!!!8kdx$$IflrLU$0*jq0*44 lax$If$Ifx$If!!!!!!!!!!!!!!!!"B"E"d"j""ֲ֡t_G_G_/h |hi1b5B*CJOJQJ\^JaJph)h |hi1bB*CJOJQJ^JaJph#hQYhQYCJH*OJQJ^JaJh |hi1bOJQJ^JhlZ=CJOJQJ^JaJ h |hi1bCJOJQJ^JaJ"hlZ=CJOJQJ^JaJmHsH"hKLiCJOJQJ^JaJmHsH(hlZ=hi1bCJOJQJ^JaJmHsH(hlZ=hlZ=CJOJQJ^JaJmHsH!!"""##.#/#K#g#q###########x$If $IfgdlZ=$If<$If"" #####!#.#/#J#K#W#X#^#_#ѼѢnZE7)7h;NCJOJQJ^JaJh_.CJOJQJ^JaJ)h |hi1b6CJH*OJQJ]^JaJ&h |hi1b6CJOJQJ]^JaJ hlZ=6CJOJQJ]^JaJ#h |hi1b6CJOJQJ^JaJ h |hi1bCJOJQJ^JaJ2h |hi1b6B*CJH*OJQJ]^JaJph)ht6B*CJOJQJ]^JaJph/h |hi1b6B*CJOJQJ]^JaJph,h |hi1bB*CJH*OJQJ^JaJph_#f#g#j#l#t#v###############пппЮР~p~bP;(huh_.CJOJQJ^JaJmH sH #h;Nh;N6CJOJQJ^JaJh_.CJOJQJ^JaJhKLiCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ h |hlZ=CJOJQJ^JaJhi1bCJOJQJ^JaJ hhtCJOJQJ^JaJ hhKLiCJOJQJ^JaJ hhi1bCJOJQJ^JaJ h |h;NCJOJQJ^JaJh;NCJOJQJ^JaJ###############ij|qcVE0)j hhw^CJOJQJU^JaJ h |huCJOJQJ^JaJhuhuOJQJ^Jh |huH*OJQJ^JhQYH*OJQJ^JhuOJQJ^Jh |hi1bOJQJ^JhlZ=CJOJQJ^JaJ#hlZ=hlZ=CJOJQJ]^JaJ h |hi1bCJOJQJ^JaJ(h_.h_.CJOJQJ^JaJmH sH (huh_.CJOJQJ^JaJmH sH "h_.CJOJQJ^JaJmH sH ######NC::/ <$Ifgdu $Ifgdu x$IfgdukdL$$Ifl rLU$0*jq0*44 la#########$#$$$<$=$νnaG,5h |hi1b56B*CJOJQJ\]^JaJph2h |hi1b59B*CJOJQJ\^JaJphh |h0cOJQJ^J&h |h0c5CJOJQJ\^JaJ h |h0cCJOJQJ^JaJhlZ= hlZ=5\h |huOJQJ^J# *h?huCJOJQJ^JaJ hsh<1ACJOJQJ^JaJhsCJOJQJ^JaJ hsh_.CJOJQJ^JaJ# *hhuCJOJQJ^JaJ ###$ $$$#$nlcWWWW $$Ifa$gdp $Ifgdpkd;$$Ifl4FL$0*0*    44 laf4ytu#$$$kdA<$$IflrL@%1+>hN 2&&&&&0+44 lap2&&&&&yt0c$$=$>$E$$E%%~xxxx$Ifzkd=$$Ifl4L1++  0+44 laf4p yt0c$If=$>$E$$$$$%C%D%E%F%%%%%%%%%νν}lZH#h |hi1b5CJOJQJ^JaJ#hQYhQYCJH*OJQJ^JaJ hmc5CJOJQJ\^JaJ h |hd0CJOJQJ^JaJ#h |hi1bCJH*OJQJ^JaJjhmcUmHnHuhQYCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ&h |hi1b5CJOJQJ\^JaJ hQY5CJOJQJ\^JaJh |hi1bOJQJ^J%%%%%%.&&0''''r(t(>)~<$If$Ifx$Ifkkd;>$$Ifl4L1++0+44 laf4yt0c%%%%&r&&&.'0'b'h'''''n(p(r(t(<)>)H)R)ŴuguVHh33CJOJQJ^JaJ h |hhCJOJQJ^JaJhi1bCJOJQJ^JaJhhCJOJQJ^JaJ#h |hi1bCJOJQJ]^JaJhkCJOJQJ^JaJ hmchi1bCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ&h |hi1b5CJOJQJ\^JaJ h |hi1bCJOJQJ^JaJ)h |hi1bB*CJOJQJ^JaJphR)T)n)p)r)t)~))))))))))))ŷũveTF5 h |h8CJOJQJ^JaJh8CJOJQJ^JaJ hmchkCJOJQJ^JaJ hmchi1bCJOJQJ^JaJ hmch{jCJOJQJ^JaJ hmch8CJOJQJ^JaJ h |h33CJOJQJ^JaJhtCJOJQJ^JaJhkCJOJQJ^JaJh33CJOJQJ^JaJhi1bCJOJQJ^JaJ h |hi1bCJOJQJ^JaJhuCJOJQJ^JaJ>)r)t))))))) * $Ifgd33<$If )))))))) * * * * ***D*E******ŴrbTII8 h8hi1bCJOJQJ^JaJhQYH*OJQJ^Jh |hi1bOJQJ]^Jh |hi1b6OJQJ]^J#h |hi1bCJOJQJ\^JaJh |hi1bOJQJ^J#h |hi1bCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ h8h33CJOJQJ^JaJh33CJOJQJ^JaJhtCJOJQJ^JaJhkCJOJQJ^JaJ h8h8CJOJQJ^JaJ * * * *F**H@:44 $If$Ifx$Ifkd>$$Ifl4crLL+%1+`>`hZ0+44 laf4yt0c****++++$+%+>+c+d+e+v+rdRE-.h |hi1b5CJOJQJ\^JaJmHsHh |hi1bOJQJ^J#h |hi1bCJH*OJQJ^JaJh8CJOJQJ^JaJ h |hi1bCJOJQJ^JaJ#h |hi1bCJOJQJ]^JaJ&h |hi1b6CJOJQJ]^JaJ)h8hi1bB*CJOJQJ^JaJphhhOJQJ^J0h8hi1b0J#>*B*CJOJQJ^JaJphh8hi1bOJQJ^J!jh8hi1bOJQJU^J*d+e+|+}+~++,,8,9,:,h````<$Ifkd?$$Ifl4FL1+ > h?0+    44 laf4yt0c$If v+{+|+}+~+,,),7,8,9,:,H,I,U,`,a,tgYKY:t h_W6CJOJQJ]^JaJh|*CJOJQJ^JaJh8CJOJQJ^JaJh |hi1bOJQJ^J&h |hi1b6CJOJQJ]^JaJ#h |hi1bCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ(h |hi1bCJOJQJ^JaJmHsH(h |hi1bCJOJQJ^JaJmHsH.h |hi1b5CJOJQJ\^JaJmHsH#hQYhQYCJH*OJQJ^JaJ:,I,U,b,u,v,,,,,,,,,,,,,,,,,<$If$Ifa,b,e,s,t,u,y,,,,,,,,,,,᠎|fT?-?"hKLiCJOJQJ^JaJmHsH(h |hi1bCJOJQJ^JaJmHsH"h|*CJOJQJ^JaJmHsH+h |h87CJOJQJ^JaJmHsH"h_.CJOJQJ^JaJmHsH"h8CJOJQJ^JaJmHsH h |h_WCJOJQJ^JaJhi1b6CJOJQJ^JaJh_W6CJOJQJ^JaJ#h_Wh_W6CJOJQJ^JaJh_WCJOJQJ^JaJ h86CJOJQJ]^JaJ,,,,,,,,,,,,,,,,,,ιιudVEd3#h |hi1bCJH*OJQJ^JaJ h |h8CJOJQJ^JaJhi1bCJOJQJ^JaJ h |hi1bCJOJQJ^JaJh|*CJOJQJ^JaJ#hQYh|*5CJOJQJ^JaJ#hQYhQY5CJOJQJ^JaJ"hKLiCJOJQJ^JaJmHsH(h |hi1bCJOJQJ^JaJmHsH"h&CJOJQJ^JaJmHsH"h8CJOJQJ^JaJmHsHh8CJOJQJ^JaJ,,,,,(-H@@@/<$'dIfQ<$Ifkdw@$$Ifl4vrL+%1+>hp0+44 laf4yt0c,,,,,,,,,--..L.\......μߜxjxjxjx[xI5&h |hi1b6CJOJQJ]^JaJ#h |hi1bCJH*OJQJ^JaJh{jCJH*OJQJ^JaJh#zCJOJQJ^JaJ h |hi1bCJOJQJ^JaJ$h |hi1b0J7CJOJQJ^JaJ h |hi1bCJOJQJ^JaJhQYCJH*OJQJ^JaJ#hQYhQYCJH*OJQJ^JaJ hQY5CJOJQJ\^JaJ&h |hi1b5CJOJQJ\^JaJh |hi1bOJQJ^J(-...../2/4/V/X/Z////////x$If<$If $Ifgd|*$If<$'dIfQ....//0/2/4/T/V//////////ֳőr^L^?h |hi1bOJQJ^J#h |hi1bCJH*OJQJ^JaJ&h |hi1b6CJOJQJ]^JaJ h |h|*CJOJQJ^JaJhi1bCJOJQJ^JaJh|*CJOJQJ^JaJ&hfU7hi1b6CJH*OJQJ^JaJ#hfU7h$}N6CJOJQJ^JaJ h |hi1bCJOJQJ^JaJhfU7CJOJQJ^JaJh#zCJOJQJ^JaJh8CJOJQJ^JaJ// 0*000H@@//<$'dIfQ<$IfkdWA$$Ifl4rL+%1+>hp0+44 laf4yt0c/00 0 0*00111 111,1P1h1~111毞{m_KK>h |hi1bOJQJ^J&h |hi1b6CJOJQJ]^JaJh|*CJOJQJ^JaJhTcCJOJQJ^JaJ h |h8CJOJQJ^JaJ#h |hi1bCJH*OJQJ^JaJ h |hi1bCJOJQJ^JaJ+h |hi1bCJOJQJ^JaJmHnHuh0cCJH*OJQJ^JaJ#hQYh0cCJH*OJQJ^JaJ1h |hi1b5CJOJQJ\^JaJmHnHu00111P1h11<$If$If11111H77. $Ifgdp ^%^gdpkd7B$$Ifl4rL+%1+>hp0+44 laf4yt0c111111122220212A2B2C2۶qdWJW:)!jh |h&OJQJU^Jh |h|w5OJQJ\^Jh&5OJQJ\^Jh|w5OJQJ\^Jh |h&OJQJ^J&h |h&5CJOJQJ\^JaJ2h |h&59B*CJOJQJ\^JaJph,h|w59B*CJOJQJ\^JaJphh |h0cOJQJ^J h |h0cCJOJQJ^JaJ h0c5\&h |h0c5CJOJQJ\^JaJ h0c5CJOJQJ\^JaJ11111 $$Ifa$gdp11kdC$$IflrrOp#* 3 2&&&&&01+44 lap2&&&&&ytG:12212B22233{ppe\\O  $Ifgd|w $IfgdEZ <$IfgdEZ <$IfgdEZzkddD$$Ifl4r*1+  &01+44 laf4p &ytG: $IfgdEZC22222222223333333%3&3:3F3G3H3I3J3Q3U3]3x3z3yydyyySy h&5CJOJQJ\^JaJ)hIhT5>*CJOJQJ\^JaJ h|w5CJOJQJ\^JaJ hG:5CJOJQJ\^JaJ hT5CJOJQJ\^JaJ&h |h&5CJOJQJ\^JaJ h |h&CJOJQJ^JaJ h |h&CJOJQJ^JaJ!jh |h&OJQJU^Jh |h&OJQJ^J3&3:3I3J3333333344:44$<$Ifa$gd|w $Ifgd|w <$IfgdEZ $IfgdEZ  &$Ifgd|wz3{3|3}33333333333333333334444*4,4.44484J4T44ۼ~mmmmm~~_~~hc{CJOJQJ^JaJ h|wh|wCJOJQJ^JaJ h |h&CJOJQJ^JaJh&CJOJQJ^JaJ h |h|wCJOJQJ^JaJhTCJOJQJ^JaJh|wCJOJQJ^JaJ h|w5CJOJQJ\^JaJ&h |h&5CJOJQJ\^JaJ h0c5CJOJQJ\^JaJ!44Z5z5H?? $IfgdEZkdE$$Ifl4rrOp#* 301+44 laf4ytG:4444455$5&5(5,5V5X5z5|5~55555666߽viRv>&h |h5H5CJOJQJ\^JaJ,h |h5H9B*CJOJQJ^JaJphh |h5HOJQJ^J h |h5HCJOJQJ^JaJ&h |h5H5CJOJQJ\^JaJ&h |h0c5CJOJQJ\^JaJh&CJOJQJ^JaJ h |h&CJOJQJ^JaJ hG:5CJOJQJ\^JaJ&h |h&5CJOJQJ\^JaJh |h&OJQJ^Jz5|5~555555t $$Ifa$gdp $$Ifa$$IfgdEZkkdE$$Ifl4r*1+01+44 laf4ytG:55kdF$$IflrrOp#* 3 2&&&&&01+44 lap2&&&&&ytG:5668696:6;6<6Q6R6~sj___VV $IfgdWr/ x$IfgdWr/ $IfgdWr/ <$IfgdWr/zkdG$$Ifl4r*1+  &01+44 laf4p &ytG:$If 6636768696:6<6Q6R6 7(7)74757J7K7P7Q7쭣udVD0dVdVd&h |h5H6CJOJQJ]^JaJ#h |h5HCJH*OJQJ^JaJh5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJh |hWr/5OJQJ\^Jh |hWr/OJQJ^JhWr/OJQJ^J$h |hWr/0J%CJOJQJ^JaJ)h0chWr/CJH*OJQJ\]^JaJ,h |hWr/56CJOJQJ\]^JaJ&h |hWr/5CJOJQJ\^JaJR666 7 7)757R7W7g7l7y7z7|7}777777777<$If$If$If($If $IfXD<<$IfQ7R7g7k7{7|777777777777777777?8ủpcN<#h5HCJH*OJQJ\]^JaJ)h0ch5HCJH*OJQJ\]^JaJh |h5HOJQJ^J h0ch5HCJOJQJ^JaJh5HCJH*OJQJ^JaJ,h |h5H56CJOJQJ\]^JaJ&h5H56CJOJQJ\]^JaJ&h |h5H5CJOJQJ\^JaJ#h |h5HCJH*OJQJ^JaJ h |h5HCJOJQJ^JaJh5HCJOJQJ^JaJ7777777$If $$Ifa$gd M $$Ifa$gd0c $$Ifa$gd M777X88\9ME???$If<$IfkdyH$$IflrrOp#* 301+44 laytG:?8F8V8W8X888888885979Z9[9\9]9h9i9j9ɴrrr`S>)h0ch5HCJH*OJQJ\]^JaJh |h5HOJQJ^J#h% uh5H6CJOJQJ^JaJh5HCJOJQJ^JaJh5HCJH*OJQJ^JaJ h5H5CJOJQJ\^JaJ&h |h5H5CJOJQJ\^JaJ)h |h5HB* CJOJQJ^JaJphI}#h |h5HCJH*OJQJ^JaJ h |h5HCJOJQJ^JaJ&h |h5H6CJOJQJ]^JaJ\9]9j9k9l9m90:]:{:::::yyyyyyyyyyy<$If~kdOI$$Ifl40rO*T"01+44 laf4ytG: j9l9m9\:]:b:d:i:z:{:~::::::::::;;ɷɩɩɩɔɇvbNN&h |h5H5CJOJQJ\^JaJ&h |h0c5CJOJQJ\^JaJ h5H5CJOJQJ\^JaJh |h5HOJQJ^J)h |h5HB* CJOJQJ^JaJphh5HCJOJQJ^JaJ#h |h5HCJH*OJQJ^JaJ h |h5HCJOJQJ^JaJ$h |h5H0J%CJOJQJ^JaJ$h |h5H0J%CJOJQJ^JaJ::::::HCC:. $$Ifa$gdp $Ifgdpgd0ckdI$$Ifl4rrOp#* 301+44 laf4ytG::; ;; $$Ifa$gdp;;kdJ$$IflrLZ%) On 2&&&&&0<*44 lap2&&&&&yt5H;1;2;3;@;A;B;C;D;;;*<+<,<®rZI;I-h |h5HH*OJQJ^Jh5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJ/h |h5H5B*CJOJQJ\^JaJph#h5HCJH*OJQJ\]^JaJ)h0ch5HCJH*OJQJ\]^JaJ)h5Hh5HCJH*OJQJ\]^JaJ&h5Hh5H5CJOJQJ\^JaJh |h5HOJQJ^J,h |h5H9B*CJOJQJ^JaJph2h |h5H59B*CJOJQJ\^JaJph ;2;3;D;+<~vp$If<$Ifzkd L$$Ifl4L)<*  &0<*44 laf4p &yt5H$If+<,<C<D<n<o<p<<<<<<<<|v|v|||vvv||$If<$If{kdL$$IflI0LZ).#0<*44 layt5H ,<?<@<A<B<C<o<p<<<<<<<<<<<<<=°쟑|f|T|T|>f|T+h |h5HCJH*OJQJ^JaJmHsH"h5HCJOJQJ^JaJmHsH+h |h5H6CJOJQJ^JaJmHsH(h |h5HCJOJQJ^JaJmHsHh5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJ#h5HCJH*OJQJ\]^JaJ)h0ch5HCJH*OJQJ\]^JaJ)h5Hh5HCJH*OJQJ\]^JaJ&h |h5H5CJOJQJ\^JaJ<<== =!=.=/=F=G=\=]=b=g=h=r=s={=<$If$If====== =!=$=&=.=/=F=G=\=]=g=h=q=r=s=z={=|====ν|gR)h0ch5HCJH*OJQJ\]^JaJ)h5Hh5HCJH*OJQJ\]^JaJ&h |h5H5CJOJQJ\^JaJh |h5HOJQJ^J#h |h5HCJH*OJQJ^JaJh5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJh5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJ#h% uh5H6CJOJQJ^JaJ{=|=== >K@7@ $Ifgdp <$IfgdpkdeM$$IflrLZ%) On0<*44 layt5H====== > >>>>>>>.>/>4>5>8>9>:>\>]>ܼܼlUDܼ h5H6CJOJQJ]^JaJ,h% uh5H>*B*CJOJQJ^JaJph)h% uh5HB*CJOJQJ^JaJphh |h5HH*h5HOJQJ^Jh |h5H6OJQJ^Jh |h5HH*OJQJ^Jh |h5HOJQJ^J#h |h5HCJH*OJQJ^JaJh5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJ#h5HCJH*OJQJ\]^JaJ >>>/>9>:>T>\>^>h> $Ifgdp <$Ifgdp $Ifgdp <$Ifgdp ]>^>h>i>w>x>y>z>{>>>>>>>??ѽsaL8&h |h5H6CJOJQJ]^JaJ)h |h5HB* CJOJQJ^JaJph#h |h5HCJH*OJQJ^JaJh5HCJOJQJ^JaJ#h5HCJH*OJQJ\]^JaJ)h0ch5HCJH*OJQJ\]^JaJ)h5Hh5HCJH*OJQJ\]^JaJ&h |h5H5CJOJQJ\^JaJh |h5HOJQJ^J h |h5HCJOJQJ^JaJ hKLih5HCJOJQJ^JaJh>i>{>|>>??KC=CCC$If<$Ifkd?N$$IflyrLZ%) On0<*44 layt5H????+?,?W?X?Y?b?c?d????뽤m`P?.!h0ch5HH*OJQJ\]^J!h5Hh5HH*OJQJ\]^Jh |h5H5OJQJ\^Jh |h5HOJQJ^J&h |h5H6CJOJQJ]^JaJ#h |h5HCJH*OJQJ^JaJ h |h5HCJOJQJ^JaJ1h |h5H6CJH*OJQJ]^JaJmHsH.h |h5H6CJOJQJ]^JaJmHsH+h |h5HCJH*OJQJ^JaJmHsH(h |h5HCJOJQJ^JaJmHsH??,?6?7?N?X?Y?c?$If<$If $Ifc?d??????KC=555<$If$If <$IfkdO$$IflrLZ%) On0<*44 layt5H????????@@@@@@@@@@$@'@(@*@4@K@L@]@аm`L&h |h5H5CJOJQJ\^JaJh |h5HOJQJ^J+h: h5HCJH*OJQJ^JaJmH sH .h |h5H6CJOJQJ]^JaJmH sH (h |h5HCJOJQJ^JaJmH sH "h5HCJOJQJ^JaJmH sH h5HCJOJQJ^JaJ h |h5HCJOJQJ^JaJh |h5H5OJQJ\^Jh5HH*OJQJ\]^J??@@@@@(@*@3@4@9@B@J@K@$If$IfK@L@b@c@@@H@@82$If <$If<$IfkdO$$Ifl4rLZ%) On0<*44 laf4yt5H]@^@_@`@a@b@c@@@@@@@@@@@AA AAAAAAųp^p^p^Lp^p>p>p>p>h5HCJOJQJ^JaJ#hKLih5H6CJOJQJ^JaJ#h |h5HCJH*OJQJ^JaJ h |h5HCJOJQJ^JaJh |h5HOJQJ^J h |h5HCJOJQJ^JaJ&h |h5H5CJOJQJ\^JaJ#h5HCJH*OJQJ\]^JaJ)h0ch5HCJH*OJQJ\]^JaJ)h5Hh5HCJH*OJQJ\]^JaJ h5H5CJOJQJ\^JaJ@@@@AAA%A.A/A8A<$If$If AA!A$A%A.A/A7A8A9A;A~~hJ0CJOJQJ^JaJhK"shK"sOJQJ]^Jhm)OJQJ]^JhK"sOJQJ]^JhCJOJQJ^JaJ hzdxhK"sCJOJQJ^JaJh |hK"sOJQJ^J(hlhK"sCJOJQJ^JaJmHsHhK"s5CJOJQJ^JaJh |hK"s6OJQJ]^JhK"s5OJQJ^J h |hK"sCJOJQJ^JaJ%hK"s5CJOJQJ^JaJmH sH }A~AAA*!! $IfgdK"skd`R$$Ifl4\rz*u| (0*44 laf4p(ytAAOBPBvBBBBCIkdS$$Ifl4\rz*u| 0*44 laf4yt $IfgdK"s $IfgdK"sBBBBBBBBBBB CCCC3CGCQCTChCiCjCnCCCCCCȺᎄvaL)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJhK"sCJOJQJ^JaJhm)OJQJ^JhzdxhK"sOJQJ^Jh |hK"sOJQJ^J#hzdxhK"s6CJOJQJ^JaJhK"shK"sOJQJ]^JhK"sOJQJ]^JhVQfCJOJQJ^JaJ hzdxhK"sCJOJQJ^JaJhm)CJOJQJ^JaJCC%C3CUCjCC[RRIIR $IfgdK"s $IfgdK"skd[T$$Ifl4\rz*u| 0*44 laf4ytCCCCCDMDD[RRIIRR $Ifgdm) $IfgdK"skd+U$$Ifl4T\rz*u| 0*44 laf4ytCCCCCCDD D,DMD\DiDDDDDDDDDDE E EPEŷܩ܋zpcpcpUGzhkCJOJQJ^JaJhK"shkOJQJ]^JhzdxhkOJQJ^JhkOJQJ^J hzdxhkCJOJQJ^JaJh |hK"sOJQJ^J h |hK"sCJOJQJ^JaJhK"sCJOJQJ^JaJhK"shK"sOJQJ]^Jhm)OJQJ^Jhzdxhm)OJQJ^J hzdxhK"sCJOJQJ^JaJ#hCJH*OJQJ\]^JaJDDDDDD EPE[RRIII@ $IfgdKU $Ifgd= $IfgdK"skdU$$Ifl4_\rz*u| 0*44 laf4ytPEQEzEEEE[RRIR $IfgdK"s $IfgdK"skdV$$Ifl4F\rz*u| 0*44 laf4ytPEQEEEEEEEEE F FFFFF!F4F5F9FxF{F|F}FFFFFFFFFGG!G?G@GAGGǵxxxjjjjjjhkCJOJQJ^JaJhzdxhkOJQJ^JhkOJQJ^J hhkOJQJ^JmHsH(hzdxhkCJOJQJ^JaJmHsH"hkCJOJQJ^JaJmHsHhK"shkOJQJ]^JhhkOJQJ^J hzdxhkCJOJQJ^JaJh |hkOJQJ^J&EEE F5F|F[RRIR $IfgdK"s $IfgdK"skdW$$Ifl4\rz*u| 0*44 laf4yt|F}FFFFF[RRIR $IfgdK"s $IfgdK"skdkX$$Ifl4R\rz*u| 0*44 laf4ytFFG&G@GAG_H[RII@R $IfgdK"s $IfgdVQf $IfgdK"skd;Y$$Ifl4B\rz*u| 0*44 laf4ytGG%H;H_H`HHHHHHHHHIIIIIIJJ$J'J;JG $Ifgd= $Ifgd= $$Ifgdkkd[$$Ifl4\rz*u| 0*44 laf4ytJJJJJJJJJJJJJKUKVKKKKKKKKKKxfXXJXxfhK"shkOJQJ]^JhkCJOJQJ^JaJ#hCJH*OJQJ\]^JaJ)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJ hzdxhkCJOJQJ^JaJh |hkOJQJ^J(hlhkCJOJQJ^JaJmHsHhk5CJOJQJ^JaJh |hk6OJQJ]^Jhk5OJQJ^JJJJ*! $IfgdK"skd{\$$Ifl4\rz*u| (0*44 laf4p(ytJJKUKVKKKK@kd]$$Ifl4\rz*u| 0*44 laf4yt $IfgdK"s $IfgdK"s $IfgdVQfKKKL2LyLzLL@kdv^$$Ifl4\rz*u| 0*44 laf4yt $IfgdKU $Ifgdk $IfgdK"sKKLLL1L2L6LyLzLLLLLM4M5MAMBMNMQMXM[M~MMMMMMMMMMMMͼۼͼͼͼͼͼۼzhW hzdxhCJOJQJ^JaJ#hCJH*OJQJ\]^JaJ)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJhkOJQJ]^Jh |hkOJQJ^J hzdxhkCJOJQJ^JaJhkCJOJQJ^JaJhK"shkOJQJ]^JhzdxhkOJQJ^JhkOJQJ^J"LLL4M5MAMMMMIkdF_$$Ifl4\rz*u| 0*44 laf4yt $IfgdK"s $IfgdK"sMMMMMN[RRIR $IfgdK"s $IfgdK"skd`$$Ifl4B\rz*u| 0*44 laf4ytMMM N&NNNNNBOVO`OcOwOxO|OOOOOOOOOO0P1P2PPPPPQQյը՛յը|gUյըը#hCJH*OJQJ\]^JaJ)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJhkOJQJ^JhzdxhkOJQJ^Jh |hkOJQJ^JhkCJOJQJ^JaJ#hzdxhk5CJOJQJ^JaJ hzdxhkCJOJQJ^JaJhK"shkOJQJ]^JhkOJQJ]^J!NNO/OBOdOxOO[RRRII@ $IfgdKU $Ifgdk $IfgdK"skd`$$Ifl4\rz*u| 0*44 laf4ytOOOOP1P2PP[RIRR@R $IfgdK"s $IfgdVQf $IfgdK"skda$$Ifl4\rz*u| 0*44 laf4ytPPPPPQ[RRIR $IfgdK"s $IfgdKUkdb$$Ifl4\rz*u| 0*44 laf4ytQQ_QwQxQFR[RRIR $IfgdK"s $IfgdKUkdVc$$Ifl4\rz*u| 0*44 laf4ytQwQxQQQQFRGRRRRRR@SSSSSSSSSSSTTTTTTT TƷxiTƦ(hlhkCJOJQJ^JaJmHsHhk5CJOJQJ^JaJh |hk6OJQJ]^Jhk5OJQJ^J%hk5CJOJQJ^JaJmH sH  h |hkCJOJQJ^JaJhk5CJOJQJ^JaJh |hkOJQJ^JhkCJOJQJ^JaJhK"shkOJQJ]^J hzdxhkCJOJQJ^JaJFRGRRRRRS[RII@R $IfgdK"s $IfgdVQf $IfgdKUkd&d$$Ifl4\rz*u| 0*44 laf4ytSSSSSS[RRIR $IfgdK"s $IfgdKUkdd$$Ifl4z\rz*u| 0*44 laf4ytSSSSTTT[PPPEP $$Ifgdk $$Ifgdkkde$$Ifl4_\rz*u| 0*44 laf4ytTT$T2T3T*$$$$Ifkdf$$Ifl4\rz*u| (0*44 laf4p(yt T!T"T#T$T+T3T5TBTCTGTiTjTTTTTT*U+U.U/U8U9UBUCULUdUfUUUòylyy^M hK"shkCJOJQJ^JaJhK"shkOJQJ]^Jh |hkOJQJ^J#h |hkCJH*OJQJ^JaJ *hkCJOJQJ^JaJhkCJOJQJ^JaJhkOJQJ^J h |hkCJOJQJ^JaJ#hCJH*OJQJ\]^JaJ)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJ3T4T5TATBTCTDTETFTGTHTjTTTTTMUNUeUfUUUUUU!V $If $Ifgd $If$If $$Ifa$UUUUU V!V%V'V.V0V7V9VBVDVHVIVJVYVfVDZ}o}o}o}o}]oL7(hlhkCJOJQJ^JaJmHsH huhkCJOJQJ^JaJ#h |hkCJH*OJQJ^JaJhkCJOJQJ^JaJ h |hkCJOJQJ^JaJ#hK"shkCJH*OJQJ^JaJ hK"shkCJOJQJ^JaJ+hK"shkCJOJQJ]^JaJmH sH .hK"shk6CJOJQJ]^JaJmH sH #hK"shk6CJOJQJ^JaJhK"shkH*OJQJ^J!V"V-V.V/V0V?VIVJVYVgVhViVjVkVlV{V|V $$Ifa$$IffVgVlV{V|V}VVVVVVVVVWW!W-W7W8WñÏzhUññAñ&h |hk6CJOJQJ]^JaJ$h |hk0J%CJOJQJ^JaJ#hCJH*OJQJ\]^JaJ)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJh |hkOJQJ^J#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJ(hlhkCJOJQJ^JaJmHsH+hlhkCJH*OJQJ^JaJmHsH|V}VVVVW!W-WHBBBBBB$Ifkdg$$Ifl4rrz%*um0*44 laf4yt-W8WBWCWWWtWx$If $If$If8W9WWWsWtWuWWWWWW XJXNXkXXXXXXXXXXXXXXXɷɷɩɔɀnɩYɩɷH!h5HhH*OJQJ\]^J(hlhkCJOJQJ^JaJmH sH #hhkCJOJQJ]^JaJ&h |hk5CJOJQJ\^JaJ)h |hk6>*CJOJQJ]^JaJhkCJOJQJ^JaJ#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJh |hkOJQJ^J0jh |hkOJQJU^JmHnHtH utWuWWWW XkXHB<BBB $If$Ifkdh$$Ifl4rrz%*um0*44 laf4ytkXXXXXXXX x$Ifgd $Ifgd $Ifgd x$Ifgd$IfXXXXKYvYHB93-$If$If $Ifgd= $Ifkdi$$Ifl4rrz%*um0*44 laf4ytXXXXXYYJYuYvYYYZZ$Z0Z3ZCZɵ}dO=O"hkCJOJQJ^JaJmH sH (hlhkCJOJQJ^JaJmH sH 1hlhk56CJOJQJ]^JaJmH sH )h |hk57CJOJQJ\^JaJ#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJ&h |hk5CJOJQJ\^JaJh |hkOJQJ^JhOJQJ^JhH*OJQJ\]^J!h0chH*OJQJ\]^JvYYYZEZ^Z_Z{Z|ZZZZZZZZZ[["[,[6[$IfCZDZEZQZ]Z^Z_ZlZyZ{Z|ZZZZZZZZZZZZZ6[7[@[ԼԨwwwwwwwjU(hhkCJOJQJ^JaJmHsHh |hkOJQJ^JhkCJOJQJ^JaJ#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJ&h |hk6CJOJQJ]^JaJ.hlhk6CJOJQJ]^JaJmH sH (hlhkCJOJQJ^JaJmH sH +hlhkCJH*OJQJ^JaJmH sH 6[7[N[Z[[[][l[u[HBBBBBB$Ifkdgj$$Ifl4rrz%*um0*44 laf4yt@[A[B[D[Z[[[l[u[v[[[[ \ \D\M\^\_\y\{\\î{jXDjXjDjXjXj&h |hk5CJOJQJ\^JaJ#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJ huhkCJOJQJ^JaJ huhkCJOJQJ^JaJ hhkOJQJ^JmHsH(hhkCJOJQJ^JaJmHsH#hCJH*OJQJ\]^JaJ)h0chCJH*OJQJ\]^JaJ)h5HhCJH*OJQJ\]^JaJu[v[[D\\\\\\\\\\\\\\]]]]] ]$If$If$If\\\\\\\\\\\\\]] ] ]ӿ|kZZHZ;h |hkOJQJ^J#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJ hk5CJOJQJ\^JaJ.h |hk5CJOJQJ\^JaJmHsH+h |hkCJH*OJQJ^JaJmHsH)h |hk5CJH*OJQJ\^JaJ&h |hk5CJOJQJ\^JaJ,h |hk56CJOJQJ\]^JaJ)h |hkB* CJOJQJ^JaJph ] ]]]HBB$IfkdGk$$Ifl4rrz%*um0*44 laf4yt ]]]]]]]]]]]]]]]]]]]]]람m____E2h |hk59B*CJOJQJ\^JaJphhkCJOJQJ^JaJ"hkCJOJQJ^JaJmHsHh |hkOJQJ^J#h |hkCJH*OJQJ^JaJ h |hkCJOJQJ^JaJ#hKd-CJH*OJQJ\]^JaJ)h0chKd-CJH*OJQJ\]^JaJ)h5HhKd-CJH*OJQJ\]^JaJ(h |hkCJOJQJ^JaJmHsH]]]]]]]{{{{{$If~kd'l$$Ifl4 0rz*$0*44 laf4yt]]]HB$Ifkdl$$Ifl4 rrz%*uO0*44 laf4yt]]] ^ ^ ^^^^t^x^^^^^^^ȳygSg??g&h |hk5CJOJQJ\^JaJ&h |hk>*CJOJQJ\^JaJ#h |hkCJOJQJ\^JaJ$h |hk0J%CJOJQJ^JaJ#hKd-CJH*OJQJ\]^JaJ)h0chKd-CJH*OJQJ\]^JaJ)h5HhKd-CJH*OJQJ\]^JaJ h |hkCJOJQJ^JaJh |hkOJQJ^J2h |hk59B*CJOJQJ\^JaJph]]^^A^^^____6_7_~~~~~~~~xo~ $IfgdeQ $If$Ifzkdm$$Ifl4r**  &0*44 laf4p &yt ^____6_Z_[_\_]__ggggg%hµ̨jYEj0jY)hWr/5B*CJOJQJ\^JaJph&hhi1b5CJOJQJ\^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph)h 5B*CJOJQJ\^JaJph h |hi1bCJOJQJ^JaJh |hkOJQJ^JheQhkOJQJ^JhkOJQJ^J h |hkCJOJQJ^JaJhkCJOJQJ]^JaJ&h |hk6CJOJQJ]^JaJ7_Y_Z_[_\_]___B@@@@kdRn$$Ifl4rrz$*]G!0*44 laf4yt$If_S`T`YbZbbb!c"cccdvd & F+ 8T0H$`0 TH$^ TH$^` TH$^ & F* 8TH$ H$^ TH$^` TH$ & F" hTH$^` dUdmdddd+e-ee&ffSggggg5i6ijjkj & F$ & F$H$ & F) H$ TH$ TH$ 8T0H$^`0 & F+ 8T0H$`0%hhhhh i!i6iliiiiiUjVj1k6k;kRkTkUkbk2lֲŝֲŊt_G/hhi1b5B*CJOJQJ\^JaJph)hhi1bB* CJOJQJ^JaJph*hhi1b0J.5CJOJQJ\^JaJ$hhi1b0J.CJOJQJ^JaJ(hhi1bCJOJQJ^JaJmHsH$hhi1b0J#CJOJQJ^JaJ hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ(hhi1bCJOJQJ^JaJnH tH kjTkUkakbk m!mooqqttuu=w>wwwyy }!}}} & F%gdQYgdQY & F% & F%H$ & F$2l=lPlm`mmmInPnop$p*p+p4p?ppqrrrrr2tttu.u4u:uCuuvvvvvwwȴȴȴȋȴvȴȋȴvdd#hhi1b5CJOJQJ^JaJ)hhi1b56CJOJQJ]^JaJ&hhi1b5CJOJQJ\^JaJ)hhi1b6>*CJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ&hhi1b56CJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ'wwxxxxxyy_zzz{{} }!}W}X}}}}}ڪړړړ{j\K\K\K: hhQYCJOJQJ^JaJ hQYhQYCJOJQJ^JaJhQYCJOJQJ^JaJ hQYhi1bCJOJQJ^JaJ/hhi1b56B*CJOJQJ^JaJph,hhi1b6B*CJOJQJ^JaJph/hhi1b5B*CJOJQJ\^JaJph/hhi1b6B*CJOJQJ]^JaJph)hhi1bB*CJOJQJ^JaJph hhi1bCJOJQJ^JaJ}}}}5~:~?~A~K~~  dhnpy8:qq\\E\,hhi1b5B*CJOJQJ^JaJph)hhi1bB*CJOJQJ^JaJph)hhi1b56CJOJQJ]^JaJ&hhi1b5CJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ#hhi1bCJOJQJ]^JaJ hhi1bCJOJQJ^JaJ/hhi1b56B*CJOJQJ^JaJph,hhi1b6B*CJOJQJ^JaJph}}} 9:MN܋݋[$a$$ & F&a$ & F&H$ & F&H$ !hh^h`h^h$ !hh^ha$:N)<Ņ˅ЅׅRy܇İ֞Ċv֞bbPb#hhi1bCJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ&hhi1b5CJOJQJ\^JaJ&hhi1b6>*CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ&hhi1b56CJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJphŠȊЊۋ Z\"%'’)ҔӔp(hhi1bCJOJQJ^JaJmH sH 7hhi1b5B*CJOJQJ\^JaJmH phsH (h hi1bCJOJQJ^JaJmHsH(hhi1bCJOJQJ^JaJmHsH#hhi1b6CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ+[\&'ҔӔXY{|͟ΟF & F( & F(H$ & F' & F&Ӕ@Ș WY#NTZ`z|ΟڶȢڍڶqU7hhi1b5B*CJOJQJ\^JaJmH phsH 7hhi1b5B*CJOJQJ\^JaJmH phsH (hhi1bCJOJQJ^JaJmHsH&hhi1b56CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ hhi1bCJOJQJ^JaJ(hhi1bCJOJQJ^JaJmHsHâƢϢǥ8EGz}ȶ٢vaJa3a,hhi1b5B*CJOJQJ^JaJph,hhi1b6B*CJOJQJ^JaJph)hhi1bB*CJOJQJ^JaJph)hhi1bB*CJOJQJ^JaJph3f,hhi1b6B*CJOJQJ^JaJph3f&hhi1b56CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ(hhi1bCJOJQJ^JaJmH sH FG9:ڰ۰] & F, & F#h^h:`: & F(Ъ۬8: ٰڰ۰ѱֱܱ!&,4:ììììì؆ì&hhi1b56CJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ,hhi1b5B*CJOJQJ^JaJph)hhi1bB*CJOJQJ^JaJph hhi1bCJOJQJ^JaJ,hhi1b6B*CJOJQJ^JaJph2q}Զն ,f]o]H)hhi1b6CJH*OJQJ]^JaJ#hhi1bCJH*OJQJ^JaJ-hhi1b0J#B*CJOJQJ^JaJph)jhhi1bCJOJQJU^JaJ#hhi1b5CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ)hhi1bB*CJOJQJ^JaJph/hhi1b5B*CJOJQJ\^JaJph]^CDPQVW 56h^h & F-Z`Z:H$ & F.H$ h^h` & F,]^ѾZ[ƿîٮhTB#hhi1b5CJOJQJ^JaJ&hhi1b5CJOJQJ\^JaJ0hhi1b0J&56CJOJQJ\]^JaJ3hhi1b0J&5B*CJOJQJ\^JaJph$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ*hhi1b0J&5CJOJQJ\^JaJ hhi1bCJOJQJ^JaJ)hhi1b57CJOJQJ\^JaJCD9:OPQV۷ۍۍzeM/hhi1b5B*CJOJQJ\^JaJph)hhi1bB* CJOJQJ^JaJph$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ)hhi1bB*CJOJQJ^JaJph333#hhi1b6CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ  \] ;AGU_۲۲ۊrrZH#hhi1b5CJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph.hhi1b6CJOJQJ]^JaJnH tH (hhi1bCJOJQJ^JaJnH tH $hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ&hhi1b5CJOJQJ\^JaJ-3@BPY[6LNop}45_`v۴ۢۢۍu``M`$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ/hhi1b5B*CJOJQJ\^JaJph)hhi1b56CJOJQJ]^JaJ#hhi1bCJOJQJ]^JaJ)hhi1b6CJH*OJQJ]^JaJ#hhi1b5CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ6opq|}ghABTUA4 & F44 & F & Fx  !h^h & F-ELM)HVh189deǴܜsasssOsO#hhi1bCJOJQJ]^JaJ#hhi1b5CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ)hhi1bB*CJOJQJ^JaJph/hhi1b5B*CJOJQJ\^JaJph$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ hhi1bCJOJQJ^JaJ#hhi1b6CJOJQJ^JaJeAU*>Qİt__M_9&hhi1b5CJOJQJ\^JaJ#hhi1b>*CJOJQJ^JaJ)hhi1b6>*CJOJQJ]^JaJ$hhi1b0J#CJOJQJ^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph&hhi1b6CJOJQJ]^JaJ#hhi1bCJOJQJ]^JaJ)jhhi1bCJOJQJU^JaJ'hhi1b0J#CJOJQJ]^JaJ@gk"0A<v+_dgȴܟȟ܍xܴ(hhi1bCJOJQJ^JaJmHsH#hhi1b6CJOJQJ^JaJ)hhi1b6>*CJOJQJ]^JaJ&hhi1b5CJOJQJ\^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ)ABlm*+*+#$yz4 !hh^h`44 & F:"$hiabȴܢ܍u]HH)jhhi1bCJOJQJU^JaJ.hhi1b6CJOJQJ]^JaJnH tH .hhi1b5CJOJQJ\^JaJnH tH (hhi1bCJOJQJ^JaJnH tH #hhi1b5CJOJQJ^JaJ&hhi1b5CJOJQJ\^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ#hhi1bCJOJQJ\^JaJbx%'/!?EJR>@ԿpZp+hhi1b5CJOJQJ^JaJnH tH #hhi1b5CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ.hhi1b6CJOJQJ]^JaJnH tH  hhi1bCJOJQJ^JaJ(hhi1bCJOJQJ^JaJnH tH )jhhi1bCJOJQJU^JaJ,hhi1b0J#CJOJQJ^JaJnH tH ?@;<YZ>?PQ,-       4 & F4 & F4 !hh^h`44 & F@-35=>?Q':+^  ٴٴٴٴٴttt___ٴ)hhi1b6>*CJOJQJ]^JaJ)jhhi1bCJOJQJU^JaJ$hhi1b0J#CJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph hhi1bCJOJQJ^JaJ&hhi1b5CJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ#hhi1bCJOJQJ]^JaJ!                _~bܶܶubLb*hhi1b0J76CJOJQJ]^JaJ$hhi1b0J7CJOJQJ^JaJ&hhi1b5CJOJQJ\^JaJ/hhi1b5B*CJOJQJ\^JaJph)hhi1bB*CJOJQJ^JaJph&hhi1b6CJOJQJ]^JaJ#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ#hhi1b6CJOJQJ^JaJwVW{|##%%b(c(]*5 & F ^`5 & F: & F @ x^`89;OfBf)vwLM걞qqqqZFZZ'hhi1b0J76CJOJQJ^JaJ-hhi1b0J7B* CJOJQJ^JaJph*hhi1b0J76CJOJQJ]^JaJ-hhi1b0J76>*CJOJQJ]^JaJ$hhi1b0J7CJOJQJ^JaJ)hhi1bB*CJOJQJ^JaJph$hhi1b0J#CJOJQJ^JaJ hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJUVW|:JK®{hSBS/Sh$hhi1b0J#CJOJQJ^JaJ hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ$hhi1b0J7CJOJQJ^JaJ,hhi1b0J7CJOJQJ^JaJmHsH7hhi1b5B*CJOJQJ\^JaJmHphsH&hhi1b6CJOJQJ]^JaJ'hhi1b0J76CJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ-hhi1b0J7B* CJOJQJ^JaJph+6}%DRf+bnҾnSn5hhi1b56B*CJOJQJ\]^JaJph/hhi1b5B*CJOJQJ\^JaJph#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ)hhi1b6>*CJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ*hhi1b0J76CJOJQJ]^JaJ-hhi1b0J76>*CJOJQJ]^JaJno R r !6!!!#!##z$$$$$$$$c%y%%/&B&\&p&&&&&-'.'D'a(p)s)y)|))\*]*^**ٲٲٲًٝyٲٲٲًٲٲ#hhi1b6CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ)hhi1b6>*CJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ$hhi1b0J#CJOJQJ^JaJ hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ/]*^*,,r.s.J0K022f4g4p5q55577m9b;5 & F ^`@ 7$8$^ & F 7$8$H$^`55 & F ^`:*+$+&+0+,,m-p-v-y---q.. /W/i/o/r/{/I0K0222?3W3l3e4444o5p5۷ېۥ{i#hhi1bCJH*OJQJ^JaJ(hhi1bCJOJQJ^JaJmHsH)hhi1bB*CJOJQJ^JaJph333#hhi1b6CJOJQJ^JaJ#hhi1bCJOJQJ]^JaJ#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ"p5q555555556666666˳xcxN=N hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ)hhi1b6CJOJQJ\]^JaJ(hhi1bCJOJQJ^JaJnH tH &hhi1b5CJOJQJ\^JaJ#hhi1bCJOJQJ\^JaJ.hhi1b5CJOJQJ\^JaJmHsH7hhi1b5B*CJOJQJ\^JaJmHphsH/hhi1b5B*CJOJQJ\^JaJph66678"8(8*8+848a;b;;;<<-<.<B<<<<<<:=;=ijijyֳeyMֳ/hhi1b5B*CJOJQJ\^JaJph'hhi1b0J#CJOJQJ]^JaJ#hhi1bCJOJQJ]^JaJ&hhi1b5CJOJQJ\^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ#hhi1bCJOJQJ\^JaJ)jhhi1bCJOJQJU^JaJ'hhi1b0J#CJOJQJ\^JaJb;<<<d@e@~@@@@=A>ASBTBhBiBHEIEGGCJ: & F^ & F ^`44 & F ^`5 & F ^`;=s=t=w==c@e@@@@@@'A(AAABB)B*B`S`|ccccc"d#dMdNdcdxdeef^fwf~ffFgGghhhh_i`iiiiii{l}lmmmmmmmmnnnn n!nBnCnDzǞDzǞǞǞǞ؈؞؈؞*hhi1b0J#6CJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ)hhi1b6>*CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ$hhi1b0J#CJOJQJ^JaJ5CnQnRnvnnnnnoo*ooooqq{rrrrrr4uDuEuoooWB)hi1b5B*CJOJQJ\^JaJph/hhi1b5B*CJOJQJ\^JaJph)hhi1b6>*CJOJQJ]^JaJ2hhi1b5B*CJOJQJ\]^JaJph hhi1bCJOJQJ^JaJ#hhi1bCJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ)jhhi1bCJOJQJU^JaJ*hhi1b0J#6CJOJQJ]^JaJEuPuQuWuuuuuuuu vRxxxxxxyy®™™qYqYqBqYq,hhKd-5B*CJOJQJ^JaJph/hhKd-6B*CJOJQJ]^JaJph)hhKd-B*CJOJQJ^JaJph$hhKd-0J#CJOJQJ^JaJ)jhhKd-CJOJQJU^JaJ&hhKd-6CJOJQJ]^JaJ hhKd-CJOJQJ^JaJ&hhKd-5CJOJQJ\^JaJ/hhKd-5B*CJOJQJ\^JaJphQuSxTxyyy|z|l~m~v~w~$%NOrsABLMԐ & F gdKd-: & F:gdKd-gdKd- & F gdKd-yyyzz z>zF|G|]|^|x||||||k~l~m~v~ʝjR:/hhi1b5B*CJOJQJ\^JaJph/hhKd-5B*CJOJQJ\^JaJph4hhKd-5B*CJOJQJ^JaJmH phsH .hhKd-6CJOJQJ]^JaJmH sH 7hhKd-6B*CJOJQJ]^JaJmH phsH  hhKd-CJOJQJ^JaJ7hhKd-6B*CJOJQJ]^JaJmH phsH 1hhKd-B*CJOJQJ^JaJmH phsH v~w~#%}Ӄԃ45MOqw@ABp^M hhKd-CJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ#hhi1b6CJOJQJ^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ&hhi1b6CJOJQJ]^JaJ(hhi1bCJOJQJ^JaJmHsH7hhi1b6B*CJOJQJ]^JaJnH phtH  hhi1bCJOJQJ^JaJBLMř݌ތ>?܎ݎގYZӐ"L~ŒƒǒӾqqq` hhi1bCJOJQJ^JaJ$hhKd-0J#CJOJQJ^JaJ)jhhKd-CJOJQJU^JaJ&hhKd-6CJOJQJ]^JaJ hhKd-CJOJQJ^JaJ(hhKd-CJOJQJ^JaJmH sH &hhKd-5CJOJQJ\^JaJ/hhKd-5B*CJOJQJ\^JaJph#ԐՐƒǒΒϒ͕ΕuvwbcJK: & F & F  & F gdKd-:gdKd-ǒΒZHI_Ε˖̖su;^ef֭֭֭֭‚֭֭f7hhi1b6B*CJOJQJ]^JaJnH phtH /hhi1b6B*CJOJQJ]^JaJph$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph!>[bcțɛ)89浤ʤyfQ)hhi1bB*CJOJQJ^JaJph$hhi1b0J#CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ,hhi1b0J#CJOJQJ^JaJnH tH  hhi1bCJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ7hhi1b6B*CJOJQJ]^JaJnH phtH 1hhi1bB*CJOJQJ^JaJnH phtH yzƭv]I8 hhi1bCJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ1hhi1bB*CJOJQJ^JaJnH phtH =hhi1b56B*CJOJQJ\]^JaJnH phtH .hhi1b6CJOJQJ]^JaJnH tH 1hhi1b6>*CJOJQJ]^JaJnH tH 7hhi1b6B*CJOJQJ]^JaJnH phtH :hhi1b6>*B*CJOJQJ]^JaJnH phtH  ֯ׯefbc  DEFde^ & F ^` & F: & Fʩ=>yzJK:aqrҭϾmmV,hhi1b56CJOJQJ\]^JaJ)hhi1b6>*CJOJQJ]^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B* CJOJQJ\^JaJph/hhi1b5B*CJOJQJ\^JaJph!ҭӭ'(>I6@ׯJKc23z{̲a۳st´״HJ 'ƱƝƝƝƱqq&hhKLi6CJOJQJ]^JaJ/hhi1b5B*CJOJQJ\^JaJph&hhi1b6CJOJQJ]^JaJ)hhi1b6>*CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ,·ķ o\]s$1CDFcƽDzDzNJx؊``N#hhi1b6CJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph#hhi1b>*CJOJQJ^JaJ)hhi1b6>*CJOJQJ]^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ hhi1bCJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ&hhKLi6CJOJQJ]^JaJƽȽҽ>FLOY 45Kk^}Cpr{ܳܳ܋ȋȋw܋ȋ&hhi1b5CJOJQJ\^JaJ)hhi1b6>*CJOJQJ]^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ#hhi1b5CJOJQJ^JaJ(DEQRpq() :^ & F/ hh^h: & F ^`*>EFPWXnoq')Rchj֭֭֭֭ֆnn\#hhi1b5CJOJQJ^JaJ.hhi1b6CJOJQJ]^JaJnH tH &hhi1b5CJOJQJ\^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph$js]^}~3BH۴p۴Z+hhi1b6CJOJQJ^JaJnH tH .hhi1b6CJOJQJ]^JaJnH tH ,hhi1b0J#CJOJQJ^JaJnH tH )jhhi1bCJOJQJU^JaJ(hhi1bCJOJQJ^JaJnH tH #hhi1b5CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ hhi1bCJOJQJ^JaJ~ !BCMN : & F:h^h:^ & F/ hh^hHS\}%@EGS$&.CNԾo/hhi1b5B*CJOJQJ\^JaJph#hhi1b5CJOJQJ^JaJ hhi1bCJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ+hhi1b6CJOJQJ^JaJnH tH (hhi1bCJOJQJ^JaJnH tH +hhi1b5CJOJQJ^JaJnH tH $N`MNdy ([Ųنuu`u`M`uuKuuuu`U$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ hhi1bCJOJQJ^JaJ/hhi1b5B*CJOJQJ\^JaJph'hhi1b0J>5CJOJQJ^JaJ$hhi1b0J>CJOJQJ^JaJ'hhi1b0J?6CJOJQJ^JaJ&hhi1b6CJOJQJ]^JaJ#hhi1bCJOJQJ]^JaJ   cd ! & F x^`: & F ^`American Academy of Ophthalmology Corneal/External Disease Panel. Preferred Practice Pattern Guidelines. Conjunctivitis. American Academy of Ophthalmology. 2008. Diagnosis: this guideline contains a useful table of signs and symptoms for all causes of conjunctivitis. ABPI Medicines Compendium. Summary of product characteristics for Fucithalmic. 1997. Datapharm Communications Ltd. HYPERLINK "http://www.medicines.org.uk/EMC/searchresults.aspx?term=Fucithalmic&searchtype=QuickSearch"http://www.medicines.org.uk/EMC/searchresults.aspx?term=Fucithalmic&searchtype=QuickSearch Accessed 05.08.10. Fucithalmic is active against a wide range of gram-positive organisms, particularly Staphylococcus aureus. Other species against which Fucithalmic has been shown to have in vitro activity include Streptococcus, Neisseria, Haemophilus, Moraxella and Corynebacteria. Rose PW, Harnden A, Brueggemann AB, Perera R, Sheikh A, Crook D, Mant D. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet 2005;366:37-43. This study (n = 326) found that most children presenting with acute infective conjunctivitis in primary care will get better by themselves, and there is no statistically significant difference between using placebo or chloramphenicol. Clinical cure by day 7 occurred in 83% of children given placebo compared with 86% of children given chloramphenicol. Risk difference 3.8%, 95% CI -4.1% to 11.8%. Reitveld RP, ter Riet G, Bindels PJ, Bink D, Sloos JH, van Weert HC. The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial. Br J Gen Pract 2005;55:924-930. This primary care-based study (n=163) found no statistically significant difference in clinical cure rates at 7 days in people using fusidic acid (62%) compared with placebo (59%). Adjusted risk difference 5.3%, 95% CI -11% to 18%. Walker S, Daiper CJ, Bowman R, Sweeney G, Seal DV, Kirkness CM. Lack of evidence for systemic toxicity following topical chloramphenicol use. Eye 1998;12:875-879. Despite widespread prescribing of topical chloramphenicol, the incidence of aplastic anaemia in the UK remains low, and epidemiological data do not suggest an association between aplastic anaemia and topical chloramphenicol. Furthermore, a study of chloramphenicol levels in 40 patients found that chloramphenicol failed to accumulate to detectable levels in serum following one and two weeks of topical treatment.     PAGE 1 ANTIBIOTIC TREATMENT GUIDELINES FOR COMMUNITY CARE DRAFT DOCUMENT FOR CONSULTATION Note: Doses are oral and for adults unless otherwise stated. CDXYZb;AGJR&"%+-7ﳡzrnrnrnrnjhXghjhU(hhi1bCJOJQJ^JaJmHsH#hhi1b5CJOJQJ^JaJ#hhi1bCJOJQJ]^JaJ&hhi1b6CJOJQJ]^JaJ$hhi1b0J#CJOJQJ^JaJ)jhhi1bCJOJQJU^JaJ hhi1bCJOJQJ^JaJ&&FGJOgYQM< hhi1bCJOJQJ^JaJhhXgCJaJhXg56CJ\]aJ/hXg56B*CJOJQJ\]^JaJphhXghw^hXgB*CJ ph̙2hw^hXg59B*CJ OJQJ\^JaJ$ph̙,hXg59B*CJ OJQJ\^JaJ$phDjhXg59B*CJ OJQJU\^JaJ$mHnHph̙sH uhQ0J"mHnHu hXg0J"jhXg0J"U&GHIJ !  !)]  Yh]h$xa$$a$M,&0&P 1h. A!"# $%   0&P 1h. A!"# $%   0&P 1h. A!"# $%   FWR8J+Jq2M0-JFIFC    #%$""!&+7/&)4)!"0A149;>>>%.DIC;C  ;("(;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; " }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?j( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( +^4<-}V#)n4zC܅4-jd}@6mZ+})s#r~qG3fi?' Uz+[AWiwoMsRcopOSoX<=~KEƤ&% (i)EF<-j^CHH8-\WU{MJomru?QK`$.O*y|MܞM{y=rq eĝS÷ e[͵/W|ר3'PQT[OlM8`<<(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( KÞcٹ $qO= \~#x޹7Nb9pGZx@]jz;m~OuV]t *͕1:zpMjYv˦ꖗ,-W*3@Q+x{מZĭST_ꚍ՜1$pIuqxL F(exP'20z~֕ν_WG͋swzeH:Z7~9Դ'4k|><}9w;ZhڞaHd 9?x};Hן_H-?ղ q8* x@W]#%VSsgkO1!!g885F k>(<[wqjtoKi.7;UWK+H,9xo`c@7_jxZEbRYuŮhAxWE7$kPG+F|:Hh#PѥAԔ.,NϺ?=YC8G/gMsXra&6z/]3I#e?,8P@OzȮ7 4jZ#wdvCr0}j?)ُ۬)/ƾ:ޠL +/ό$Oz=FGtQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQQt‘ s98hU( _HZht1CPWK!ԛ;bpKs?(=Hx`Azyf[E_i60FqbώܚҠ /Nap2OS޵h+okU=R[L񞛩?٭ʖ֭ ȃ\>ƀ7=ik|\͇[He\mTo ~olV&xkJnmI%FP2Xhto̶q-ͭ($P6{tŸ,-m$! I\`4Q\WƀEyχwmp=qڴnZK'fm0d*RD EhX ] 4GZ!9G1epq\e} . ;TF^X޲٠yueCE2YRY]R4RpJ[NRq8%93q@mxH/#4^d0H|@@lO@hмUx{ku g0܂T>ޣր6-᷇Js%Y_p;wSϸ|MY)D] q?WRP3ៈ^NDWM.$<'&l5oPi/wM/v$}k7?me,Ҕ(ǒ}7}zmxoOG Kcyo=>ºZ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (څhw1[[ǍUrp2O,\'M?< zoAEsxG=7Wh?1@y _ǦJtW? c%ƏO<#C+4Q\'M?< zoAEsxG=7Wh?1@y _ǦJtW? c%ƏO<#C+4Q\'M|"?z\/AP][X[=VF2UG< .~&_kOaM]RE;Zu)o8=Ji-~k }rmVUlsc=^$>)FikʹF}vzֳYǚJemd(yF2pqF :K[M>X Q @NL.2qԞ:jPEPEP^uW~1f.n\P=zvz-q>lmO2e%Ha 4+;~ "Q{kyǼZ&KV\r3ב|V𽞡4lBO@8u+Ožeoym'8dj o^Ot>1۪l@=@%+Ὲ֦h$ |\{l_.9Y]&'[ Y'1Wɡi2w&f1R*# ¤IӮӮ,-EU[y!VBqҀ8+>5jjV򱷇NX ~3{f7%r"6[|?M4:ID*8֧50A|*rx? 4,q gs<ܓW"ʁу+ )#U'д4_Lk9KVLjs$AiQ(HE¢?(O0P N9#@J訠8k~y/M.=S'hIEG%/o'BDno096PԭR+$D"ם.K}G%۳-r{vFz$y;WQ]??SO"="~fzm7p7G}5r ( Owm5n3#q}js_x}>(ݡF?-ʂɜ8g=X0ʜjK*Yݙ BUAnpq\^FiYS[VrѬ̠OUw֥ ݍT38vjh:7vͳ9۹Cc=ם?~ˮ9Piwh2##ǽYHѵ?k J:2i~~d^e֯^G:˫F&<I$kt3ئ\ZZ xFP-~klIs+%\_Xמ8_ prq\jZV, ^;y; ]i3:/=#GEW)"Hz bbooG@msIqeFW-Wi㞽j3ϥy~'izԼ%)Ī':v]%1 phpz`I;|[ X6o-U&.\7:ߎ ht1-[B2GHYa\'PQ,XrR|GlY#8νh?@`vO ڵvHGuG'ҸK|gF++Oop+_A[iSR5Ii.!NGn#ֻLJtD\O E509㏘b wt4P=\ӿh ?.i@ ^sNu/й:CEsxG;֏@#B] 4Z? wt4P=\ӿh ?.i@ ^sNuO⇄|;>ԯ,4[+k[%^\W&ZsE+iVo?XҿVQEQEQEQEQEQEQEQEQEQEQEs^0񵏄 m8y s[WHStFeJr)^&q!ӦDaK+ֽDX࿰>'g`|O#+g?{?]X9`|O#(CGW{Efp_w?>'gE?";EwQ`g?{?]X9`|O#(CGW{Efp_w?>'gE?";EwQ`g?{?]X9`|O#(CGW{Efp_wdGk\Mt҇&mR0 >Q`gOKI#g11N2xרy5_7< $7}"u]QD(vCc-;(QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE|cmHbs\7?&ڇtF-vV_o\ TQEQEQEQEQEQEQEQEQETSAuq sC "V<RYjԧ/󝑱h$8+9\ UOxN9X0Un 9?}*$QG"+2Vf.ncnWهU>VZ5ztRs%>[s d`q=g_xF}5M8:9 ӡLh_/t9]c2ݷ=n}Ė~Er*:Ԡ Oл$1s9Rḧ\Yt)+$1ۢ8i~MCWqlٵ3~@ݸ;~\-gQj ^-i+ ڦYZ0du{OEr:rCitb:0=1Z#%N% Sp+)ᔎ߯\ё@֏;meusZX"Cj.~c-UU/4E!~%Ϸc9]}G=n&|dO`K?m# dQ&#g>¢SvQEvh~@﷦{֩,V](>X91wZ@Ku(\jz6f+macC@psU|mk\km.*Yf.mG>>!I][5Mkl JvC`Ž POv$Ю֑`P 0 g ox}D]Eqn"@Q;1x ;@5d\y~Rs x0`|8㟛 ;i.nfHaKpRMbi<έ}4xć x>v`Y4n#c+t׽SԼ!7g-};ke%0FzZm^gn._^.$5.k.Fb ͪxO݁k[ 2a@] 鮋"u `84|;-n5wax qiGei ]"Fvr% Hm7w--Mއ ϱx_Z?9p{O_x{ª|-`?Q?"+w/Xۏ /-ɹHf5xo|2uݻwDI.s/ksᧇ?7u9$uإ ( ( ( ( ( ( ( /2~ָL_?9(WyC Ҭȱה?*((((((((((( Kw|.j_kFr( (9뺞edGhWVK16 A~+2VIj:fk/4Z|@u|2YAie=˪A l3dPQMk(6ЎA ַw^SWhu{QWK B[!lai"Nqߏj|Ci_kh,'[FfF@9q( 2f d uKvH2WsP3TWǃm>Epwa0!{Ȯ.fV #f&y<GԚHo-n-2=R@+H'}?Z / Qg ]F8rZ^LNK-_M NNW>:^$ѣcEȦ/01P ߭i\\ixzGk_cgmk- iK"Froh_'~W%yixzMPYtE\$xO$g>6 to[΃P:%ɸ퍎93؁cm; ;K{OJW6eoDw :SZk^־ox Y?2T}c u'֎'[,b6ۈD@铵y4D:֥ZFD(%2qߥmm3N$<8UJ! P@gtځ0(QE|Ro8bVGoֲ>)7?1+_#? kIGcn(PQEQEQEQEQEQEQEQEQEQEQEQExO.-qq\E"d==AQy -fGoC4QFU=pq\ύmú;j:*9$ nS>1V\?=>,٫qtmx9ޠqk;` · ⪶^NFQfY5 ^2b۷\cހ!DsϪ^f[hYZ1ݼ 灭z俉n#XԺJ+9qmNj :η%̎*bcRp?<3-$yN`6,䳖Mk(qO@A+WL&)5-1:dAei^^岀n$$<36÷zu eӯ4i;Hr1iϥc~CoC6K.ʆx! g35]J~".\ۥ<)4O)vw `rsewxxS<5ke0z'و`q#UotK _M"Uydae$GxP>$vckyC03E߇Nn]xV={OU%*"IU]7\?8|=_#PC .[icii!Ea$@ϭkŢk+dS)Jxm.p99毌|EZxKJ5ݬ](騤A*kFK8cl\&:3Xarn|ϵoc=|RHH$ ZJuߊ&pl4]ԛoB#&`HFv[`b9 E:u yO *Z((((((((((+-WJk$U:?ȱה?*WyC Ҡ( xKŬZ'`WX qaO5~+kI.oEy@q ݝbH.5xCѕRү4=?XF.m,eM|m8'B= sjΙoY9kk2$} [ypx74vN>"Gr[ֶ^Z4K^M[Mե6[yvH(`#q@QEQEQEQEQEQEQE ſ]-ԿTQEQEcÖ&6)u0H?Xjz5;ln?'Šs#ZΛYL[WWѼ-z#1ҫxJ5{FTBvɶzTU8EreXLα]BLǾ QÖwi'mwfPZٯL#4@ʄ *oh @7ٍ7Mvݸz@j]9⹻PGmyne l:dMV>%֡΂6pYPsBs[UNWŃ".6^ͿӹuPIbD`@%ҝjZUՕcͫu 0C 8#;Y EM<'#2ß ǦHxZNn.+똄/qvXF9ءTRy Ý:4MUෝ.- N c;x9-7Wվ9Lc{Yvʘ9*vrR5K $)SlT q2p9h6nj3M4m2Tp28&=ih v^Iw__#^`vۍv=VPEP ($Xqĭȏ6Ed|Ro8bVGo֓4QH(((((((((((( ƺUֹGL n.bv3z[gm(8Ey6GCt;bHKU#-IʞG& ?B^Qvkw!XX/W3W_Epe;?V [N$؃GnuEQEQEW I]!ы]pjYDžr_*z<-!SEPEPEPEPEPEPEPEPEPEPEPEPEPHE-LJH[sgrn=F}s__"JN[uO'Q^Hyc_9]86C˗<F< >7_x{ f#uoJ? rdAI匙[$n=6|9+ ZOlk;쁀O rzuփZ( ( (T(^I*$(Zd$Q: ,@I Tm5<%\kaR!dp9p~T~$sώuؐJ;c^3=29}45dپ:Eg眾F9ʂ=Hx̉|cgX?zyG7#G4}I>ZXkF2t/ tg.1uEQEQEQEQEQEQEQEQEQEQEQEWIG%v|_ea@?XҿVfsE+iPEP9XBkEB,ux.j8<*UM-7Ig082î1]MGZ,Ϳ ?Gt#8jzg|OzCYR4h"y&P(ׯ-PEPEPEPEPEPEPEP.j_kw~R3]R3EPHQEWꋬ] n$cif~ּE4/ Mq-F[F`Fl.?<~TQVᆷC}]!U F Y\n;k5Wc 7A<#C?; ovy~u ߈!u7iku ڤ^Qrp ?e\ţPE9#sjľ-}+NK[1d@ʤ݃= 62Ŵ[ہQ7((񗆴Y(3|\Fp*ƥKIOYGu őF70-CFt难avN&FЦC^(&zCt̗WrHT|N''2$/m嶎D9̈WGo9j .ZHkwqͩi1 J19]IiY[\iqVWIx}W9 rz^3MZ/څ̑XOmȧfw6s]nGڌje6LeRyǥqil|Qo$דOB$?u] +9=N`KI\щZ AmZL;tQE"(((((((((((((((((oMZk$PŠ<-!S_o\ ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (0+N r_Fz#p;_K.--+x#{rO|FN.Tpor[9W5MiZMCZԺrKxǷ@_QmNic-BIh=qd%riR w:}h6@v8P*Uvhe6/DdSjPEPEPEPEPEPEPEPEPEPEPEPEPEP\W&ZIG%t~cJ(ZU4@@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@w?|[a KmxZ]/hu B!<{⫡y[-Pa^O<϶>jQw#o^h\/ vH$4 QEs1-N[4~-eDv줡;X3k6jW,d8 v s1c~3Rmz<0m[7R7n>\p0q{}i?2u-6P~bTqqcԷZCPNx.0ƃiC3|}qS<;qpa[Uxut襎G:W+c)Hƕ:͠Stc8pR@-p?>Yzkh^)Zv Xz?:񆱩xVwsE- æsOQ\$Sm'L=B([4Kp܀a@Jx^[ /,.DǑАA8"EdxvyV[V cv{X-uEҵjVڅoLr}g Hc,vW;;u+}Jm&KA-WdYO$t#7 n{gg~Nq@X(T񅖝uCoq. m@o;xn'4h~):q^B"gWWnWRA <'ͮΫgA#o ``]~iyk7WͿ nžH[jNOd`KI\щZ AmZLmE ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( 16??1kI/,x/7?h+BxpO9v_o\ -LJ5[&;.rO=$A](((((((((((((((((Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@q_jXrWk\W&ZsE+iVo?XҿVQEQEQEQEQEQEQEQEQEQEQEyof> iWc"u .+hs]-ԿTf9('LmKȑ8HN6c$8f]]kOnYx'*35@ϥG.yKkZD#Y`;=O귺UƓu"?x8#+((((((((((((((((((((((((((L_?9++-WJ9"ƕ^P7ß,i_+J ( ( ( ( ( ( ( ( ( ( (s+L4EFI=˹Q;ƞ*nWRY"! ;n`ĊcW\PrjmxFELc?w9ҝkiWגjv0̆)՝0prkC͚5 +3csrOZ״7GǃLY'Ku3@Xn|IYZ|#h%/θܼ##ES_|52I$dXcyێ;zW9=IU݅Ě. | `Bc=+qژk}7ŝwI@XI5.]iHOэťyI#M^3֤vG8!ҢHK-]!J@XOt30/ړ2p H#)fN篙?w9yOw^Ieq3\2&fۆڼ85w[t{P;qc)n OEPHQEQE|Ro8bVGoֲ>)7?1+_#? kIGcn(PQEQEQEQEQEQEQEQEQEGoo$R}ן}S 9BI J'qA# ~4OizwcxmSHFlj ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (<[ckuhrN?2b袼j]DF}v'-wv1^YuxDaH?MEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP\W&ZIG%t~cJ(ZU4@@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@w?|[a KwH[QA!Eokך,^gڬI%p0{3J)>dOWӥ$oxR؂r˷ 9_|]gW%ۚ [HTBy!ty֮p4h ay:4>[vNR'!1rsXz [7 [XUzׂl.8&53wcԅK=9*ƉK i{$y``lc25}vޝ@"IIfam}{S|3cZi`v6袊EQ@Q@Q@Q@Q@Q@Q@Q@RPM?>$𯅕%ncB'Lz0^s|q/;%ג$nỌz=QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEdI煵=3=ųjo{5{钸GbzpB‹qTE  ǟH1+ -wngVc+BYԵ)uˡGmt["U86xV 7]KTGynq[c[ZG<-uCYj:uDܴ2[x) `3J&$[ApcPvx'@wύMTm/պA˩xMi$YA *\ b3xxmCð^Ks{1x F0GfҴNmGMqp5bXЌvA/5WP՗Oc!p ![w:.wY4 ,Ӣ@~^9Qֵ}xr+4R˹l!@d]}13mkWŖN[,޴n㓖+е5k?Huf/iڤI ?EVMu+E|G-B+̀;D #8XLJCB(G%KI\щZ AmZ$Xqĭȏ6E&i(AEPEPEPEPEPEPEPEPQMc  RW#KUWQ%b Oj^!cZ}r^XF +N1dPkj8~nnֱz7rZ, ]pq5xO,VB/.P`2A8O|cYeD?!-5wqLWƱ$z(yhĚڵ} + ZƮUF7rNr eU1e^m1˺* {4dWkShW#!K{mF MǚEJ _j}_GOi9aٴi#ͫ$6-w,`'s7 4CGֵ 6$"e $c[gyKZl|5&xZV{Զp*#ր=b[,*e=SIoakai7xgr\6ekB#um\֑o4:~rcБ޺oZxV6.&.#3WP^)9M֭tٴ69Z=&6gNH͒قHSy[o;y5oh^:<:5;&ӒJeh[yB7pq)7 FhWp_uty weu_,F;]ZuɚX ،M"t [#>P}FEy߈R_`B"FIpӻ+2}:z?<>|O/|0kpI/fr@Ijw-ey< n-l2Wx+.4|I}Hȸ6v\D'}:vαgi&*\$Ư ˻o ZbP( ( ( t`j1bm^\61½j]TF}³8S@m.b ú#SPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEJy$`u$O;{yu=ff qX<pOL环e|obeֵ* #s7WUi>+hkG%IOS?hhZo.,"Kc1{F gq]9;tr~]v|u`_o4I|; ,7b vz}zuzK@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@w?|[a KwH[W}JS0]o+=ćiJ1;NW!s 賹1x,-ۉ$0+1ӾE>O_BWwB.RWbpG=1Q\Ňmk#i^6 9Jmlv5d7n4 KLkD>I9v,v4W;x,lǴӮne͝r7mCi^(Z][J3-'YWco zƵ&r1$$ jXI{N{mDcve'<jUwhYD]qr'+ߊfz -2\ALI[ppxz[l&q0#I#dP"Z+Qu|-tatn'ס_}Hռi-aa9b9:Q\^:l*I8Ìt=ҩ^0h2Π]Cۓ9sHHQwW=4]F:\ @9$VG|Ek}U׼=rUOS& ȽW$î c⌌;xXD45'ϒ#:0nr9'/u?Qɦ=bv.9u⇏5ClxNX>XY~9W5}O4fZ{1q0-wހ:*quw=خdLo ϤW-HA?=3ӯ/GtZP[T18q]&Fq}(#š_Ö:Nnbe+qf,N; 1mr+XSHW)W<Aӽz5@,VVt#icyQRq@%֧G]UMn$YP> nJ瓒7{uzgfOzih! JSnE+ШC]szΓsa$W!N@b 8㿶 M#{i-Bt5ˡ>X( *TgؚꨠsIV >%kAy0?4HIvV:xwI.WP)pyZCnIHW큌=O6^)u}I!u;ƻc?)+8hM&vItS~u;gv0WKu{17ۓ3EQEQEQE's#Y0P V%q 5_Ov̶zl8Q|ʼ~,;;ym`1 ((((((((((((((((((((((((q>*u>f%W#Ӹ%hwľ+<)aR .%R;*^[h$4w%426"IйOsZxQ"uյCoc\AVl(-vq?~j(úgtǰ-Vxە=6r+Rź‰W6`B:zWi:iiq[D=IJ(epC+ =+uo$׼ qs >t Erk`T帰u99(((((((((5/5?|[ap3όoxVnV%~aұ=Oھ}o'ScJ?k=ŴW|w̻^8]ñ g/Oi'whӧ]@^p|~ռQxK446x[zO [SZO6Y._'lv@p1%-YNu dKi!e-۹I/ zt5zζ),_]^Hږ]F1לzNs@t.qWoy>}!c GŽ*Y;r?1^Es7 $ڭ!:m[ڦl@H,T~'. ڴ-Okw(Lպpw:vzt\O=3938sod}_I߈48СyH??fs;QuP)<#I 򭺛MjgM'tE`y K-6c:j|/wuãx7Rii;D`3zd|EqiKDBqH30K`u9 u=GL^?f9WbT+ aIqkQ;صU6 DkwMzxvM|V24OtťNTp!/$NF:[g-JOG-֝;-\ pOf|-~t 9[c@=F2zEgk/MsO/vQh .H1 c[oďAs^) {{$?6_coxQxoIcI"ml Ia22rMexRƺe3QOH5ev0pȯitn !;@8#=ZE G@1`O5.ޑe.i3B^\5/©gpr= vo=Y!H;}BfY fA;U jxINsֲYvŗi@@nlczhz~UuZ­PceIYCAm/o`Z2T}n uVw/D<sz@ EPEPEPEPEPEPEPEPIKEyƻZ戭W~,bz5y;yŦj#=W 3NCWugs7p0xdF ? 袊(((((((((((((((((((((*{Y."y$`ܚOtY R|<$z{?1\m~9'bO%ڑơUG=QEQEQEihK3`o:2=ǵch>4E|=;m1#I:zs\WV~!ӞTKOR<;ז?O\ng9]sM]\uac@QEQEQEQEQEQEQEQEyof>5/5#9nAnYZqgUaCҸ׾]BjbÑӟzjxŰsɨ[i$n$a԰9_x+_X[Fh|-9v1ڸᶵocg6!a󐀧nk-..=r$Zt"4iZ旮Biz!2+GC֫O[_ bkC\Ƥ$>"k/#p5Y2ʄ+7Zfwauݱy{Fpˌ1X{NN*/mKeTeKaZjQGqm(%%+͛LM;U>ԭ, C0D9#*H5[k5$B$ X|M%P+#̡ mz~5r-B{w 1N<); ~"x^$nPJFaS \iZe47N VIIr 8U GAcoeeX\\w KUH_c/ږ{OnjrG^kW7VEn"H&i&FB(8'tv.n ;Ҽj6Ou4qȨJ+S8Һo tPGi?<`s\OÝNg y}r@Kbֹ ͅ\Ayג@^:W]m4RdPquǿJs.FO-c`6?g){d[ s>_?FRI샍qnp?wiaS6V:͕AS'o<٩uMHi^꺍(ȻPs8$ڼ[YZC> =-§V0poIWPm`Ok#$^i 3.;(c=Ktjiq42}:cUž}G=uuo.;zZF WZi.ᴻ2H;e 1N/H|Mሣ2 0M=ǪPXE}cow&Y#$`` OA'%KI\щZ AmZ$Xqĭȏ6E&i(AEPEPEPEPEq?sb[2Z9^Xt϶uu]~M?:+ʌ0p:`R((>&cY/|,tMc2~Uåy֗]ߪޒ[Kk/gnO(+hh(+!6|$87hQ^l-o5غhrdٷzw]Nz RZ[a 3p gր6謝? 8&FDʰe? f,R~㞔$2^Zm^(ҿ\Տ \:ߊ'g^d͵D#[:,Fzb; +_lLXcQ6r R۶:N.!nno'BJ:zw +/Cf{ $o'<3D ;YX?_JԠ((*g%v ,Q p)`>ģ,|oؗ=8=yw#9~%\KxXɦhH.uIoP9钹/-#:4}1|h¿no6Ncq끎w-QEQEQEQEQEQEVyֵ CA[m.k`Ap=>x+}!BnVk :P91O[\RXsHr3n4j"|}ՓDZdu E29TY#`*r@Q@Q@>/ῈV $zz\_D7F+Fd%8׎/ZEګKst#QYZ׉toĒjVCVwuFIGAj]\51wupJTc@QEQEyof>5/5#9n!ihOwKet޺:(qM2WnAssO\XWMIqeNד[4P(como}웷y{3/ýS4i,|0]cb( teבhvaach*( cT߉Pmwm3ξPU^Et' >¢wnUW[7v l1Rx'W p}4lwJ ?/ tZo]rA2_(E)(mX2OllQ@\z%Yأ$M#C1cO'ި ״2X@wDr6I9cJݢx?L5oD1q}rӼJzxՈ|5Cg}KoIsupw|nӠVj:%լ׷kd XQIlc g˪oTq& wP8?xR6l5d͉M$lAkԼ'jVV"<iX}kЦM{:󁴏fdi6CXm`@[͸ǻvgy4M7_h0n  bO @ 'MUmdWy,#88gxRz%WHq' h<96K,#{obN8T-4&zsG$f퍮IaǿzE p1ƨRE ck=O>͟.K4dEwtw:w=}=#1*Tdw\֣^jriin'2pHwjmWǏ*yo;Zn>ռ9@Lv&R>spNٯ@4];AŎiڙ>IryV<|#M m 1_/;?J_C]?TK FMZg?L.K+ ȈA #Xt?qfsnݷ^zfxjzp5%I^6+J+G3CHuK-[P@\m99ʜӯdD}WuXw'@SOj4 hLKڙXXTe\8'֪#Öz]}YYces_36m$yl/v5 :C%RA/>1$x4N'/nXʽusk8F¿85k`d +ћb,۞͍V^boٴ.{yF ] /sdwTzj&ٗ0g(@qq(m>=4+]ڳ2İ^8mg}/NHfv#8m hO^G-6q鑞}-WzI|dQ=Aשu h>% Cr0r2qL❡x[Cn>VbI٠ z( ( ( ( xNVͫqG!Wןc? ZvGYp3B( * ;ềP=sEPEPEPEPEPEPEPEPEPEP[M6Ł*T#fcg,PĽFmP=VՍķv\d%@taz ܿ "z+X,/cb`VwZRV6_.4A$p%V7vA;s׵uxto:gtݿ9ӮyZ^G׋%OR3k:νz:|&5{ET?}ˌ~gU4.H6e$)a8'NڭEPIFEp^%4sں"mؖ= ^x xI}.Md%>ð'ǃXO^j62YC[hxd=ȴӮkw'Ve;^V#>@`K{hc*GUp*j((JZ(((((-QEGVsORN㧸=AEycxL[/7[b]f:S!zxL.]0ՇP2?:{曨 83-@w *+O\+Qr/[)R 8=5g4QEpEsKyY"%d2G+[\_Lo]$7 3"^ ӣXwo?o7|vsi>"[1pbJ0 ()>.zXn>a&{p(ڻ22?'nH%SrBR7ϻ٪%}VǚNeXZ7aHsq&|!w@M6neIs2 ֒C~D-m%Г 1=iSfjvEpeJ.A-<#e#K/R GRaF>glrpn+.meO$F hbDRwx9kW`n[a+|ё*tN@c!.|Ag]񆵫N/.Kl =~m_`v6袊EQ@Q@Q@Q@Q@W5X|jzt~\Cm"8 IEyƑ|Gմk-I[/&;xּMO $Kϵ\:i?*į-YXZ}|g6Ɲ"\, N\Œgj=b ( ((OAZMQI*a~PjM4Kd]ʠ1zƓW,?xi;ERbҬSd;v9F@wWa5ZͲ9d:;۷\ jz4GIjX rG}ZxkKb7M+XΙHqqsq$vWFlr:qZա6$#ȅc8 '=2=]76ŅztAt$2'ܷ27VVIcn;YLsMB$Q~hΉ\lY]á鞔P5^Џf]NUV;Ǎm_!2V=JT-\+IJ,]{oꚭ]%#/#zMPω7##I+ V+Ϸz}麕wYks'"2q`Os4dY#WG #7om}B}0\yˬD++Qྵ̂5'AC$Obh| iKcvG}:=F!vx HU5}@X$1Z9У~(;+=N qR 3j&k>,gR[24)&2rNN3@FEy|<#S ,\^I"݀@a"*r 8[JkrD}8Xc)03@vEy֡z5ˀzt/lV,mxU|;¾5mN^#;8!1  r<zVE-y~{m5-13YjsFخn:9Ҁ(((((OnxcR#ͳa+V8>m[8~Q|ƼgZg[}^ºz&6)Rl T~9+EwEp|J49+Ew+sW,+h]ZzRꖑQ PzQKE'JZ(((((((((((|Hֵ2mCmN[4 BsQ9$d_MwtW į-YG#|d_MwtW į-YG#|d_Mwu[QԬ oce>q|J5(luO'k\ہ9(s$ Pگ(Nzl_['l󶻯x_I𶜶Z]x$<)ٻOS7h և4Mh#X|Wp1b)h ( (9Xhwe-+8 *; v6w[ۈFkwg Įs#Q|O ANzuz=IJH_0sB<g5;E0\ X=qֹ-5;=6{wKn@yמּ b/Q@9r:'ZU){/[ 'lss=i>#xVKjW[A?+k^kO7ڼv>k͘jVH?b]m *X}ᜎ`O6 -$X?vz=txKK qH=9O&燵k;m/^1O\^Am~62s^+ |AFHة "#W(>5E: 1 02b$$ƀ7FhzuΧMIH!mGh;58#źF+\42[4m\3޹85 ΕisjˡqbRҗB75_6KAkHLbN9'?0 X$⛍/U9%_c$+.ᎬI?\sxWV|/jV `Wt}G=2^u4cF [ ˏzd uQE1Q"  }Q@Q@%-_bG m}G# }@9sZgjh~;B9kF I@o={s(CFi՚9d`!X)郃cq@d3Eq M ,R(dt9Vux?5<C;Kf^`|_P+sW,?C "hsW,?C "hsW,sҼCmk5 "Fr8k|4ֵx"Q'yɱWv€:ڀ:(Š. u>k;}9\0 rۮ~qn++;ZGkfjȊi1ǿX pb2y4$*Pr+ueվpslR4xelXGuEe jV:jjm26#H:,z/^]#Ԧ +/)TprzNy^{D=9w7y(dLi:;,kkZDXZ$uQϣu՝;KQmispN:>-+xG'm>KKGG HgXsһKnmLJ1:Z-ռ&Ll 62s׊cfumcVح2AW.c޶(QE()7?1+_#? kY?赤#ER((((((+$WC:>.2 ȏ6EmV/?Goֶ9MoE|ѰO? ѫlWYe}JzZjDێIhB5PEPE嵅WsD7<*Rh_Ɨe=y*>܎w⠼qݯ˂$S5t*H[=@;yRXePȇ*FAңsg`vHyOP?x1tj~!݃ϰ%OƐvәm"hN0{T]UOiΝm*I*hciʬd@O5+Woi/-TIOޑ Opx1PNh+ú=ƍ7Բ\MY^8Pj}Cź&!JYLbm1S\xBԟMmcG7*.I‚yi[Euo,ʁt9 d} h-E\ ۨMx0v ;zu;äȹ1<۝[OnQ@kn9;}A ,Uד;2yn[wAqIr!W` z@}źZ,I#ŲqEwW"P f;w;GOZ14 X^Stߘ`z$ܲx&=ZE[`HgH(q {WMKK[F\ sBsuå-QEQEQEQEQEW?Thկ22F;W|`Y~fMcQDb?:€7>icHnA$ẇ?@~Q4T@T`S(< ץ\|)^.Z:( ( ( ( ( ( ( ( ( ( ( (!$˧_= 8:Z^i B^5Ru)ss]s~.6I[jkx"9 '4Rךi5| RQ?8uz<3Gs)1UELmW=Fi>FG^!$Es#τQB߷-gW h~&HX9FH8k@l!LmŴș3ɫؿg`>69]0Ox{Z4[Z5 cj]?ºs Οk4Qʒ @999z(E׶'*qޮEQEQEmGQl%C?u5#å޶\_^{yH []!iwV:+K!hĮL{ ܓ̥.&˰/$zW^h9.r;Idϗ>~ٛjp'VvkV:2_Y<) C:3\[c%ŰD|`e\r2 8{.u?7r.2 ȏ6EmV/?Goֶe x"󯄇4 j-;.?^%;]Z# $AעB21@Es_?_~SCԡԴ$Au|<OMKKj֖ەHeps> /d/p&w$rI =8'#ԓ4 v xƺ4m#SLjG=Ci|A]6bpCӎuQx>ٮ7M𞿬9 }^V{Q$ݱ#!nxWF:lˉ!O Z~'5ojqZB%2F2[8' H>]6?fݕePk0p@yKRʿ.dFݏLK}7ýO0,PA) }k7mDn<03h;9}Wj# Ft?"2= +GJ]>Xf.^(\Hdq8AMkKz wYmbS=1QCj m%_\ݵ`(Rߋ/ Gquad\YF?IYk_9\3_8RI ?L8NY,~bJZᕏrNH'Lֿ֒m  ˣ/o肻>mҁ ?/l>׺ob78]l%m$,{ ?' ^ƫg sMơ$RA Op}k.>( zK:m oYl+$88ڝe?oh 8ϚƧ(|:<;i,qvb0|H`cqwPUƵqmZw~U$s"46I[['89O`}MGLJOsV#yTj-qc qqxWOxog=ȚB0B w# ]kK'k; %రlvg$s{XWp@0gG,LJlC_ӯgje쉢-6ߔ?X~(Ah:B&+\s@EQ@Q@Q@Q@Q@Q@Q@ ^sp\mq:{H9w!ףל|(%K5;k@EPEP^y.>K-zy?S.?\tQEQEQEQEQEQEQEQEQEQEQEQEy+Qi^^7C _WPEQEQEQEOSu,uhmh_cG"m7 {ˬdev̶YN:rr?N}\Sxx;&ERo.i{eAs U |BXmZ:N%>ÚhZ((((((( Z]+6]1Ds$ a E:Kw QOBG}ևZwX':75İB{ =8\zx-gNET/8Ͽ<a(PUtZ(((("A5|mc]&э]~ !oItF5wTQEyl_$^ކ] L$GQ$Ӓ JXeHe]H!#3S쵛 ,5hmxzB9Go_,Ї.{esN*+?Zxf~´gO?=V,ߧ´gO?z%.2θϋL?9(g#? k[U赭(a '+Q_0'@^@#~ i_>cdRi>!ђ%sIEPExݜ[Ir9:J⴯hWxċ,ohfPx:f~ZռA$?whYwEd^ +VVk \\\-if2B]:.{%Ć١ {~=(n6#8{DZFZHmU^=G[xm!vw.=s@TW5/xmd B3*Xfp1R̘@`FO\q|AxgHb7qYXhRE2EZFJXᕑB@lAGiKE%PIKEQEQEQEQEQEQEQEs;F^s-$lCȧaUicHnA$ẇ?@~~C}kf)95E~ DE(¨EPEP^y.>K-zy?S.?\tQEQEQEQEQEQEQEQEQEQEQEQEy+Qi^^7C _WPEQEQEQEQEW9^.yw|IG=DZ0y;kM!lbR{yRhH2uiYKe}mżO-Zm-ؙ VCF{7Q|3#Św4p%"{0{[TQEQEQEQEQI\NjyxR5jSqoa2HOL =O`q@aXI]Gmmsɯ9k|UshnuzvIgJFJ!ͶQIQq @ xoKƚ]<=VPEPEPEPEPEPMWA Ck7j_^׻&M1(((((((;⶷i8Bp@'!Ѯ4 dkv sd>3i{^ՅΚc,J.`h9 >w-w գ? }k-tAhNHPEPEPEPEPEPEPEPEPEPEPEPEP\g&ZsIG%l3D}-kj|">`@Q@0:HF"y1; z5yawkw Dԇ-sZMaVt16(mJ3pq\oď'{+n-d'Qr=7vx.]4Oo=s+=̍ ǎ1Ե[K~ZlAmc|Ddka8!Ha@ơQ`(*ѧ7]2ߵf1ww=~))ciN;_/' {skŃCd8|u8*? vZ~5Ma $DHEgccOzW6K3[lJI!9+i:!-!w7xd?I=\oq"e%\rA1W~ܚv-wy-ﯿZЗOkXJ Ga59ȓP:펏DBe'>} `^|]cj0|#{Px? 於 urgDXK2IRqϯzEw6<eaEOEPEPHHc[t 9 R-Ӎԟ@:+̞# Xa=v;oQ>B,?q٭_?۶y+jZi;'\O=wMK 2-^N>'֕%-PEPEPEPEPEPEPMWA Ck7j_^׻&M1(((((((5ύ<?' zUyđcE@EPEPEPEPEPEPEPEPEPEPEPEPEP\g&ZsIG%l3D}-kj|">`@Q@yŰo#&Lj+Gtl _>K?̱Բ|\~4ЂAE-suOD~"lc]88'Ֆ9mL46b|//7?L)?3n80=ȥ$ZS[|[E[1 W=pGN׿[?)Fw7A\ ӼYn4B5' $efJ/otɊ/Ez@=(yllu-j㻕܍_x_l|L藚bjvȒ~@Ex^;NK{H nr^gkEkEQ #Q^q?7gFgʪ 3*Pi,<`bޫfEn ڀ= u4W|# qIhon:29 ~}$Zk*𶥬upgX9j9댐Vr(':ޭ-R43\=qv#$'\N~.[GӦ |~G;a@;}][QH#t}ٹ||I#+NZ&c[kUX5{H1;b^O~\M.Gu%|!6*0 9;2&k{%v>W 󜞴ytk2ۉݨCfA}Ҳ"^]AYZ\꺌-qD1xrGwgVqpMzFEeY> ͤ{wr3wƚ=kvtT_.fkA3gS9Y&(UsJmh˸xg+/߅tθ#gw v1ӫPi7z\V"-ĢO,n0jy|/oP`y<ȠƓ#ּ~Kg{]&xu{ȭզ`tmʠ24K]C]7V{!U ~$ր=vHw<1%A5j ( ybW+-FUS4/ FƢvкo|8<[0s'v? 騪FF((+!j/ ++&_CJ Z( ( ( ( ( ( ( ( UȻ6׈~]>3Q1%vOLqݽB|cx:mmD}ǧ5\G~5 ]c뱒Xcxs~>->bn8 'r/ႶQF6 =7c9<15%$asLߞsw>.^G}CVɸbz9$'-GZk>\m?z08p=* 8tQEQEQEQEQEQEQEQESUE{k7$MWA Ck7j((((((+>!= Ozyw/g&s(((((((((((((+$WC:>.2 ȏ6EmV/?Goֶ(`H x @s2O`z4eX!q~F9b4/+_ӹ zZZ{wq_|qԢ)&n:w ' vq\M<%fyn쯮RXld(Qԍ׵vP/]FtkSQ: U $<~5xJΘ9EPVdܬQ(:WKEsw^'kbm$`+H{WG1KEqZu##}.FZ&}$mӐ) }2X5(${:N$^]mhK7Ftۯ 3#xֲ5[ 4m{1Ki,p7(IsA(o0n\YiNe\4r+*[ ^rX׵n,`" A;ӥuP9xbD}o;XjĖ62NbxÖ$ fky{kH цz?hRZտ̵-V5}'s=7B]?Zư. 3L9[Pg4+Oi90VH6*}AWPӦ|Q-n⹂5X6r?31cQօ>uxhx0Trs\x ÚqOs}w,ch\ 2\SkE9OC[:%RI2zn+nEA֓0"W(NFy>ĚnmBJٖ(¨?)NIb(@hV thMvILl2c1֨इۘO.[;sQ@Y[8-ncT1 f(JH|O2##E?SҼFu[jZH$s@EPEPEP^y.>K-zy?S.?\tQEQEQEQEQEQEQEQEQEQEQEQEy+Qi^^7C _WPEQEQEQEQEQEQEQEQEV7'x[j֢PS'dt8EQ4m?A-R>'.2θϋL?9(g#? k[U赭((󯋁tEw(W =\j6HY>pԮ?oS_Z=06Nrc% v(((((((((((((((({Ǻ7ߘ24hTE?`j/:_Gtb]>FnXd7h^I}Eкz**( 0(QEQEQE OrסמxK?E@EPEPEPEPEPEPEPEPEPEPEPEP|M5? Ez-Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@5_^׻&M1y^> 6Ơ(((((((|%=vG;HtlK-zQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@}7C _WWM5QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQETy^> 6ƮUE{k7$M;( ( ( ( ( ( ( ( ( ( (.2 ȏ6EmV/?Goֶ(((((((((((((((((((((((< ץ\|)^.Z:( ( ( ( ( ( ( ( ( ( ( ( AmZڬ_ȏ6EmPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP^y.>K-zy?S.?\tQEQEQEQEQEQEQEQEQEQEQEQEy+Qi^^7C _WPEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQERR@S/:^2$lta=Lr3r'4 ]#ld\]qֺώv3|uh,&>.2 ȏ6EmV/?Goֶ(((((((((((((((((((((((< ץ\|)^.Z:( ( ( ( ( ( ( ( ( ( ( (.2θϋL?9(g#? k[U赭(((((((((((((((((((((((+!j/ ++&_CJ Z( ( ( ( ( ( ( ( ( ( ( ߌM/l[a}Z(=FslkμR?>1_J<ŧϷs1@oV"B"` ((((s^*F4&HRF8Hyn:Һ:S/~o/훼3t.W09! ǢO8zAX'&F ߰1=ҵHh-!!r9fvW}Um+[it٬]٧,YI  ּmIVEcg,Ğ@c{?6YD0jk*6ZB2O!Nӯfl& N0yBqT7wח6ƸS\ x;};~UhVu[,dy&dITMv>UzU_ijam[,wۨ+'?tt݂c-S[,K ӂq@]2Xtۥ& 7یGQJ_J__ݴ)'ݖh3*28'=]U|7u{kj,3E *b9Sh~]:Wz30EvryɮN<'[Aa< @eH!IZ(߅ekU:x$`D1ȍ\kMqCy.v2' EQEQERPioLkOKHZ`>7R ny诀d?z5QEQEyď_E^^o#GQWPEQEQEQEQEQEQEQEQEC4L63Ɵ|[smn;5 o*`OCA ѵ<+K 9>\-S}?(B9\ }Ht?+.+s0Vxϸ k((((((((((((((((((((( XHGxs Hƀ: +_1G'Mږxb}SBkB$%xhF1 x=Ŀ^xS{aG"!p?x׽M /4GR:Wgi⻍;Linng.7|[iuk,фP*]=Owx~ gMc P]_1@{/_ ǦBtW? c!ƏO|%C 4Q\'M?= zo/AEsK=7h_1@{/_ ǦBtW? c!ƏO|%C 4Q\'M?= zo/AEsK=7h_1@{/_ ǦBtW? c!ƏO|%C 4VWdՠ/'E7## {U?= zo/xK1@Mw Be"Azoxz4T8 >'+ex}w "b~d9 z^M[𥮜!m V<Ez{/_ ǦBtW? c!Ưi"u=7VFJA:@9 *))h((((((((3"ыu㤟µ|%6-+OxRAkg_&u; mu%iBSHO^:PzoN~mnśжZe-BYp=KaAz]Xuu-CeٜHrZǠٍVKkd +8(5xuu4AӷϨ9d~d-c[֓; $$r=z>xk>[4GJuGetdĤ%N=$MXi3_[%uE>B>#^eE1 5[8MĔ9sֹ J|4|ZpľHFeL'8Eni5,c_%8b8ٕ@Ÿq@:yt $:=R͝7"g[![kmil`y7m/!z·+&VOVkCEnG?SG 抭m\lSNdpTyyws>#5A;jQJs 5ĜcPfuxb^o_y7F./ i]V[]ݢ o 82Xox)4{:M}./0nP(P# gڦGݽ.o.!S_Y]ާm,Fk4Z؀X5}?Os^XԜ\Z۴ cGUd~,e{&y;˭h#ьi` 2}>T{;Y$6[|ֱAvÞ:2Gha,B1;\x{@ӥч#^ EȚ)nnomC fbO;x<kXeχ1C5)$m8O+»4l&"u'{}mlI)+ lJrHPӟ^z­zmu [}6Kut!HG p:;aL[|ϳ18zcnz^٦m[ gbrp:L:NE{;/7w/"L>e#؊lwiWvp.,= >>ƻquC2%ž>6ߊ5xE_>=I#922UѵW>2[J}pۋkG (vt,o5Vv\1DD' /j>#kHV[o*u6%棨_ڽ6ڦSF*@A\H<{{k>ZӵH--3ʋVt 5? .dbcd]IFzq@*~[Z}m ݴ3vn&"%^S[EscUNj_ڄH4cw6x.H ,Dst׃V,}F-B٠ bI*xZWw%ݓydI1DPvCUJMj k[̎܃+wPxŷrKɳed!d ևˬiQ^ͧ!`mlG#hB((((s)a%&PO:蚀մ;Dc.9AF[Cӎ?ҭ\Cma`Kd}ޡu(((;$? *?_B"((((K*CK+F3'8&};(X! 1Zo/!z}UȝG@>Q6mYF h 'ܜM4Kv9>&sj]:2㶝į[]O38_G%mؿ?Cݷ bk38_G%mؿ?Cݷ bk38_G%mؿ?Cݷ bk38_G%mؿx7ǺƝ6xu$m2>r9",a[h#ZEJ#M. `?Cݷ bk38_G%mؿ?Cݷ bk38_G%mؿ?Cݷ bk38_G%mؿ?Cݷ bk38_G%mؿd|mg#Y,#PW{Efp:W5XC̈́Vr\|ڌ3>ߌdduB>0J#;? 5Yww2y''A>i2ӹQEQEQEQEQEQEQEQEQEQEQEQEQEQEQExS:PqnQ}'lםW sy=6xK{b?5Bs@4Oxg|w4חw +vy1ǾNMu#±"sK!FDc2kr][' ? ZOGEvco(7-i?VٍoZ ? е[4Pf7!kI(C|-B֓Ql@][' ? ZOGEvco(7-i?VٍoZ ? е[4Pf7!kI(C|-B֓Ql@][' ? ZOGEvco(7-i?VٍoZ ? е[4Pf7!kI(C|-B֓Ql@][' ? ZOGEvco(7-i?VٍoZ ? е[4Pf7!kI(C|-B֓Ql@]?-?VZs_) ͛Ðvg}0}vPgjrj7+jX'?i7ו!FA_So(Ip8ʅ+ѪME (((((((;'?aE=M,qA^učW~-Gs{ygOʽ ( +;Y״q-3J!Y7[x+:m4u";ẉMdqOhN|O=Jhmc w>vs5aWt-d5. Kv=׌4Oj7f9>rD3n''^&6v:6Neio[m#`Vo {/DQ|wr:sآx"jYVQnyKx->q)ޮ/4;e]Z2D#fiw1=<f6} :Wq[bx%"zeXgVsGNZ=mP69ǽu4U MnT-u`#7#fy##4ō{am){E,7Bqހ/QE? |o<" !IF?*j@6MXUaִC'"z5Q@Q@m#GQWWHUQEQEQEQEp?xoöɫ v5w4 (3RǠ5 +k$]\$t* Geѯ@ibmwVdg^wos xm`tKm!H?Z&)]jZi d2w3q_׎;CD#K-R$1 (BrW#$gۥr^xZ~麼mmNmVi`3rzށX>]iR+SJ:|.n\̠Ԓ:qUwH5-jUKfј)189$1v;[ eL~onٜnǦxM\?q;mً6ϲ/=󿯵u .4}{kw8$1<(;io%xV Gl _ZԮlgn h.0MUO$`F ya Zg$F#x2#x@_J39Uzn}e;$_d]iw6,^alxȠ8𝮺NJ!-4WIe*pQt}j{ꩩYϩ4Vh9 uwσ= }WIlz0H5maigdVlUa}h徂%E- fʑy +F(}uTrq#?w%4Sӈ#~LxOư3m8h D 8x/ 7GG5FB=ذ>&6 $is>cٵkջZ9Tr)zF5vP%e:ޣӠĝlКŜaZ\o+12G?,MŽ΢,7:umM,͞gdPz9oh4>Es171=OC6 q ┵v x'h𥶦5t+D X'ʭGqS[s=ڭէϘ'6yQ5|s< Q:K{MT20xwχ4‘jt7kd0tju?HIӭᲕYdpFRG<O5TPVwi]gnuh}ƒ4#{-v.01SLMEuAv}MG~8pE |~}ٓ׀XT?* 3GO8k?O}pB $=?aJҬ]Qӡ\iSmQ*qc7}@ r").A*#7xKx#]P 'N6k~'m|;e0)RI'@Gs=:w졆3u+8~2e-@e qҵcI>2n G;?փ^xt5{+'ɑt\bNmE5fϦhf⿉)Zp^%R)=sm1 "7cO >xO.u3^ĺk (SZrT=AW4[Vd%؆KhR288eh]MM R#hxNU,Aᡶyc(*ܩ ɮ<T?B9t6ԗR6ћň³Nv<p|y8"o =Oנ[5#d!ӂ0\H?_#ܟzFhj""i!~5'<3.ui4KF-N xB{4w־4OE [wv&6]'삾+w5^겾sN91U|Y&ĺ+O+E;k2}q]QE?x{`/SLQfF_VڧbAfC{Hh09mHj/2K5#ݗc(o?_B"GТH((((_M]pköɫQE*u*@;7φ_BEC7)stzs<]C=n7ف)mҡW=O9>E >ܥS[۴I13}(w3)tMKYsd^}OyGpJ'nH瑜֡_ m{B+"0p1c5 =j-e-łXc6.\=fF}"=&-gȕ2N^\MC@ռI=o\G,sŔrvN8O^fcRMcIM"2Pܜ֮#֬43/lR)ݻBy[3kiI3F|xns½ X.r^1toGӗQ}.YS:$M qVe*HRAǷ(QE 7fm5$LQH((((((((((((((:#0Wם|P_O (()QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE&q5z-y׉xC\ ^Rj (Q@Q@ ܓi4Lw8='ž&O)W9h$Sۿ@VL$k{=eM?j#\pN1[SK3)sZ( ~$?BL!9-^^ucZۮ_Kf~"QQUuѧXOxM:s Geϵd.r[ǣ&8@ /?4T#ky-|5 '?f#mm?`ۻrqjгOk/!p3mqf:2 y&~qpt6Hֱȯ&X)$xzҲkm{:zml2R\99{zE'X״okVie]sMR0Nv`?0^g,;A]L/-˱S*'`c(Ҳ(Ri]BK =k5Um+4Xpp=99O=nőcW]Mo6AwB V圾#agum[8hAF#<:P挊W'^"hP#:".N@ldRi<'gM&yj#UC.FqNyffÿD7auc|$"%Z,Ern.Xĸ'(JZ((((J)h(;y-]ʅz0EKEyÚq.BX wUʽ !%A ԭFgV*j(o?_B"GТH((((_M]pköɫQE Ai}&{|{[d, p+VkWv:A} $g\ArnAnFO@ѩ+n=L/ ]*Y#F/6tn߭\#*H ep8#q\|V[)ȒGF[?*lP$rFW53 4+:?] Aƃj$wrf`%|& +Hu-,qjjyW_%"q7\.7.MlB&S?G[t k1/>dfr3GcUt:I~Z^G0B0T8w 8;9gԮ4+Q^KDM7u2oF:wWM;2(T{F2 ʷ;x$=gL߈4f >jH"㐂rbqa-V8m5-W6T$^l> ϥcP]e}:]y 4+N0W.oѵMN-9w3ƛUr 7[ b`E*5'>F, pL0t:"XoG.TQ U]"h^$'[k;UPTH oqwt;M/%}qk$w̰E p<7[mKY,4DԢTd,C`U4RZӡtY1ɴA!EPq\W!kIuC5Ǎso\&_o e袊EQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@y<aВ I@EUQH((}}kY{}q#t +Oc=ս'8$'?@u4R++(e 3K@*Fw *…7;*RhbagO7|v:j ( ( ( ( ( ( ( ( ( (<X!\?E:7/+jMVEP0((:יFVI6QATz|OrH<֧^Ʉw&uP1wKӢ} 3*n^yV>FxšզY!ԞhKI pnr=+5M.Y4脶(RE>Ў"WygxFF\ڛdIdU Ò'ZN{7T<374D[x%پ~|EG<{VM{}k* i-8",Bܞ?RtjM&$>γ0@B0O7|5WN_^M]HLpPQ@ f '=<{k!0fq]=Et7--lЮޡ>i˥x FU*M?(LQZ( žJ_fc;qQ\CinG 1$TzzV)^k%zaI:],׾ӻv݄9LU ^Xе5 nRqb)ۊ QEyď_E^^o#GQWPEQEQEQEVS&o|5aDH(dEqm&c& e?k~#=xV > 6cS>Qz:-X+xbVc="5+*sֹ_]!+\Z0\FN7r;rdc6kԘ̢FL)94f0y1G(c4*U =9%Dy3Y-tE${k3+>qlZH6Vϔ%}8*fNTjtc%w:|"%l`$ծcjoKq+r 2rTzP6w լ9C,jOG3F ciblu(q>ື,'?/yPVF#:f>gs*MqiGHՙ~)j6k>nozcޣlu(q^ U>$sszOh xCQhTƧ]j3mI.!A=}j [+]R9!hIU% !bIю4F:*N::}ߗD&V(x6U|oe]fuq\W!kIuC4q;(aEPEPEPEPEPEPEPEPEPEPEPEPEPEP^uCFa?$E:#0PQEf!ER((+x=eqqqq,MFI޺ mSO!-Cu{;6;mSM\ZK % $l uxU}6/ iR̥PPI.9`7g4cWGB'[ycqh#Q1 xsnꋫYD)!6^ {g'r7ywF<7dn>oknglTi爼WjΚM4fyq(9~ (h}zon qg 3su=G^ ~.Ŕ:)"*D>Iv^ ү4}.I/%U U<JkBⴍM&o LIWmr復C={>4pĪdK##Gh׾6< %+WH$;uY`wT:x]e!m,~ro7yN:wx[At߅wp[[{ԍWqBWzׂ'Xb㑯"b" NH֥[Cb-7M2mq@y1nO k~ݝsZK'(2`#n7l84|[K) ̊p]p,sW]79#3Nc.>txBmÖݔr;\8hN cӬ힥eEs Jƨ'<~'գ!-j@Egysm8>V.Dbj%{ #uiqo9v_XǮ, H$5kg xps927BAf\CmJmE7ʌGÚ՗ ΑslE o܃3ִ->–Vzk&ٱ2 Qxzb(13 ![K; /Vxv-;O#d7',sUVNt;}nYI <OCo=y"@C :ti5QA!EPEPEPK?^&q5z-I(QEQEQEQEQEQEyJ=9}J8~ 5PF[ƵCCZ=ܣWE' CPY[VSY]% I$SqY'?ˉ.46;IeMr9' ?ksÉ WhnLdx?s)؞' pui8 cWW]r[k~gpb]'FO`k!I^hV #gDKx-g`s@WŇ=C"\_[\KHZ)V '*C]}&ovc91^ZڬZ]R4@ʤʞ*]jگï\:uͼ&hr|oA;O-sWMaE#}NwqO᛽]i"1Nx9 d?&7ҹYMo'c^#=xKQ#-#My.A]KsjypVB.Km nv<P>$O.|1O2Z}+W8Rzz犞:Ӯnhn&a?4[ dakR}s]}r=kn.v%Z_˔`l pM,zj$}!Ljd$ ۚao x_FI 4p$q*uAv2xo|GǎԦk1$L+-:FeVv:X`@&6qEEܳ1Nkm ټL %Rٛ0}Xq9-STLLK%pvh }i?ѩ[hӽ"K5* F%x=+[Oԭ|sC" pDEm5  5+Kt!A%rKu}oHO]Hi2\CʶS8Y0 H< pV^V84]aQB#qp=+.bw*s^1qҁ{O^kHd&8ܤ__\xMբ/D9B6pAk~TGt/eԽJbN\`䞇xN}*MԠJm 7)!< cvOxC;6~-@@Xa<{ xrbmli@8OZ}-_Hgڴ̏u]?d fcA,13뽛.,y'\=QSiv:6tצXl 99I'Ik[օ]RÉo'I&T99scǨuͯ<3y6z'{[,"$^8C].⁩k:5uj6 3a$dr8c~!ֈu_ji N0#p eNs3|@md5Ѯ&2x 3(QEQE&q5z-y׉xC\ ^Rj (Q@Q@Q@Q@dx]>$ζ[irX(kcI_5($9mK$I$ee# !iˆg&wD@?s^^r4F:A((|m]h:,gOdocWk U%ܖů|cqjƒ\jz.`:|j@ p &sҥǚַ=ŵVkeeb@hA Z%d򽽾ff,r@է\݇B  :[+jo=~Bx)ڟ;QORn +af }#y p2h9|eG[kQIqkx;_&w "3*F=<]w`^$~i0<84oH4'.U`Xb$:ZUI\Koq!IbrG{eydTA}=¬rN':J!udR}4dB\[3Vc$ӐmM,Tߏ^2=Z-=Ťf?"Q9Q~-uۉm"KKP"h/"CxQ)GL܎GkK7.nyFy$bI=hzžƗڭKdc@~zU7]qce2÷2H<hKE !jg{_p;@*@b\ EbI"+=Vq)gaGJ|aj%Um"5 e6%$Oր;+|ii}PݥPw sw56/^ݬm7IInqw +F#,^{E՘=xEQEQEQEWϠd֯4 9gфZBIpPG@O55 |JUu*YBJ 4-1%1< 4ˣ$NRPK"{QK@Q@Q@Q@Q@o>jk_M]4D(@QEQEq'5񖍡7gYrA;+R2a.y[/v ߈b񞵥k^/隗mh~qbK*ddpW Kxڲ}KXWF!OTܜ2O}-Sc)˭o"ڻ9'$oh }aq}t ' $TztΗ* (ټ:k^l,[4(QEA{7ͿrY3]}x6U|oe]f&\N(XQEQEQEQEQEQEQEQEQEQEQEQEQEQEW|P_O +kξ( 'QEYQE(20hu)/w> qq}MO lNqϜff?,  cm鞴suź_|-L6WQA>"k/Wo<)m0ysxHM2E.c , b)1~)t:0iZʑ\Gb^x5kph9i_W&*\G-aFO~:z ƒ!GPFaiA #E訠 %IG=Z]j,in6$[cs8JZb9$&ڤhrmN|ٌ:L`%B"T<֞$ZmNFzr:Av o#YēY0 u[KcWhw$O-ݮw%mv/\ 2O~-㹒=NXI,k+$nkI烯] 2Knr;sg^(=h(vk?@$}f;+e>h%җN]gFgc$_(s?ր=[5|AB_>fM+dɔGx>i7,ҌUɶ(ڋ=C2yyNEumntxZg$3Bo|cڱ4_2H-mxl$IrH[98ַ`gǎG<Λ;w9vmcº]x|IrmGgovVDgC zT)?iwO d` 4r;nHxHW\xڈ^s-F;s$xLMc>Hcq#DYDK.G 0OC+}h.ՀϩI>"-QU # Ik sX ~|[s=ã^0#2 Dnof-tn'GNjuQs^9cu=ď#a3da<9_Vk6ݜ4x@@=ikoZ<,c76bRO8>EPEPEPEPEPEPEP|L5OGè㺿Dz֓E7&y 9]M>J^@bD{-jPM\J#r yΛuxcþ3ѣ-{-*q_-K_?so=*W1^F0LnT6Go{KHl,RƱF' dxxKCaOHbY 6@$`q@3t8>FflsR;#t43h2ލOmL-`yZ)w5{$B#ck@ EPEPEP[O;o+mWsM )vn5[ Y!@ܐ+F|jl·P%S=YSp s(+xuKKk×ZXb T?_!d"uE,~fXrOֹAo`v4(c~ +siZiS6m9]OFhCZl:*;`}Y\s*&mռ3YE|lNp y$qڌR kT{wU[,"8?Ͻv8?b鮵m_FH[IJJC/Q_-bhlxIcgۻho+;ӚSf_e"Xhr n>gOƹѴK xRu%S@Ys3jE!0 #-W乗N! ĭ4kj1Q@/C{/7kʹ_MˉE ( ( ( ( ( ( ( ( ( ( ( ( ( ( 0x+ %z-y<aВ=(1 (Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@o,^WWםxK?&`(QEQEQEQEWcI_5+;McؿjP?Goֶ#? k[TWh Djn3z5yFҼAoy}F9X%z-5dEt!A uQEdB^9'h~}\1Ԟ!G\Wg\nQ0vi[Vm`ibF8jU g#Ҁ9X>G/ uD$K0GҖ׷A.l$mak'.w0iZEӋYH<zW(}׍(]K"EhϯlVj?_j-epo=lʍ9`};qc kbײ,{uw49'70Qk:.}mGjL pbzOb/-=Gvcx85mDҴtQuNb|ǚtk2i`Zע1OǢjIpҝNܲa0=kb(((((((4j4VP'𜶧ywz*dFGnJW3pYIuQEQEQEQEQEQEVS&_ 4>f ̜QL HnA: #qєhQE (QX*9b7S\z{m^խt/u0??$xsttP0(C^ӛX/ŐDvr2r~4>4&̕y-mc2mqWbkĒmުNWp>QE g_3ߎq}QE( 7fpԵ *ng?Qe%Ý-&FI%WOƓ4E ( ( ( ( ( ( ( ( ( ( ( ( ( ( 0x+ %z-yax2sq1bxe?}EUQH((((((((((((((((?7/+kأw?Q׿"-SZezRQ#|*nBx$8¹/A&\;X\G-g=mllqכ[xO:ݥj77+@@ڇuٿ~ֽd_}X,++LkH; R0xy[E4k[X$5+Dm1=qIP~Ǥ^[ 0Rry;v_ #þIPhk*#`=КҼIXxGG)ƱKl軰ʬ+W'Nc[48RFO6$UЯ恪V-JBgT8'N2+{Uqۘ^}Rxe9F N7QǨlp.U^IOt*յ//C py$?"9nn#wJ@ EPEPEPEPEPEPEPEP\[Kfob zG]ynj6k%r,K#TvAi#XTQ@Q@Q@Q@Q@Q@Q@שּׂY,mє^ioi-`$% rEz&(⽘P%E ~;/-?uw'-?tY//]\9QY//G-?uEÕ-?tY//]\9QY//G-?uEÕ-?tY//]\9QY//G-?uEÕ-?tY//]\9QY//G-?uEÕ-?t~+Bёg/7Y1EÕb>"(>SMgoQԌ8guzj"FUF-"(((((((((((((((xXxiʗHkgbp.qv +?/W$fjstDbFĤdǿl:COB9h' p0rqW0~ x8w?O)m4m5‘w|<#EÔﶚ6H;yGZR>w֢wMMp?|<#G);QqrF\);Q G?\9Nii#{j.>Shk#{j?H;yGZ)m>m5‘w|<#EÔﶚ6H;yGZp Qp;ҍKoR.?˴`1k#{j..Shk#{j?H;yGZﶚ6H;yGZR>w֢wMMp?|<#G);Qp;R>w֣rF\);Q G?\9Nii#{j..Shk#{j?H;yGZ)`V&v6C(ȁX4}W9 G?ե|,:\C C{2`~_ҋX/#L~=w1EKH(((((;McؿjWc\wŏ&Ԡ ȏ6EmV/?Goֶ =/UObS['y2XnahֶV>ژ͜Q%6T75}B}5B֗vLz˞2Zܣ!]iդ@cS|Y0\[_A!%+(DӡВ3Fz vLc dj $q_/OѷtTQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEKHAo-z-y[$K^@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@q?kR,4?݋Fk3D}-kj|">`@Q@Kw P2xPsO]Y1)XI2PN:u5HV%',7S:<_@?G@Z{³iZq:G<r<*˂:xxcibȎBgl]hM\iw3Ǎ.= z>3V_,`|=:RZ}-[}<&mj嶽VsM͡m"2E6b^3mQZ\|A kvY "CB6vLrN3[ I-2[m 4`mmaBa#'%-Xԟ\(Q~ vZXٷoLP' kL އEKܔdqm6/ ۛ}4Gn$BkDvx g\UҴ.&NY-X>(zD6"S ?c4_–gM25X@teUvZ`REPEPEPEPEPEPEPEP+3Q:_bu`H<08UH^e%3nox. p#jYd\+gW8(((((((((((((((((((((((((((((((((((((((((((jZF;" kkξȂ'ZZ((((((((((((((+$Xv/cI_5(_#? k[U赭(C^u'>.`K{;F=:ZE$GitUk-,fK#B x!{A\߇oD$(C={[Ǟ&]5@>~m~+OKb<^bg= /zB5r"ѯt&*]K%nYGSzXu)0+G;ⶀF0!>vV\Ӵ$4 >g3IS%R?wD? zZ hn,&A]qTKy>mV{k)8eBAq^Øn,-ǚɿ=:"X3Q]^EZE |C]Zl:,7Al;wvO][2v 2I8WIӭt˻{x>u " N#ڟ4`Npp9+1\Y0.d-s=#PJ\@cߥz/u"(`~~U}#:kWpA"#i*^L/g+&|5k-^)"{[n%f#,P3)##%5kQ3`%z5[]Z(-w<3WL &2W5wtQ֓Mpr]vo(ܹFqf{Xe&4.?wU~" s2ZMfY5!h-eC[ wln*1o\Tމi~Ƶil={YZN\umĜ^@ EPIKI@uz;[ۢ4$|F ja_ZA(|z-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEKHAo-z-y[$K^@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@q?kR,4?݋Fk3D}-kj|">`@Q@yŢ4ˏ u%Y6(cףW'?M{D0>Y @Eub|cMMI5~k/\РףI1gyyx@9Rz54{.7&2BU(Rx:/5i! fMՀ EꖚkXsj$qMT k0n|#auO X| Ӽ!i+|G sw(VS7ms[P%9xeExR2"WalHZz#<2)𝱞Q@xbɵ]"Ѝ)"06mt ߀|9k7$қba IEq˰}/qH6 !䠓nVKɬ\ZcP+}k0t? ä_\wtws!!Tp;xRk;}J͛0ApA,HRrߥo@ ž-кbַǑ0rOpG5(5֯WSh $DPk34-[X%UIɓرvɨCo²5Ŭ[kv$/p{z(B+?_k7jCP.Сd:6.4mvHK2\GFswQr=+9M.-'I-(tydRN\KK?-' s0> ! b0^:AEaxZwalyQkVmu7QCW0m9CYXº(mjw:ۮ/-720c!P(-|(3SoI] ZRѴ.K=>Xd{-qg?*(s7V7:mׅ{\ i٠C#'' `478\ ~!ѧŚxN_id 999\uU;2&yyuo4_ n6((((((((((((x5 -J+Dؗ9F 'ҽxe`X AmZڠ((((((((((((((((((((((((((((((((((((((((((((((((?qtLYcar{b( {C.|˓ mx)AEձ.u{;9Vh-Z8Au!^_k9;_Ǫ ;_~̓7*6yÚsZ[,,jܙX-aGLuqր:m[X==;mӫz@:9=}g_k4/j2 M>; =[kJ{ MCn8 p{p88k"cB"T`:(̛$zmmܺ>k*@v=0x{u>P9~D#?@]5r~-}xAj|pۜPYK^kagW?ڮHWs`^^[J"I#`PQEQEQEQEQEQEQEQEQEQEQEQEQE5]]C+ # kǞ𯊮56س"~_0AS_Sלfּ-n!V`7}hrox{X{O:=W|+߃im.'r>UoREPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEꚭc%ucCrk_M?@]/k2`Gcm#8'`k#MK݋Klu>,( Gĉ^6uIe@?ʯZz*8f%Y#u `zGQRPEPEPEPEPEPEPEPEPEPEPE?i~Uˌp@MVFnR'r{WZŻ$v()IoH=O@8 i~#_ůx6cm:@$nvOlQ$1q @(uc4ڗ&m]K,VV2Pd 4rFr=-ݤֲZBC*xP טiڿ«u!&|++nݙ-=YOT=sN\,GU=ՇckF ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( BqMX8wc Oa^a>P.4yt '@"K?u @ hufyԎ %W17O DR Ja@\VE./\,? WHPb<DžV1?|xW|oG4dasq ¿ߘ<+>ZW2}hsq ¿ߘ<+>ZWѓE_-[(_տr'֌Z,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǜj?9G/ ϖ~c>d,ǝr>׷xtG? s,u \Oa k}qy{\|A*=:9X9o|AbfY;Yltmq ݴWʡU=)KEPEPEPEPEPEPEPEPEPEPEPEPEPEPE!8Kſ L4#S$ Gam>OMgoӓIVZMv 695w%/9 &)60*3厣NzdKxY]z 0! _`cҽ! !5 ơU@(~#>e܃]K!y=O5R@Q@Q@Q@Q@S4fKF+y#=U(&>J~y5S6du%ߠ#!)]]:|N2˅>{#}x:֮ΑEGwT;\#9 ;aԐ܎y ^,k$n+)`zhQEQEQEQEQEQEQEQE\w|{r&nu=~98gzrp9 0Ubd sNjkm'6^+:|6o>"j^ g9[~>8o@)h k(e*@ zS5|'+Uľ }8cRv;k🋴ilӤ!hoB=c WŪ:U֓-,"ȞN@/v~*KYkZԕR8%A{OVE-Q@Q@Q@Q@Q@Q@Q@OUltM:]GQ[ÍN2B'b ⹷ HPrH b$izjZu,2v ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (<]αi>ͼq \NXk4M#MO`@?'{kI|g=)am jpSנSFrzQL((((((((((((((( ;}BkKVh'B#t`ky,F;A57%{dzJ߉ "KGtQZTOH((((((((((((" L;kx^YX*ko / hPeamH~gh9kN;NVN}*_Ğy#^=MTOcYJ厠εxKz?b/ls} F{Ğ[ZGmk pAHPҦK\Vw?-_BJEgnrUNp:j4ͦ˧ Kl $ ws ۜg׊hI![+s,0mogfs{=GԷ:LJuJ[Ĥ:pb89#-mϡj:Cu jX8+r98>i MRm.m(PKOY(Ru UҠp7*N'+[Mu-[ShtEHw+)@W87boe$A1@ $r}!~6]BPu=!{RVUeh[A6V^0kCnpI U:1k"fԎ np (iV:5{vh9# *:}z5 TWV]d Q Qlw@qKOg[$ w` d5W~5it5Q -%'ñHFiaZGuo'Tqqy*i+\xɮ̚t3C1J""1Lt$t` Zcx:6}92=|OTЮFЖ[~Ur=y ҩinE4Z 2{랋d띸zuu GzuQEQEQEQEQE⑝QK;U$3+nV3woٞik/3!0nY`Y!+P*\`%A8ؠ;~.aCtWQ=Gx;_^|Mnnv|i;gpG+ӹ##xZwDw9m#/i_^RY!]7'9ڧ<(lo-GNtɷ0Mw(<y&Z5qkZv ȥ%el,N=umiuCk?4&! 0Kd`=i-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEp kwU3J/뽯U#9nQES%v&uBT ]K:.e<w"Ru5gD&}2JmdѲ2F1Zͬ\,Td\! 蕟&e{ 4:eE ÎW5k} ƶZ RT⑭d#׉մxRMX֗Q 2>i>JǥZ]C}g ݻ56 A55y)ɫ[X+V.ztZ5ay9jkE&'ktl*B}s@vf?뺆XIxVEa߅7W"IP3Ӆw McȐꈀ3'Ҹ=3ŒYK^"ԃ!EUQ⸧š[ܛy>x@Iכ_j:֧iKP. WܯL Wq.D7 KxցZƥQ@(Gzy;,|I໻DPA4;tU 'z`"8,pN'5)艾cte~}+%cxUH@4nUPp2I7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7Q ? 7@7U]K7^M>]FV"cneh8 ny$`ܚk9K, od IԪP#z/Z-<x-OS54 T/AǾO+ҽ;[H#(*9 IQ>u29=qO{]8 (8M/JϊAgiC5mYe ;{ճK_KoH@J ßjŖ"k6O8#NRw&AKV½hib[+d(=vj-!n` 1R,hT`((~ G&څ$1o"xl9PӾ*O߿uo"o[ '@Hܲ'5ieė6}Ҝ,P3H&, / ~&wl`sȭ'mC7*4~ClI g:^}f7Wi`ُLtGcXi4Z}lrR%(T<')u H4#M໙G RK#p\={G D'j(QdfmH 卄hK{.㸶&E FAEKQ6Ф0FDj"( t%vi>(-m;_ ͥu ,[ \v\ֻ Geڴ@`oH888&q\G{ợKqޣ׹99;+ 3 k 3xc8'$(((*i%KId`G}ZCԯtO\rI6վ,ǩj&h_u샍Gnݨno7c B؞n$=unp>:lZ~lzܓܟSVmmm쭣!% @JZ:/6۽hyw60BHT\(X|=m|[鐝9XEAhUʐN={culxI$S*Ӛ쥉&FU `z;qD2&*^ڀ<;;Hگ3ޭ}8Ğh]Mp\s~֤K-u] kuP`|6=8u@ p@q(i)h xoLFvr8x)G"-3__EDvcv0qԪYkjsm2xd=⸁'D)::0*FAu)/"ڟf2ْ?>/MPkEq_ A7PkEq_ A7PkEq_ A7PkEq_ A7PkEq_ A7PkEq_ A7PkIoGf(o ֊oGf(o ֊oGf(o ֊oGf(o ֊oGf(o ֊oGf(o ֊oGf*Λ;e .ndh`w7J@eQEQEQEQEQEQEQEQEQEx3J/뽯W (9 uTQEQEp~=ŎhqBXa$_Y _Y.5GZ[i\Ff#;QcEú(-{}D)RZO2F~o`3uWO]ތpr H}+]Ǻ Jm,YxʗPмC4cDwVkr3,e#qƽs|/M{{|cUAZO^7ĘԾ3 u޺*( u>/7/mwLC qn Ğ м-ygdzՐ+@֖wxM5$Сg X,!pҩKEp(QEW|JUXSA*:ω8x4T߇c&s t>84t:ޙՃy%tG5[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?𪚟|1Y=-aIo "PtPn_߾%fZWtҮ"ppџF^FEpÇm{wڢ A8+gt4W ω >O]m.8bzlnqܐx9OV׋eqtL)9W2oo$H"4,z($ג +^K%䷚SBe'+:vgtG|ؔP2+񮇤~K4{{ BQ!,B38vAR}zS@O䃜֫|E/aGI'eu mCQnf72\D*gۨBxAEg=9ksLӭ46 >6G' u_Sb5oAC>8#jE7Z[YD~yI8Af|1cT_x݅Ơ>u9n@-'ڷ]F/6ҐC0.?V E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# ?+V[?o MHµh E=@-7# |qo| kO2n穯O;#ׁ?Oz-%-QEQEQEQEQEQEQEQEQEyƖ|p֬uH{( =zp4]Ce4EΥ9'ȮÞ!>ca7U]MZ(EPEPEPEPEPEPEPEPEPEPEPEPEPEPEP^wͺſ i(I{)^v1ziv>g ADzܓҹ/e}b3ޱ+q~ e&\OA ( ( ( ( ( ( ( ( ( ( ( (1Im#VVːq$DVێ .Uwoxa0t_C:szWR^++I"drA{V5H,ZզF:rv=sYZÉi}zLmpj߆>$C~t?ڝ\B/{l'װ=r0Z6"}z^E'feC 68j=Pbe*M}r2NzV9No[u[J̗֓(9,'$izFomwn7WB$X5Q@8OAuM3PYZX0 Ԣ3:M ҅w2 G85-H`b5UU^ފd1P[(]ŕԟZѴmCJ^v!p g'޵(j?hZ}ŭ\trc뜚e[KOWԵbw[E{*F㣐78[5Q@Χo{=cSҮncX~0U(’?0ڡ?qKyp'X<1y<=e 1l/L#um"F֨x:;m^U R-ۮw 1U~b8$GEg_i?n,n/mLm|>`1㩫Jꈀf8 ROaX~)+??RĬ3x2ش?Ku#ˢhij$zŒ-juQ}6xRbSSŸt;mN}nNd%>=1dWM~aiu#IO@0)h ( ( ( ( ( Uk#,uɖ!6ͷo0M;#`ap1 >|zエĜqCw?{+rX` i Dm6\=?*8Ԛn1޹ )Q.cJ⺪(ZG^[Uw$L2΄9'O Zx%͝ݓdaH 8 kjѼ+OOyE䛋RRM4]O_9ddǷ8N5O8՛¾ ncqu+1Вz;lx;^T$䁞@>s@|F/$.?ArwI3g>g`g=PEPEPEPEPEPEPEPEPEPEPEPEPEP^wG*J󿈿=xqPREPEPEPEPEPEPEPEPEPc:džYC6Eyn`OoŽ6ޅ|<7Q1P}߄Ci[o?TEX[^F!n"Y?B cHö~BA ׄc%ƏN'C+4W^v .ߺ.w'^M?: zo]x;/G+лe~rxO=7Wh1MulBʇu? _ ǦJ7׃]tºw _* ׄc%ƏN'C+4W^v .ߺ.w'^M?: zo]x;/G+лe~rxO=7Wh1MulBʇu? _ ǦJ7׃]tºw _* ׄc%ƏN'C+4W^v .ߺ.w'^M?: zo]x;/G+лe~rxO=7Wh1MulBʇu? _ ǦJ7׃]tºw _* ׄc%ƏN'C+4W^v .ߺ.w'^M?: zo]x;/G+лe~rO$=;K?ֱ5?~Ak%η|ia?ն|xv# GkbIteӴ[5o-X .t2"t;hpm4xȿI>OC6פҌKH((((((((((((((1?UT.ter m@Zì u.^?}l3ѳq >zi]]@nSʟB:jF]C+ FAûfZ[?O9ی'[]vٴmn<+M>@>kZ( ( ( ( (?xFu[L4ZwXԳ$Wk/uA/h uQn:nqk^ k\mg\r%6`N'6Җ((((((((+wtXs?5cQG8#:/jx[y Ot2i'XpfS؏$W+tO;R6-UTנ `z3Eq M $r(dt9Vu%QUom9o.H-]I!¨  {Wj)uIJvkƒ3G'aYzzkMxN'=6{ݱu98Zm#H4Tp$$ ~\+r)h((((((((((((((;#ׁ?Ov> ׬5~&4l$W'W?u[P< %1Z5Bf:OڞT*EuQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEP<" ,F9.⟆n!Y5 &糂z{^4"h9]eaw N }]un3c]8վ}w_c'tls~W_:5X[H#!dCxΊJZ()T@d  XZD|%#AHYߙ|?[t?_cc ր45:>xsѻz}o_ ౾k:iy؞ ]6i~KKhWV'}iPREQEQEQEQEQEQEQEQEQEQEWQӬk ou$n2#FjM+AyēO\|[]gĮ[#Cײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]v:\X]AsG"?|ús̖݌o^ƽ 'xZxghO w(n=8>PkK橉=V<~"[W>+Y"'ײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^otײ[/]wtW ^ot>2xaŽZ}\XQPY_Zj6Y\s)$N[=QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE%s*NP%.b?=] x K?$ƈNصXW2D: ۩'fa}]Gsm C"M W3FFU2=A:ԼfMk^CL0?q0@Npĉ.oBUΨ~z9=+ O?IyDoΖ[\s7:t e$ub9i7RȠc xz>qWt8PEPEPEPEPEPEPEPEPEPECY,2MKPgKXq:}g@`;$Y"CrH b&e3 ) :'{Q@Q@q?kR,4?݋Fk3D}-kj|">`@Q@Q@Q@Q@Q@Q@Q@Ujz%1mڥP_Weg.PAЌ䜎z7A b 5ăt}KAX_tŴ\z}ީ+O!3|@'OՍwUIQA!EPEPEPEPEPEPEPEPEPEPEPEPEPEPUl,+f#V(gk: K<ɴCJv,zoRy^W zV]e&{Ĉ{><\$Ʋ*taF#x߅nR]-2Bq>e(AEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPIKI@q/=/WW|vJj((((((((((*+x䷝HB2H- wJ᭔ݷg|pZŋyھ#QXhco$pn2?$^Oz>z-u~DM^x~:MW7[y18 䇋%uM/񭧉!K[`C ;jZm?MviH`矗#ֵUlEK\~P}O#5XS߇lU\Ld2&?vˆFO'S-rZvS2IhŢB5~~>.I%Gwebvyh;McؿjWc\wŏ&Ԡ ȏ6EmV/?Goֶ(((((((q]w?"k@4OQNku$EU=Š(G#&uo6k΃CSB%`8+?"׵+鵭E7s6^A@US7*_['?k×"hVl 6If=$`=jSΙmtz# K1I+7622i68Weǎ?IǪ;Iq?edƶPgz=mVkgy[O^Szٹ[ $x6H38 >_J5DH]unfVΪ7/ϷnuUu d[k+>3Hv:9<xSC(I Zs`ȺCOk/ovǝ8kwZ _mfX"ӱvћo|ų t=q)]9h\m٢O$~v_ "j'P|KXG_bm@GH89p+CS$s?ԍұQ͜P;|@O mO1(I ZsgZxEV b +cǮF2kZ"(v{\|~0NGr}Э|1RB㨓&}cдVaA#,/=G#(ֆ@e0) ֌ͦ+Ԁkc% mL4:[ԯD(FGJ)`@-h Wt躵XZ] <e?,83\eFׇ%wuzgvqnjOo EnGԷx[l>wF?*CkiZMFXb6~z:W7xBU֯2"$yN1AMtڧo?&#EVHQFS#{ 0H-u᫝WSU}M$Nv3Ac8om^]7ڄbA I :#QKE}\GDe;r1֍Nx>$7ܗ 5YWrS}3t VwpZGuo(X?X)ָģn$#+=My}_?Ď ĵ: $J?mٟƺ* Q TK;MvC>ZsLuQ@W[?*X~2}YER,(((((((((((((((((((((((((((((((((((() -%yA j+?+~ xwW_3r:*iO2yR$+-bv*u|+mWIz%|d!+ȒFRW#1s.p]Oqq%g 43\~} Ojnak]+u){k9ch uQ@Q@Q@Q@Q@Q@Q@Q@Q@ E-R@Q@q?kR,8g^㏋1zt)]nd-@H#@赭|\Y-_ ZhOrChIU XI 0I^@Q@Q@Q@Q@Q@Q@Q@`DMw?"k@4OWK\ï'/zQE*2jT/Z FHd |ĂN;riPe];Nl"`jI rjд~( wgVvihBFmVr ~-摧GJIl p``tREP ++{ωkx"`"o`DMw):תZku$EU=Š(G;Wns4Mqx *7@֢^hGeYH" z^կL"N6Q)KKŴ10W͡Y Xp?v qY׷ wblj[fg]F //i ޸{M|B-t[^O$Z4,23OZi~:+><8u0(|?mKsIw"HczO͓XCik=z @3ږu|[3x3ڲU?"[[X*@~l*vsڍ&m>9.@RY''IxYl]6W;ZQ J"]i&ếA *@rS<3&]VL^t팴w>H#>S⭅߆a`ễP "ǯNج[AԼKL,)rʢOXz'9JWKM-ѵ$`2`qNW-sR#{Y[a>Þ001z=;W<5=hqF,y0V `V/-/u{+{}_Jk>c ,Nmn& cWkzj""e2@` > V-֫Lp#Lל;2xjMOJO uƅv 0[ڦixwwbc&g42VamZSx+^|:|CV%d&X qj֧ Bx~};YKKek](dTcw1H|QoZjsYY .^84c,BN6s5 3Tu Bm.[,Y|J)=xth:Vjid)\g ;mDuy T.t,͂Hrqm7E ZTԭ*2dcoMuu]n6#1nF\<[g/o;"[@ '=+:췈CSieաO=ԺyB^Fk|))Mw\I6>gXG}/@V1WB `e3P+֫iױ]tɍebrkZa֖Nme!)wZ2c  ֦ (W<[?}O_,xGodtq>)QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEyƒf_S? 5uwП+Ѩ((((((((((+ Xck :)A,@[ᏆD_Ϭk q',U}]$Xv/<-X֚&[tQE30)QEQEQEQEQERRH<>o#UF[FH\73rlweziB n2 πuϣȑ6E-&i(AEPEPX>9]| Su$EU5I^k2{Q@(6xNYAA\NqYnWCks0<ɜ9;BkvhA"-] >i FAk~VMyu[Krv0"7S!חLԧ[A.Z;Arcw` ǔ$*( CissqkrOjTN12*p_tt %">rc,ǹ$~n&χ#kx˧ W$eEy,M[ƕ :؍,N힙ڻ &c)a-qN}==Cc%Iup HEgZՅW01 IRG\%guU?k'Γ.'ՔQE"'xFۯ:;VwlpNOVk慓k &S?swc5 |%d'odV<{.{{ &`7$_L,vq{r~D7(iz,O1|\CKAs /SWQEH>.СJ? B)ǫ(y$?P%?|\CKQ`<(izH>.СJJ(sw 4 O=G$?P%?z%X9; _(iz,ǝAs /SQ 4 O=^Ec B)Ǩ _D1|\CKAs /SWQEH>.СJ? B)ǫ(y$?P%?|\CKQ`<(izH>.СJJ(sw 4 O=G$?P%?z%X9; _(iz,ǝAs /SSſAQ47ᴺ]ߐg?zX9KÿtmriQO꛶KKz)} 9^/ͽAgQ?:]^K2մ3M='^O$09(0((((((((((((((((((;U;LtIȒzMyG x|8^6r~ $1eNi|~O? Le&6lϓwvqj$]}eh)[y2NHpsL-*Q q^yOͭ|-Ԯmeusk˲KV Ԁ>l q"0é -:u 4&я 84Ҋ\OigMh6&tkayzǍu?xgI$P#e yؚcߊ^{%a"*ͱR21­O]>ŴS6o1ErQ.=:ڀ\΅igMxgEpœG@Q@w:z=]gmR/ w$h_ KIDڢ)QEQE5ެȉ>o?_O__]-s_ֺZ'QE(7ta.ll%Cqeż ֎ґFط_|q] W:,%5;]Dj7R8)" >ZxuRH9KJ(gD~)lɶ6 \@~j Xʣc`~lR ώ,n촕y^i Ela\ޯ4'?]jgK*4ƻ~pT0g)9*f,m!Tv:432jrm]Ye@;&GAEsӥV[ˢ:|36\pW>՗[<S. x쐇t7 I( ]>RaE`16I 44ꚖgtMcxe[H\7\8z( l&.Ö%âK@;sOWE .c⫩ ad<5M5od/5H^I'd;$,F8羮iM~vijgH?yG0 3l5=Kin|%@|?<׮-#I4vO$ 4%xz+ie/ʅzol(d|EY5HpO"JG]Es+h>ܾrZV$[tQ@Q@(X~zcǟ>k'ˉeQH4hVׯmb+}*|%?Az (B+,7'dpa)N y4WqᯇP[4m5u2fCϧi6nl9wV24oeCdϾ}Rxq>w=*Ƒ P:j+?B֭|ACY)ʛ]H$Gb (^1I ^!޳J1('?o/?heGsѩi)jM(((((((((((((((((xw@ubJ:pkv/45khw:'}zk#~/#dr|!$3CU?_[2sqjUe7{FuֺeA=ϰ+-J{]2vk=O>}^(((((((((($Xv/Ec|YgJOx֚&FQL+֕ky3[fxC ll#W{E |0Azm>*7@Z_]j 6-լ\\$W9ǔqthZЭruK8ن,Hޯ(dFI`j@rwCm )D`$ ='j{ͭ#VG%ڵfURKIX$Ggu KӍMuw 0CK45Ѯ/\BrIP3c3\toYc[$6!´L~Zuվ-Pl(Wܠ3=@X/Ni\h^8ջZTegMaUBAbOa^S8!9i%2LEhrpjFЗM7ܴe8C;Lt吩'.mt u29=_Veu [$ e{F@@^QoO,m.-_I'|m${&8t}oR5Μt顲ʼn[r ;ss8+ZZkmi-1ǧ+x$K!} jդAk'Γ.'ՔQE"Q|s]_Ew^g-Š(3MSJ鮉"u #"/ÝJߢzvn|Yb@㐮)9}=xvOmq>ojܮȧ8w 5Ŋ5bʁKzsnG5"k7Qqm9lB9Ι Xb.|w8$cڻm-ٚxg)o:ԍ>7(m##8>^{xg%zuʶZXAKm<퓓ӟc`>Y\ e&)P<xEȊyXdQq"ڀ7x;$6k;^V¯h үYm)$ĂAs rEzRƈITU$c'֣K;XM/}Osf񾥥j~&vWˉ.Y)نX\_^Qd% A?wWkopU9Jr6ߦi4\( [q4?8.?/G>q4?8.?/G>q4?8.?/G>q4+ 0k`Ak\_ʀ>yN Rդk-+ EoNO ˜ zעATyqq*^G/ATyqq*^G/ATyqq*^G/ATyqq*^G/8.?/G~%K]K{MY#2O$``k5?% *09ՃX5]GZ{(o'&h0In_((((($Xv/Ec|YgJOx֚&FQL+|z?,]F].-:9Hr888>WgXRGG,Ldzqs@ZƝً.+ ۾&>ƨC_ \jcM\&C7= B{)&[llk4G8?tz/kaa[٘[o=I=@t:LjmmF A! o\ɡ஍ ڠ<bSc;ResT,j^}VG]nmⵑN㑸qU56<}6̌r99#tUxoJO?DuŠ(G;Do3D )juz4/襤"mQE ( ( oVD7hï'/z_O__]-Q(QEW1y˹t_iCRIP[8R%ӼYxՅh*Ds3l2R`ޫ>l?Ŝg,y{}6ǵ7MQ>my LnJ @ZWgLmme|8l{*i:kuX[2^ܩH{}GluKլaosnv9#'}84m7E6cD(q>ڭumO=Q <컏@ :T@MqzK-:N㱴$s#1 ǫ; IK|FG\/*ƹ5[Щ}HO/-R!~{՚:Pv m!0ݍj=*ե]H0ȡMڸɼeSPм%mcr֯q9@,6܃žѬ* =]k"tZtCH1=2_sFwt_J$z69J_0q ڛa{JqEr&}.`z`L*(U@\+n B Qiay.-|$ddsǹ5ov4r hQt繏;tg\uʃNմ-QBIe6=7gz5߄4 {)W\=b61mH_Y_k3[ T7!<|T`7$+q}KԨo=<vqIoX]Mom{o4hY=0&,2+KK>Xlme-"S6@ `u5>PyzeۑU4 =Xy<@5b=ĚN<ȷiY' LAEk7luK;;=5 eq$E,qqY)> |z$mas=3P6Nu/XÄ ̀xYp$<.2DᕇkiFU\W1׀s^Qy[&sV0usFYdt*]& 8P<V<Os[ 42 V#!E"Iuh "!>o=ǰ^b44U@U 6R95I5;5mE. IĤ+f5S7myns^aȯ+WƾtQA{`Ar s"Ň,NNsz@wڦFjh ,a$uO{Ki#世-䓜zcc6>oif q:b\ 'q䥯"[+w1jǥ.Tkv\!>sO{u 4}_>aKq$:^66, 9wIy&L}.YC`$c02qQpvwz I }28wZ~}PRe3+>Bܠ9b]S:vV+IK1YL`Q8}L['O3y[nuN( ΅{.:`[Hps '5|H٢_'hk\ď aO*nz0&EPEPEPIKHzP/Ztu^i{yWz##j"xßf%k?۷n9KЯ.u{E_i"cz|>q&v}ZͿw6ѰCjQFGxƗK)5kN}ԮiJ!P*U02Hy\]am7{㊥6{j߈[iq{ v<`wѮ5k#AorƹbY9Rpk6V1opeV`*8ckʯdZ%wsOu<LO40psq]~y}*kdַ{}(?1$N2N(#ּWu.i{f;?RwtZ\z ε{io}i0;n{@K^s;ۋo%EŪA KiWI z5QEQE!8R}>F$3Go~_Ao-z5Q@W`鲻<G2( L~xj 6MK+-;S'(rǥ,^Д%]\D\]$;k9jV^kEm )e=xրI(!uyh}jNWhv^ty#ԖV c<`Ӣ(@[G #BmZDo3D )i3HTQE"((|s"&`[Ճ5I^kkWKTd (Pm\7\'ߍtg}c䰥˲Z+YX/+Ttk2k:6}pnY!Yn7_Ѽ%5kWXԣCK p)x 4ox_k:mjK[D1$ 6_2ir.tn ݥ #=~vOB!}. [*zd9 7_dY=o>WԬum?S}3Q 0JY |(oϦmrYQ<$A; pߩM8  GG6 +ULq2nCbo?>VG;8==C𽶓7108^2-ek{ iI6-VgSWCMZw,.h$e(8'#:T7o[Dh=>c,Frzn}:o jӴy9O֭Yh+g}O\%Q0,Ҙyt/kv4xM6Ց{xI^'g=֎|vaȍI,{n?:KӸqҺ-Vì_zJƅm< Ҡoj|Q6ak"uXLNWpIa03pk s[|c^^KwHwÓ'Al{uw>/zlwzӴۉůRFqܑzpqQ뗚k@>+{U< >k~L<q>ׯ1sÎhI8Wv2(t #O BO/v:cNw+)<q$ ֢( (+ξ A歌I6sVvdj0|=r 3q#cGjY𥆳smx]Y_ZYʪz8 Akn6{ {ǝyy/+sނ>iVDB^ObG4pIp`(L\UEs7XЭ5bnQ " șrG=*-GUmVCLsMa8̣pA3o@\ρ4c᫽[̻AʎсKT/]:q'!-2r{PO^Mi,WwLŔTa8<*՞kcjZM!S10<ڻF8hQ@\ŃzT6j=s6Afq`p1zt_4mԵ]BуCewt#A`;OutP^s=ftn-q 㓆^EsVw$I0{9m_d0s׾s?iQԯ/EsqpP'8ZӴ!֢[\ۤ_`bNzo}OYm k:˶hXC+0y=]Lu=Ɔ8fHaS=}M^4+Mx,R/rcgsN*ZjI{a2o&vH`qq@\>{2V@& d=V֟ea n.|\ݛn[=bKHn/Ć"[qJ@\r=ȏYMrUC }8(뚻hzޅ&ve7$)e*mJCw;8 'v cO[ϰb<|2W'@jQ<)gj1iy}_f#sa0u+A/_ u2qTzVmGr{g޸{e-–-O2FAz ʓᦏ%T$FByʌgI ( (6+XRuڠwGzyď aO*Fff$3 !G|OM h(())h ? y=r.>ߨzͻ7su?V_upg9\sҴ>k zlS( g~\=s]5jS񵏈vkM,Frs]ψ3>Y:Ul$h卺둑:*(Ѵ\k 뺲y>LV 8,K1=?,tQ@Q@Q@t+ξȂ'ZV^u7D?QEQExzTZifYT#koPvF{vG/ x a%6s m jGcԵMkQeg(g(#U q(V-f;]bM1˂wiQЏ\ֽii {|_6Q=0Ai X5xu}WWmٮ6"B`En#Mkbuь_58mq9.<3ȇ+ytCiA6Ah ;rx< 8ފ_Zk fl͢&F„sǭ2O IiϹ#hL#h kO Y@f96#sgJw +J}5K;,рzF0k[iV{/6 1KQ@%wZ#1G5UXPR{((:տ -z-y֭%DK9hh((((,3?݋FlkEm'akXR|5"^0赦O|6w[̳VʀPHI5 [EƆ햞4]m%儌+;'h xv]6XHNEcRG\/'/˧-'x`ǽ2QVjއ{m`[i7!-ds1?3qrE =REt\uWVǩ$* H9k1sF շK@G{ԇrjz74MڻAp3?-C<#gO~&4 RDmMs+ nHj ơå}F'symj ouK#k b$9|Ӂ@qPjqu_I|FuB$vPdF#+g\zu=EEΐ'?uBՏ*7=Sƶ:0 $O"YQc>R8p]|/-ƕ躊WMۗ%"D#p#y-ՆyghscO/tK +908=8FuxYvk^ 2f&% ykI|OHYOh2yd)` }]NOxu`*9Xb29]| ֺZ?tFOp(QEQEI' Z8lr@l55Σ}] p/K<,Vkaiv06cWQc<:ficBPۢHJ[H&?O>89mݞxujYtImRIq0.Kn=իjd#q&,Sύ pdQ\$; ;~PԬ;w9Vg^gl,5-,1?x ^hk49$B[_ʺGwyiNҹ cŞ&5{66vo5G]=,zEpH$5'Ahki3jzlV"VO8tmnEiֈ.TTv,oX^,קtsel7Iik >ylsIֲ.ZO\t넶/m#|rgph lxV>2iiW6v㹫׊Lz [6Oa׮EcuK-*8dB̰FH's[vwZޟ l}0ɼeyd7 nSC022' Ƶ?M,!K{&]7q du;^x$/yPZ&vöҿ|]u=("|-<J(AEPEP_,xGodu=|5e(Yx3J/뽯x/wcgTxf܅Q(9 ַ)#MvsaЇm&iMƵqjNعT @#}"OxȦa gwQtzyy}X6z\ ߑX^U>]LGa۹g0.~hzԷ2Y}on%h#Vu.*9[>7ZőI rjBŅS})<X}MFWqcv7);gEKxwR>$4=~MI.Yn4_Ţݾ%w1=ӕ=Y+_'ǯSV{#Pn]xڻh7>%ޕg,q)FO3;88o_<[O .-+L!oǙm`B(ZB#ڹjw%kAհ:WE\=S-4=B[o&$2DZт1G.^R jzy"R FWjJ۸moÚtuLD<7sלtV:/Ϥ y?I#pqÎ+w:s`)^iC^*ԼAo',m,5) [DC`#:X_x/R XŪ鷲˨]Xe Z4{v[/n=;?! +FqjVWOLW1g"91OP>"]': i$[$^%w<j_ hN[]Hqq*ci]VTN&팦%N*^i,v )b\UO'zTzUxm1mVGap[xlX]ŰxT l;ṭ^uL3#: a ԃCԖ:xXʹT)#S-xy/e&CU  @$6ĺivv2GL8 @tc9izփVEeOYE1=Z39K[7~^q{V|]$'R[AN o95j%<=CM[>~~E't; Ruuc>P}߇;BH.R1ǶGmI~#};_߉LZyӒX Oo՟[z+&RK0.9Z懫[/hQOoY!MbM mj Ace6 *b y6;gOax~0Sn"0pnq9[=3jMڦjB !^[qqYl"EY["xᱞ% 3?*N|rW;3~ .x.|G&c$R@@ysZ:N4i]TI˜|SPB᷿䚮)[vSpǦA@h&h5|Cs,iwŴ>\F]OӬ$s$@X=~)hu -3Mdrgk!`mR@Nz{hv^16ϳ_e6[qlܚS6]k麥eү.JiqzyoxOߴ ڪc$sWOIu//l@\ď a?*9tRT>+g_<.f7P8~)K︆/mct?Q}kÍ_4- ê@c= YG$Y?p#,Mv\_ʏ.?/@_.RO?)'iT?eh ?^lŚI&1'}~( ? >|KgϜ€9\>,M|AgY뿳G}~( ? >|KgϜ€9\>,M(cWqn5gϜ™&M7N|t ~7[fho O*(e7[fho O*(e7[fho O*(e7[fho O*(e7[fi A6:m"ŔABQ/ P>~.[9IAyv m?!zϤ\[dK@EP]_qEz4[.u#o}ʀ#,xO!{MHwAwŖ9926y{_2Ecf|S(*yҹwqx_:FX_=;(?bhHm>P팂`c-CXjV3qsywB 3V=qyse4[߽ڪDeЍį?w9Yy&{s[`㵎Bϯ_+E~ I @̎#i\pA"-`Z#UbJ[ ի C[MmiD-CG,xYF@s׊ҭ<_=;]lv1#Ces=Zz̾8Kef$8;g ;T.Y(V7"6bKs(w<淴~2zh{* e ~^yךnJΉq[!U8 sP>xݵhJZvU9m`sۦ*hPsfI]XHviqRk^/~-KgkȠnFݜqڦi~.6ZQ8,E@鐲#7"ӎi\{Y61"<:Wr8zUyEHan-c:ؓˑ03H1ZُN&kgmc9 Ӣ( B22I|R: @HW@iqe<8:Qi8{dgםhnH fv!V'^#*##~3X_ö5[-AxW(F9Ii˝'R\VZh]-Ի NyrztGcSnv%bʼ0? EWj_tOV%QEQEQEQEQEqR|5"^0赬o#? v/t9aE4L:(QEQEQEQEQEQEJGt٧K3S!G^Q@uz4/襪_Hqw$h_ KIGcj(PQEQEVD7kz|s"&`@?t|:תZjEP ((+𵦱ῆ6N2jɲԺF* 1'Q@7zj7Ե j_IuH *8xcCQ(HWr<|gi ㌑n@6r$ Qh l+6·گZ%ki[1 s9⻪( 5.*b59->FX˂ 㝸Nu/ j~lf4asB?6H]Z>oH-18е; 4z@YI,M9;~ ~T'Z? mIF,3 Рn?a6vnU-h nj<3kD+-[,0u5wƺNXXiH^ M O!>Ցlx]:JKJ|c'{uך=g]헋|OyqnRh,x8ֹ{ SԆ๼A\]I,yR@,0x@^E嶞>~ACl^~]vZRl&w썃q޺Jsk5,>tld-#S؎vxfZkJ^[66p,$;.4.+NUm #zIoZc92 ^W N5S6ko%\72P;s`tϥw`e4}YU,:P6i0+M.AT/dk 8[Z.4SiS͝w$H 2P:O\|<-.t[#yвUO>][Y_ٳ}t>ֻU y}NP;H(M֜|KcdHBd"qWV3Mk÷:](I0VEO wM+Wl;-<ř;2NOy' a"-۸TAeq6+HG!Ў }w\d>:Ԥ'+Af.tHv>:} SԵ[i44LWcXp۲:+>6H/u \id.ŸL9ACO{_M?EPHtUcB9,3K QIkz[nⱶDo!?6=?(⌁\PUKp{ru6ߏ>l>֯e[?]Y> 78;I#94Rhⷓ !\% v#:Wr[;ˋmk]Rkbc2)k<- mjLq_E$\t8@P`((:տ -z-y֭%DK9hh((((& P+[ke?;Ismx%8gxR=@g=zs*"Ki@AնJ9=zwM\AJZ`/mvHߛ1?I9?ƝguEpxShCPEÕ!(?NOArVwTW 9?ƏD<E)4\9YQ\/"??'pguEpxShCPEÕ!(?NOArVwTW 9?Ƣ^3e.0ySaEÕMN!6>H)ȷb:t3mZfka c) n9;T?AX>\iJ1-tw{a(aEPEPX>9]| Su$EU5I^k2{Q@UVukik ,p[?3 Hx"&EsTcEw E!iq85 kV+qyghd">[#8Nx1l4IL%wKcrv]zޓx+K,n4*^3xHyӵszU_hLi6E3}A=GFՆb.ōT{ r#k14m)ฌ,.:)Ǿ$ФbRfh $$@}0$T>\%ƫ#{k"_P201UGo'E(AjH {MGV{ZAMB:X[Pe$rzQ;+PV,-nELzf?NFccCXVN&Tq6 _i̒n,0G BҀ{3| kF&<ېn$`?ը@*͗luK}:Mt-Ρk ;~d 4|96R[ڵG3ÌgNdV_7CSFdHTNA9-]᫻U&HXQܕ!A3k[ $EH^IEQ&|+#*ŞկM:x畾o$`F[dOJgcj#MQ/] [M20H8#\u׼s\T;{uUl=z{=Wž& u#Bۈ#\V;Mq~c NNK.6 d$ 'Su[ Y-r[Wmqz]r+ λwkdF ż  ;>WՏ_E~ .fiFy$bIoXN7Hb`ۣ̹8 $LKPa'sfxCMmKLg!̖Xɮ^Mt?Ccl3ǭ 1P;Wƺ6ȭ4^imDX6&RL|=zOz=yCv [ċRyJ)h<V['>Ee0G>य़v:G8qhŻQGHml5]Ir(;⪖4A?6iڝr4"Hݶ1W d#v)h =o_x&`9ާW5t)Z)%&e,d|c<>֔9 'j:t-&2Kco Q Q@?o/?hЫ~$_ P8z0&EPEPEPEPEPEPEPEPEPEPEPEP7?J󯁿 ~+~3Q%ڽ€=(((?].،zMZP)'qRP$<"tϷ>kfR' ݝs8={oV ؽr_[[$zu cٵػ60&1Exϋ;wsqjiQo`U_e1{ Ǥi Y&+GH#7~NCdAmlP+b@S"ĈBA@Kmh|Jҧ6X.6݌t-+" s'.b.5c-Q@Q@Q@y֭%DK9k+ή^~`O|g'@EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPX>9]| Su$EU5I^k2{Q@vv׋mdʎ@-ԏjg]{D]csq禮G~:rFjv- \[E3@Hã.zqS@Pt}NtJՒ{tv9$z(lm&(HIaw]Z۵707G2SPx 7&weΙi5 d@8R0*ŭZ[EoglQ E_TPzh,v[&b\DB:hAѭHlb9DۢtpñZP1Z[A4CorNt@ u8Oo I4R WV$[xOO♜ 𣓜qs[tP25CimV|c{Y$k>d7uݻϽh@\(QEǏ?|O_S<[?&\O(E?/]p kwUH[QA!EP-SY4X}N68V@_¨j^ jz΍{oukIHH |O_\xCm-?PQa*r13wkeqMc5纍'0\|r3 1/-t{bjw6;%PA#ӭjZƝ[J Hi +( 7 |i鶲%m<7nڠVn|M+\pݾ(l=k?Sز蔫? SOZ5ơ, ;Ѐӭco爼a Ǚ,fikRy}zk`foƋO 27=@,^Su]?XNy9d 8}@Smf^npnzno&o' sqq5KLiEhOƗ=K. 22pyt,ze~&kԵk;I\dG,ʭ\vxd\'4ջeZxd.1r~oMgS#uk/-'`LA0p=:F׊ak:+I>sq6 ~` kV]lt JI@1(I3sq^uysFO 俙PǨEіK8]rLgPx3@Xlu7Sk{dc2NHC6\1(CRl~$pXׇ$(BX8^}|=heCM<ȹ6[>A@Xo;Le[kC" UBFXqޛk^ ˥Ød ϧ^ugiWRQ)XС9[+k[V&6wVB *oO@X/|SiYyRN<=:ѮnO,Gke_x%^ 'B<ǺA,Ya#^1]>՞_Fykُ6d`#(8@X_x@ﭮ/ CFkYዋxc 1@paoj (Q@yď aO**߉7Ÿ4TF((((((((((((CҼ]_ŚzgF>bd[8#)()7QYFEr6Ss C~5օM+j8ɪO3S(?X~ 1Xړ_ з*O3S(?X~ 1Xړ_ з*O3S(?X~ 1Xړ_ з*O3S(?X~ 1Xړ_ з*O3S(?X~ 1X%xOúgRDc,VꬹGCZ_.|)\Oi-#cRI8@Cb' oLT ? zgPCb' oLT ? zgPCb' oLT ? zgPC?K/[??A<'BZЭ[ԥa-'r~j &]uUσ 8tl4='Jfm;L.0#j-Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@`DMw?"k@4OWK\ï'/zQE AAN>*7G ??Ak+c@ѹϫXY\J8V[`"h:i2 R8Oj]lz:q5% U>}+N]5yt5q6 がwv:O xoidIܷ핑ycZ'FXSԭlğsΔ)ozוxKϰW \Cl!lg2ޠ*s-f~!:tRܤv"Bc[w)A{yhdH2pikaüoNm댌foVT_G! e0?7`w怱znkho@C__̖wus:[Z+m2{ 'ڰ4;[~"Iif.mt$Mx$n'8=1R}m]quk"8?:ڏΕ JXDB7XC*HSTgxOŌi@&[R~u`.G9׉t@X)!XD@|ʨ{p81YxkT[ >J[%bX9P8yCzKaz}"9@U9'n8#fk>'څƒUԖЭRK$]Byq?En@P(_C$۲|7l. S%ߓ*QZc֧zk5r8~q4 2{[m8if癶h@2N0AmRRMMtַ(veI#T5eͧbiGfc>oy\]=Su+Ayay͹H}EV=YOގ՛^y6R흼7-hA?+=h o"Qŝv 1B<8_h7O,y1Υ@ןMĦQ9=sH,v7"l'h/5k+yU$UeA%tM6l{+k"uVA#I3Z=u^t |nV"b0r~_EEFr( (1 \\5͵ݶD7v梲veٟ\6y+@H[P;Wӵ \,E[CPEEWNd{=ݰ+ ݬуs̍:v&{_:[}S,ǯV:15k6xgTPrFsϥuP2b֝ wIVؗ$*j߀kl^R$3]-&e&/OV[h7lۈŏ?Rj+\SLwqo;FHܞ}z<7)7VYg \er=p: &vd"v,lWNI9 quPQ CiqTDP@AXtGRQQӮO%C0u¸f?-LVJˑ;g;棼V}ee ^ +o~ )89;l4M'Rqyw n%i e^swa?tRt[ֹ!L^$ Fy<C9]|OHӡ忇{^#c?QC*;)i-IQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEXiJ'Z?ŏ&ԭș:ElQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEVD7kz|s"&`@?t|:תZjE!gH񭆧V&8tN BT9>=VӬLýsEf[D+}ZGO2`)NqSڍ+z.GjoH :g(mSI֬^R䤋Q}U𶅥VIlX"F7a;Go|]6Y^VVPW~_K\񥆍 L"I&I((q9zCƒH Cx>jM [-6=7q[xO;o5(Ja*!2gdg#֜&ЗRM:%>rlSހԻeckZGieo$Q U_U-gZ71iG(ο2G8>WZ.QuMNͤ,3P:ߥM6w5[B+J$$6 (&Z6Ӕ2D#[`P8}YyI%rcb1TOKpZŝکis)ucϿJ?xNmuPeR @jjvK:G(oy=M[ % * !լ"D$9Bz=GAҭ[]4oq9B6Ln0vCekNP^I'63;"?xԚ hk9{m1${_PP* BRJvSAӯXoe$;{g_[gkEq)$\dPKk;x$ xkE֜ɩiR&X.szyǫi[\E}o$yV@V",sV#9IbpYNCЃ@4NҴ(`$A0sHOZx;úM`9Ċw=v+xk8j'o6Xz׍<à[jeIm\\]x7<Yiowsw i=Si6.~|Z_h܌#Gp;GE4Z5Ȱ,\cGhƺֱ`6gol9@*"E*N+F]?F5>eQ %ؙfpqj\{h~"v4dY)۟p@G#4kEU4MFeߚ@X~zcǟ>k'ʉeQHanmo{yw#s=@oC&tbm;Qm[_\p+ꞧ͡Ԭ`9 *P&- <@"m5en'7,G= 7??iܞSж6QG(PzF^{ 7??h4\9OBhkFGM|#C&)[MMy(Pop= ii=4?.m4m5|#C&QEÔ-o 7??hrѴמ??FGMSж6QG(PzF^{ 7??h4\9OBhkFGM|#C&)[MMy(Pop= ii=4?.m4m5|#C&QEÔ-^ZFd%p~&_QSm[[ܰ(rks*5irHaǃ9x/DŽ>?Ko$ 䁓Ot=/C>ag =I5zIXZ(Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ŏ&ԭș:EcXiJ'ZQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@`DMw?"k@4OWK\ï'/zyX"b*Ο=u,F%(7:<_[Oq[A؛,FIyI֝ͦ|U5-WC%clVE\`os s]m>, Mh#M`.Z_-wMmmeq$qa@pliV>`YY0 8xiWھI9@` F?p9xST:Ѭ[yL.|5^i:]0т@\|1\O9gFS (;Fo5}cke;MU[KW 4\yKxLY OF6dPU(6{`~TN^Ǟ(-Қ9MǞv*zBj K>}xm%3G&Fҥ\#~{רdj-kHh9۟LqT!m/(t[(o cړ+wڜj1בac+dz2"{ùĚ,")*z0#=hkxw#.Z= #as|3/C-ׇ ՖG_{nHp:81Oi1э6{dtWkKnM#ww}$@Mjc[-7+X@q@\۝_HO J ]{Oյnn6mwdT1S尳 mb{p)t 횜F4 @D%hsAZZ^yس@ԓx9(O譻ÁacswN}rj 3tZnik; €;Aq+ϳn[^R` 's]Ny_L jO)mM+M&cciEuo-k,3!IC) B(sxRVcs&9f]Սs㫉lSQÑHRc2Nrunvj 5 (P1zb wP;Vm16KQ[[AgmK1(HA8JBX~zcǟ>k'ˉeQH((((((((((((((((((((((((((((((((((((($Xv/4O[赬M5bѩ[3DuZآ(((((((((((((((((((((((ȉ>o`DMw):תZku$EU=SP:?4RMNKS2 z:+~Xo–3b2r{`uJ~2M,Z,2TX=8Ͻrˆ`lbԁ"2BscѴhZĖfku4z8q8bVQyOxՠmGgNhb0Hm摏g8ºn#m%({z:;vp\j֑[#<24lSߨ=j׌5emoqsY]N@luA\o |2$D0Ƥ}+PZ^ictQp[wn<2 $lXz85xC [;;Fvqx B]Xhu$c\x[M IHJn]P' cޒ0ߍJN"]nj3xthzniw,9ޑJ#r9Wix_I 5XFb;W' rN3޻Mz'4GhP$},Zt}*R ZRY##=r>Zڟ4uդSI`nd&-0k:/|`[qscvy߻n3ݮ$yuZK 6jnv!Ŕ;0{;S>uc fy>ho񷯵rO\BڭEP_x ؓh D+6mT3}C$r`7<NN( 6ُm3aK,JX* ךݸom5A\kVqݓ)'>ǚRaBHu#&9ðr|4 ٗP]UVv)hbL P {{K[+jyrL5#E[KQ/tr})|).` wru>>|ُʱ|;ow>ojYHoq!olP=]n[V ,b@ OcӼQגYyr}"Z>,t[[KCM4S2Ys`zCk&}N&s]ی㎔:A5 BM5XUk)%Z*4oo5{H]5}T[ hxIo^\]h<;g B ƤdlO=bߊ|Z [$ֺ^'y)>)QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEq?kR<#"f`cI_5+c?&hk@QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE5ެȉ>o?_O__]-s_֯)IOSQ|*I xTd/+Q|1tFmyLnz<⚺u p<0wz5^_uM1;-B l¦NNqxXڬ.p*\ @88;P U|C\iWRk5ǚ/N =H>kX,K{hcjGUGPև-֡YNIV8r*-z$-+QX ]#Nj'D0mڇR{ cE4p]"^f$岵myy22mG>"|?rj N[% ')ĺ,+kI@zcu¶UI `$pyK {uYMs $ cGZok1(DT aɰ񇇵=U-^{Fn IV4^ >7#yPV^h:VAՏ>@[R:57w{8ְ<+-GY5{ym8#}#h'Z8ƛ*wIVV*w`|p#'S\Zx؋ 3qmPйѬe)bGBN9>柩H5`S瑰 3KI #Y䪒@rejoVn3ToNJ3*zj=^j7qZ sUthͦ\,#2hJ@#;h6Vxsq¡%? `fmgcR:wt=[P:~Esr [c"jޙڋR+Xڥ,}X Rͥ>Mm(arp@4Mgmq<rKnšvPLdn86>$ѵ-*mRQk;ugE'` 6/L%Ss!mcQ@jK{R=f8G?Xtm3W`Ԭ-CVh>=*? <2 Ѐq'=8u7P6zͼw ]F Es°NmE,Ndcl흠B*ѰuVI *Fsڒ:F}oۇ@TyxUT6xzFmȂ ]pG RdalNOf [ z+xt[)R6BOnm յ}N5e 4dU1S8}MKaet83s`hB Wl0#ǦhW=)q 떻-n%OF[==OHtzoؕޙ=8>E4eA-b0';v9'jf5ԿGkDF6OX:"Zx7ڐӭyns词}4cǟ>k'Γ*'ՔQE"'>ˡ;Pԙ;5N|O{i -k Tt2l1W7VcAqJ7 +[=ryMÏuxAwv&J%|]w;pP. v?]X9%|]P.뼢1CC%|]wQ`8?H~(ЗctCC, >?.H~(ЗcuQE!B] >?.(s$??K?!B]yEc v?G$??K(pP. v?]X9%|]P.뼢1CC%|]wQ`8?H~(ЗctCC, >?.H~(ЗcuQE!B] >?.(s$??KODS-hk[fq+(r~kٗ > Kp<8'һr+g44ЄQ_Dy=O$'w's) ((((((((((((((((((,4?݋FlxGD-kMcؿjVDŽL?oր6(((((((((((((((((((((((+?"k@5X>9]| ֩y1vvPZ=J>g=*ï'/zgl/MQ 3<˩HX2RƪNbH@ t2f=>X纗T[O0cOJ)g;hQfe)ߎ9U6nzd=_x͏h7c=_s4k" #rYO@?Q]i/:l{x2G$O &)h;Ol8W8MJ;] JOm1ͮՑC:#GP6d'P2:Oyj&1kpafVٿ]CKXVF5;\D}@"2> +x*m%z0h:T񮕦2iZ̗PmB%א c8un[\G:1/1^Nngf0_ x*E4u>R 3 0w@\6˾AFw$uұ|P\in,_Osd9 a\q^°j6ב+nT%p:diٿٿa>䯕y.s^8E5CGQqPxfI<:*jW2_hݾF!(P;\Y]_io&A,^b8adUM*+2ysKFh m|;^/ k}h%կ75äKhX۪B!-szԐ[$oI+* Pܳ:ր VZ/5Y+&Mܓ)WA.'&$e[#m$ɒyPE_tKm-4tT6}Hm*BqS|16R s]$pkdCmy®@$OO|)um[VOi1Av P[\|CX2žr!1wn8k{k"ATP:vlְ Jǧ xW0[EoF]KOj"[|WҦ]"iO.Lv=JഷK{hcjGU-N_Aw :w/q_M:5~+Mϴ6:Lng_>o)SNCKqR:6--0{tDlq[ZG6qog,{v$pca#9gZԴW67(%a8S:ޡ-WPѴ="om.U`WAxF~Rt}0JZ`I$]J8gx{E~4v䖟1<[u8${AI"d+Ɉj$w (R4L| ?*`lm|xpq*hpJ8r7H#->r@V'}ikS&Kk<*`"s"uKI,aha f t`=+үtM+R(oKV@):wkZ^J퉇BR3;i*X$(Eѹ^T23#/QALJIMut.1P%7$대qI K QI;21#+ƨ7[vvHX9=9j+ ]վB@RX.Aj߲nق3p&7$대qTm4{[KdWwsJX~zcǟ>k'(gh6^,6[AV\5_Gi+ʉ(hd10W(9 uTzׇa߆u=\Z")f%Gpwqt׷O*=ỻ4pOv9ۄ3gJ?ݽT|-c@n]oåGy{jw{{`v9EL#64AJ~lp^"5Rq5|AUR{L};ܤ#$qEoH^3rֹV)OivR^ynbM z՟7vϫw`3ןZtl?9'ʷMI$TEJү^3,IvUv gZԴM>IK%5;žFMs[_ënuXə00*yj7n%ռ躾me+@(NNq8#8o-Wr0z=A~|85ΜG]+)55i:lVwzu1ԁX:|9o(gYk%U6,XEk\albI^+xGW|pG :+mCUV h|yf7Ÿ4TF)i)jM((((((((((((((((((?McؿjVDŽL?oֱ,4?݋FlxGD-hb(((((((((((((((((((((((|s"&`[Ճ5I^kkWKTd (Q@Q@Q@Q@uJI{ t*Ft Vt>2mΥ ʖbPރ#F1ua<>?Im 徝eos*A 6m z}k nR@ceeP@s97w◅5+ApМgbwciUw :α33)bv72U=wz?=0y&meqgj`K`\j@Gmncqw:C$A6'X*:Ŝ71IqmωXp*2B(((((X~zcǟ>k'ˉeQHg_{_뺮Q|s]RbG,j${h$9XTLp{f1_)ǽClaцzzsKm"r~EauuōʖH0r0HmY^;}b1_eH/|O芊`3.PX!b9 P [;'5 i͍rD*5sMC>le6lLX qNz|ի[; b>'u6pC_9ݏ\fg rn7m:0B=i"FT;;W'>ޑdXEڤq9}WNH'tNBZ*BygO@B{{F. Djюn ./foTƷnDx[8qTO |>ș٧iP6`>S^Ox, X+x&Ho~^ɭN[KHJK8`ePdl}+VWPAC!03`=ISDZ°1.vjFNx޲5äF"):J QDݒ;۽URZmY&E36b;88(nL5EXPOdqL-涘CoNnlrBZXeE7WC؊-B{ 'Ēer( Lo x^C -la҈ h|=> SGkM9.)2LX€0GHֺ6alĬUP[ӓڀz|EnEϮI6Ь6 KR5 SM\gq$_ P5▐RԚQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ŏ&ԭș:EcXiJ'ZQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@a z>|*+"tQe#~T|6ey:>Ɉ?96Y?oб<|Š(((((+[{ "& @H9p ^@P<2 ΩtQCT}@ \Ï ,~[vn/)C0.c> V4q;(g(9 [iڨGc ۉ ,1[[`Tc(9 օm--_O5hdYmaɦCzԾxD[ÐJy&29WWf \i6 4/' 3ϭkC=* JR{7.f NW,}SQ-=GMYtZXB.ӻ `1\t}3OX[DHULja$ p *i_>͍j u(ЭմrMJTw>Ү'O{M!H9H,Q#( zc|C=6F\[l5=|+Y$icƳKۗ#p? =;vzu;ʆ[„BUF<h[]\=fp9nRO4/hW4?Z,-oaHVfYMi⇉VXcx.gG9#z҇p+KW_>h$B㣐zjC đMR(`Jqt.yt{"Pԥ[*0COC=?Riwad8-B`ˏoQxGKyFC-ǚxdX:8Oc8-ukJSFٮ6*2Go2:Yowd{?Lj^&VbധcW2R2szw}3·^I]ZL xNx uu40JOo?t|`{ YLlxTuu #ح|KET,<Ç[$'KZXլ__Y^Y"Ii"u$9~- F]^hQnPH /c[':ͽ.0A 3ۓAhV,LPk|ѢV ^%K<?sa{ weop&7i %pnU9I z^OV0^qf#Y:rv G8S [)弽vx'#2AtoSw<<9]]1ymyq?[])0lC`=$L4M^(hVNmx7 wM,[#L\+ d0Y Y-[PYZ;;Pz!`8'w:4j̻Y${WZ.!{[Y<b.~,#a^sYkEw8O4|d z -Dѻ1cwc?iu+-RUԯoeC4 0AMByw)taxg@uoxQK?p(I 被x/E^^&Ӣ-5KibUas@怹.Mۣ+[xtv?6>֢ɧ6umM]]X4 M4bpW q ~{P]𽼢k{g,.;!,l5xQ<.Tp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? G._?W{<y14ETp_|? U[ 0{B5kǩ#q?*&/ȥ j.+5x5[t3y9 (8Ew^|%?Az (BCOҼsv%񍶇C3.Q"@ 762AJQ\O5/KOe{X89☭" 2+YGOnV ^Ҥqc(:޵ϧxUv tTn;uֽh(?o/?hЫ~$_ PTw=RU)u: R .[V>UP0Iz(((( ȗ:Ery>n5`'xV>Pڽx#4)ee<AD[đCHPt :> ief Ҵf{E, [s6rO$g9R|Dl5-'K.!. v%Cd1(a5IMG"+Xd{Yw=&4"g Lۥq$)g~iw I GR +"X[߅ng\0R k8ޙ?JKz&2M6w @zda>Hmu{thT,tGb:P3]CsCda*>3ڹIU!nc>Yl&;HU2:|[=++L962:Զvmgm E98I&8O K=[UUhQlVN*$gE MgJ(0,mľ 7׶ZtI!f C`TFM:+`N&oxxglsOֺnWX%`a89z;Ngm=a,;Sy5IFFzz k[:'{7VaFsxݼ89ksGLGqon" ;dVz.akrA(b`.#) FK)PMMocy$ gqY"Vem0q]7ԴOKk{ WqOk)v+LaFpHEP 6t,|C۶Y' nwGr{ ߉7Ÿ4T_uMb:UH3vߢvr=ktp_LZ65M:ޤA^T* pqs(*bh?>է˨{!-_~ENr9O5t_uE8Gn11 =zc1+KMCƲV[nXHI16Ḿd\qPACuϯY߉&Yeeb$z6"E.ilOٟڭ+k:u,d2@wV}Y$RCqy2&2AW?uN>:WFT6mkeH5y@H8t5㫛 Yb[mdzu׉4;ϱ^k6#-+'49=O5acUf L{1W =V ,o薺eݝ݅1*@P `ZŽiv׶qiq/d+v5ڱZ\Bo0I>ǓA@E)`}w ojV8=£8'Y{˘3UHG!Sq1NN9=jjN6$P}2;*V}4kƳn.W9+g9_*0xoGti.HBa?PAҳSĚ`Zܡ}ޛsPQ@((Gzyď aO* ZAKRhQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEp kwU3J/뽯U#9nQEQ@WrDV񴯴v$ HFF pvWw- 'KnQ5""k>,g;Xٗ'ؐH#ߥt5iL\iצ8)VŧK-];%kسJǫ3{`cxHCYIjQD;zry'<oz%[Gww"1o%AF-x#z߷sE,iԵk[f x##* b5ӯMhh/%7Wy< տff It`t>"x{F|=aocs䳞?!'>94;нΟm>.Z87?:gh|:ḁWPpwfH"a\ I;OI_?pߜc9| E兏5RIR@)a } sڼ֓ºUeoM P x[=szΥZjt}Bkk"}kᶙw`:6qwWPigUl; $KQ-;8ldc'f((=#)E^^{#FSf–RԚQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@cLSmlBB0zdT5 O5|Nm؄2I$UO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlG&IƳ?U#??U#?¿2? e6?U~_O*U~_O*45 O4k_t k3_?_? ?M|+C.W]'cWEWEO_ ˤlZvwXulHqW0~ 4UQ/$P{EP(9 u\/?/Vepk4kԴ:3J*;=dRr8Fos/./eWhi\ \78ev&5(x CU63 I8RX`fs5֑dno^%c$m%Hq\P;+m" DqFGcO\kֹs Pk).txBL*@F%v7l_@ԥu;y[Q4RF2Js3v gMV<łV*r>֍y/u}Fᯅ"eկ&n]H)t[uX x;]T`9^ gX~t<~bLjSseiG[}ΧG 2Kk(m#ܤOޱϊK˫ҶMP$tM{; B u{<FP秷Q[u|?/-+-,* ] \z/5߉1xvVk ҅8*J' fmEp:ΣW:~6m[0Q.6b$pk&m^_Zш̖ O)˻vG\P;EpMG7]3&d@c 72\d`c5ֹ[P[Vҭڵz-ZX5{]~H_67*"HUKjú_mݵ4wojA#ޱtǠ\:8M!_K=>D# &,Xw5B#u.[ D2P*=25k>"R&Kx⵮[˟h3{C889Xk~$_ W?o/?hw=R Z@((((((((((((((((((((((((((((((( D/}M+ D/}M(((((((((((((((((((((((((((((p[y*p[y*h?!UPkִKC>14'i6h<m4a|3ݳ'< |9M7Lz0u`ca>hnW:-,׳Fm1<1q{o|k2;u8`h8#ֺ)sŁ5M)_P4ʥ[W >`H$wt/uu)f% IN2( _TfAq('!%){e*4xLC-+9>ump<ʤ6#BfHx^:F{J{hkIhm:OC<'%^_\kt&>U*cvP8}cO}V7OW+@ 0$zg X A s^u|fR9"d;]] i>t낆k[Xr+TVyЯ?d/'xwnz訠fxW) GK$+|[wn8neg/@]tZګN˲ 1m9p3sQ@\5_1:NwX@mg;G k>(:$%՟`Xk(.vTP8Ջ aG6bA O@qSW:c[jv mcr/=9pF?>::( 6=z_GԵY"{x-|1%wNG%k:E֥zkiIs5fgD_RsIuEsҴ?xsPՍ_6w%wܴr ~BK{? 1]hx VdԾғ*/{\;HukE)`Gbj0mpAEj*M(.X\1lx[?8ⸯQ2` gkwtuJq1Tw'\6\֯<{a|:ɃןPFʏs-'JZEQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@wJ'oUgx&E{e$02ycON|s.CMs5$\ydžL}3@.χc^!l$˒$L2 uڥt=|A 6ڗ})&I$pן9ѭ2x5m&v>Kd`8;N!d'oq@F#F%w1EI6BUH񬏉-< kxsRDEjƫ d*A@ӯ%'vj\;GN (zj?k0kn-tՏSX62B,hn|Qze⩊Fw|(8=qѾlEo'jI?熾$y~/HԵU;p=h&hHaAf1H?ۏ|i|Si^ id ]J`ppp} xMe5cbpG$pqҀ=ZAuk[$QTtxgV,5h3$cF 6=9e>9+imw\sr{}sLce'͵rkj|! 4xV霏N[AHa഍[ws{ke.[iڎmkl K_,jظvc.τ?Kܛab<7-8ٷP|Mhzpta*=* ]YC,<UKgd|q=+ǵ࿆wͨ?9OlWJ!6Msmڑu&7QW= ۾(~ x[7KV&-gں. VZrmu eS4{@ 0 zc7&ۏ\q@wx_٠9AFd`bE^o!]m-#sb /=q\w(kU>  }]s+zmێ9SNe6 ơ@ Ym`%Tt"Cq?mc#d Xu ]R c("IKW w=V 'E4}:%ML>Zx[ax&0!\ݴ+/'.4ANs1*׉>-xY<0-d6qf{^xº{^-ޱMe(t(x =3ү>#-=6);`ۚiWgqsoAs2hg}k[|FYwQYc0ڀ=j75Mt]nv؊Q]<,R `P[8T\09ǧE/s|΍Oϳcn}qy'}2VlVpn1XaK>G=Z-Oi Bd1sS-tmz$Va»2qr:x,xg(+YA,`;se [|>nԭ}VRdF@@>U'<γ∯_giyxc!پ\s:9 Q^ƦE*LWSڞ:wu@Wv}q@ xjm}V;yw< ?l^)DžUi6OI@Vdg:C?ī eUṲozՄ-we8@#a O9#1-uE /zd#8cхtP_ZCwm Y#p1Xdל|'#Z/GSg۱:1ֽ&$B PQg@QEQEQEQEQEQEQEQEQEҸ?N뼿wҸ?N뼿wQE%p(Tmgڜ.!^Sd=Gw&(cnm5Nf?p~BߋP+#ξwr]>}E<m(o?Z( #ξwr]>}E<m(o?Z( #ξwr]>}E<m(o?Z( #ξwr]>}E<m(o?Z( #ξwr]>}E<m(o?Z( #ξwr]>}E<m(o?Z( #ξwr]>}E<m(o?Z( #ξwr=.X{X~b<L`n58ojבN`m3+R@Š((((((((((((((((((((((((((((((((;%7Ӯ7:axUqM۽q?xuk^+м;$169ھI>&ּ=mu{$UbF ޢO zfْ0'ryHIIuxPA B)|#_#Ǹ>zZã\6IER3Gbռ7eѲ5ope aZ|o}sgivȓ;}GLOwWz,n=˒s!C<˃4t h=ͥvlZxY20r+*/ 9M'>[+1P'Ľ6]%uYϗ̼œqzֶ{R-. +FH| ))pTxºOgn0Zn=+ ѴحL}ffĜ{gxǒ꺖ݥTj, #<X{ϋ[_LZqOXΪmUni 摬I\vגn =p?U.>x:Mۙn;Y pKtu[mݜх2@8!j4sk-ƝCgzYm.1eBK忇*3ڀ65 hO=́GnkR,5,X2>޹|_i{o]UզND3 ^=$~(t] "Rgԭ6\JrHP@ $rhMt}Cr푝+MN+'C%Aqiwc K[ $yS 9 Km ?#%Wٿf19hӼ1^2miM>TFT׌g Oទ74|Qu+a"e evPJ6:tw5l?<خHмE qT&Utkvyb,W99h\y^(׋.5;FKxr=Ef(%Xm~B0׀GJ3xG‹mz_\g)a p$=jwݱ,Vm:GKm@ |Oi#Fӵ+q=% 7prIcLπ|-}S lt3˟ 藚higGQЃןzi [>.cLಕfS^3b`5!FkUw2rUq@VL4-#$nɁqsU/{ #dV(ngb=71'8:m_R4pY䏔2yV?mjB]fER" wv#+ߖPaiz^{YZno=́sp:Jk沰?-t ,%'9$<{VM6NG侹JZn&H 6'1C#tDA>sWZy>}qn=8\_L:QGҬg#Ӯ&Z Oɦjro䜆A,Y_Ж!U}Il`>)Rŏ88OAPijZpo, 'AAw%}>m5v=>\3+"A 韙x|oxtlo8 8\( 8m-54s+=%5x"$Vm~e!ʀ1f֦zL ί$wP-ɵH~dPNXczt _.mZqx#.і?UOGԵ OsxKh ܓH'Wbf;?şn%Җ74<ġ2 ݒ9v]-,,4-@,1[, d@h^AҖ ( ( ( ( ( (W_IշwBW_IշwB(((((((((((((((((((((((((((((((((((((((((((((((((((;%7Ӫ+zula;eۂyO皿J'o^@~ %3"3&1J((JO t8 iT,2.0i-4˿ |BQu}g Ls>B Gkk^855Ņ,W'=GqV4?s%zΟfn@$y@e4_6$WCn!u&!V/]/QK(221cq](p)YP\ƒU,r! XGcp 1p$zV*iHgIc`njpkw:iP[޺YXej7t'YYM1 f_M]R\-RPm-Q<`bPWott۹?饺e/*F~K}fz][J(,w6 sA^N0$߻>W5m.ZҮ4Ė(QzpAEq^!<'}=ngʳ F~l=ͽx\IBLh-ج$f tc<v׈ԴIEkuC1^W|qqڰVXu9vԞ'd+# f<^&-׋"i>G!j6sEnMM5}*PK?⟞ȩLʅs3 i_s#Nl9aF [ZjUY$7oRT䷯9+ fO3xM59 .Y7ykA8 <]j:Ǎ,4_Z>m.Ƒ}&k<1s7\ʍdrlwyjyhOJ?-$y/v b)x=u]{CMȚɲH-O5WVj^:WY)2!@bU'q4l5[SmMvB'qxbm_VK]V]>OIHÂ_nwaHǿQ5{Q4Ƣ}dx\dmO|ENHWSoYX'm[.aη{&s!FԍFvI=I5_Ϩ鶮ci;2FMVnM.Xf 9L8dU/#%5iWX5AQ4O!IA!5xZjzɦ5_D`Y 1w m͆_izݭF/$ b N9 + ˽SZyWM|;6sT=k'#ikr31#s]-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE#to/]to/@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@wJ'o]3ƚif<ʅ5|@_i?/|I#xVG!y9z:ȁу+ A.?Ja<,l8'=A+V (8mZ cShjZuzB&_e=sj~ޛuVy(2r#χZ{mV(4u 3džuRC]FO$V WM4/,4 Zͽ\.UWN?*"J NG(ڢZ3Z##޶\}ytTfk` e {pqxKz@G8"gi  w0}i֓ERҋ8Cd磆d8hfduO )KPEETOQnC$Q_1=+vGK>M{G+F#\L`8 ?NO/4ɢK:,fre|[PsZ&%7dB$ItsrۭOe@䃊ڥޓĹD\p.x둒hg.!޺s*KpB}615 d9p M$VzVԶ֌lQb2q@Ȫ> xPXEusaG$4C:@؝ c~[9 7vE]^O"i^rhc_֤🈮[2U6O2!ѭ7fŧe%MZIt1#bGi!q[p>+W[t~;MopQ[F"O<<M3L5kRhafЖnʍFKxZou g-ݘHmLo:]Clڸ.53j6gn.qHe2mvջwXxM t^ L cbGzQ|e>mnQ4mxvʪ=[r7WUG]9m/ Jmlm̮F\WKyn ^ ox Dmu5G_.5գ@DmFUw@B=h5sO[ fd!#)+){,[4cm-̆WiL1\7y\嶟_]Hcl!{4(߽ɿcE%|6OnVm8X__g5{S\ Ÿ\ ntK; U( p y V/zu~Qy۩|v$(֟kwqomjs̶6Hp2TFH@*qCm5)ڙ mc$:MvKZ=SWZ\z6kq *Jvqå }7^.kk+ RȨ +C# e 9C'ĝ6ccm l`;~-EgId3%?.qޤԇ]=?W?@_G}G"Mee9 B s3AbyVZmhdKbA.GМ sEjdcH#XWZu[E k@(11ut:~zڊoIĨN}kO*i rB  1ָM6mO:ot-KPM&Y5P99*}˪x_C^ӡu%yX 򃐤46`S{E4-q' T|ۯF `i-LiJLH<\=OFu[gnK%8ù>S#mx_64uէXJ0&#ɠn3 kL{}sީxHu]B_e;WI#c|EBM76+!T nH'umCMv%^Jd9=^xN6Agn?d2Kl2 }0NjD: ]쳅J^68y[UIi<)GG#gd֫G}=ʞt Ɓ<~\@KPOP. E[LpXcrG\sV?X^ͨo(2K+y?Juoemg^7A1[ ~F@MCO^Gk}uݡP+fx2HOqH=*Tʜd{qN+$Y"e# K@Q@Q@+/$Wx+/$P{EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP@_iסמ|@_i?5O iZeI.UvI@#ӯPQY?;cy&wNv=iEP/HFq~H˶b\iGt}j]>i7ͻ&@0J[nLڛTۜv~O5=$idh ,;2g0=+˴c\~j7Mid|L4rl眑HMk{iU]iR,2FN<30s@@Ipz/隌VZۺ02< VM[b-UVCJBuLN8\f5w\ixE)>ROj=~h4{Vz&>j[OSuڀ={t \nxxu{;O:Dw2y H95sDe׷ֺz}꥕d/*OZCQ;W- חVӣ^WxJAJ_j>*""Ig˕X'C9".U894L cmP`QKE&G-AP{R@ FKE&F-m)h_AK: Z(6J6Pb-D?EYٷoŶ=3֭݋KKE&ќ⍠vzсKE!PFj8PmmPREQEQE#to/]to/@Q@Q@Q@'4SuxPhK`cImE%-N-R{XfY&碂L{@>s~MfXy6ۢ 9÷C@Rgjڷھ$d{Y7ߝ1zz)3USRNuk#Y%g( tU X״+1 R|1S~ ))hjZ՞uamr\IOAr [c+s+$y۽gߢt斀 );UE,T}1gSx !PEghݞbolK]vpxРp3@ E`w^'yi~-s[lz[V,*`v(}MVWP^@I520vt=PMf @3T]b^`Ă}<# ))h(Z)(ju"Xi6 8AT6R]%/B[,hPqpEjYi`/c΋M2-ϔkzߊew#YSp@E%-PEQEQEQEQEQEQEQE?xuk }cLX20pJHx'2Y[sXGF=BoO񦍩ji=p-Q1`9jM&[RVX$t!19(uimTWnQV 4AV|k'yYNɒ}ͪyۼ2=mR*6Qs0*z-d#HFޣ|`ս3ZN.\G4`E.uhPʏh-Ԗvr4V8ČAVu%vw8"i N>]{'t4W;w}"TY KI%xa>ڥz =l/$C8V d}ng̯ $/LlU`sÃqqN:5 ?RV+iK:I(127 I4X.k'K˙m=-$[ʂ#\sSxGҭu&`H2('(b4麲\RIo-sMdVSşVԖlN<峮;w1Ҁ= ̨Q$+uuoAܶr$!$R!Kk=Rme, mU~Fi܌ @gg_z 4NMY8Uv' zPOK\e%΀am\fLYۅ<OzOs8n9`W*5RIlm,-w Ǧ@tQEEsq(IśSn#ysX/_S6^uXjDW9?݀99;ƺVxrm'K {X܍ jР!Mdjsn ķ>HU-F)IVgikqMZj7ch"L;)UF#?ST< :~${M/ڻJw}361~WMXf1${`9<,g[VC]"b` c:sžq5A>i.b|{ Ih7޾w;c=Ԇ8^ SjzO_YitsəBAmR}Nzz>cYQ()I )@ 1;s>0.4whujHw!@kYkƸ`J!8:f&3^ΉOͪYk+1E$jr*zm^0 Ox[_JiMBT<Ԗ$t_ZaZɜ3̌*cEeg|%ΕXYjzkYۓ91I)j˜b|cv1%w!c/Ʉ3>q(_`1ޱ-#e}7 /V_-RP2KJ#-=#C=Vop1=I&ţK2#V<`henu"hƣhlu g(na)MOӂ&ZVfb2@x@rAԿǚgqZhi6}<98>{toA(׮2\Km j ԓǠ|L٭ P|e8==hέoijzn)qsj͂U uvĺ\u-cc4hf@@$րuMu+]:Jg+x 4`1mst uռ1ylOn*˯iW^:CzE%7).N2yxAv:=3k{;&yoۅ,( 1St3ž_A,,u 8OMvchUӸÌڴaeR[j7MSė {PZu:(״K{3?;$0Eip1L:uu Ůb`ʍX*XronIsjU{=GyUGNOImNմv26ki(b nOZj˥+i\4pe`rW}MAsj/{w#cYp?[v-lY2*ɸs֫O}B]Sw*Є,.rad;ecXxOokA ZiGet6UInu-ut-/tn.Uܫ&@=I$v2h5>oES-J\ lC<6NBkuvk;lr ״*,6d|zsQk^ך9,l3n!e$G~J]5qjmLA)G8q9ƃG񥏆eXM$*DG [s)Wk\i#5:JY.S?s]w&Ҽ5iLֶC!CTP]|B]o(ɥ7|ąc(Ğ0__KsakNbܤ;s{csMrš ͔Wnva 񐭏lf3ž_B,l5+4w F# $ i-Ok pZXGm8bC,n;qn׀4wQܖ L.pAZB81 {okO$s_Kd"%]ž7 h~Xޘ̦YtčĎÞk>Gk=z4D\DzG8zV>)-g\F;2pAn?O8v?U^Uk"%!E`=u L[!մiRCʄ K+ľ+X4[c3CP6O\Ҁ1OWm WPæƯ#GMs8=0nWQOMNiO ir=Gv!N9?8 2\^񦃧ϭͪY4r1G"&QG `fk0mORץҭbx"Nϗ̐?ÑumwBԼUNKvsat 65[:l^JԴ/epntk)b0 w(댃Z{j{.4r*R>Q8'fjw1{V+`DqS{e\yċpqip@J*4MM:c==BӬʱ]jq]4dŲ-G1'׀}k\喗ͧ:,wD( GX1G9-5OuKbIBXbrZV:"1. $8M6_\d:Ck|1`jv*mwO4Zs=@!x(*ArWZڝ:t{K m`H= 7RxSӂ[.•U1\sy4&+H F6>߷i^r^j>ZEQ)#fGkzׇ;-Cs1ZYA,Nxzs_źCChֺOkp&;0˷3󧷆u--_Ij~}K ;H`H8 Yt KR}NTGXeebsgn[|ܑx^Ҋ!LP0zp}}#6ŦKk;i *\edJA9~w>",tq-[+7dv <1ۿ趺hݩm>H~I# ´+;DmYȎo/8zc(((((((Q< _S:İjZL"n3*H'ps3}J'o^@>.4_ my7pIa{ ֢(bґ\EOٵʀ2OUzl[Y:@}maT[nQ9,lol.% 52[wA<1P+ EukЮm,Ow /uAt9-~ְap4ar1G?xwPe&ź18ZeY ;H1"*yGk{w ̈KcOzF -b`Р1ʀH^U ^̊89E܃ B@ߊډmmvXc0Hn#О<8t$9l浳ga-rqOᴥYotBɣ$vIV3@I^@^bC QSc&42@7S@Mv/于}CF,˶78wG\W/ͿmEZmm9VPN{=FefE,t)p- fuVRpZ- 8`ڠ|lݻw:PK\~_ŧнam U7~Y9#+K(bBp@';LCdd [ہ`{?&J0lp}+Ϡ|oR'SI!hy]GTh:o?5/ jN]8B#szvF:Q^gg*[:Zm$4sݠHY֫xRMKwafXycWn뵛 P+8+݁Re9#nĹ?6ج"a)@H#yw6i^Z6eK3٠W!}3=k-G̯d׆\C9' :[_NLX.LB[nJA" J;P2gיkѴjLK(uS<7 UNO^&u(]ib͠xՎ6$ϷZ$aPpk/Tס5]'Oh^IuI^8*Rğ+$Ӵ V>nmy>hvp/^v{|<-[_.$Ua2$Mz]"8fW8\w;s+ΧF׾!^ٍXZ<ќV#W ix|Cu?l)z,>&t~\$$j @10NOR}oM1Ú28Ҩj:/6);jQ@!Ik |kmk^!7BWl[ĭDq0yO ]xFTֈl,r 'v/ ƥÚ:M@*_C+tnj-C÷ݮ[Zey{ ZZ>wd2i]Je6Pt*|?*S*b8a$s)'NG5.ƙ|%ՠRkf6brp2y⺘bA"j7X\==[=xZoq$ؼ)|!\HMJCe̲36E;@'Fcր=N)ۤuCF}j晧Y³u?##\:5uydM-i@q?\Ι2NѦ,n4t,_s ByULg{wjdiZx.ԯne?1` ($z-6ރG%S4k={5ymʬ q@:R# V_5ؼ;,/0WH,d5x2~'4%[%cvCzg _:m{Iacc!Pߘ7u`YSf89}ka$Ir9\Ɨ?|; :jX\'eW\sNHy[h?G^V$*z8B˸$S׏h4:Z_G綮Y  #zWVo nbԖ-`ĐH H$@y5,* Ua8_,3u ZSn]-a)#732Xcң{OMgd4ӭGhPU >=+OzU먌OJA<.Tf/xlo6#^#NMLeIe, r}qLM AvKmŕ|;W8&=0Ȋꅀcɥ I\_>յ=Jyͫ$Ї IFL^00:tZkW^ӼNGu(V\3Ae?Ơg_x*tdSi<sPF9}kn N|}3NH- EPNszixK¾";s}1Cη'0=bݠP4p+izo}"*7F8;/ΎɧivkYF!V._[Ǻ֋}VɊ\E#q L 8-,K+H(T A*g#v :dW~6MխvlRoa!푸c Umƚ5-~}=J]>V&8#.JIAȦ`Xr@+ǵ$Ӽ#E,Yi2ڵ˴k#+y`\q=kOžt4֜go5X,owIU=O\tbBH88}(i1p2q\hzo~%xrYGAw#% |_,F⛨Q#Soc򁙕A=OS|dRy_``[<^*2|$񕌖kjyf_2#?t1C29SV3I1g a'ݸN(ҞDw9 =Idij>'sn#]+ĻdLqM~#kBF;[gc婑 >AKM./bG,QLlB{@yą`JJ(־l h̑6PT.΅m'k[L:0$>A@Ңc{p2qY%סށu ̖v,G_vr> oV 5)"Im=yϭsZͺ\5%jY\ۻӰhngXcۥYt\OM[((((;%7Ӫ~)^xG^JaY} s^G=8??xub4չ%ڲ o\dg=zdk@բ[[={QZCgkK0HA8 (87-y'5o]ֵmhvZv""wl`# "Ӽ5\z5 Ylct(3ef$q _7eVoQ ##Qe=Eo"U,͔^O#V$}ylv+tm8ZK;zZe -'[HS#sހ+igEQMAaK)S%l˜8^7f յfVګZ8.*8Vu V<Դ&L|ןӎk~&<4 [?d`eX~[ (8=&sKN~%r1.* s)P)C3\:EF̫bm0?kt65uBr66kyl.h,aY|lf 삀;k.m໹, N6 cOJK[_c-k/bXۻ!Y^=lWW'tcImN__FVG@*/Ar=1"Gf8PszfoQxiXvN񞣬yY3q|hblȠWj6-.uy%&8smSr:Tk9iE"P @R{g ~;#ĶWbR%2NɽpVr;Zv~o5DE{k5ռ q2ij1 hυv嶺v; fbqN3Z׊]R{WQдk>+.mmUy\䫹Fہ.rI#fG;j;C22܅'N#pkk p HP.@d*SO4xOxJinmvaI2ͲR rA24Oo+)Qx`ff[j-ZՄd(@roz4;oQծbmBd"Ƭ-ǧQ}kgAC8[ {]t ߛ{Zo/4. mqkN? WZǤϾ70|F۶ z_YznzZ)՗ h#vi}z+a,bWTYFP)\ +q5 VӬmSI9FG~iԵ;V]{TGԭź2j6$z@mBPծkYRJ?18L\ )kxuBױX-ml#p7@ gAk^&>ka6ayGLI"1+0y$x"?Ė;j^]hi-㈟`~S=5<);}JPJېI_pm( jgT4mNͦ\F"h; 2thΦg May{# <z((((((((((((F\'V_ \'V_ ;( ( ( L Z(/Ě7ޣg}ykDyfVDLPu;aCGvZ'FRI'jvw!{ЋXEnmx0j?Wgent#XdȾF5C:Υ+m:6j1._{/(MYpbrD{ uNO0y+:(0B;ʑT)*Cm?I([sh3y B@ݧ9&6??6'o7c&jK;Hڤ*p#؁x=ַ5OwFQR(d?(/㊿6[Y >ӿ(TrxrOXJ|Cww$P i PGO>!P[o{chKϙ8WkVSkVHdKu y5M{F՚m%u.DiT7,Ĭ>lxdgNsbJ洟i>|@Ovz ]R g At.<[}6#0j GP7OqY&д[(umL [R@۷ p>>{K׆ItQ$u-4n`v7㚗X񎁡 ;@%C!8VUE;Gրghۻv5!7@B5 F׳x}$Pr>mk~_pvP>L%[ y0㑎Uxst&TA`>kFY~4QqU@\MCKKe흵̎HFv13 3]^h4,exP{p=T}2S;. VʱFdR^vٚDEܚe֋W*!]O L7mi楯 g"YV5sOlEӴkF%eˉ t %>?4}zYӯ<ɭR&{p=@ }wDҙm&S!̅B}[`fq>7ormųOצ87>?䖳jR#G0(;֖Z&{@Gz%끚|w&u}#\K%"`Yc 0 Fn 8ǡss}FVP7TaFU{{oxLҵ2ѭ 2)Me}3]Ua=ܞU$|G$s@#||6m  ::ޓKjQmefI"m>jk f;ԔaaDٞz֤ҼokRΰ[ nbKBx 6[ELq<ꥃu-Zxb9<^(5pq#DW,[Y%) Vtݾk4VpcVEyT|-WuƩvb1ʎ94ekm3U5w©olp008Rxr9<`|BNl PTvLUZMr^L 6]0OAթ$HieuDE,@I(O:_o,I YRS(3߿U鶺>eF\= ^k4R,r0 OV5hk}SQ[iV%cFJ*98 n.5ִMbmP5%9t,aÊ/Bi>=o/Q ( 9Һ[+5 /m7+ CX+d3>,29MP o̤sj^ L:dvAC{jۓt<2gj=R%_g'6*QŒ(~<@vrk02*+4ya*29ֆM# VFwڊ ǭs (dӴi4YRFXuZO[]z[9tbn3M&i*5]:PX,Ew!Puu$7( yUْ# p{-mdm5&E(!$+h4e<61|Y< ƺeǃ-F"T5dv,rxۜxwVoe `q :sx 5{}F_R\Gm}4ǖc8/P@'mןz_{6}a7 `6wZW~6o=1Nzy")gmTg̾p)66Alk!VhwrYu nЉ2v2pAKj:ݟt>ܻ )88zP\5mFg=VlڠHn9=QMޅ?f(( `vn=k}tL|q g=GuP/xJu][^,CE4p$E$/8"w( $V'>\u+BMޯrZye H<`kNȮ0zh e2uIdĄ}u mOOKoqD=ՎsAxD4.AE@208>oQ}Ϋz]o[T`0V]UO:ͩ&I7+G.|AדLWh\.w9[4P66#ik0XI.ӓ1Fhm*4B:gWAEsx.)V/yc<0lϷ.4Vm/U05d90#5X(C=>jvm5숫 * G|w5v $> >K͋YFpP~5ETҬFYC !F mP3¹^kh~$KQϺ4sfC~GhúֈCγyRĜŊu54^6wt+fu kZut}FH3J2,;6zqRxgCÚzu3rXf?Pm\1>&u &#\T(>a0}+f|}o]w3S5gIiWPu_¤מIwe4JX6=U]MGHb5n;Z%I#^W ( ( ( (<ONۛK-j1 ]g ON~,!4] U_)99zGt+m/uon#njנ(OZ5k/4 KK8UDXyZ{O-1:;L^< EHzc^sg5h[$Sǐ98Tu!Ǿ)zZf7 $[bpˌk~iBIUte'SlyS `2[au#ݪ};ǐJ|R͵SieFY$W<Oԯ4pY})5Z= }~*ugƖtf+iSEKLq=BIJ!1bV`@#9rzKOk.hǖJw+RzM_ i crwaye"(ep\|AO*OQZt4_*9mx~"IG0%c12j.^_,&b1 yQXp5K+]ЭNHpBb?*+b8@χEQA$Ȓ.&*3)f%z|3jWK5̓BG Epiڑtn'|w6 !#01@'~O~^ӻsƙ$RZiHE*#+( a 㧵txO?Q~}g;J~) 0kֺ(rLbf?ҷ|!9 k]',xIP>c7/RJ9ϖ'bB Ҽm~ 9fLQl,n랤hUD֢Elr3p?*g|(Կ~}qWUyjlp Za<$6H<znu-9fW`dhد*A#/ocaF):`o"E䋏eq|?-XĐ mQ>QF;zԚkFTܜq ~ǩ']mg[~ܐEy*r(##vAMV^R4HZ7l`*Ihм=,izzA43;I!q8qqU|,z4xƓ)^vg ÖZGek-i<Tp'>?UӴ5yPwnڧF s8۫*i=9!$I*s9'O;F%KXfagi$a8qPmnoSSJ<'G>`=s7D]g)s~/m,Lm`g8] _I{sJú,c֖i:Μ4F)W###Hdb9߱k̛]A56EK?NHg8fsInkNQ!-RD'SPO? cQ삩2TBxT'Qy'twZ6{ǧ[,)' `St+Kˈ35rGP'j RCfcnMW>"U|W'ȹَ68kҵ_xsZ7b= "HL67pf=~9>Ht݁>ϸ =yM3kEb16WRt qZğcdߏ>o[_wp@j0p21ۜTwGZ<"-n!FQ,I=CֺG}%4œ+L[9ST^ i$r/os&aF #yƻ$FC]̫GKݣLOSFlM}k{mF]FY,qTt|3ksO,>y7gRa8]gQnm>[/4F ~#\.zWǠF·i>|Q1\_rNN= Kl.J+ԍ@$jM{n5q$/F.QEQIFhh(((JZ((4QEQERREPE ( ( ( ( ( (<ON?xt>|ť[iw'JKz(<ހ=bBխѣ09 (|A hwP,A!g T<%G$^ I b&095mt?-95C< 9rFF}HX}D"3_B"# %W{;:XHNcicV(}A#ž֖B<4R_=r;漨CH}txM!4Cn6#okZIiaꉦY>t3`W9<`@I[v56PۥFR|%֗Z^l319_Taux4Դm1u&{)VI9!Iu''{Kww=Oƺjivְe@Xas9'8:,7 q@w39=:>ijmv- Ljjz^3qji>ԫ${N:!)^a սP]tꓓWEf?^ѷ\ơգI4-3?";;{c?&f}%ɋ[nc8?2&fNsv3YZ\O52-&t c>RK Sb5?q^x4a42ЭLʀog\0O<qh3>x*]A_f;6QEPVx>U 9#7 kw,vz\sxxo uO6%P|'$ 씊x4zT_>=RCv@zm3< lpTGv9G Cak[Fѣ#Y e8`[#'kQjErmn0;F `ޭǯx#ce} [Mq1W*3t(XbYZUD8@MAs׳5ݍıs'Бqj_kI6mŽǒ<̀ f}J}v她;*!A۩s ( ( ( ( ( ( ( ( ( (W_IշwBW_IշwB(((JX'HoqlٷvǧW^ֵ Vc;A ^,LJ|1/G2鸊tm|EI4!mD\ca$:]KVZ#62` G^*-r]^?W pbnbFHrNqv x[[M[h׊b$k7m*끌9藖J?uRWM/,6`9'Bx{k:E a<^D4g`1?'z >5L I 0`ĜmX~0U`$H|cI4ȊD`z$n;_>!0%"¨@G`Fu14Vxpxy zh|w'#)+ubӆ ZL?>h5jEIJG !"7Z%(FgD|!NG|LU]i>0eZ 0*iS|q~ާj+x=?,A80qbF9ӀzsVon|/7H}BYmi\23 &`3///"熟UZUʁ-<Laomz+;#m'akw y>f<3M3dY\Lг4D*$3+{ <&v[j/ Wn~PY75M;S'qk%+i0H]|]ww\h֌t譾ֈ.uKe@c5KŁIktШ5).`s=ux](q9*4)6Տ&GEi>%G+F" H5C$.5\h^sfB. ;mv{GOԚ v)~ z+#Wv^Bvm] 4.mۻ'qZoGxPмG3\G{4Жȹ*T:}po_O|Aa&Z鵝F 2 $v:@ڗ/SXG47oInXb U.Ad:b񺶁^ϦmheNXtls\׺Xk" P鑙"KR-5\yq_\#F )8'>]/JYh%!ݚ#]HNnNӽu2o}Mv > #N~h0qԺޯgᏊýs d*JhvoEk<aZo7vg=kok𔫡yބi 2[ .{ηSW3o>fHF3`;C?؈1lk]xK7E$Gn& @(H\ >٩4j:Ήhj0B.?=fIb'n`~1u^KmOEuB}-$VC52m;@^q|"⬲o{Y_]_I#TS';qǧH%Ņoha1~eP>a Njn Oeԯ[f $ eYjjZ ]g@<6i! ܵrVDĻݟ_ǬZi F.VN:u>3/| RA#F.%H I Q$8t+IUӈ2YO=4CSԬ,Zouq_63;<HN09[I>Ww L֣0&K?1]M}BՌ>WM >G^54_m9{![y#e,\FVx \"|'wJwωkڜMusm| `i<3߈}JK=v}sU>9l\O-.RڭO]߾sx{Bm^KG[xb2scG5xڿu %Ӵy rЪQ3pMQ٥xkz&Ե].;/l-p #r Aʓ鲈.e}H#9~ee>9aUK˖#*@;W=k/6{,>\ݪʀKI$Ej nn4gPfy:zgKuBr%]jN bB vO Rxr>˫Y" PWrJϻuZ5:f0Jsqd ;bAf;|cZjv#P̰ApkpVpm0#?:ޝl% Dr3KLW.^ֵ-2FּA9Y"Phs>ヂsiZ퇁uXFKFMB쓣RHy]ct/Cv!?]*ec;Xv#/x;V1sjj$q,.P09$`dipv!kymvAUñQUwGC,Bמ`2bP[ ]+ŗMm%.Vx `qT[i<'&e  28%H'IZǚކZG[.olDر d#ҹ7[ԠHlX;cDP9-y=oľ-|=W@K{J[r9 z [C;$͡ d%ib88nwWK/9:nU$Ƌr:#FK+}CL"A7 #9/'Kgt !l] IeU$3G= jx MB-opXݷ*1 hD V-“7fz}ǀt@zDT oM3C}F-X$1bG˃ԝ84E5um7 JRQ :kxw↤ڙ0Ϧۃsc`<2PR/7;k+Mv@qߑ@^=tu/mYj4ѣX8F}+O{?W*6u9CԼp:JHVGS @rrF=k51i8B]eG P3:.Uk'SnҵĸAK񶩧Wz4ɝP]%0 )<+/u )&M}Hc$4|G@qr*; kV)X\k۪*]Fm. ԓSݷnt7CQ@.$(Ć,aBz[cjieiPܯ)"Epao|Ӭ GhRH&Ŀ"'I-5Q0zh/h]O{wF.T  s[75[Mcóiԕ&8: mj_ t{mKOP#Y>$  ~oWx/ kya$ rOpx__ ij3@$Lq\HdF#zGv% s6AsixH]{×S&D.2?yu|GgŒDWR#[kUWiN? ik ,6McRk UUzYGj^`e-8ۻQîWO:m,n|:湉|{gx@еn .aǹN{hWVK,nwW3LDH<(nd|=wf}֓) "< l*r=+KF =I=++FA;jq\L G #1ukwGdeVgbrH$:T¾+4[ KOělߑA8c+񿆬C\6]B*FoؑS)4Y ;c;rf_~'i.ׄ2*0=pqZ4]B4r6Vے7+krjQg̛~Տ$6qGj/mq\LwC{͓úgkX-`yG~3/)Kf]++=ȟe >\ g;#9k6*}U$;q.'i5{E^m*;@ EiSX귗F&P2'TN@*2Md-G̞i ġWϸOxQ@4][RjRzg e(p 8"Uŭ'՛Rԧj*(hyf#~)|coDċ`|޻J(|C]Ye-rE887X8H'? Yxbw]N{Yb^:|+8kp5ω-Zu]2N7 I1f:1k62Hkeh|H>ib76vd`= HJXm$ Z(((((((((((num]Ыnum]Ш((((uX4yDLPd|W ?5MYbM׾}͔pďsQ8>tyuk6ִ-7SOKy[ ]7v8'''8Z Ku}+X+&712ʱ^Y mWĺ\ȳ;n@Bm$ I'F:+q]xnN%m#2aF~# p z&*:tUo=p2O\>⫩|Qu 2(뻱G]Ub:}|*QL#ʹU  pJ2mFO77Vj60M^Jլٙ+ʒ qZ`e_O麴 : WO1/3 hұK\5犼7hzվc]}HB`vB $pzx|#Vck:~tjMn<('1\ǁ5WYNaU-XW8$g3PjSGa"+1[X+@S|l|חw 3X;VL*.et>iskV4SpxGb2:X\TR͹Kc0yQ8/jZHRԖTn9޽zhVzŝEꩩ\  8zԢU/ԝ&}}&^2Ⱦ0*O?k/gU8F.L/C4K-*+9.q6_-w8MJKa ~z7y:-[5MzR_$Q@wu w#i$lTdaIeyc1>ܬ2#ިxE g'm\3Ӿx b,M4YbT&we3:Q\WZeΙumiVQ UXI$YZKj>ĖZ9uxy2n @1\9buupd0n{mm5_[VoiLY$qlw*Xjy1I*­. 8[]zXZquog vW H :)LKfEyncV8 ۸sF9p|'uja{t6j";98h$um}=\[8x1}hѬ[} K%SiI|1yžC !17۷{9l][;xul5CZ^AJ1;Nk>К{X,7H qrsCBuatK|>}댎:ʀLHsOA2nd+тX-N;Eeqp60a9$WZ_Q-z?Z C7ڗui7 .i3#  suC7R$p\RH `szhKUkmfl̓\t%gzo g={WYMm#LL[KK[FNppzpqVI6)4 (M(`cg;P^AwVԴ+Yu?m.oe>Noq1.cagmd,`+P GдK=m["lc "(-6Cmf71Ts\:aUIZ&w,@8KsDJ$nYd0=AQӼ?ih%n2xhi`Ӿ xn+뵘;Yg}/yV)`W{q_h3]Ktgw1YFEobӎleY#׭sh׍^yJx-"B\+6H =÷zm{YxB-ِY_C c$PJ `+Ӭ셕Z@8¦QqMW?i3~_IH'V-C#VӮ/Y5#r!cԁc5>`{f[Tĝĕ:hӴ;Hlmfo M\((((((((((((((((p[y*p[y*h(((> hŦr15Qɋ烟j^0 m5+{ɣI`Yn67@^H'+ƺ$xc2j13'%Kd_/  i7:4;m/oyD`g#ox.mwLr9s Ώͧihz|7.,0Â;.5Snemܠ=7SRpyc'4 iWdfӭy/WC i{/$w N=*m\xċ@tV7L+Bm=3]EdjZ$Ѵ] 8(-_:uՌBK URqs,z;RM-RO0 .XCsѳWy4^ӼcC_YxYmEۑpU^s1?u _IR˳ӭ%1(PNzzpeq9daXsXzkX^<#H yrc%)omV2@ U.Q%hk+!`n pxր2>x6mzga|&vsUZtiwqR[6Ff@__]'I6-?RIsTGَ}<͛vhRCm᷁Ies@マs\t.{=*2޼Г&V\.F2zj8ǵpy_NU}"e/ NӂBjxgHӼO[ۨ6As۾;& 9M)r:PGP,eHuuB2 8 0zgj$Qm>HjmH}-%Q|f]kV?c,{awc,܉ ,UakK{9B͝1,M0 >9ڼ~׵Qk4>qJEk Aj%vyx\s#y]q_ ucCyyTHcbW8" o ω,.,[;K]T%y<8KsMK86@\R8߷q挊/jCZ[ YFcY{ (8dk^G${U NQ@.iO\:4+[{SF~ ?G jwm{sZsī] WPID;O*F׬%ї\ڄQꥠ0VR7Hxڌ^)e]MJ@ `qR^z ŴYtII˜91]VW@]cWhQjm5L&Fd'=: cw?KsonelU$s:-?Y_w/ct@]_Gm/amyɃ9z*5|):AC!W;ŒP-'Ηgr') e@+ ZӾ#j7iLբ^gE65a[$V:ܚœQ+x\UEhdPRҾǢyW ˜ry& ݦkyhӮYvN2w d/җ#q:N OV2e {#i@v9Y~U`M5'f 9Nk8p(?^ZJ{ubt1]Ei:F.-WR[K: z|N mM>btǃ޿|ݜwV߇.nnmݖ:֩zm4 N-gӽzl]1v4P1ySMw˯GS hmd\2=q8-7LJѿӵ,ڑhdRIS o@q-wBiv&D0췎4bK8$ @ pU-_TѴJy6@-;Zm:Z8D#4-dzI3Z( ( ( ( ( ( ( ( ( (<ON[i=1$`tݪ?Q< _S:_}ji$^@bH #`ր7tMZ]m5[PĊ~i6fB{xq5f (8:rDC$< iu74C(V:` ՇbzYG*G.g䜆 X֡< ~#tK;{6SEW=fMxBouOjncM"(n F0y6$:ޟlKohI=E`7 kmkIhEDŽ'9rŮKm.D0Hi K1 )a&|Ah[@A{vGb2B:@+2I}6WWX].W 9;w3Zլc}if/e1";*O'n~Z]*k9n'j"E), NOnh޳/ŧ]ڱ&;pnd,z^k{i1bIaq`s})Mm>m. Pw:#Ђ>Cѵ WQh 9(((((((((((((((((((p[y*p[y*h((CҹN쎲4`Hn~nۻwsҺLPGˏf-AϷo\mҫa_h~HP`;ns[̡A\e η׉~Ŧ Ż1Ă=~@<].HbkQc*~[`s\ʼnX~k%і`QTGr=@? 謼 -]jFKW[fg*8 7iص#khp,0^y!E'ql;"YK"I,噤H%7A9b; 34{^F,Jխ?i뺚b21=$+|M"[Ϊȱ"qlzz=p1i0ZkS\Mi%mFFNO< c*IҼsneJk)hDSRxbkyoqnfb2 q2t nT{O\xaB<*>\z{J9.fa#;spexH?5q{{gM/ Gݴ~CYέibmɟnBxh+VeMs.y"D\ ]Af$3YwF +-aY%f!*)8 [\u8즽EKn-(00T;?Fm{/o6(BˀGW庆X=Ql##˫st#i ƻ$׵&^EcF3;8'8aopt߱}n~4-oX65e}W3?#\n6w6}ieRK,78eg,Tu'zcXƗ]r:)qoS`5Eu'#E rHPe/?YjwriZ%â34yA''UmEmYkڅݮgc]S7όqcvzntkZɸ-Ǖ_zbhA:7-9:7Oꗞ mRlr2NA- ;ih>#my PYkmҴGP%y531 '*C`yU_R붺B!0D,ŏJ5&^?_ vO <+qۻ#8w/~ oo'K}CO7w6+’I ul 4 cx%?fy{9ۓwj3OЬ|/cq˥(alEu_ |Pe "EfFyvN '@#}M7ݟhfּicCe &f*D,7g?{Iyj3/\jZbE}v1']qV kV+jS+9U|6x xcX?e/۟l4kƱhzfoXˣ&um+ow;pXzhx=Xzvg2fX)z֭ςG5Oj]ZGq(FF>][W=OQؤuh@k[sgzuhÞ7m6iagxݽ6:sZZxQ𭦙4tU1> E6P_ì_P$DڡI'׌> [YwWRCYfni%Mi,Wwn&x1ƀ `hG|Sy cku&XKKa/]V;,7B?~Ohop^9wlu!2:V{ĺjY#D,F-lv+: .KqQp(W$_u;Pm2Kvk(tINSzVk^ucaq3 25-*H N5}}KijLfpb L$=(mtא^޶Fnd Xr8 Wj>u_=yQ $vyڽZnjncOլdmF 랧V7¾'%Ԭ Z<2|Gꍎ[?P"Ek{+Lwhg{fnx@ꖵc |5څIR%;Ģ;;q@{_s̶:-I.Kpzڸ=3\AmBMr q,f *8уI$s˦,-o5 c4,[d7+D~3'>WYZ4h1xkw^VIp.@K)L U]VlỶ)qۓ޺Moͬi=/ n@^Ok3Nv(\PQEQEQEQEQEQEQEQEQEQEy(zGy(s?4_>%akHɓ$tǥ{M-dVJl:×Kumͻsd9j(=k2xGm6(N[ƒd)Qk,мA"j1H*F29vewnHI1rn>u#ZRxJ[6֗Re$Vܔ 8تA'8U"(bĸHLl9S\Ҵ8R]SPG8C4wa޸KuG7 _$eݷ>sO3|h_ 4;??ſ~ۍsIm,j[5Pc;@Lu3XI_LX_doN+ʼLv4qN]%/AbJ20FH9vx F-jIP}XFC6H=:; k7:ݕI4( p94MDTmlAIe z=#/ T/; 'T,)ya&¼d`r3לP^5;E۲O{ Ҝ~,!tb%zgםXvO]=.M~Kg$lVfvin!*GNJ8|sOxjKmS]iǔug9{zՍG:6̺kjȪe)$#^y|0zds?یگ|INA o0^wv{B @P'9o-f^d10fǨǸ31mkO1c~;ֺUD"Vo[9(gf0O*WARxx"x+pxAMAL1Yxa(or٬my[ֶܝ~|xzoԿ \kK?|h(((((((((((((((p[y*p[y*h^XO}r NPI8XM & >Q(|g<־ n-Hث+8 AoEU֡ G?Gssi]G#'ka,x;^"'[{;԰"tگt6nφ(a2<8ڠr[Ǡ&: +Fv{+13 PVltWxS`jS:[>xSԀ(&_'ͦlĴ$yP<ϖsWsJ5B}V)KϐcLdzPQEs:oCQk-KM?ekVn03'qexozW5oP5먣2r6Pgoaih򽵴04;SaL}X7nȚP9k=2;nCK}WFı! |۝+c'1R.ms:Gk]ZK[F>N OźVaivd6dȣ6rƺ~ ⥖ %ՖU?o+<\.k9cta򌅧!DL0p+W񆙢ߝ:dIc$s;Ev]Kh?=9ƿ +gTi0d s3ֺy;$@B2(Z+զAۯE W&S01GqDv2 zuEs~H4RMfMc;MnYtwM˅\@4W=u]*XOFuK屍V6M#W>cikZc. zqsW񶗢I+ˋ WF$֬h^,|Aou%[&uowH ?m764PxY]uu&a6P4ǻmϨZ4);u[}( #'ĽYRO ;Ppcs3. @ۗg92F]4ZXGks g4Q\o1u) D\h:OW-]&S[Fd`[Q۟3#rrx Z+Y}., B%k{ c3"FARYEЧ֖ɴfK:hqe#!Gf6+{{zݰKY(ǹ3\ƭ˭OGGkgofi|k,өOt]v^GN+׼J5M+zsqo`2F|A+Ҁ;JYKp8 ጻp:\j/|&<}Ow<\N ! @p9$oEr_t{i-<]KY( ާqEskoyAusz92HcXEDP@qڟ i/%mo x9֎CӬu;K WPǽFFq'c@]?WH$AnPf?Lz&{ړif-P~bHluM4}2;z}:¡zp=tZujSFxKr!2 |a?PyV5 (%}XPL)k:u;7̑mL5|Nޏ>4EBdX=w4^kďVM iG;9\-VQKsrF8nHki}=j.Nh, n}q@5%RѵKSӥm pAX>!-";{#:FzPWP\X]6H>X_.l|\\Kocc''k8%vx~]Ɨ x$vwjmB߆on~!x{խ;nmHv5A r,q".S:n^gQ@Q@Q@Q@Q@Q@Q@Q@wJ'o^ψQ< _S:V^ !侸dJAq-Oր;Zjޓmٱ6Qp>]( ,-۞W0n?LbґYv>+}_iC֭Xل6 7L(o xuoVѬqdsv{mIbXK.9O5({=GAҲ=_Wk&Ӎ5.('ƨNrI8ǩX> Mt,+*xM9te'' 3@D~cäkaoc4V*$r>w[#>:Wx/&Dճ3Dr\36 7^wAjz3[ ؙ.&_pvx':MWš:\jzMԩI$cv@OR=fE]X[Mf`tJaaťéjyEn!?oFr9[xCTJ+x<(KNFOcҀ:-+DҴ8 . Dc ϫj|;cJF!PTqdk*["{;i2/t7pqsWuGYTmӴ>857\p{6ռ}ٮsDdsv9_qƖ:ES!08$g=ϼCMCğ uyl :5Z+FUeX&CO,>M[)⪱pK;:k;k4d8Ua rX=ꎱ_d}WKxA7u'?KjZeԖw:s!Uf pJ$0 < ~"-L[(a_^cQ|bxz-&K˗NkEv펔hLHvmk+*S\J,|rWzvni (`ak\u!W-/f"o-tn_ۣ$Hχ*6) /Ktu[8rG$qFF*MK>4Q--4ŷ2(Gpzj}khim4sݘVm@H p}1}fI]7E-MJ@S?HC$uVNiameo MD2{]/q%ƙ!;0Ê9Laqhn֮^22FϦj7z^զ r98 NGndGqȻX)$<5qţ_ԧVh4(e^{PsEq:MBM{@6hanBfPA#h-njn,W7:;حD79$*q€;:Jla{y%;ms E=dj.nOho< v)W#9<"iY sq$ !cb@ >vs+4mkRڵP-սŪ,Ж*rch晤i0#&(0ـ 'BvKq[jo+-ք@1Jy$:Z+ź}-gVI`g2FܠIQz=}K]4.4 (Opバ֊tu˯0¥J_zd` W]{ZEu MYAQ@Q@Q@Q@Q@Q@+/$Wx+/$P{T?_C<+Amݳz23]<  Uf//_RszWEQE`xDMw& Q;e(\tM !ծrsn\[wqsC"xPcpwJVQ?=E%ƐLQQW[zϋo[$M1-%_*G}hUiMA:{UkKA0<,8YԞ@c[{F)Y\G[P]Y[ uwt>Xkgm Nء@989&HӮ"HUdu*Rx%=+#"\YMa 5brs늳gcO.iEKԤcٸDX0 pq^ymP5yeFc$s6R%Pq7ú5 fDѨ#yr$N@{+owo7SC$~ljf#pz}3Dh-3OWn:Q4DG tӨLJA,1G;OU\=U^dGzحoEB0sw\gta6ifJ<}aRŔa d|zxK,VH 6ێ}1^"EyCMOKU/udVy DT :bH"HQ*@8xM6]Co~$LGoƹ[xR#2u>2 $_PǿOԼ=kgy$c@=Ut?岷h_Jc: 8-zUiW֚o%Vu/+$ P Դ Y7K֋W+:{P7~#%K:`6Pq]WĸQơQU@K[C<-٘v`]7 `Kuai{h֗v\[63 C {.Փ\k_3˦U\>KrF@סUk嶄]4~Y S9[y,vv]KuIYID+G:@!#7mQK?r3~[Z\h*͐:`)Ͽ鬡ɇ~ NAp1(@8@Ƶm ׎n[KkBY8!X{tg^]cZ3jЛ:-\'IRGOLתjzkyҧlŝ[@( 82%ޓg Bۈ6lYp*ɴ1|WKY<嗅6:5UЁWE7rcqq@u7GvE5כ 0y$5:{a?)d.57lHap)pGCg>jd4䷷]>AjKx* G p4$iS[s,"BCTڽbhe2Z=7 *^{7f~ }W.;{wrk\Vut-.h69uF~@>xJWay4Mȗl ,eB`XGlU<~ [-oREً.N8F}y㼲#1#Ƭ\muZNX]>#:zP% 푴կfG_Ox1K4*~RFGsۡb{q@Y2ȒI"@`yy=!w[^>\6+33Wgcll{RیdOO𶁤OѬmf[`qV7#稼%%/覮OK[+hmL8I PC;LҤa^Rqvr_ \-+inalK> 2?"MgJ.sF7GL-Fyq֪j>uRmKI1yW zd+{o Zjͨ/BΪ o^JiB A$eucGeCKfpAlq/iKWts3v}I\ʀq@ 9>Eǧj_shqpTs# m8=-6QsREvת | Z༾nnYI5i4K+ec ,J<1q4j5%ťS;=׆wEP1 .>}-&d,P*EuSq=2lIG3DORPxJmXdvMKjD,2]\dՈ-APsk7q$QCcHcod?(9< ;kg 9: V#E460B[@/Q@Q@Q@Q@Q@Q@Q@Q@wJ'oZ-gxQPFn7 |V_(z%U4]#MӬ$k~QEQEsط_𱆽4z/Y|+2~wJnryOv#4du q}::tvb`@r(e*An|.mM)%!xʧ*8Ty8+hS]+i6fn̦}mF X|7humFKV9mX69L1^+_\5$4#N:..#2G5SO}[P"شqSy53(;zqWgZii ~8 QI|:t1"E MS%5oj#ƗZhv>!(`aVbs׺mnՀą7rs wP9]/R-,4d,ls@\Ox^bu[X^3CnIG=8Mv98$fs%QY~[Wwݞ==Eeڼia~Њ9W*[q("OW!t+;K[+l:m%bOڙy}ZUMZ;;/I-p^Cw)T['<`qU4 7^*ֆgᏲ4r IV.)`j[$8(5o x_M>EQѿ#p| eE@ۈֽ(c ֗JZ;$lYAx~5rC+2ymK]?^MkŜ\ZaK=af` 89hw$e`c^+m_Ec`j($-^[1mug,Q}tlH `WWEyo],5 Ib6E>Q@n?:<&Ilc-IPٍWL6: {.Z=IH1G331m8Z9}_VQ[{cORP A#5ZN7n|KC ̶ioig;sbǰɭl-HU VH=P67s'GJִ SKyܢp YZڤwRA}!Y3*n sh:;[kImJbUie{@'I8ߦдI^[=KP="5Ey/G ;Dh֧+N$Gz ZXAl  vp*zZ((((((F\'V_ \'V_ ;( ( (1W75{,ڠo(`:㯥a{m_V'69\\H䄍0  ω6խ gBGfנOqFmZ[ n͠bpdr zs:4rxItKgt֬(2FN eYDM`_-b]8 p 'O6NY[ FX,wFuq;mfwWJv$c3|iZ9 >J%41}Qb"`=W# vV" -ip[52Ik=љE A1X>*F61[J[8d^wT455M3V wiy̜oIM?:e[uܧde!קn$@tȭ.^0IopfE\Rdv&ӣmtF e<$ y]7QH x@F:]u³i^,C@OP?wO30dVH.<FJ 195a/ 6,ͩnYCn܃IRI4ڿ|sE|?}aiif(+9A엒Yu6ie.恤i 2FT|Izua3F (zb&֬<;7`盤*M't否'Hf&F5;Y TwH}%e[J;H6x (~hsqw%w [iv$pؼv-jm_NE"|6wn@#Eiکo ybu9kKų[=ōΞ6g#pWul75}2N ae$^y [bnGE ~xڴF rq+!\{mNm_ϧˠ_i[Cq{=ٌ(S K2z״i//֚I?M(yӌC&9ttLaA1gGn=s(c5VcRJH\ +rfE&b}nQ`4{Ic[~c*΀=A:Y^c'uhs.\p0"|a{/<9躂.nEôJTU9vȠfo m-;NBz I럵|5=;E.5M?Wc]5 e2=?E##+H!CfA2GZhf @3^g{]Z:=̲Ps%{k2( 1pq=#{5Mg5+22 <0U)9zٳVyvP`!Vy  $Þkbx踓B_sٿg_\0ռCjwZ( Y>U :z]lZUuOG|䕢BEǚPJF98ڀ;ё\xPo&F#8FB1UMsF?7}{m>/ݬj'8^QzVEVu+M*^ΰWswf =I$Whk c֢U3 rimPf\5桪zM.4{wtB2q/v۹'ƀ=.O\\=ߕ[m{M DHdM:nu.G$jV,dWxZ񿆴+ʗ"b2 $ A<C[,&[/xv4%κhò. ƒ?G+h=jWvWqKdng"69v^}a3_&hcB/+\<C5',oӵ4W.;`W'/ }']fќr\a\zZ+}'эUW umjF6BuZCs5~'Gw5c#: 0H\Snּ#hqϪ麥س.@d*#9EU;=NP`088:HOꗺ7z|lB^8\O=ko.n5g`xt F dU}>kK4KW;UY'njGu4z34Z YYgޤhֻ_}H!|4@)V+445uvm:LD$U݂:vҌ\\R~j: ڧo*.P2;U]ix㓨8^IHG5, wI"9![i SӴN4k?0Z97r|=czNJuz 褎 ûp4KNI,џW*[XOEw4dPigUy o$"^osRhԧt%ҬbmZ$y0PA*_OM|EYMR#e ʪI=2[AdPGv恦ͩ{<˗lwca[zF87C>ƏnTg3U׵rh:DVuq=YʅP'_NdEpy4Gڙ/Q+_"!$w[>jZ.o׿m"CvN@88 "ܬz>"{˫vH I}> :ۀ9-&f'z! qI&v3<9 KŎEXL0;X7~橯k' hv|LBN$v|8#ֳH:S:cY]C+q)%gan6'~#8No&}ozw|0 溊bȎ̪J ռG]+FXZO1XN=HxԾ(o&]J?.[{pG_\:EwO"FUqY~'օ6$q"ն,G=Mr𧈵W6m,rV1'=Szb~GsIYɢjR\I1reQqXGsrOJ2e=99hw#mas1"G4Ke#hsol~Cgt;~$gXĂ2뼌8P?ww~:fx|pX^Xi:k@ű";Iqwnv cJaA YuO=}\܁WE01Hy⤛F>]Ye|G9uXЧӿ.x@oje2i`$${`*A,Hhឭ?ڦGbO#^C9svCmD d9{mW6sG{VFSFF;Gl-e;Nu8abǞm=(m\=nQDlHUBϑFhÞ#/ Cm,$6}㞕ixo^ԯKmRTϒ["H&ASO~:NYj>_xnٹCc=e$IQ8%Nh|1sZ]K| [`ln<=Nߋ[sJپ+'m큵Һ iܻd huok|w6igrHQMzV߈f5i|9aq@$B.2W<$8t=X9-w:|9cl&)O]OA֬o kkn!q2HOz8@F/Z]JbKP\Z(<skþ*VZK}om  u^M8By4w? YͣiZdmKpA}Đ]8{"(n%s$$C2:c^xkEfyrќ^,{-jzn܃$r=s^ >`'{o/۝Wչ:u +3X4rHҒdE9Yœ^0G9^,. 䉑sF*W#UqO z4*g-,Oj hW55ߗP乇cg8} t'$"F S@ߍMWZ;J+ӓWO$q隤t]n5;]7OҦBpg{!;@U'ߋ5<;{^Vg8֯-y]2iI ?ZmxsX՗Gn%8rpE< }g۽$!8.v;f杪IiMuaKdy@>lNyVrxxMt]#ZK} m뷮hn4dխclDy8\ 햍c.8;ɮm!%8 wumWL冣cj:E8Feo 9]Ur }gY/ؚBuzV_a)x'hlF SH2:g50R twZf{YįwdYy7 p9s@k(vMJY>k s#Vgl5[Low|."/xϳtj- چ"ik('s=܃ހ9Y[G[,G 6yw-{詋"9![i+JN(F$㟥nQIu((((((;ON2Ufi#FNcZ/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PQ^w_?B@Ey!~??ƏBE z% ? 'A4W(Oh/PJ :UW'A5'M C5кh`;qh(((~,;HaɃX4|-i kZ6שd nu>@MCIxm`ïV6~" đMm7f R\ѮO]$wS%վm+*\:qak7׃ω G{n-~aTb\湯^jO͵HF`naؚF]Ů{sJQun*?y% \:O_J]Y9nn:t^!ğ<Վm=ͯt6jJ %#$cu:^j:uGQk)\PNz(-ǎx=JL2GGt¹\=j-xqn@C vž#\-Zqj`}s1I{=#wfpeFD{1t'P?|%5;n|aeq <`ȇ+z9zi6zU\E$ǩAYZbZhKx4[<|3;I5j7O>"cjѶ3u+6]>!kKX}F.&9ǡEKklGW86ǯ 汿_JtcmHGfݳcӌhZ e% ztI ʌ`InuN)Ԗ_5@i-* rVb@+sW|7Ϧii7zZ4v[T e=#p \R6ݮ7P^`qz-W6ڒ}U㑆C8yui\ҍNECr)-9_njgү¼1YKZP,_OP %B7*ByGMyi_ϣ^ XUdhGDd`C0jE-?B 7_RH 9M?c=@+N~vW30b}a\,& ܞ~U:M^jim˦1B}끌̲M":eqNT2cqNLsWxS |޿rEs47 GYC&EzH4)$񪢓S 퇄,X漸h''6珽\ޣVxoRi\! 2>^ .4B2 F ikWڵjW ^ _xY~(!!PمeXۮ[-Nuarɧ߬I397q jWѵ" XIc8l`d~\'4<+ym1ך|Ml&֝4z~oSL8b2J`+([К3UӼc$}G"{su 2fX]wX(lLv9Gfo+ST!& 8E('9h:,_|SxZ Cq/n]2Ž<5+*\ͥx*+c2W2cwqvp+ X\,f)"frbyk&Oؚu -"Cn(\&UH1=?Vu4x|KjRy|*0VX1֤݆M5-*/-. iMKu=bMuk?PӬ.Q؆06F{r}&ejgRUG{= ]B N1Ͽ8 GkMN$;̰99: zKam%kDh+'85Ma{]JE,FNB4w#cEUE*tPGWuMk]P&[FUc\r0ynk-ޘo&dR,m&-5aW<`;Wz P%/2AqȌ.v1G?tGmH(`[dPrYz` 7n R9X3%$3%iZX5DK1' s@@sH~y|lٿ~zg96Oui|b &ӣ[u?$nѸbgPHo|7K iYbXGHG#<ֻ<3m&_5[U aCW1Tnt}JմKk Fu-a-%yj@,rq=7ᎋCnE] K`P`ܖcB(?zxy6:CV[kkb|m+g!Up5Zj:m͌ȗ0Ld~uy ;uX#J1TGjO3÷ӡ1ߝr o 4&3n[4o_:h+R:qg!U$9[ $^dz3pGNk0.{]ZG/uqG g )u;Iz*TI;&EiyqZy`lD==Ԓk7oƲ|p>tn1ijV곬#8*IG9*35xjTմTM%,XˡѶG*NqM _^5?]Bk8!cTvH$u?Em [%x(v9=|RC.s|Kb9bWku+Kþ֚lYKM# U6pWk) * t}h?hZ 2~ϟ0&t 5 DljIn#Ya r#te#J/YZgi/խ41Ԑ * e=)m_ ?hC,|;iє7rI=&o 7Z Sdq9@VN}_Vҵ$y"T,=VxMέyj./ĩ$ﳻkbfy]qf<i  Gq3[5[f$,I錍S+i}K-@"y#93@宙i⯈  yYL7E :oAY7<;cWѸd_@{uֲu/UuE4HHךmt^K˫j6K٘*Tc(cZM>îQIZ[= &FNo M+Stkk}n Ir9].Vm8bGCv׉ogPwF[9563 * >8kO-zsX`ˣʖ2(񆧬:4I!771u ΠNx=GĩeE|2%Z$@],˜|OWqo{4{C)#}&y4 a bӥZqq³"g/t  0Kcr.>b/eu"Zj32)׃,po]ek:nYXţɘb9UN94EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPREQEQEQEQEQEQEQEQEQEQEQEQEQEQE%PEPEPEPEPEPEPEPEPEPEPEPEPEPEP`zREQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE٠Fm,`{RQJFIF``C    #%$""!&+7/&)4)!"0A149;>>>%.DIC;C  ;("(;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;p" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?j( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (<ѵhhz0%=GBy턖‰5NܷpcP}{F{xdso{3OϨ^)pݖ1 v>񅞴U5#odp9<a"[Ѯ=]~؊`{MhZB)Hr5H((((((((((((((((((((((((((((((((((((((((/,u gʁ>>I7dY]mxoET/Nٛu\BǓ֥P\׏,ï>>{WW؝~+o8O _?69w =~IF?G1Lv?ʽ:EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP\_kЖ3."8$yE\?Zznu}/hZVPO&&'ծ=ޠt YX,`cqBrO0f3Đڰ"gk3#~5-0Ydf`q9?:Egj G;$1{c:( ( ( ( ( r|)r?я|] s>?8 t;\ӟKc-zEyÑ<+h((((((((((((((((((((((((((((((((((+hy$qfc Eko GA*]+G=lٕ+yBާ۵pCS%:t[b#/A猎УKؐI21֯@h,t)ջYpAq=~?{Zt}B+xj(gԓ>QH((((('_{F!Ⱥɨ#BC=o!ν (#Q{>5eg]cPc~׭w2=hm.࿳E !AB _(( ( ( (g=|.}tǢ>ƀ:j+ξTombc$'^@ :2=Ey=?I칖L8+tέf cO? Q@Q@Q@Q@Q@Q@Q@Q@Q@&@ikȾ6K$wNsqh2=E-| Z83HA (((((((((((((5$gٗWW Kku%d:cLn 1] yAr}ӄ᲎z+WPEPEPEPEPEPEP\?όbHXėDһ}aր-8?3Uu~ ]wUKy@I@]W=Wg~+ýqєPQE|oXUoY]ޛ{ z~Ez_m-89̟͓fz|ms5WV4SBu<k xx~ F<,l1{@Wi_^]Ŧ_Q ++˴CW ƿGnFh X̷G #Ě8:Ն?ƾlu;Z7rJV= yBuݰ>R֗P(b0O_*[\gprFX}ja㋯$VKhě3zG=z |G_A^@Zo}׍PPAz>C5o4#☠SIYmزyrmU [u6 5AOv (#Ѕ}KE_Yx_H}B1D(Y4RmZ7U׀f\46+ߏ\@-o7 : V+KkKYddʰ^?SKs)Cy$7+X󏍟,Xo@HNM|]Cc2rV{e\VߊwI$'F~kx9 oث 襎xXdYUƾU!`џFR iگNd]9_f_ր>hzk[iꧡSmREҮ5++nlu>{>lO WFC\ #?u\nn+B~KH؈v:VV $']KmJg=9Չ#u*è#Wq_Z7OqJ6cx ǥ{y?딿k>7\k@?sѿ/WGsѿ/WQEQEQEQEQEQEQEQEQEQEQEQEQES$&CpAO<E-դsu1^vMGt ~ʽ] :V +'GOwmms\[ʲ*r K^Cx@&,E{z#Y֭Ťߌ>RQ@Q@Q@Q@Q@xw [KHD¸R?½ƼWJ?-$VZ+z9"Gu5٪]/~K=tiTP3(gv?v?-:bHf$);;kλo8MOIHGߌ?^VÏ5s!3ϱ5(~#ߞUW-ץx&[Wcno6O%R-Qx iQV%x^Qn˒qxLNʍ6j+tmCDKmJխ1*9S]џZw=MX {CVx@+[iMR9ơUF@8|G_A@t O]2,Ðd1:ќ2O0?1^@]AOv +B_+>7?I!^W^#Ѕ}K^ W]}[Ų٤䢃 x׽W3Rgw)o@ o1dUAItJmEa`s>fcԟyR7p |!^@q閉oLBDrT׆W=+kTWh~kuţy@~HsXXު|w6:g,!["Ň?|#eO%P dtkG#cU0eZky##H ͵U͜1Gnolr C i^MlA&bFp=G9\\ujͨ_"e>(_sZY 0P?1^'jGzo_Ǡ(+5؟}zMP9ʯewzQL;kλo8o]ֿ?kþ+xLh# g~x^ԏuk?\L1(ݘ{|ZZg~EV.tmRNM۹VG#Rh?1i( ڗ5Y9rT;G3U|3>iPs*9 !>ƀ-|#4gYQ;g4PH2XXc8cXEDQ0_1hޡE/3(*H+~.l 4Fw\ 0o$,GG=U .?W?yjV0jJ޻yrB0I{ZozT+JbԠXPѕ mRyMg?G_FWqfu+P|xt'=ր<ᇈ?ryv,>G^# Zn 8x\Zw]zM\Wʃ{w\uEM&If@m֯\t~tH5 8̳i勢Lmzh?LVPZÔ#vWMt"m8mP#\=I5V CA?&[g[KA<ѱsMvz36/r'xmn\/OuNg$-$c aàx'+ʾ7\k^k Q0e{T"_;G=bЅ}/_4x;G=bЅ}/@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@=.Wk[!HZZ^xFxW 0q+ܫ>0nTk42Y>y>$t6Aـb$F'F? xv6Eτt??,KyIKcm/ބw@ϡ}RE5 ;{>5Ox JA=?>/xO~aKN}g2VC}V` tO\/Rn} 17|>1-#C#rΙt$V92/jwN$"0{ @+6+OZlpW)jߛ (= 47^&U$mOA 9zn&Rsy0zk \LB2%0w+3KvڥEE,W :Bk~xE:;YNA?uTPU_DuOv@n}AP' <}F5'Z̻GxdiFI64#32rqn@z߇4GzXIdpO^V\_ % ,zHWF Γ9]EQE{Hף XCs/̿Fι[R?})?wP!.ŮNC]H\<)DXQ*ª=)PYցx;mV\Ep#<ؚѢ9Q4M⫩KE5:aW- O*(?Fдٵmx^C#.b$(9]g᷆5ylw9i-a'w?|`:(aca [HWEH=sYx?IWWEQt{YiИm MV+HlBp^zVY=7XxIv9(((((((((((((((((##-?>Khp-e M vJk2@~F-+P[ߡ/YmDx#+\j#.: _)4qW;ؔt⊂M+QO6Ֆ߳Dw }:UԶBèk˞v6yMwXгjjjx6f=3SŤ]/ڵE/?A)g'hgzQ/&֯DQ,SIEq$vZ[ >U[}Mkl~_$קFzjb*ݲXzi4 Zl+/,&4}Că؃+<-.[j˲exoI6\]În}qҾysō7]a5\TGwc ~=>W{_)Kis X\:7k U[8 srkw(B((((jƝYޥw#[ n+ϷI2¾fvA9ҼU5n+.f= za@P"Ju0ϡv>3P>/$2J€ >OH/W'/ \[Z׮%B*]4T&-1E8-ָ/]nSD[WΔ&Zjq-b@rW=sGU ( I5XC3tkQ^pk 'eoʙ nymw[$xxFe=eYar3^@Q@Q@Q@gkm6kw6dG0OLZ/^>֧/tKi~im+DI!Ǿj j{%s>2񭿃ѧEvǯֺj6å 6Pq4?[Y.pq2ʸkѫ>#4qw;$$дQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE~G}mcCq"`ҩHon-Yܓk"g5bF&4Y_cFЅz {TV&J]QEg8QEUҴ˝Bည&Pa>8oyCo\߃<:|OHt Lɵۖ5č#rrk> FyH>{b/S<]>{)%|z^_]Z^hRwB|t}?ESQ6ŨǸ\65-m=k-G?MXۆ~PRCy8G:z{ot^.0Ld`S<#./k'N]-q K4|fBjmmq$mAȯ4ԴkԹeP{ZOGŚ2驥K3 cָ:MY5F236H'8=땠ZqCo!ڪHvRF>3^mIJ,37kq8O/?PkwSDZQ&T8+^cD:"\+J//:r(4KV.]`=Ͼ3\ETyCu|lC#kkk_¼So̚^ -ě3םx׾)$bVs;{Ԟ~4aKN=ϰ?ڀ̾+k= ]-7iNp1W}c[im/nQ+- ?\W[iq%M1WG*GPh>#CRmZt{1)5!k.ie'kg0O_]\]0VMpsu=>m'SӮki nc$# qZ>ۙ-@gvPA8x+ #xOkOwݟaN񯍓f`j.vmۏcY xDQwg9Q+鿒P;$:kd49#73$A;w3uhҿ WӴR@dڸl/ʧ ".s {7J UJesʧz ?Ooᱱ/R/Bε4VSNdyпp>Vl5Ƴs$%GĞ!7b%}硍o˯ A_6׳9ֆxr|>OUp8PkĘKJ8YEWyA^q\&oyz9[G> k^& o#rK0QԜ M LYӂDt35$-[ .O-܁^Etk^GuŏFl紋WP|fBjc&U Av)7גMY E}\Xou>bMvOy/}/|ה_+ȝה_g//^zWe2OÏJA'y??ʣ}r_*IO{w[{ws/:r+迈 Bt~cM<kHG'? wpҙNvPU|hK^l13r {i?k eiVҭG?F`k-q"%-{OMҀ>kk~ SEh`k_% MOAgD 'eU( kTdЫ}OO =鿒Wו|pQ7J ѥ?k/ ѥ?ho^5u[r@ G&2B=O\[xSwסEޯnO{B=v$Vg=>ɪO9ՏkB ( ( ( ( ( ( ( ( ( ( ( ( >(AMN5>vlw89ޣ` I2IIY>FM@$t*8o#b+Z~Y(:o3;ۀO_7״|SѼG쬴=糁L:B5AŒGSƎỶzI|2f/P4{$.|A \4_K;XllPƊ;( Ne 4(m$2@np=~aa^Y*WOߖ2b>9_€>j[[ rчU`r_NhZ:gFۘ?0G^ ^O״].Kl4̷rs/&87גMY Eu#k$LT.FsrG'zGodž/3{S@\'ѩ]es=o5XBf g)=}kȝה_mISuլ>m.c1 i"(!;L?x]};=/h7ZTc*qߐ+O(ҧhIPpڡXz /FiX^ =?Zgy??ʾoG/dZ XLClW6ptRqqu.sր>[o~?N#9? _i?U MGA@ʔA4w/:r+?]jl3\MxmOUi|:]wӦ}ᓓ w8z=/ڴɨP?\׉ɨX@Ho@Y(o^ۿx;ֲuޱ۴PEGo\\S7ct_ܚ~rx> zI֩ |E/-M0 ?\ DŲ$ُr_+^uo_Tϗ_|[%κ}!(nwo18Pֽ<'΁.Uѵ0$ ?}𷈮|-Eۯ"p$Cg}h:&EC'<=Wk 2vm9m- (+JkeK`r2b,=~l-;Dx-scՈ}}qXO>g!3F2+(;6~l삓 59?L>W=+>`&[pga!8xPEPEPEPEPEPEPEPEPEPEPEPEPEPXvkEJ  k2iIFPA#?K4M*n߁QΝ|f+Yya?+uD}nS%Tu_SíunęWԧ˟¼j5uULw1哨/r+|MX`շDOt{Wꌪ8ʆG+;;U(E/CEUjiڰh[S2zN!sZxy<{EhXhZE ;eg62S]+In0={{0ԟ/9a3PekՏE}7ZE$d-=31Z/ ֑yoAȫc(Rkba>[kiO^[;8xeJp?,1YJ 8']["slV&dW,Ópэ4xB(u(F gRGnآZmEY.vQ@Q@Q@ʊY(I8Fڗ13z+hj( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( )D5 Aw;H awZ'# \$*Hk*G⾫N?Fr u=Ƌ):OEN'1?ךi:Vm.sFG['7[Xό ڊ? W *Rm]Qʖ=bF;UguDVwcU,}]~PXTs-3 uH]0$ddz3~,E<$Ь_Q\Ͼ]z/،;|ɱ?er}2AT:z8!rP{g^ XVxc$TBK=71%`]G#u&M:>&uKP#$=7˯1E;4u9fhzUOF ~g8WuSԢ[T0./UᴅAԕOu,J[XF{$Lx=>}k_6gՂGz[+1ހ9 cMcg%݅Jan0p9$޶ϪtIHֱwwq)R&ܑ?\hu"s?wER(Hꑠ,@I$wK/ 8,知Kn^U?zki.bf'(kSPeu ۋf>U+<7LIk˦QG,}jܹaLcKI{HѼg ZRxz~gOl[ [j1.d9 ??Z_xDrD3[W:>oپ:P}hZ*eQU(hTA@QMIAuaiQEQEQQCfd?I@Tm<(dV=` (Җ ( (JZ(xQ<ȬzO=(kq5WVAvxFJyR h 6aA@@7ok_?)ƾMY]afw9,J OS\) c+l"Ҵ]>v X~(i!縙!ZI*$2_-K_F'WS=j|c)??OҀ>wY U*'*s(uhWema9lz/ϱ?[x7q$k QsRzB5?W&R(Z\_`2 3@IK@Q@tnvU8hDq@((((((((((Oý>]vD m.0Đ4acJt[txp,HȻ)z԰B[NGM~RGխB^YI*)ljVRn-?Z׍Fr:ֵp=Jz6?vȲIJ!ʸ} Q( ( ( kKG"F2 Eyb*rOdcwz.g ^]zK-jr&3ܖ_rVQEd7:75'[`2kߴ?x{CXSO\|=mnl\Kn9B?^࿋GA,.B0Qwnſ nI4HuRbxT">G^ Hȥ VV ՠz\+)jI bIjMb? "+!K8k8r::}z^vKc5A(d*Mx' wu>x3ynt`%bɞzt?z?m S_gEdeT RTms-zͥA%Ē-**ǮAy7cԞI xXKir[y11v>^?X^KX@Fu>>}KjVƗmڶnc=<`|LX<I F ާqTL4c Ĉ;GIFxGA_FxEOhHݬa,rI95=}-O@ƫ}w=S]M$bfaf,ŘbrI< ˫PhCu\U6CE.$UQ6zjZuE$a h!3squj-q<0(-͞RVpdo`;-7Gtx-6D2ĻA>ּgy-hxNg \4݂2V5?ɬO1~Vĺ_'gbgb~U>1+ܿ4}6g<)vcPխ/^H?b^6C1^oxH[O4,r7=~&NZR.;gH#NMɦ;2q!ǣYOG =ķG8::uxV$Ǟ _3I##K+YKԚQ}u5̄X 2$FFFja>BZoC"&xs>4Xd&UHbyO~)eVzyboz^KYNCЃ_-V2iՄ-hN3W!$|(s>Rz#+r>PyEPEPEPEPEPEPEPEPEPW6m.|`Kqbծ`c F28Fv ]V ;J##gހ1uOj a&׿_ynԺ4 Ձ]}P1C@Q@Q@Q@Q@kb|¾2Q0OyaҠIYQNB2 ZE#SPbWi4EPL<^3ԏΟE|GM!@$ZʾG{-l_&FW}Q} {KW(<ԪJo-_$SR>|"V^i"V^9ό%'~G1W|bR^G,ZEZS,t6VsC}KXWk_ק#Z$5z_+]I{;4I&I>MFԯpsIʟh/zmD|"gxSZӮFa, 10!m0sS5?a=ƥ{5mG?. Zx,?j߇ W/*uq}dkhXg=Q@Q@Q@Q@Q@Q@Q@Q@Q@S-Hm$"}GqW( WQj1\>I;OQ Q\v6ՑE6n`ǹăCg{UOZn;Nހ/kb~t*roL p??uQEQEQEU^ mلЏ2_][Eq T:# Եmu{!q4C&O;+N (1|U?hau8 uj~k=Jr|)(SV;f꒠a6Z/a{qk!Pʮ^_a0k7DF 4i_=ዙ זRQ}Z] [/=7 hk~|> fNmma]x~A5y1< (cǞOTeRܗgctP7ZewoqZ|s=: qbC28+ߵiNa 0a q<=+ u`?5) &x5ہ@5_z\uc <z¢@>FDU"A4n#1. 3E*#{/?E?u] B4=]`\m'4f:OÛ};&[IdhVA Ӑ & vOEs?Dտ( G@1UuM6Xg']qȍײG*/ 5uچ[ rq_>755'SC\W*/  GwD??O5?_5+k@,<7 9]a.dþ㓌T֏iiSiͼwm 9@. +DX_'LJpU.kXlP('gͦxT r'1ܧ"мKjyeҮe " }ϭ{x5ѷ>r $(qs\)oԵ =7Ÿj~ T}ReT*Xx`G⿂1 2hmH2YGG=+τ4 2i)iK&=SV|iwqcuݤ 6 ℶld|chN ^|9ֻ3\Mfmٶ5~ h{5-@/SuVkksw^SA( "78#p>WQ2΋: W~6EuFȁVV8mׅ5W >3m7$?Q}PZ[_[ 4r(e?|=_.qdYQ9c⟉5>K'kkX]hY2Xz @n2m2jr|7M."vy[摾yǷJؠ(((((((((̨Nkw:4;s(p#}@5}jk6^es8Q`ܨxx 95 hp $ -\}eusG&Mw o?S?esܡ\-1d" vլs8{VU*e?gWyY->tw>ECsuogOs2Cg8Fh4J^v֐?i/X~ҷtr*iJ>ԚF16NV#)b~&8>5+sY_#/#9f= sÅM,#v5hm 3!V?4apF t֭OXIP~Xq#.{@t={ų3EnFUc~54`c*f[QEQEJK=1-m cPS?ʎ+]Jbv.sYzFE}SVyt9 4f%άQ@Aڪ;ft>nu--ob*=rrЇPjm(qUxX]gM2s|6W#aMvcw+OBcg+e?`q? :(Š(=J({KUQ.\+cjzeݵ̷!Ú!/2FA*a DMH .<'@"gYF\]1˥^)kثwseIfQ"9F+|c ^Nfx); 8ngTu958 qRI5W3ډ(3JϷ'o}u˥iЄ/p#?(zʩ.5'>nf:خZӓgnv1OjYFm)`(hO-lNIPMI\_U;rڏ`72jլW *zQS2VGVRqat5裫Q#`XO͵۟AWM8ּRjvx uSwbZ]?# uC#SЃiʥb®=|­EkIIb PAEew8ޤ j7Ԋ$9vc(μUh+\2,m<4}N=R: GCKQ֭`b8:,A=Œ'4nSLGE&}ͥICO?48ض[g1 ʢL([B$'׫GŚ~ߖ+??ƀ/lzmEs$wI#ucU7v8<4qZV̚|Cww 8py˷C̛^0zuQE!Q@$TR5tAx??6Zx4E?g&3V.9m(Y*ݶY#y"`]O#ZG>&YMxEq|pp0F}xiMD4ΪȑY,0THf=M+;"wF\aciA ,<6uhz׃.O El#`mEfN3^C e[V_,_r*(9ky]7?~55kg#Ke<^FyǷAU(g^U#]Z?.XG>Q@]qٹ_ 6 ?F;WMt>3^E;̷:ī;D Wf`ԴR((T{yk9њVEqPfE0{ RyQs@]F BV楬*:6F-#4ҠS.ƪ"}UϠ6Xb6MH֤ȡv qDP?$֖┎SQE"S?'E\ S.Š(AEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP$$If!vh5*#v*:V l4  0*5*/  /   af4p E$$If!vh55j555#v#vj#v#v#v:V l 2&&&&&0*55j555ap2&&&&&$$If!vh5*#v*:V l4  &0*,5*af4p &$$If!vh55E%#v#vE%:V l4 0*,55E%af4pDd%)tb  C 0APharyngitis"`Raa.2,잙%$=F5a.2,잙%$JFIFC    #%$""!&+7/&)4)!"0A149;>>>%.DIC;  }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz?j((((((({x5MnX-h, ds0{T9z2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2Q2TZl"QxPaVP=2kR((((((((((((((7dג-y#N pvҤ(((((Z(((((4QIE-QEQIKIZ(ȥ((((((|}F\Hm@ccZc-QEQEQEQEQEQEQEQEQEQEQEQEQEQY%h+nyL.3®CDP?˝?ۖD#\_kǺOyk) YA^z՟PtƐ \thO]J~v MIgiZ&gd$S'8z|zơhҥ {<*Լc"jťm ܿP:~55;H]DB3)W6ۇRO~KWkGeGH#ڡDž`}r#R4%sl3j[wM o58LᎣޡ..ueDh4!1su{[ Ko58ZIr| 895^^/Eiqrs$e2q\?|ogm닏둤ͨMFO\ yajiyasռ$LN:YW~:ZQ̌UiACZ3k:l_-iA M/ \MY541$ZѸhC+k=>Ǩf7n\?Ҋ{%'d_nzʴﯖ\*">b{+FV;۸o d9wMZTۙ$``jgo jeiYp#YFXSs\_u/7x^YS }+wI^=]L&8sޮZ}͝RZ'[-=2;t4u;(54ncK-%gUqX79ZkQ̍i8Zj-W1=!NGVݜc޲m|skųlQ(=ZhS"v_¢|Gk+{ RBGQT<9[\ψŰ߻ݩbN&dAÆ0OL[mIM>mACQA=HNkr+m([Оj/el hwJӮ BXC$+> ]Kkc#q9\s֝EvkjVfO%|iEc<љQb1ex-aI$fD>`9 9֭iݕw 8eoV]׍1ezW:s*e)A=Ko IB#&0,FsӯU,4laO1 f}?>oE\\vƒ[z\};%rC#^ =?OxD|jv ,0cL4f闰ix\0㡥u+M#O8!r6=~ _toYuw.IQx¶m~'VfSO@kRTV(`fUYR[ϽT:ݴ+=¬jxaҮj^XGqo&vIeN?PjQEQEQEQEQEUMRˈ" ed&-T )7I}ajʓƲq\QV((((((((((((((̹+s-#kl`cOӢOu?Uȋ:W3'K w\B j/xWmrxZ9xȄ?|+kúf&DžF/ wGSԎ:w>4zucik׈W!GY^QGW՞Y碌7玘^x3KitOanҤ^z05 K KC)h,}Cg|"7议l`%C | tYEq,2:ڜ:z\֞O(?C5';Ẅ~$ƷWao]|;]Lq"gˌ> -?CVXS8 Mn=.K#Eva~~\}@:&an,.a, ë98Whauo[G^b?_Z:/xӢX!tƒx}j=MGԵ ]BX̒ bc 3dQȬXMfMU2`-CO]=7,+.NX=+X D\`8~IC[(Ksm2IѦӮbG{~cV>iRSyeh՚C0'Osk/iӮ?]z4&1$Ƹ +Y< .m $ `zG> M't/Ld7>L FoNO'J(5MN(-`@0<`APt~FKݰ08`ß# !KE`G;e/w,n]aT0wO6MZBs8?`ꪠZk2?SQ4 $iLz|GՏКuI K孠X\2G\לzMM4 V/R($勷8#7趒3 ϡ95.ZåExSiq*G`_8 8$s[~+ҵKoDFam[Yܮ2$BgZy/t+x$S!H;c[j7:ML0껙pg?v^Ӭӭ7`=s:W"& a(cdVi4My1vzk 7lkmL$-UI&2:g<vVg]A2O*uƓ[=n[=͝س05,>Psv?_ZHҾ7n [awIQC4GAԥ{Q1TSŒk&o |A4h-Co$7mOǦ]+>Ѵi70fu=O'N+}Oi>sIommbh? _ٵtg着Gدb-iFK Tf-=Yi6QiomvEEITQEQEQEQEQEQHy+̄ZHr!c=J?8,?ݭ*((((((((((((((=+;Kq=ē ˃~V"m{UQW|{^ֺB|fUQyדtڼFF}ׇXnbY-S ~mZ1-"h'r&_xr5ŕM$N"pc9Vo{s 3%aӑ}8^-*KG {r5p0 s[:ÝWkyluteM~>zz{cnֺm HGB@j?&كZZE`| U \P.m5/A&r8\Q ]x-ZM2)5 {iZi(ݚdwdt#5ޫku~ڂVVHR(b\,I~]yV/\X 21 Sм3^'e]SDea:H13Rst-|;6_\.UdH8$|=Լ7oX MvV$3J?babaQqnXu<[Q=t ZRNJxws23O ͦ\jS>quTafӨ{o|?wOյm&..#s<`|ck~ { 1᷵.rE98S׭jxxG2N ? cZo4kw66RZ$yu8QvP}akn98'[uE`bC% CU%euӥg4~p=Om-Ҙ-[9ݾG{Vσt3 Xȋs~¯kz\z֋y#G-:\f3DgbFw>/[x+T"i."'zn yM>A6:4vR{#3jFJԼ/֙j, :Lοx\U݈b-lap{t &<_{Ov$ JC,fO-;Oh,\$I 08{c xΑg*Do.]|Ud z.}{)Y9'h%6\ΣksEKuHi]mp {Y9s7{osvl1}iGZ^C_jލ$ dW@]Ns޽Bsί#/=yRQ_Y}AWmx]+UYнu  ; =4]/Vn,cSr}TMqC}{KwqIY8qڏ/u ޤЪhbr@/Sx>$ක(WLe'S9R_i#7q<-ⱍѳxO%ֻB̝A]_1Q{bχ<3ïxj3-+Da 1 ğZ&R: 1-è)Ic9^ pV] Mgi/gQ_Mh>) ` 5_:_ 72dy8Avs.sd#v*k]u/w.kYCjc@ۢf#ҫ~ ?xVn6ZY1 ? ߣҌQKE&QE`zQX uůױmY̯FБ[▓QE-5I#h 2"YGЧKwmjR,$Agk) 1(TQh҂+ּkwo,wmEJxcHCZ|,՘OS׬A|=i%oC$3)vlNXAZTJ1Eii(Z((((((uߓL{veFX9`wƴ2AwQEQEQEQEQEQEQEQEQEQEQEQEQEQYzK ]d{/ņ HbLREQEST]/J kP \UX<trF WEk^D;vqg9z(((((((((((((((+ ~,Ӽ#I|C`f2{Vz5-*'.`IgZEV^sº}нr!V-fW;]i\U2ƕQEQEQEQEQHFk?CN[iZ@Ny`ܮkF(((((((((((((ʹ-qvrN7rҢm VaMWpy~8Kj:R[\ʱ,Rh8>acs4QX.;Z [W],=򧸮o<{;*족myIkZ?n#YA$=G(񦵨|9-vQ5#AV<y]M>n7^j{-' rF{wXm~ZV%P&T8\ 85ue$]Iԧd(gez>1z=gft(!_8@JCfIi6vzU^YnBz((((((((((((((W4<5y"($ܶd_5q41ZWZ_[)|{gxh;X9iW5 krx[;mKkxO'F nwI6zn]ݍ9 #(' cS|kikxMB6ku*r:T.m|Lm/I¾Ūdcu Oċ iڋHi* mK^)E޻kSd,+wY "uH0;𮗪GOk& y>\tzצ ((((+2{[Ȅ˦1´h((((((((((((d,QQfbpMQ"=.:| ?K {Z4QY^&С/{4Lo^A|8-w6YL$TqyvA(O{0h'$Lje`T~A#V|s?:My, +%qz3QogCox}-x9̲H `GZx[IcPpU_ kʹNַǩeGe9k&`lQaNMYXTl־&hl4Eoah"[w#0d`c9کjZ,&L RcskWNG㪾Ӵ7cucN8#[-bCî߬6-͌lVB# y:~斊(((((cd(bBsڴJZ(((((((((((((q PmcH?ڽjQEQEQE0Ȫ@f=iϴB O)ՆTqI$I+h,p&l՚ a_iQ]V87')|ٿzxV 9ȊKǠ4UR@dګvg{or ~3G} r:H2zuA,@5^Ql pU|*QER3b4+S)h((((((((cȑ;UPIbpGY:0eaA#ֲUϭx_R-Ykv RxwOI֙\i-"B*YTn+Jie\d)-QEQEQEQEQEA{lSڹ*Fђ;1QwR]ΊȽAÁ`GV袊((((((((((((fP8/!!ϳҢ)f &(E:i$j&X7|~gJdh53Mp͞7]4"Ivt]$Bִ:b_Zb.z$֮BkIG=~`݁Q!VcfxK5-/Th඄HӖ'8֏x]$e~}tw+G.[d)K@Ǒ5"(((((5/=௘.cO,]d?iEQEQEQEQEQEQEQEQEQEQEQEQE!Y(y 7 "91US&"Z_UHF?Q 15ǃ,5;iiKnܨ#Pqo@sWb+7:Z{͍z3N^w:fYh JC{$r$v8 fx7V0a{klZ= ǽꗂ|McNLk7Θ\+ԚYm~xA-,bO27 A7t6{DYnc]:s r+-*ľ/4k(ÈbIHl$zS<} i5p5xGU:uI ??PIjnk Cd{ٱ<'=-Gxޅ5:g FnOc{W7x|Sc@x7Qiw _3pr[ =4[缹Q15ZŶ]wG[D\ܜ>z^i⼽) z>V*_4=;x+ ז$#MuܛK;y~^+eyf@Aqq#Ï78?J($ӛ[k[-<08>+XcRfhg~?[~˷Cn>wv,.\jS`E,sFGu5w~ koA4sA"F6nn^mfa kx͏wR/o,"F$|F((((((((+$Xi1"^0|A[7U'>< v}鏸7g;_-|F|SZ}`]>.8s{|F>};"?+z42ɣ{|NFߍ>#Y}Fǩ6EQEQEQEQEVe]fikV#7)omEQEQEQEQEQEQEQEQEQEQEQEQEGY6L9d\ #0Z[Em:*?!SQEg"ƊʀO֖+^4n#VF8R9+a#HQ*(UzV.k+i!2 킔C]!U#Ў~iwuqokj-iO*GѵUZkF1/pYwqwk9|^209 Փ =;NGk DO \tW'0Mv&Y< t]Mqγ K{gF:?l|SGI<G*ʦق8V'+?lG 熣szyI7iLg1ִu ]Nk{yԤF@/{qa&ɦ.kmvV=/Y󬖶+*@vȬcN5p^$2y\@%ڳtYjj\}p =@>P)ڿ,^M^Pt,MA UxCN7PH̖Lt`{+.o#PcLC-ŽݏSБ󊽧xgNvˤ:̆SfXSMpǼ:ag&dC[UHc'=88xMu/ji=:9EdD. !AjtwH-ͧwdnٳnsgm9[i+lQ KEQEQEQEQE&EQEQEQEVotKow:Eʐ\ 0GoJGa[YDXoąI ұ> ȁכ*<7P[֭.좒{(. @[ Iڻ)1\xpxzK$Asz)KK{\ +@$ojզҞ_2\-źBUW+A8$iZZxlϪ4A1PPwuxzOCm3`d߿#c5g4nx;湿լcIx,|g `ztw(943n='յ5SJdy8q[ۀFj3:Vg%fC{O?i|gdP&pǽU[M]5OLb]3V'Gut!KbJmy'3 NGs6%M8ܣ>abT`1]E4ޔ]Z.uoY, vQzZ2Gڍßn:9&O zvlv-AԞ ׉!e_G s, de' ^KEQEQE-l)ym0zLtOZtk/Kق.- YA8ɫn˵ " p)7 ҳuyuƓom,-pLH)r#Z`Rn4ŚƆ- - &] `?Z4QEQEQEQEQEC śNѩ:]W*((((((((((((Jͨ9A;OT{H>VQEbx^o VW!,6!<f 3퓓mcԮcxL(0R{9LW _(_V<9GU4zf ,=˴V:Lw64jޕb]} ceW 5͝[LdBs!s޶I  Oak>xxk%ǕqXn{뻮hio7W3bBI Dt  .="?10GVDڽ(?Fw!NY@N{1xsOMwKxA) ǙԌیVb?Ŀ[j3lݤVE?q$ 7GYo߉WyH~mVe˄;I9gBxmmÂ9<:&'6j;n.Kv[r]n!U6 tOֻxFPQ,{ _Ouq`Zcr}1 W.lu{hd,y<|WW/t$.uO?egۧ~jO-Ix3E.)>V9n <.A?79?u+-MkY]B+p |~+>^kfrk;Y~!ͼgzax_u/ɢxk]NC$RSV QzׇtOx*L yjNȾ`j~%xRϷ3h($6`jd Lr(;}+}Vts [U^DX[tyG+_^hgvr޼˞P+>a{+Uk /8>?|[e w bћـm >أM ̺v5 :6y\#ZyO) s{ t<E +[-HΉ"!$I UoZIj=xcEM#aQJ[#,ߜW1|5u׺Sq5Pl9d-n=^Vǒp~?Sֶz>:$vZ/:_˙$eRH|57)-֥o4 x]]NOk"r~BG;r8&t/E2jr+:+'r~Q<+M⟈R+BL,ΐl-d8{EQEQEQEQEQYJr~Rќ;~ ZC-QEQEQEQEQEQEQEQEQEQEQEQU_pF7 JJk2|˹$5r(jzmϧ_D%B!8>h_?kI☮#NA{1KEW!QEY#,9\gaO ˥xVk12a ێ[~*u>)ԮmZߛcm&|͈#hk_g@7y9Jִok9J֮$JU ''mCS;&[@֬!͍լ9NG$;K?j>X ;-:2[xGS=5< ] 4|xvȅm9="wo0 #NT#9|EyGMQGpq0;Z{[;Ѵܺ~ӣ3|c\׎=y eH >H?\oq7sU&v@2 d*rҍCC<3]m + <u}xc^ OAm]ϯi~=Fqogz3dd7`T-/4x]SK&IcK\]G2qϵrZGu+τwP:y`%I=Zz环y4+5$^S1`Ȥ眀9Z:NNe2ɐ=)ŧIx{Q:469 ΆbIՎcQۧͦ1ͽ~g g=j赛9  n-%2k"·7K-vjGnַFPhT2CTtKMG[ZI@O'|dn48jAtl$\';k^[G|AiGIҢZ[#y{fֺu`MIy x2\mɫҼJ5=[㷆U3XHe3I c9xGN6]hA~vޠgIм ajVE&] r hk&l`kZkFmѰ\ =k|=(uO&UE %Dظ6>@b((+^Դ:>tA{H=kOi hm"D;X d{"^o|ag2¯{;YGKBP_<Slm.cQI^|}1PcU rp3WtMF/:l&V޿3BF3ǵ.7? bb6vӤoQXS^>(j:)5Y|ߊ-QEQEQEQEQE&o6RPq!YZ#-QEQEQEQEQEQEQEQEQEQEQEQTWҮ-;edLF@qʒ;qާ [tsƲ!d:((+?[tV5pM(&[^Y|o]ij"hD2& g,u"Ҏ(\W:47!d-6+A0z};/ẺijF^|;EŬsyBW]湩-Ɯ-(Pn׾j'z>}*+w^ɵF3IR{R^vZ\e ӚAf= =};gxZEA(C09CS^[!ImB)$F3׌ z(e֝{ahvQ- b02]q:x4?[t[Rg1féV;B3^ڸWz߉fl纳E{˻a  N|WD׊,-杻ksf` r5~k_k7w*X8Q.p=ТiL(f $*7q\}u[7[8vUNIϷ3(nkvzyIx #sץSӾ""QюbFq ~  ӾO)$>6To;J5=Rk/ 4X=ʣgie2+~5K[[Xj'v}kxxM׉cNwÇVA pGq]CzviPbV@%AO%,52zTֺ+9\r5O]eM(gZM 39Juo7~$þ6^K$Kj!g^ kW֖et˸ehe@p *{cmEQEQEQEQEWPwΫ4ր F˪~' xSHIVm:n@"ɝW'c_k:$曣+j4'q‚sq/ĝ5| IMÈbS#NqӜvw^!`֩i7rH.!L'*qQw^DͥjO-jS񖸾4𾏥܈#ffX<ʀ&x_ʼnXqsMksbUs{tbPҺNZi07'5 "&A8}\~5WEk+kKYu pNqۏZ REx1@Jjuk[T//M?@n/a+dHHWM ~{$mznW;H?R?7ko M i&_Zݡ FЎj^#RѼ_>o{{ngo-R@ [ם'?BG뚒jݦ4kkA$Tڜ"ynt?$5Ir.<Ն1+ms CP&ѭ]j<_imphӵ4m5b 99v8^fGՇ5AW6"#V8% kK|/ws}w+ILml;~~v8)Qb kXqYC$)=1G_l].ߎh;tF=wA?A?6_OsIFfqxNjGR7zPDx[Ma[D(8#; [Us%]Z*̟7=?V>,xrLnNrDw,AhqV~s'YzMxZ|M~"kǿ{c:\F>fkck8(9Wl-ܫ2y*w-^[Xhx<u?IyckZwIE*V>x;Ú5ѺӴk[yx˟Bz~mj -xkpPoT=qɨtR#E,AcN[;{9=}h}Kvѕ6ШGlT_[Esn[# |a6i-@[Y/m *=۵sqMMoGJ|ս-VOϽzj=k,zPC~+BҴ8 V67 =OSZVR-P4hlu5f5 Ae@YG=E>@4),4{kyF$81׏Zc鶉icmglQ U98ޣѴ8n!+-[HtK$dYB@nFO=yOߗ[yYц+&W> Ūi%sڍ'@4(Z-+NW)-=OUu?xoYV\NH&V R:5eai[%V&vQ*QEQEQEQEQEA{ek=wc|Relא)) (DQ +֗ -bi8rY~.&ϪCe Jent$ckkx^FTc{ox^^6Q\D>R::+RNx$gI Hn:2硤M6=Eo$O-7KM V)t3U|;]qjwech#>ݫD REQEQEQEQEUmB6^[Jaƽ\rxi4f흃8i4ךG9+8=z=Ϣ]]Ack-̫y$cI5>.Ni.Zk}.LkFl+ 2'vzeRB9˸E<#Jڵjɤ}V)7}2++T[ekVeFƶ[{uܲᐏPGzo> 6kh`f@O`mxkM$.쫖#{U;/{Qmw8#}|,mg* Fih(((((((((2M4Vv+R#bw9G#߇% sM#I,pbOsV/-9o.X`KI#tP;¸+[mmI]FI7+#滷[oшoKq1ް>!xJPڠ1Rxc^軵ӗ.8#VOimrڜh+ \)4h.U@8+<gxTik&Nz?]-QEQEQEQEQEf.llЀ$K'8;#&((((((((((((K[k0;Xug\#<}OiQEB/ꗺc2E9@Xa|sYwwke,[ !g'}N3ޖ*!|z(U~Bs4[o'|.nl4cw6Cs]y-G#O+O\^jM%!p}ֹ_ CGE[Uk26> tP+1`pfg=:vᦛiՖ`=Np\=k$%u&5.}_{\(aư~\>sx:XݢȻ'=z>Hfd翵u֩qZUޤ&R0N㸎8X_%k_]j֯E[v 3i=1pqBok/ɼMkbK]&7̱3) :zh3 R-^;#H(am H]sw+pWL\s%m2~Qq?j{=&^<[m8# =C05+r0  J;gTeKlJD(B& Qܤ?}p3MNK 'EpI8{#MrI,\#;NX[g> 5σ]yHQRY[ dz)uIӭuG0on^a=̈́Rd@ jQEQEQEQEQEQEQEQEQE|Tk4ы[~šGx D oT 4=9.Uk:$'LJ[{FcOiAYlLzWEǁU@ H+#\T陦}F ǖO(=GIžF2McA{X\lP<+^@Yqȿ*Y▊(((((._ 쑭GԢ((((((((((((+7VW|7'ɏkJ(IʅC+aGm3~ѵ4"S]+r({Gd-oVO"y[(HHmZZCcg l8@sOx8Z( EOӜr;wṴ\P3;5Ŗm'm}{I/4k?Ñ;zӳ𿍴 Azb!{v3۩9mᱞt~xcFB[NHN;H*EpvO{_ dҴoDmuW<~d xPxj;/QeyQ Q\EʈO66wݚ`7eo/>ОRcv[v};b oR5a6+bK~UxwAE𵞊Q8mR2}Ic1exf'Ӽ5i拾E -xnj8OjZ%5ީ)Z ^xbxsiMwN!ymnjKH'sw?[o B%b fbh1xZL<ueN#q\߆|yh.*rlh; 30u"h(02 EQEQEQEQEQEQEQEQEQEbBľ`{P$e\0n_lNYõq+yWz[e ((K4 n-%Px'q[|w "HT 0$ǡgcՃhڷlN{[vpsG\~+WVj\!m;T`X(㩩|3,o$xOI𧈵Mܪ>fcbۊ,$1nJC | |W}.[[t_0K;s^)źۼmq ˑq=A;VP@@hM:F-KN$\([XlꄤM>gqѴkO|X,`79YI<֯on5R?R4m: 5Kkxȥ+K}?^1b$h@++.EկNA,_ˏVM!#^/OIE1O{<{"EqyUķvwԺ Gmu+0hR]qn}NG4(((((((((o.'|gj\W+)x/T^ &/6BDBkyB ŏ+W^ fxg$CS/xgz{vڔ%A Xmw rG,I}O )A TlYv'US"дY?֧iO,wnpQ>\OnBj(lYO%jB8}FsL%׵7֧S("<Ň͎Tk?˭^vk$ $aO_j]4:֩'؅1e&tyĿ/AU 3TO7_񶡠q]<0Ap-cGak:A {˴v qq" alEQEQEQEQEf8[F,̅;oVI袊(((((((((((((ۯ2 bo"Fo Z"((((OMsV&jYrD :Ao65ȼ$1~W;|K&j›$͉/]j[/&-{8[t}umWM0Ff@sP4+WL4qZA=Msí/\$e-nbcir#GnkwIKf47摳~1s~wjCTm06[rIw$Z|m#@X䏜ϽzWO-Q9 `&՟ xRkiJ[288 $^Dp"ͽէ&[UnRt*;3KMRE`9P^qw_x'B~jm_~:REQEQEQEQEQEQEQEQE!yzopcqon-lK.;_6MBK9$v v<>D oW/߈m.Q(X-f c`L*Nc :8VmrTJ{+[Y6ͫ^D`hagrxg?֫^4 :FRʇげy5z[-IDY'ϵ.kp5r\!(c'Ϣ\EZ$%%c r{ *}h{^٩C+GR2~Rn3ofuW[kK9烙>dpm<~=뷢((((}w '"5`sތSI v3p((((jmN~G1 Fj{kt!@=(((((((((((((=+7De{>;Bpс}AN((((aEd!Mpˑ\J~{TcȻo&GߕkxO.-oliטN+,rp+ľ#^,֡Ь/w!8yt~+&/jǛ?<-6a `nHG-u j:vsC&9N$wP~!]kr\[xn4$"`rTq|@oWa:vifҳ5 +[? ?YX\] +g~i_iB$/tGqҼij~c[[+0ez1XԖ'XwϣNnLcNz99U=1kSYkiؼݻЩ=爼muM.M>k ,-#@sYx/Zh!CiI +|Xk#SnaXԀy>x=ֽ:((((+2}UT/r?&}R袊(((((((((((((g2|0s|VQEQEQEQPJYO2ll˼ry=y`/V<]Ȋ= 7bK? >U2F $^?׵? aC=ˈ-/D$>&ǧVOiDy}я][xr_h5ˋEk'3Վ"Ey[I݌]R'dL, F3g,Mm}B[DHC}/2xcua\}iZV/:Ti1ێ?xKsk_FFΫVMo@eIqןjw_/ѡmuNaY_;pAV7Wэ[f[s&~%⨳]44a`Si-9bJ_bsЊ5e_o/a62U.ە?[MCN}-J M?U;Q#9*®>'Xm#rq@)ǀMgR:qk|˵,h]ǣcޅm'Öi֡v;yOLy=O9_y5F,iy"ZV l --|5e+slU0T?zViZ\mGI :rkw٥ZK[{&_==t~iXccAm4~j((((((((((eaqep CsE  {pj=+LѴ}:J&՘M:$Y0?572H+  \:ҽHm"#1J\=rs\Y៚5m%@Nss[zt[EM-e Eo~^卍o.GC4jnl./cfO\[mqП^*}B,328>uQEQEQEQEQP^ܥN m#$*-*[].)y7LS.GՉQEQEQEQEQEQEQEQEQEQEQEQEQEQEG41\B̂HR2 S'3ip2A%/ԼdĮG"((((((=(((((((((((()1KEQEQEQEQEQEVn W(..T9v'v>Z"((((((((((((((7^.#oS؇Z4QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEVd>]׈g a@ewø޴袊((((((((((((((WMѼz@x.d80$p8>W?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]ʥh5j$p;+k]p@ZUFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]?S_rFl?T?mu(f~5O]ʽeaob`fieif$rzVh((((((((((((((((((((((((((+;/ (((((((((((((((((((((((((((((((((((((((({kF((((((((((((((((((((((((((((((((((((((((A"^Ѣ((((((((((((((((((((((((((((((((((((((((ȿ׻&h(((((((((((((((((((((((((((((((((((((((+;/ (((((((((((((((((((((((((((((((((((((((({kF((((((((((((((((((((((((((((((((((((((((A"^Ѣ((((((((((((((((((((((((((((((((((((((((ȿ׻&h(((((((((((((((((((((((((((((((((((((((+;/ (((((((((((((((((((((((((((((((((((((((({kF((((((((((((((((((((((((((((((((((((((((A"^Ѣ((((((((((((((((((((((((((((((((((((((((ȿ׻&h(((((((((((((((((((((((((((((((((((((((+;/ (((((((((((((((((((((((((5nFxtѝY2|ў5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǨ5'#z#_<:wIǪ4+&p. =ڿkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=GGN ?FA;$ytQkӿO=PƱe]\O ^6\E##NEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((((((A"^Ѣ(((((((((((((((_Bz?ZQEQEQEQEQEQEQEQEQER?^((((((((((((((+;/ ((((((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((((((A"^Ѣ(((((((((((((((_Bz?ZQEQEQEQEQEQEQEQEQER?^((((((((((((((+;/ ((((((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((((((A"^Ѣ(((((((((((((((_Bz?ZQEQEQEQEQEQEQEQEQER?^((((((((((((((+;/ ((((((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((((((A"^Ѣ(((((((((((((((_Bz?ZQEQEQEQEQEQEQEQEQER?^((((((((((((((+;/ ((((((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((((((A"^Ѣ(((((((((((((((_Bz?ZQEQEQEQEQEQEQEQEQER?^((((((((((((((+;/ ((((((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((((((A"^Ѣ(((((((((((((((_Bz?ZQEQEQEQEQEQEQEQEQE}rYkv6..Ah?}'g7uݨx{Q ߏN׼{R/j_ݿ^Kkнvv{/yB}??^Կ;G ڗoh׼{R/j_ݿ^Kkнvv{/yB}??^Կ;G ڗoh׼{RPcjZA [- ad'5:/jQEQEQEQE&(((((%U(((((+;/jօ-QEQEQEQE&(((((ȷ׬ Z(((((++V_V)h((()0)h((((_EQEQEQEQEQEQEQEQEQTttCjEQEQEQEQEQEgxECѢ(((((((((ȷ׬ Z(((((++V_VQEQEQEQEQEQEQEQEQEpU$Jt_/(ƾ#:xrҞdx"$:pGקGy(ӥFVk7OBTڷ.P6|<$W֯qsZ(ȣ"3FEdQYceN;Ly6['ҡ|C-#Eh}P˱PF>s+^Ăttm4dI6郚[u^&p{@k?`[o X f/KA53Qp?p3Es-RxfGi%;Hi`29Zü?t{95GR ʖy5O|gץu.iڥMɸ`pAW("Z7Z2=ih+7_-_'kF(((((տ%<իEQX-~#N֪Fʹ6Xs~) h.#Yco$Vz\5 2M/V]ÂXu='5w"xbYm1+ Ƕkw"Z2(2(Ȥ$Y7Ρmw{(6} n2>or]3X>vo?On-`yf} ]#.Fhȣ"2)h+"'%uWFQEWxOQkGZmy<'zg?OmS_]GODz~RĪ`Z]iZ?.x,y1;IHl榿Op3Ӝv PjϊQu:i]XۢBӨoa 2]XQZ4[y13ǵ`\:3_J]|$fy0[9#V:& _9ɭSwvaEh4M/MtKO5MJ/VѵtR;wa׾k|m1ũj>UM͏I=l*OxvxrHCgc w~YF-[?#(Oc.TOkGFfukޕ}$HDr~|u?^ j% 5ok }1Ea &^+Ҵ=SD5V56ؔ |aN+Mh$弰_9⾺3EpSuQ5WQizƙm3br04cMzS]"A 꾱xC7yk icyc/XԴijkw|gKJ񃃜|zZӯ#t[’>άEUA]$گQEQEQEQEQEQY {PwFh)Og _%xg[@;]񜞙Q[׍oj3WZF5, QgZ ν^92[ܾ2>իS|A/&wX $7yDwWw'N^K_LۀK`#z:z'.u+}43Y^Q89hvW2G7LQI_A$vkV]ws4Y1W$xW5{"ԼI-7z<T*/<.3Өj5+ xBwqQ燵? xZ}KD6Y;&X|zgPMokWב|VwS% ,+!F=ÞDEJ ]eʃO(; EյƱwwgpi#AXLF- NnJ4iwR`rץz%+x"54c ϏNk.Ev1IWr*Ӛ×>3&pPwoPl$}Jߊ,>[_x>8򭵒a.wezolw]xUƕY[h%`y ?/\wSFm2n},*>2n^}kk,敩]ͭ_-1?~!|I3^NcA :UlU9$sUbSmiffwx.. mS'с8ϱ <=BT֝L-n-g'OA2?x(zzѥ(((((o hO5jEW%KI\CZ֗l 8PKQnSA O=7X|[VӛK[Qkmi#e z}Jqw6mnEUslnb}W[[Դns I9ڰ =-Q~DwYV\rN1N|M\ ߴ?͍iw˘. /+z}jZ|k\j7laN`܇%?~]9ZA{FnrCs_kz? ^O4kŧ͹ugއsX\C7x7vZIEXF{cp!ƿm Kim[v0A }f\eke#ʁ=s3ԟjvj~#<+jcqswn~%F@FuݳkVzy=]JWdF]OW/5FJkKKk)pKr>z}?+FR6cPq< .OmGS.vWV%7ۉs9ݷψ4Wm{66w kggkuyO21=+W>"Hgw}u9ͥԒ$\ֽ(O*W_:/jQI\W/m${Iⶹ?3BI ==|]feq1I J[[IQ3Ga a|CuxvYg}6_iHg'IVt>)4Ʊ pŕr#$Oa޵>ZNj$.ug2D$ᔞT#L[bo4[zɅe>;GК.YŴ\dei S]iKim#oT*B+|};.uk-Ω,|e7JBkNOx4-B a!dPdBO3?05Ϧ{66ʷ!Hc.B$]7 xIԭ,g"@OO,nBfxHTs!; 99xBUFixgO]_hd統5GS}֗tMK\ä]=,}sA=x3Xp|Hm>u5७[=>i<;SUl4|I-A(-wtl:u_ hPh:i $ak(x#T.6IW FWKO}^Kmqɾ)\"i1Kv?Bw!zGL?-]/čgi>K9Ȏ B]z~y| [A %"fbS\燵qu˪h1!{)!Ea+37umswCMGͨa#\17]>ay7_ ^i; gXHɍ IU Υu&ug%Q][B]"*@9ϰ=x/ɧ۽X$$q# 56#ХRx%<( ZuM7O&2[+:~]7_SG{>mY`G20GLgM~ cɚdj}߰ Vz|<-ǦBlEv5LPՃ^\ԴӴ k쫳3ݻsZS)[Kn+=m5?2]T;G=8M|@}ckwqs} UGb}c]^$dE3FBHB+;zeށ4Yu aF$&a^#TZXri]o,60y:罥+7_-_'kF(((((տ%<իEQ\{KjvO$j(7Χ95e Rc : ЊЛS2v_WZw:[k2d(˙\\:?magm=<@c,'P=9iwKWK\YR'ۂ3r{S3.4}VovJi7O6$\͐aJ?"W Lo /ZUUv(1ߚ[aysi4[Mpg#,b8zOV7nV\Zͼ\cdsU-WÞ9Tڝ} FU.djƧ|H=Ιd%[ 4g̃ X[F}orm^2.j,' h:W)\y>vv;? |?&[$C-.ZKg^<3K!|wº?lڳ]0cCOSNƯkj״{Yu1}1ݡw#R=q]wm隖e]BccJ9'G#٬.[asj=]Z]Xu`{MO_.4Hc3.=Տo S32cXqK]wV×]յݝ-z;ns—:j2h:);<#޻*(>.ȫk_I]~ _QE%hhzOY:7'M=!+9\?vdUٴ֬RLFFFx֗V|U{[٭`YH+ xMĹM<̋#6p28Iҭ]&L FI>\hVn HPmU~q֗QF`Q}(-QEQO QEQEQEQEQEkF(QFpH'q5B5jj7VѴVI "4[1q{v$gYڦkfXnUPXZͮkiC7ͳ,=ӿ5V_76jK iV_@PNx.hEC~nMem8cu ><~5gwm}j6w\A')$N[EMF((`bw`g4QE//A5KEQEQEQEQEQEejjբ(#4֍ T5 Ү"T9F9.GoPյ)n6 0t+ky'E(P2I>.żI<;qse<&c.:][jntq+MB:W~^QEs^:<Ege(GN9=: }u|D8.N/6ˌB澝(((5뤟U(((((+;/j֍QEQEQEҼ~Tad 1x(_Xsi'Va<$e!#i Ϩ{)hIe:Hܴl"w lוi? Kj1+a:\"/RXO3ލGYM)0f 7ap;WQEQEQEQY"oRY?Z4QEQEQEQEQEVV!-IZ((() xxGD̞LMs 7}V_/ZWQE`xP]3:1MGm_Յxg4_73*C  `Q}8jGo XKy5ݵ,d`*uQEQEQEW wE[_OJEЍ\((([Tm/iT}߀`O+|t#g3⾷w[pFe{|2=k˿gxw_߹7k}b3)2[8!9# =;։Ub ^wJ\-s׺EQEQEQEQO QEQEQEQEQEkF(((J>#FVڼ'@0qąQ/ R黫D>S+oZJ9gG*A>R1R9U@ơ"@B~;_4o iv/.5bhĥWp ۳9'+';Nne]PP,u9gy7~&xF-0\Z&kY=CzqmwRukDwuh6@81&a~m7Rk+YYKH*r@1+4y䈕Il;qI#= )腷(((+"'%uWFQEQEQEU{85 +meX`:<W7^ho?xԎ$9[ӱ_)|q4om߳Bp=3]QHNk!_[NIm-dvWdf<WREQEQEQTttCjEQEQEQEQEQEgxECѢ(((;y=|w-.-&w*D>-EI^5\FA0<Ҋ*cX\\H*׎xCWn|/$W3e`zVB61#Z|9еk 6p*+ٻfn}.ȫk_I]~ _QEQEQEQEQEQEQEQEQEGGjI?6QEQEQEQEQEVw?^?(((((((((zzѥ(((((o hO5jEQEQEQEQEQEQEQEQEW wE[_OJEЍ\(((((((((:?WI^(((((A"^hEQEQEQEQEQEQEQEQEVo[ԿO֍-QEQEQEQEQEKCyV(((((((((O*W_:/jQEQEQEQEQEQEQEQEQEQO QEQEQEQEQEkF(((((((((|E"ޥ^&ih((((([BZ7ZQEQEQEQEQEQEQEQEQE|]V@+A#W(W~)却tVԦQ7Bc2?;fu OX{ >1 kWմESHJ$xǦ^\fzݽiWomkrE]R<. :=[$F9Sj<O20=:g#xJ_AJug3` =y}cqi7ȁ8.FpGb+zOhe̋me3}9?Qcy5 aq;gǠek xTw ]2A v3_nO|Qxx{XmcO-c#HÏĜ/Uifq}ZΩ*2rG5%4K 2-JT` S4lk̾ k!÷ЬMڡe;ozCh֚U+"s##𫧥y;JIyiWZka|rxҴ4|Swzz-%cDݳIBmNlR" sϨ[. ^)r3uj{hnyCi0)A@FFds. #^ҵ/|?yi;]}_*P wsV_N֭ޙ{ 9pcXqP̓۴&rbbCI뵳W[EGGjI?6QEQEQEQEQEVw?^?((S>'hX&Q N튠 iw}k >ю\v44/bT,EcB:g8=2bj)[ZЍ%CK˿ᚱ]ּ.Ұ/{N2}}Y#uo1?KN Y0 LLj.4ҩ`9{=8>o7slt6ej$7[I"<*,yZx[]LqǮ8oI:^v5bIG Q 4eNl4[ y#iGt-}=+U176[Yo6bJ&#G&1nV،OGCQ(дH]VGTb=q>zү>vC~V3]E&Hęrq+]G÷7V:Q%,)=:xTԴ$> g7!|;k kkŭO$"Q?wZ~c%ޟwdw_L{Kr)ߒ~+G Z^7 #Toh6.mkֱۼi@mNsϭ[f1xt/ޡaK2 6`cE?"߈m,5d2jø9tWTѡ6V֦m/F$J4FoG s/]OxTkZP0MB5Xx6/Zxu E2Om}$(:'CһQXѬ(Twp$ʭCp:nM/X9:*>ŧKd"kyz>T]&v_$]n#9ssoi~*4~D겺'6QZNj|Y6gْFt;O@֍M+kBAHTrAm[M`6B1:6і~*߃?O`~4f&KTh)3I>7#MOt $!X]K;z(+9mI#Iy/P`Vo-O\aZS涹6SHФ9Aפlp2OxK/]s];yX`NISҢYg|Gi#W5YżX<(e$Uk[s#FI>hm K#]J "5':w3򁚣=mRX6uxbYc-AvoV~ kvE@-FAu, y zzT Ѭn|{RL,I#3=Oe:7y4DVQ*8|a!່^I.!`;*9RTttCjEQEQEQEQEQEgxECѢ(Kim6cǙ|B KK4oyx9Ӝo\GA#?Y-Z' &b<*́WFzT+hotV,\)$v2< t%#$BhqY V H$ެ#4NKXI1F{wҩpqCB} `3ŀ|V$CŸԮM}7 kn ƹpI-#EPņ@ZufK@t[hn1 s{H'swx֙w+IuܼspsPi:Ɵ})j"1;t{+yދYj?kj(f[P-:R[h|IJ,tp*?g{TҭaWn"8y9-#9|7?>/h-cjx_ Z{C$Wq2;(%뜞=01^ms}qyE;-vn]ψOQO*,n`ʰ?#U? j; 4kا˰IA|Sxłu7&Zvk 1ƯEQ\'m? +ҿ B5r?l|W~WpxLFS5A|L!v֍Ÿ*\^"ˎ?R~<xT?@ .˲A@3x'Ko ql'&Wd$^}E O&[MB.-gbFG#~U={ޯoMTM +߁:c5RÞ>$ٺޯY鲜\ 9*w\?=+N][DF0?A\īFG4q f '^][ 'rpUDrv~kfc(I:TOk~+ ckol\`d;ux_֤&T<\O-6jMUud@ G²m/J% x&񾋨:mV\HHy} }> /MWl,QT`W;Roi(n"BG'TzW$nmn Jׇ|3uxZ$Zw P?焵E7$$ɻXr$A=Nri j6#-bca\k7ϋ;{f%F1+#ں x^X{v!)Xs$4nv mom0_zZ* mW(((((Ƚ׻#Z4QEQX*𭏋tq$<.:09t߉PH5V)2`}S 4um/ڴ 4P0f𧆡f&.JĎǯ<02}*<)s:Z6KqmS^^s]SMD"+e/n:}{X@Q̓/r > ;d q~Bw<)z,6\S*i& x_լn|Yy}NOduaZV5׉Zxx Nzc/G z}f fRO$p9I""~"xO.(++}H:3z~麟D7to ݲi$v qs᫩"Zxf[A`֦#1LcZcmwFΣX^>ʒ]E2A)u'aGСq%+q|)Q߈lz^BjZ(+7_-_'kF(((((տ%<իEQE![^ ݼ1.u:gⳟNĮz+1g8[֬ꖒA&FGGbܜz.s Ȭ,@-Cv:4c!#ֺm ºv[EjEn,ry={Xn=uMq42 OQ?/?*GZ{MwKK8΢VGR?!W?o-u/'ȷH;w$Ӽ!钍JY_Uc`Td7$44֥ׯש뱘X*a?4t(u=,CwT:bL΍+xyo"FYZgbX+(⣃>>8 oK6] 88JZu|4QEQ\'m? +ҿ B5r((-G<$QцC0Aw]x4Oml6^\QKqJ cf@h\1I bsX*I;X Ac(8FO~ƲϪSPYK8{T=*KKZE\LssںҊZBp3̴˥Y_sw~ddHrGv5Zgu-J k[p+:M֔[N?xu$Pi0[Z5*MF'͖J ksZwzE \K4O=+w7q޶ECO.ڄ[N^KL촄ZFTŚGnE^5뤟U(((((+;/j֍QEQEQEV-$K{xs was[[0tG]@19X#mV:޹Ol0w1I#5E.洗O-ՔL`G =rZ.4os7V`YV'n {}}/xgŐ]@ֳXj/o=zppk._]j6yW7+pqS9ߏoFuoׇe֣we$duacXYt˝KAk +WEgtسs k_:e[Qر۲02 1$V9QE`~ <;}=e +B8<=oQEQEfEKdMhEQEQEQEQEQYZ?o'h(((PKy5FD{Zv_ɼF~K)漼ʴ?#'޳l|ovݮ= ]{G3w/Fqی/SAԵK~g :1Tzq9oukZD6cbIDG];j1#oC:#Gsp"X +Nm߅SĞobެZީ_Y[7n(LqGnEQUu>UӧR\!Ib:UM:O,IG#rX;z<բ(>.ȫk_I]~ _QEVOgum!x,f7^ ~"h^(/woՉW+8\75қMgM[;"DL=Iγ ڶ>k8#v 𯊵=-R:)PN(֮@-G7dbe}aBB"Z|lY X]^$PI!ڈHK&_ 慠)+WkYFM8QHRgGk"Ɵ t,7vc# VWlP7M cdʎJ|z+/Z<3K|JuvE91TV%׍-%J31OUEvtvzN+{]%ͻ#uA5z(((ȷ׬ Z(((((++V_VQEQEQEo i&[f͙e1 8av+UFu֬|G pl(n ~]6:q$%zǜ^yj?/tk5A0qμ'# 㞩tR8cNo.?O?'w/0EKsxB6qpKnV#m")_7SlVT::YhLCZb} Nq52tm4I&)` (8%wqf((((_EQEbxDm{趮/Ÿ4ijmvkP09' facYQ[սRJ>_}xCĞҭ,0F?%Yzvoh妐>R0O=>3>nAoe%_eڷ5\hzV-nt`3۴u3Ix;2̨Nj-`n,S!vyR 1pW? ƺ,ڛ0>Q vG|vp+^2ȑaH>mu mGUf74 .Fݨیgigĸt\)%Z1P#? U:%iڭXTUOw?$__5aSGp3+?Q,3>MS[oXk!(=uᕬxng'S (ۡ8Ɗ(* mW(((((Ƚ׻#Z4QEQEQEW)!5,n/?Jϊ>[T4fQu q[h$d=? ?o/eXtaj'BrulCOE+wDY V f7<5 Jũ2XI!Mشf?vw Ȯ|OłLK4뱮Ily|E> e3)y6bi'ֶ~ijO]y2Bٸv?1*ώ.'K? س%δ%OeǚR>Q뺳k|KZ#&^ZDWHǿ|{WmEQEQEVo[ԿO֍-QEQEQEQEQEKCyV(((6}]ijX- $6T=s4>iz,Ik>yX9Vumw%ލeԭ4SOs\"i \ܤW/w{}kGf_ ōe4e͟d 6VFQ}:mh^KF@ H }NE.; fGq{"?\}oZF46;6HUլ][Ú Kwk$(ϝ nj i3h崄D%I@cFCE.)6ѶiqF=񅇊uH+>#Ӈ3F8<kkEҭML]ı:NI5zC&=q7`ޕ[G(5뤟U(((((+;/j֍QEQEQEb3@#4cތQHT݁\PT0zUF)h((zzѥ(((((o hO5jEQEQEQEd1A R2`#R3ޚAgiQEQEQEW wE[_OJEЍ\(NQEQEQE%-QEQEQEQTttCjEQEQEQEQEQEgxECѢ(((((((((ȷ׬ Z(((((++V_VQEQEQEQEQEQEQEQEQEpU$Jt_/(((((((((5뤟U(((((+;/j֍QEQEQEQEQEQEQEQEQEfEKdMhEQEQEQEQEQYZ?o'h((((((((+"'%uWFQEQEQEQEQEQEQEQEQEUA]$گQEQEQEQEQEQY {PwFh((((((((+7_-_'kF(((((տ%<իEQEQEQEQEQEQEQEQEQ\'m? +WO*/-I۾`T^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]^?V ]O[A# ,ʸITQEQEQEQEQEU]Ji6h *o~?_/\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\._ϭOvgq l~8w՟/\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\.ogRx6+n|)h(((((N{hs*Y[1@#S|s~?_/\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\./\.v60swq~?sYg|s~?[Ğ#ͧ.Y$YA8 ▊((((((((((((((++W_VQEQEQEQEQEQEQEQEQE!T/mW((((((((((((((𱾶}Ln)O i<ۓs+`+((((((((((((((++W_VQEQEQEQEQEQEQEQEQE!T/mW((((((((((((((]Eh[s'ă.3u$ lA $<0䠵9Vu-{OoOc [n@OGpyjZ((((((((((((((++W_VQEQEQEQEQEQEQEQEQE!T/mW((((((((((((()*K,~'NF c`h  jkKJO'ߚO@$NdgQ`Uz֗tf#mryU((((((((((((((++W_VQEQEQEQEQEQEQEQEQE!T/mW(((((((((((((d1 3泷fK[& (Au8&Gm8ׅDPKEU{8ob\VCqU{yznuH:) ih((((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU((((((((((((((Y 䓈nw`Î$պ((JsH-{ܬ;vDqF2@?ȪKw2j;IF rg'q(((B3Y}0kP9=c) 7q apI0AAA"(((((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU((((((ȢZ(L((() PIVY#?zg楳KfyYkO&76;z8ܚKEQEQEQERU+<<p2//cdA[M@K)ɉCF\-QEQEQHN("Z) dREQEQEQEQEQEQEOCyV(((((((((ZG?6QEQEQEQEQEQ^s .;C'F0YvxW5e1kZS/#n ㅐz3B+/jx$`~/"i6Yj:ͶS2ByᛁL}#z^ WOKLP{*_ ] [OWSU9/\VtCÍtߺY6;OOq:V)]Mk0@]BKO=qU>)NlLsh xX_xZPSK/w$R2X5->L:d+6Pq ע-r\zĹsqhH2[iZŨi qm0%sAjEQEQEfYXAR{Vy{PO2ӻU힧8&Pem4XGl7[4/> "\RǾ+f+ּw zaLt#KEQEQEgk:hu;o(Y9} h}iuPvKd*# `uj՜7e%YOL9 x:-zwt-QEQER- G?GK/MXu] Ƣ|yi\6zwxS1=7(&jwqM?c; hFø``35x^COdQowD.w@CBO/58[9$ԇh|C!N3LZT>j]i:Js$2֖_YGh<<ǾaW*c|G _\KڙcnnXktzptu<= hQEQEQEQEQEQEOCyV(((((((((ZG?6QEQEQEQEQEQ\ſxÖGLjQg5m5Rq%F=s) ƫY45鴕r~ϼ_oΕOK}qw<\݋.#+IҽFǃ#6-bh#!N<G6buy.^8U2QӦ EǍ5jB©\ $J1^,r|!`ko %U+ᏊVEe@lwt'1Ԍ(k/Ek ƈƨЪ H|oѡ>nu{chcųjnc gM߹YHu??Gbxgƾ.Ri:(y& 1g8Q/+0AѴHDǮxZ4xcFvN5\=Fl:]D7}:Nz̞K4Ts s`h).0.Hm<: I~]x-d|‘CSY+=(G-8,gx29Kطt~NmEwR~u?jPTA ߳O#MkyNzOA'c }x9=GpyZZ((Jz_5/q%nkƺjZ얮o9?=/tw\[+q_ďӾ!$11`_j,jWBqYtoix#T7^X\>⒎IKmz-KCփ[HVD69?xryT=H?h_gkRk;7G֗hc:mĝclxyu+x%MGQHB>U~EX| |4,Ymvg#n|;үt|LJd_8*FT?((((((_Bz?ZQEQEQEQEQEQEQEQEQER?^(((((?<1\\IK1w2sۚxTdu e# \<xCSn)|G_b=q9k˙<9;mce1 sxU_i^ZLLO~$gvs=Mq[:? azpN W~ [Ca4VkxxvdaOkJ_^jVrYk+u+FB 38;Z*2q#Oxvzd9X%yk$c'^l Z<m˾3Úׁu-"ᥑLH z6#AҴ{0@ zd?yEs/闾%{#z注Z&5' `jC);4-O់>2Y誯P--2eB[KϊZa,mtk$ []7cUC%:qK˙UMzS~4̟ͫSgkž?hu( Rd3\m>x cxץZC [U-&=!+7VWUI7U¿kyо6sʐAi;Y\KLO=ǭ'[>dGcg } xF\nV}ό{G2 __{2b'!(xܹ# U((CXz`m_Py%}Zq4gVs^"lޣoZ\zKleΡ<kƭsj0$UzE$ީz,uGKМol4Z onu.ǘRKq{9.g60muC]:EIQB![یV|5iM.0βG,`n2Qi&iZ-bz>䟭rtÞ%Ѭ\Ʋ"fy_·3 kfd=ͺIf?QEQEQEQEQEQYZ?'h(((((((()J9ߓCjEQEQEQEQEQEQEfQ9m_kT REQEQEQLT6F731QMfN"i-dq{퟽8'FcE k/EQ*J(e XUӴ-"m4XmԒ#v'j5 ~# 5}2 0uaj}'BoiVZDpXD,}IO֦t "ݭHbg22DAcxCY_m]]̫(⳵xw M"aސUԮ ƴlt2l-!\(*)t6JK; h$Q.>KTf vsQgYiyJf\osՏ4Y:|2ZERghG?}MI{emZIiyO*RQ[-qˆc Ǧ+xNP7k99UOSVwUM?Җa30L1qzڢ*7sFC*G GUsiP`  8tr)h(((((((((('<իEQEQEQEQEQEQEQEQEQHzU-#AU(((((((((((wY8]!$:5],n5;`rПC `ddb)(KyL)۱IB0o-:qPņǨRBHpH<PjRU# lhho0}CnxWhEouotg8I5n(K[6|I4gH+]|Oag--͋J܃P|ExWZI=>s#,1Pr9LՍzx{Umd~O^t:tnL>աxO]'m.V0U/SF[t?b2yov{Uv,|kSYƶp<\pߟ֪]=OFYe>Wimr@p'~~|S;Y,44jMG!yzUG`-59|nl$r#V w=ԼU^kVvXeS c>MRVD0ȱɾ91(`z!^zדŚ^JK}:C 0Qq͍Zϧe-=%v0JpgiGTu+ťCss$dlNsgŦxa=Žoʹ֮:^#[T/ջrrItwGH>!o˦gy]sm93Y)5m[ĞԴL%ዘq&p莯*|E42ˤ"`Ȍyّ/k&ӥ0}H7uD lNJuMFD,Xy"Wў9L8`p=k^??| E?x^?`nVٴ񋓮]W\5ic5?΋Y\?w2n|ŨηrEn HΥF^3p> {O=Ŷj.nmlo 6q+o֫jI)W Ux<h8l#Q1`qĎ.|'a]j ]A@^"syrvaǝ} %gqu9~͢dtlhldqa\߁<= jM5#Rkiz!GSHS㯦=k}/[Z-DWЪ `ӆ IM^Xo9u|i,K"4e#i_zg*Λ%%LJV{,fw]eqע7X*uEv{6x\/+X%Rg drzs՛I>7R##h_TiVn#Reiiu 3$ڶԨ6lsAO 薟d6e&řF8=V+;kh솞E2&WT}MmPϦj𶆺k+gu®IO5KX|,xCN2A[9I9EYx{ AO`q;`EҴ{O ZhWHPjHra@',y5k]6oeݾhimxrj|+5k%ñg}w܀@'[vkm pHPa¿۾gn>\?whZflڭWq#nUsRAvVQXij@-ctAUu3,ڮ̪0$ p W#OŞi %($>ޗMҬ4{Agkn1 Eas%p=܆Y zQU/#OYݸ4y:V[) r yN:#Z(((((([BZ7ZQEQEQEQEVV!=IZ(((((((((Cҩi_گQEQEQEQEQTttCjEQEQEQEQEQER`zU;G\eepLt k{heOF_~# *-QIdS8&R@T`pGQqO8Qs-2FemlnIXt/ CWR٦ϖY޴. 񬑶ʑpzpjjJZ:nhn;m!ld ³땷\H F zμUPȅ8"r+Zφ|?uMOVbP ?E/.tU$2}T>JZ(5F{fUNr39t5%[L\H0I;*qߒI6h(((((տ%<իEQEQEQEQEejjբ(((((((((=* ~O QEQEQEQEGGjI?6QEQEQEQEQEQEU{8nU#)!r?Um<,Zo )I@ sKEWQ{e}> r܀q\›Bo5:Th"b_pr[+sޯxźݙO [ی uu{€BgsV,'dc}|{rG8;U[GHo5 ۽*H,.Y JkIPm7Wm7(4)@]T Lט2x0"4!_- y s{ks_ITO6a$d/$,C^]k{]I<Ȯ#=G]Zh>KFA€N2 H=x$=6Ѭ`MsS[-_[7FNWv΃t~kQ>{L>M*j6s1:]ǍmWe>eȚK/-sݽϵzwCZ \n~tꚭk]^I Ŗt' H\sYaZYN1]ipqLJGJZ(K"CK#*"p2\Ow[Zt2$Tu#5^558h(((((([BZ7ZQEQEQEQEVV!=IZ(((((((((Cҩi_گQEQEQEQEQTttCjEQEQEQEQEQEQEUu*YgKFg6h3a cimu XdAA #B@^Sdj2jZÖ+R8 e_~5x>έ4{iK ׏jnkGUb9ִQyx}3#lf>^{ X2FA-qT<$Zo<_2E}6QXa.4z,em.fd9VUR}rެ.#8:?Ws^gS kjoXqbN'?69S_ur]uXgxkYo঩sȒ^ R¨e ~/xI-m)z?>ضygǗoJóo ԼF͍G\b@S[;T$mTAz 8l˂54;UF,N5 }Cy9n:uk|Hcm[NHIA(=7)*mz?-H}v-٦2f$zE}I$ܢ((((((([BZ7ZQEQEQEQEVV!=IZ(((((((((Cҩi_گQEQEQEQEQTttCjEQEQEQEQEQEQEQEW5I%r:eHԎUnqCE-Oq'v$ QEQEQEQETr1:"vbP;qT7eY%^wS5^+h(QQ8P=y'&(((((((o hO5jEQEQEQEQYZ?'h(((((((()J9ߓCjEQEQEQEQEQO QEQEQEQEQEQEQES]Ыe#7:qLֹܟs]Z8㌤`F: HmCҌ,z9SKtr((('F{yVYù9 jKKl+H>yt 3ɫTQEQEQEQEQEQEQEQEejjբ(((( O5jEQEQEQEQEQEQEQEQERKHr'z((((5뤟U((((((((Jwi{$Sʺ2P{MVGD.x:) $+D)h((31޳|ˍYq_$G]z5_4\Tz((((((((տ%<իEQEQEQEQEejjբ(((((((((=* ~O QEQEQEQEGGjI?6QEQEQEQEQEQEQEQEQHJ=4ͥh5l11L=B0mu "Xzl{ EMEQEU[UwngsA(דw fk[@) з((((((((տ%<իEQEQEQEQEejjբ(((((((((=* ~O QEQEQEQEGGjI?6QEQEQEQEQEQEQEQEQE&3Tn,d2͜ 9$e%qߠr1y4F`Ar3}dd[-QITnoiӯht4M>;y^w-5ĜAy.<-S<)' V$3U:k?̹!f?q$?tp WaqEKEQEQEQEQEQEQEQEQEQEejjբ(((( O5jEQEQEQEQEQEQEQEQERKHr'z((((5뤟U((((((((((R0<k;:X͚~h?ׂ0ܶ,RSA)٠߹|Az,ڎ (9 l}@ Z(((((((((([BZ7ZQEQEQEQEVV!=IZ(((((((((Cҩi_گQEQEQEQEQTttCjEQEQEQEQEQEQEQEQEQEQY gisY0( #=2 [c4fqd}$Җ(((((((((([BZ7ZQEQEQEQEVV!=IZ(((((((((Cҩi_گQEQEQEQEQTttCjEQEQEQEQEQEQEQEQEQEQY~"SD 9<{FJS?Ul|\G U O sV-QEQEQEQEQEQEQEejjբ(((( O5jEQEQEQEQEQEQEQEQERKHr'z((((5뤟U((((((((((w?տQEQ^1?+o.K:ġfqO{k"AT=Gem o v@/Q=6mar$KuO<|*c[}P˞0\%v jTz*j(((((((տ%<իEQEQEQEQEejjբ(((((((((=* ~O QEQEQEQEGGjI?6QEQEQEQEQEQEQEQEQEQEN?, W(ZZLZ?D u !.'[xm6p>P}Z\MCn1׶sW=8T4]sNsfb28<0_^IJIڪ2N'Ecl"|H8R.",!P/$O]8mŚ Ls$ĺ{v[]C;QOB+*ϣuɂ[.vX99P^4&Mr}+C1KrAoWj>.+k6}z6HiH~ٿ iYjWxgMz c;9ǹUxW5MYTҝ-!@}GҸw0zM[{y/qv-;c]4)牖j6lqrppq?R(_ |9يom೵Fe{^=Ov.̫;i'jp'WyTE:((((((o hO5jEQEQEQEQYZ?'h(((((((()J9ߓCjEQEQEQEQEQO QEQEQEQEQEQEQEQEQEQESU)J(/?x]4qGkl(7y}9W#Lվ\)-R~n@㌃MfqOkZDB5AHCǮԊo 5S0,pr?#JNgg;CW֣I% cy >=qJ<9+KFo}FR$ 0Y>ZMvZ=K* TgqjQEQEQEQEQEQEejjբ(((( O5jEQEQEQEQEQEQEQEQERKHr'z((((5뤟U((((((((((w?տREcj~x/5-O$usV-*hfQ4q*BrT`p2IǽI{I{e>ZXێFzMuio{lpG< ҧiK8`A,0@@A#,mm |7!v9'zm @EŌ'7v3Yƣ|o4;9 ghORã~9 }L7FX 0ՙ?)s1ˠXXXB㎣$t浆dyӖ1@a+1Gmƞma6b?,@PٌmcLZ7,0JU+r((((((o hO5jEQEQEQEQYZ?'h(((((((()J9ߓCjEQEQEQEQEQO QEQEQEQEQEQEQEQEQEQESU((((((((((++V_VQEQEQEQEOCyV(((((((((ZG?6QEQEQEQEUA]$گQEQEQEQEQEQEQEQEQEQEU;5\((((((((((o hO5jEQEQEQEQYZ?'h(((((((()J9ߓCjEQEQEQEQEQO QEQEQEQEQEQEQEQEQEQI\ߊ:n״$2>>FWI]L[kZ|31ZTQEQEQEQEQEQEQEQEQEQEejjբ((((nmx^I\*'\ީɨh3y7Q>7Q>7Q>7Q>7Q>7Q>7-V9.#ayr d斊(((nbbDpw d ڣ{h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~h{~k]Ybq0ՌXAЂGZkayZ"۫1$ƴGߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚ?Gߚd6<^GjYݡ8P:4QEQEQE20ʩ#]!$V*ߨ#j4j4j4j4j4j4j4j5CPK=>I&b"ڣ|/^Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7Q>7惪.渏BΑ|l[ɲ ׮F?gһTԒ5}⪌ ????????6h8]:`EY((((\Y}_AQEQIp[Ak$0I I'$ƥ((((  H6QHT\ II?KEQEV}Zo[UZ(((A"^hREQEQEQERQKEQEQEQEQY"oRY?Z4QEQEQEI__Q%jQEQEQEQEQEQERb((|7 ɿJdj((((*KEQEQEQEQEQEQEQEQEU i[U(((ڇ{5EQEQEQEQEQEQEQEQEQY"oRY?Z4QEQEQE__>JӢ((((((((( 2oҙ+Z((((s!+/5pREQEQEQEQEQEQEQEQEBBZgv~(((A"^hEQEQEQEQEQEQEQEQEVo[ԿO֍-QEQEQEfxA袊((((((((+' ?J֢((((\J \QEQEQEQEQEQEQEQEQEP]E_(((Ƚ׻#Z4QEQEQEQEQEQEQEQEQE//A5KEQEQEQYlu:(((((((((&)((((W?W-Q\W֞=+}C~MGM kd ix[v*-KB6rb}?OT4^^]fmE r]A;pz?zsx:i-"[K τC6zv. '4_S71s[TdQY>$`Lo?Gi%ѴSl>~vb4,xTW*AI4t\7+ҺEun:(_KLگEQEQEVw?^?(((((((((zzѥ(((6OVQEQEQEQEQEQEQEQEQEdoAZQEQEQEQEU+ Y}_A( ğXO, mJ^2>KiIII5 u<1e=?>b~.xmjWk<yq!<3[juR 2 VH]eVT5!yᶚ_iB<ƨ,_bW{^mKv8QXg49eIu# 8 e$=,mswqe&wRHﭵd-@>]n9vx.ǡ}Dn9Dldz`>!<S1ݠL9W/Ϡ3]g/_P[; J;swvmǶ3޽%c@0` <;v<3wSkր1 b1o4OPMrgƩ`nMͿ|AyO;gUx܈\\`d]<5j46Q[g]!q6uuzniC!W%v7u;seЬÉmu_:o97ڹV9NsQEBBZgv~(((A"^hEQEQEQEQEQEQEQEQEVo[ԿO֍-QEQEQEfxA袊((((((((+' ?J֢((((\J \QEp6!񶁮:$XE04cj.Cne@־"񥞐lV?)nVddy2VQEQEQEQEJBV_Wjॢ)1Fb08b 0(0)iQF( (QFQEBBZgv~(((A"^hEQERQKERRRE&ih((+7_-_'kF(((dy2VQEQEQEQEJBV_Wjॢ((Ic49O? Q{f&T#VۖcRkW:rP%ʭH,#'ҩ_W^1D-[ yb`WE++I֦ԓU)Ie[ҵTM4S6- y~Uuմ>)aXmXn%z*Bv r;4fA((}!-3?jEQEQEQY {PwFh(>#^io,$~u5;Xt ?QIwm̫(–Pp?:SXݽ V(v}&ͫI|ql~bcG=?X om)ll *u>o1^tpU@ҭwmͼ,3(xCz\濩jhF^aO5+^үE 1TGZ+-(Q5OBA;%TyOcL.״kM8^_ֺp3Xz3_}Z;Ll*qY~nu[uR/U6|%cvַ̭1mА6AK[0rzzv5rKinn$X p@'𤴻U T4r/F(|E"ޥ^&ih((+3 .|Eaz[mzJwn#c:1מiZě kK,o폟N/iN5}~|Vthz:vŰ&TsЌc:sknn&HaE;U/]X3);F_jǏֳu4Y}oC!رg=+-c'Uܒ!ʰ%u;-!-4'[FV IdtF(*pq[hza[Rݬ TcԌPO \rp6i $񰞀N8#Aɤ,dS9AgSׅZݢr'\}FU..5(Żo!`>[?ҩ躅4k߬ C.Ix^GW.zl%Wͼ 7zfou{Fe`'?ׯzÚɵ5{{Jf\&jZ˹cvˑgh{G4Bi:7h +G^wڼ UI=ݵ C50팚|9ھߣjW|S,r?&,ס&;-.;xj6cG©crjcY-W6͜KeN8UG3j> Sj7eJ1cbl[^2 ǃ4 eΥ!9azG_yi% nenTd_EiVR#%=+^ҿaj&G.I`c:UjЬn %`A#n+0Mu|6.\Kqwn![d3Ѷ׌Ff4?a=r\Gi39 2alKwƚOR }2BeN~n_|"J8`}xKFPl-A^?zi\X\ df#REQEQT/%gmW袊((+;/j֍QEQ\?&sO?]bk8*ř` ':mRuMIMZ6pcuTt?!4E5;,A6>OLmrjOVV} xu LȻ@< @==E鶖?tWJ-cT|8 ?*.it#a!ߩ z-7z# 0͊ݦ'Y& g[[,P)T;0~ғZ=ğ6E 0$w#'qXwğj1am%KXK$b~c9XOzxY[I`xu ]D0(/pv^pOiqMX۫8fӧIQ\+ Zo$}e$s`.էkbI|*A,{>X(u#EI<ͼ7WZ-ܲf$T|c־6i;my"*8⛢j0 ,|/Lٵn/Z(KgpzU2fK ɰ5Oרci lX}  (+7_-_'kF(((M^I Հ8^gowogYpV1݃4-L:me =9.-`* [{QB$(Dm `) m?:IuqN정EngƳ=/Ğ?l `t*' [WTeNJ~"hnXM>y1!0ĨH.#SƾDAAQ&?j&et+]}Pӯ&cMX }qʞ8.ږi-Y?_xVE[ـO.܁Fzt⿄|\ԾѣG~0FМw5~kWѿо6Ileюlj]B8iF;]7L)nkkH!" #S=:oK$-Hc:ƻD3`;WEdoAZQEQEQEQEU+ Y}_A(([^jԴ>o*6'}235_Qt} M%嶭KKGl (9a\dmq> uj"腏g25rgc]gs/$M\\~fnYR 9xuo#yjj-.ZVs{`fSMIuhsXG ,a 3= m-oNt'GW6 +(8#5GO/o|r[(ki~/N%Vď93ԂOOztZOMGo$@\zF߷uL{/~LZ9RHEt)%?hztugN8O>xzSm5=Cyrc9?iEQEQT/%gmW袊((+;/j֍QEQX~2'/{y)nB0{U OӤeweT ʮJtYHox[–=, !2G3~u;%X}VKIR62S{>𯄦/uZjΠuMgkm[Ƕ> 1f9.9HymzaZ6ϊ4{+iἎLG|Kk^ vZ~I)hnb';@yFjGĺtkIa#ZhWil$Y|%_xSPU[Kcрo!LD&7DaVX-#<}O:3\Qi`e̦UQlOP:c'g^o-K]*d##K_ 2\x_Uƕq#IW;=n6ÿ=~O7MfBhߒ3Aݶ&a b7^X`688ɭ?bT\ y!3 ~;q\;{ me [t\Jon0A ((|E"ޥ^&ih((+3 .|E%r~↞#owfFOl|!ik}B%*x>Z[_ Aĭnmy89(g'enc Mug3"Qۮz֟7q]hsAJӢLQEQ(QA98U'FӴKy`3M"f˷S>JQQFcxz7>5{Cp-X`HɌ # VEmoFDQة)(b )h|7 ɿJdj((((*KEpD9΅Yݽb)۟n*+P|-ntp'{Ĥ8=z=Zm.ᾳݷ~b;{pqֵ3ڰ O wD؄bKHxLњ(5?C{)%kجU a'k_PEOa%O7vΟcFAϰ$ SYKۤ|F^>ԴQT/%gmW袊((+;/j֍RU o֖>1==fP牭~ۥZQCŹ'տ4ϱkvVSUjxR۠% 5cCTx3K;}<n(OM񧆵;Yk3NNՍfc3(+)u7xP9vsraI$ ҟEtZ4= 5MVRI@b=vj햡g[-͍7P7I!pY^/좺'SL2cY_[ZZ bcBF;rk^+h*d$ ʗ~Xɮ%fuO@}NUPy#pQUm;Z>%znktR)U#& zA:} kVO{ۘmLng9&3Wgq7qqVuMsK ꚅf.`:“L4fٮ4B%}?|YZmX/?,|qA犇ER1H1eU^?tqo:ԗ3ͭV*Pg\`:fxJPKU+ Q IS5 F_@Ӯl|[kur#ʹ+Qմ":7 POSQi>"gҵ+k͟|E %~`. ީgJPc,2b@$ZBiZ/Q~5E//A5KEQEQEQYlu:(() ax_e׬b2}:~5%m *Nݜc$w7^1b<p>k726v^T@% ʧgw:u_o1IJʓoaBPԒJIYꈲn?Hbi4FWy2+GTt@[ַx=I|fsaSO>}ڒ^ӯEcpciT${^;\L >UA͜tǏ\_}>*o~nwm#,d$`⺫]:CoY"gBKmn2Y#qQ~.r-ufs,QzdvkNnm'%+b8((|7 ɿJdj((((*KEy56SJٴČfی~5:|YOi~,sb$ 񟧡QTuxkJ'E%w"Ɗ͌p]zׄ 蚾&ľlFx9_ uDiѕ.TzՋv~2IpN[rHFs8覮kĭ#Cm:#|b|F ojҼMyARi-W.rTx\Ҭ<=k]xW]rg[;b,7 h+#F ߅%2# { ҿcҚͯ,[Ɇ۴loN?u[Y@Պ>X_u [hpS$JdtRIU|/mK\;Ij6WQe OΑ#ZƷ)prxjy]n;O8!7 n݌7׋< kj!վm+̪;rI99O.o]oY#e'ؐ%>$sU&{-K"9 ؛hWVz ܱYF:' uOL*..cPDvHˆe^7P+g yM).o. I $<=0jxFޟ-KPxA{iqrehIԾ mKWgZjz}ސ$[P+%Td "O^?ƕN 7UigWIvoc/~'hNa[fs ͸g~&e` ~-[{Va: ?3${t{/QxsNoY,Kyg!<+lbI3]|P,fg 1^Q[xW-\6Nq\!fVi\n$`zq[.>ӣxTMq6usx̒^~_lkͬ_i'<ݎq٩h?趫QEQEQEkF)sּ^gW!- JS;r3{{'uJ]eiźc! UOm)s5ڙ's}''q)zWd})HGVo!%mNA|1q}R+ 5f;<>-E s…_3]Wv A'v{:߈s/ _gRq[,R7apx*go/~%!Kre0bHTktv]k,ڰq\}p{{ |1VOiQdItw@Kn#=O$} RKiwf,KBy6>|DwCZX('csMxy>նO +Fm`kGtH}_Z2MJ7>vCEzDcP* #9&x/ooO-HѠR1qkOĖk|=ߨ9/ rʍþ1] t{cMbY]nUc1qkX~ 'LHq׷Mó7-{Knz袊((|7 ɿJdj((((*KHzW a_KS{9M-cKf>t U\7pZ,\D%blB/Γiơ]ynϴL\~5 wZ' 2:>LP.F[%^|;}{Igjїy;qMGjzHJFjuZxO-RͼUa*KzF6i* 6mWis1-7;S[&Bq!`y#>lV6?j [E/m?{g}BBU)ofv0t|f[w-2{-CHѱ_آ,G392Ycj*mWNƇGk3ZCc2I8BQ'u:gM2)({g5k-KQo. 'ǧ/i5WI 8~t+(8݁LhKs÷ 7ʛeeFN?\U{?ڇ3MH^WqY\s!ϵhxڞt/š0{B[CӏϿqa[s?'Hdh_1:dEP]E_(((Ƚ׻#Z4QHzW |QB#w615 yR:qz u=zYRMeHJ8`0 O-Fе].M'qIqI{<xcDc-.ɘwt$ҷm6t9 rI\Y;N2!\|9] ?(_nL4Yi,.,dO۫ ;Tޕu;WxB)Z 켴oV~k~ӴVL7:WHwhQ jr/nTH|Ba9:Uk_ LjlذX?ܒ08vN񦿭,- ܻw+xvF_tiݿvzctQY"oRY?Z4QEQEQE__>JӢ((kzlz΋yJw ̽Wp#5z/ 2 u=(#|H B&cU,v ytfr;gvh?C'thn/f}q_|,My ^D&8~ x[ЛWM曪%n\#ƽW~BxO2xOhh$3ep *m'牡,丳FK;Ko&nK 4_Ki}I_uH[!0w5xw~:6:rd[M| S 3 8M+ԴFTYZE< {zgֱd_/~[Q46X񄍁;^Un·:Οi7eid]Ȥ`>犡Kz}.Զ%i+IGFv~x|;/]'/˽>va< ˜ Ϡ.y]GujRDʣetQEQEQY>dy2VQEQEQEQEJBV_Wjॢ(((+Լ!k^&SּuD*Q'u?,?7 #ֶv"suQEQEQEBBZgv~(((A"^hEQEQ\:Z"# F?oZ(jMMPy̏{.G*AZ$vjFs>((kXOa{mp$MwL}}Voddx=QEQEfEKdMhEQEQEVg'~]+N(((((((((|7 ɿJdj((((*KEQEQEVayḡγY啱Ѫ MX״Xu+F[1kZ((((?趫QEQEQEkF(((((((((|E"ޥ^&ih((+3 .|EQEQEQEQEQEQEQEQEQY>dy2VQEQEQEQEJBV_Wjॢ((B3^Wx}sjCqgt*v9̜oW^^2XG$vRf,`g _]x ޡuaڥݼ/I`\ V~5k#jq"4NTĥzҭxúcxT=BAx!CO I<6bEľ8c{-OʎgsuG5xk_ 4%󒲴b2Quj\[+Ep>sE|4h_2ܴRB~mqRxK[97tך,>Vq]ic JY9=IMOEQEQEU i[U(((ڇ{5EQEQEQEQEQEQEQEQEQY"oRY?Z4QEQEQE__>JӢ((((((((( 2oҙ+Z((((s!+/5pREQEQEs.|^Ԏ}ye[COku? ~5oZu|c5՜\yc*_'r=j+=o^"[ 1!Yd# !['XY<dOҿoFHI[PkW-օ/-fK(-W`7F3ֵ1cÛ %Wx| & WԼ]#`Yf,p|8 X,{? x ,n$m>Y#t`T񶧧x7MwpʶZ@$dK`]5qxfxxկ5I亼9 `~>MOx%Zodi[)"~(((?趫QEQEQEkF(((((((((|E"ޥ^&ih((+3 .|EQEQEQEQEQEQEQEQEQY>dy2VQEQEQEQEJBV_Wjॢ(((LRIT?[EӼ+vvFq߭E'@Ҽ?,^fݻ:'u}`Vib(j8|9Lݛ_2Fޢ(((?趫QEQEQEkF(((((((((|E"ޥ^&ih((+3 .|EQEQEQEQEQEQEQEQEQY>dy2VQEQEQEQEJBV_Wjॢ((((((((_KLگEQEQEVw?^?(((((((((zzѥ(((6OVQEQEQEQEQEQEQEQEQEdoAZQEQEQEQEU+ Y}_A(((((((((?趫QEQEQEkF(((((((((|E"ޥ^&ih((+3 .|EQEQEQEQEQEQEQEQEQY>dy2VQEQEQEQEJBV_Wjॢ((((((((*-QEQEQEgxECѢ(((((((((ȷ׬ Z(((d˯%iEQEQEQEQEQEQEQEQEVO7LEQEQEQEQEgMO4e`57[??a?Ə;4i_NvmWhӰoG[??a?Ə;4i_NvmWhӰoG[??a?Ə;4i_NvmWhӰoG[??a?Ə;4i_NvmWhӰoG[??a?Ə;4i_wvE+ \ޕKEQEQEU]NկD`4LT;c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?Qg?c}?U{m^ċ9ݏ¯EQEQEQEQMdWe =iD??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??GOQC<y$ED??JF+(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((+ٜ$$If!vh55E%#v#vE%:V l40*55E%af4yt&u$$If!vh55j55q5#v#vj#v#vq#v:V l40*55j55q5af4$$If!vh55j55q5#v#vj#v#vq#v:V l40*55j55q5af4$$If!vh55j55q5#v#vj#v#vq#v:V l40*55j55q5af4ytEZ$$If!vh5*#v*:V l4  &0*,5*af4p &ytEZ$$If!vh55j55q5#v#vj#v#vq#v:V l0*55j55q5aytEZ$$If!vh5*#v*:V l4  &0*,5*af4p &$$If!vh5*#v*:V l40*,5*af4$$If!vh55j55q5#v#vj#v#vq#v:V l0*55j55q5a$$If!vh55j55q5#v#vj#v#vq#v:V l 0*55j55q5agvDd'@|  C JA2CAP community management"`Ru-Ԅ8d^кsudFku-Ԅ8d^кJFIFC    #%$""!&+7/&)4)!"0A149;>>>%.DIC;C  ;("(;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;Z4" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?j( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ((h((((((((((((((((((((((((((()(h((((((((((((((((((((9(((((((((((((((((5y)F{k^`ۏ8^WR~d$%A?έ  $ֿ[/VrC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QErC'?h  $QEpZ/M+N&KAFVCEws^:fa/ҊZ( ( ( ( ( ~&^iԮndCIbb+?}O?|t? O/ O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP/,_2xG O=uP / /ZoOyֶrNB7*2>=M:G;Vf=n?[V ? TQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEO趭n?[Pȷל_z_y Ѡ(((((( w{[[; 2#דE߹K=Bd3+?\?-މkp":䌂##OxKM4qhwedfݖu'\άӓKDuƌoYΡeg$Q]vƲぞGS<m$nfc5~*k<{ Q$6ހ8ko&^6d_z,zU{o#6IiYjWpܢhdL$jY*$^w8%ԅ^&<pUI>33m0ϴ8=>K)yʞ,0RH p<ի[(Lw1[7W?S\nCk6.In~`3k7 h#k_IDR؞:ԜSK@T'V}.`\$ szm>uWgp˟L iuİ;4?޼ž ###9{W[ >Nfu}e>Y T$c Rg'kU0ζ571Nhh?nϴ.sz{˯ڴ6\6a={Ȭ |qg_Oj ׺egAp ڥڢ^JOAsKY>Z "'`:8ڵ;RVv ((((((g_ 1eQ\׎bG-t(((((M?a\&((CҀ μ<|g&ei'd뎕ZدujK=1Qۆ 'e| mcZz=X,_!3n28ڰU'-R*pO[_f+xYX@YԓLγ0J dW'Qh5Υ0(8;A͊Ψ))|1q1uc۱8 @R tڧ-Ĩ^w/}iZ=+q B\aSUbm\ч:-wfu!ʢ +p!8 ,A>geyʩxVՃmh8 .@OM5kx4Eimeiq 9nf5'-RTvO_P죻cQ$uGKqgi,Q\ $.xרѿk_?/T7qQ_+bosk5[6\d~j^~.]8OLΥ>N_5rK|˘QL|SEk*U*OCBmF6gp +>kgh帔B)LI GThsjXy*g\.nX(ӏ'<]=ݽ\\OPɑ*^5l>i\Q*M+%SXPvwl-ɞ?!Wyp=1TG[)?Ƹ_ r# M:?52hm.͹G3zRMC+X%Icat`AO+c\F .3~ji 9X,hn`=5j^;0+Ui˪xlٮAJ9.om,Z‚&:ds&epYY4R1c񭟈SC74]>xAX`\($ 1:W|FV\7}zv;mNCJ*׃V_#GS]Սq۶dgO|{h+jrzPQEhfQEbD}{-CLUpOV?G׿qڴ4YEZ(((((((((((((((((Oȏ6Em'?G׿qڀ-x{E/hw[/VQEQEQEQEQEQEyϏ.5d9}&Am v1!ҠncֱkXtȾY29݁kMtvKZj[_ :vSjrʘAcp1Z%gSmw E01#?zNzR◰ܞXTV{ .=ceo,mvǷ$ d\n̻HOƽbЋ7tJC>6;mt۽ ͼ$5x^ɣ1Kl ]B@?*;hֺ$ڿbr$89ܼ=qFўQI0\zs^i+dy$i7cS;w8R,TQ''((((((g_ 1eQ\׎bG-t(((((M?a\&((=)h:KxRYDic(FAjgW#M)mȎne5!y ܑJRi=Z-][[G]x7i|Qi+A#sW— VTxXue`9;I)5[@KæޥTI-qMjF,8%yc8zN6$YPU*rm=XJ)8쭹\OzVsK߶!Q,HV#G9ҽ'o^,BI>]mk<ĺZ?]J9^ J #eGKuN"P$STiLQJQ[s˴ U]"eY+"x;rpTX^x+S]]:1p˷$'Izn(:]$-Mi;⊗AA'I֭~<hu1Z{]}m'oGPW p Tw#uak<AG'ҷWкcRڿ3&-n"q4KnaG Z-~"ŧ]kA"ef=q:L )ʛr拰U(]%e.Ůeȥ`tiּi^;@\rAQ^7XXVg]sAZNq:uFH$Mwدo5ˣw] SVKGӮWqݕ { OsjM`j?%7Rӿ-?ƀ4It G$ O :+3]zw .A;hN@ޝi4KoNӢ?%?7Zӿ-?ƀ4It G$ O :+3]zw .A;hN@ޝi4KoNӢ?%?7Zӿ-?ƀ4It G$ O :+3]zw .A;hN@ޝi4KoNӢ?%?7Zӿ-?ƀ4It G$ O :+3]zw .A;hN@ޝi4KoNӢ?%?7Zӿ-?ƀ4It G$ O :+3]zw .A;hN@ޝi4KoNƟ# mZg"DQkH|ꈗ(K`Mt:_l"-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEV'?G׿qڶƟ# m@t?bmN_O#g,JqW ZOGk-+F1? ZOG_+n/¿-i?Q_Z ?( еG!~kI(¶ _B+B֓QW' F+RtӭZ(1~KB>KIn4ˏ3mDRHє:n G_Z ? еV-nZ<]b5 Zs4ӬQ7|#@_(/¿-i?R+thw0n_@F"kjwwHQwg?_Z ? еR^O:Xi9fKJsjw"31 J䕽FI?1 еG!~kI(¨|A5(4/umZ1dsǯJ..!yqBEP2O@?W' ? ZOG'ƤM~HVGl.Yv^}rEW/¿-i?Q_Z ?Oq傎>POB+B֓QW' _(e# >NJIҴ>;H݌8+_Z ? еY?O?_'WY Kl:gJ/¿-i?Q_Z ?xk:_vHc Tui:%wvډx.Y*t4s еG!~kI(²>&hZGkop'؟fIz^Pg2y3\޽(!~kI(B+B֓QX5"OgS`ڹ:N Fҵ"h d[{Vr= W' ? ZOGGOCPO2\\C@H}J]ƓQ4ĻH-Oq\ X/¿-i?Q_Z ??EY$,jdT 8Eitgwii V^(OB+B֓QW' C񦓯^Em/`he> еG!~kI(¶ OB+B֓QW' ۢ1? ZOG_+n[M.l4]>qف,Ȍr2kk_ 1eQ@ EPEPEPEPEP\wŀmPZv5Wo5 ZOG_Z ?CҀ1 ZOG_(mhl}w0=h']n\&K˫q Xp ^}r,*ent +RRT Ub q=Nk׾!אLXr>R`MGImso.i٪Dž|/g5ѶѪ;7Nq׵_~SM_Ci}ڛEoy hxE3L< Ia?j-WW:iڲ.!gAÞ=b_[:Hm03GZ~O_e2pIʐ=Pf?@ "|<ڜ?dd7q@U̥=: sր4k'uEg% ҳ5;:#ƒ^3늂:+_^ KO&~N[]-sցqFhƝ\KK60\ts>7q *FNRCr} mVkF \;y=003|[|3{bs<{f$|mervas4Gwm~ehVT\"+wu+μu5ΟRM^qi ]T8 rOv/ M=4S7'! JeLyU<`#ݯ_e3K,PN\wgN9$5;Q$J$ &YrWvFZ} P=}PҢ"gnv򔍐q[Շ95{4QERf ( ((JZ( ( ( ( )(-Q@Q@Q@4^mj?g\AO趭 3AV?@((((((((((((((((+Ɵ# m[uO趠 ^oK8Z5@@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ώbG-t3MŗZE-Q@Q@Q@Q@Q@qA¸M?aIK^aXArP_-|8b~!h'>G5-P?^ޏ^i:Un[ȧ* q@5[3 T9pU!_<GTn93i7sG4dKWWG$ڍ%Ǜ &Dn~8 P6|O1!6O.Igs|TOHe}F,V80^ho/Lq7%IJ)Y<"X4@$˴O]`cv7ھ)k{Pə VPO>wseT{@ZPm]xP}We5syR@ZOF[XyoI+FåEj4_iw; Gp /7ejveY#GS=+nTdݔwy*ci} WyNt9pJ@b$Ê<>{%MAd$wӿKg{!qD4!Rp qY>$Ujwsk$ Gһ|:$o3&limw|ǂ2O9d_M Λ.Hd@vSh6/n541a*jsZH-6AxSsè_J@~Z 5V606N~gg{NEʳA`'m9@G/4,qƥݰI'/Śvniu:g1 $84 5;e';j/0hZwdc0e\ ^L KžCb`#hA>rMgLJ}BlvI|3xWVAfPN,}9wN%QiY_6?2/1]G9FѼG7}'R^>VSVK{oe m'l<#5eEh++&X371# p^+X1ٳM$Χ31`l1PmIVwgYMI0 ycqEPE`_|=CshW̲L#h ݔR p@;[:o_cfm^Q\fexMF:((((2Ս+GgLs_J((((4 Y宔W5i]((((((?}O?|uW_I>:+7\KD*32Fx#5X.񅇃4د.fY*-YO9#)4^ᾲѣY Sbj4_u].SIKaA>9?wQE!@o +q[q%YLRY'j lᶅXr\9'5: ;~?G֮Mͧ^v3l#Vz-|.hG a( @,׍u&gxvt6 eBA#P+OW#o 2*[!lA;Kdfߌeլ4k,s1qb}017KPPHcLW8y7h+Mcr EB9z5xHj: ݦ;&CHl_:]Ɵ.kcN%.9<iwq\iͳ1YLi1$*;xb[i'2eY]c >GojJt<7=>\8YZ% / Sm1' rhM"=Mu$UKo-۶eO/ Iy6I,Y{Z0v1jvVpé3Wm K`ȼY&^P֢2Vd+ d"E|4IMm$ 6䍁 1ӜʔivcVmTB> s.N|ۂSe E^EK0DLJd P8W~hɩ\5^ȉ<̧$PM/~J 8UM8xRдo-x"B7`xn.<=_(Kp5-Dg+xKCO؉mEp=7!),m.-bP(;dP}zޫڬ+u-!!*(YNO`zĺbд2QKe)xpBIhS>C: :emsJS?migӬsL1$#K#MKcqRMyCZ#tnIK)h@|u V唷XwokZXC܎WpVֲZBA*xPЃX_|;^厚Lu͜c#$\NcѴhkk]l0ȭ!ǚX0Ac;(-bJX-ƛ|s:&4:uI@3_rH8 ԗِ1ieo)ta#YO ZxMs,Kgd #ßZm}=+Z zlڞ 8}g!s29'鵯 Ku,R;8*A8N-:{K_X+0;a8\)k] x~jv[^Y 0*n$I#UMkKD1hn d۸8688@Z:ӼWF8t3'9Br*`ۏա*'+?Ɵ# mZg"-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEV'?G׿qڶƟ# m@="ޗ^q=f/xvVn-a.7E_ň;-+ Ohiz}tQ9P,y~.׆B͂Wi}3^fQyq/E#0Ye^(GPi1I#$1߆RV_GqmL~Vc8aԞz^.k/"w76 pqTwY3DzM|]UPyFRyEb|MYV²[#HcǼRܑ6ִ_ZOeww!/iqO!NYrFqgk/.,};[7d g99_Z뺜rjz g\ O$<.--dm/oT;[In½×rh!B ;9\x#ϥh-K .rT}Ry>7Њ|/YJ%daIf82O+ ]=XhM11G"^c\mi\%_Z[r;@'kky᷹IeR~Reg?7™u h]LF7fSMw9?#@Hyk{D3X9ޟ5[mBv7q ݒ}@^}{V'-Z!M6"*<xCJј4fpv19AhoiА~/%m nO%ukye%8##9t mkk%Α*yk~ ּqcLǙsP[s:p : ׍xOW4jj r٬2 n ,88״<{זÏBN𷈭fx`;O;p2=(6ԼIoh}SP}De Q5 |3mGP\"^%́Nvddu'ScsK>o!/Jd_?t gϗG5:FVlim a s rI=p+>k׀n/{H1fpIpqRW~߇fYY7s\.<#n"E|Yր:j( ( ( (93MŗZEs^:fa/ҊZ( ( ( ( ( +7ރG]qA¼Vjln/%[vKxBqlעQ@7 ~#Αuu0C/$H⾐))h?d J.uEđ0pG*y55Cmm>Um7 7lrW'qo^͏5˸ia2xKWB=?zIYtI=;:ޗc6Zֿ~J~qLy„<5kUCtlR%}9$[Y2`u3]ZCrʳF(njjjSa&ZKKmon"Q"9!7}Np:sWڏ"bu+7qK5;"#}LؕmAEu^#m|O\K;w$X0 ;V84FK+˛Ofovqs赕~r[Eɀ'}5k6iG"˦ȉ)`6t6{hΏi >h^-QKS)%H gi:mާy =\ZgĈYLgh=յc]Z?eo"@nJc$hUŇ@ g ;YSsh7eVi%D ' ,`a+Hl,]ƱF?!Y1ZIn/n0@b085@gu/]o,v eB˶6 8'W-%u-N]/8̟c1<0WǜJ(,Vᆑmuk+s=p0Nv)T·csw&KQӵ{hJQʫFqN|eo^l[wrI;$(gero,-ۙY 3.׏ ;S@{oS r1O6ᄎ;@Cտlny3`2O\f(8&o9_\5չM 0y ~i.%-[R}.YHdY,aZ cBY8axwPcjzw%*}fB˶"ipx8KK;6m׮fBЄ ں(((Ɵ# mZg"i">`ۏա*'(Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@bxD}{-n`ۏk-* >X)g$;U9-+$W?9(t1W*ɂY?ZyY<N$h.2Y$d<;' `_ Cp$QpY}#X>-^yiq ,0dvf,q^u&xmZZ4r*1'8{WS\E^/ǝD n^8kBW@W'$`x"-7+i9xa rB<`tC3CA>j=NZ=?^! i~!ӡ̶Lr<=b/t=kOU 4J~꺿R:3G-8Yf6nk;!LJX.279,c>3^G/57HOx2J#`Hq֩Mc!uM\옹Q}G$LJS΅ayb3wo0YCc=ex:mE]y3Őor#zMD2xFrGs?{4RM Y8 re yw~*vV:t~] $I^)/h|Ga}oX^{Ih^w$ 3&=WvwsxSEK;Qԓ_;k^|=bS {' A :⺿e6e RXgd_Fqϩ])|2`EsZ'jFgH n:A\/  7VqBl﷓~ uSNb1>単˶B>\²ZTY?fP|)jkY2;X):y%s&O4M7ۥt9O\@2{g!D^jy*mO]׾FZjl&sBd{Z>N i.?xL;3J̅cpy5.GVc)#&@񺺞 ׌@$ss-U8d| j"2hִBDHzOGzD.`3e%7 ߕs[zHAMXc H|w-P{bdRGNxZeY+xD!yx݋M@[v9۞q1 CS}ZF&1 R3"D[1!1f,|1c/^#mm$乊5 HpOl[5Lx)Jq '&C4_x}F$UX>efԝI4$X Fph%bcu6΀1Շ'wHHP^:z}_P}.Um!5+[vTL07ne)ЊҴXѴ-N'vʈ Ch(((((g_ 1eQ\׎bG-t(((((M?a\&lj_ jHaKʼnWʔsw5xiop'<38V\cp@]ϊ>,|ai׷=$QnH{yo> VdI}nl8ԨKI@[L`a}R?3v~P,+VF=r=`co1s;Ac?iJ񠵷:Trmg9$!C?$k[ MxRW2l\t1i 5,K__Y}{iiζ&Y&Rp01g/uk&S)cڲ"ZlxQGe ǹ {oCNr[yNIPC.x9gx};Ğ*⹀ 9v_${jOs/ iZΞ\,o&"8?NG"|1ቼ?s\jj3R$A`8; qݤ)𝽭N;PE0GpHo xIҭ.l5g ɒ% Y# Fq޹ K{e|u}j[A-4$h:o I9+Ӽ5x޵.uFTɊ[]Ksӊ4Ax!<-uqRzUO KZ֩֐V[#cbĀ\J}7u)on$mۋF=1Ue]KZ)fD2'*`Fs\Sxf`ۏա*'+?Ɵ# mZg"-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEV'?G׿qڶƟ# m@="ޗ^q!cxVG_ 46R\$uȷל__ ]j=G6 d@@T j u=OCfZ\u. .]&ФּKeǿw#K6d}kVWudvu [B SﴜPSZ 3P#fF.bKKf Gs<}{Yൄ'QA@kfojٰ͵hƏ Gt*׈-[TZ5[HQi2,;] xap1[k:e휗d)02r`sRICb/廁-  *zF>=isojVR]{xќ,gv:$O;X",c*pFFA4mm7W @=I++H&u_NoHU yc(Uu}wV􅦰Ku,TqHa[|>ưӥԾb\-ʰKɞֺi 9u[#zi 9S_v\}B"vcR}2H nI5XY @7?Z _u_o̍~[z薗 $~jV-q`=3V]4gv 2I8P[h:."yw aT;(87{=?BtFPXo.[$NUyr9=x/躝.&8.QCM~Ρe=m٭`e2yx,%όNnݗ;dHi? M冈mu]bFP׿q]0RZfDړzFr0'a]>4V @Yy#4h_u#۬ uItO'/^8zo%Msf Ȕd3)mÂsی[ҵ]ڕd8]xC%aoqfD~zpNhݬ֒\Ʋ:FFyC}mmq~4.foimmDF(D#w=IJ8gᵕ|+axP[J,FI,22Ib}aW{mCDݵJn>Q@~ǮMnH*;?sw 6]k>\.1"Lv鶺q^$"OCƹ<\i^1Fǖ`[8v`3g wP!ռ?ym:C;u!Ր E;u ZfkpխT&}n'a>[gb agv8[TP)}qqa=Mu]8U6`x`@3׮]Bx=s_VAoBrǦsMQ@Q@Q@Q@Q@ώbG-t3MŗZE-Q@Q@Q@Q@Q@qA¸M?aEPEPIKI@?7-`ly|<]kZ^U7ȲKVVA#q84.4\:ƙxb0;VUCd /8 ;jo5x[;E}6@=ϊt[?$CKGeFq;.O"񖅨2>h9=GqkkiO0[9Y6硭;cN񾕥kKeckDzAj-ukKfG8H_O<Vx{VP 4^)"au 5\O)HuX'TNXA$9WCAҢ9o.5g| U zr(__-ֿfm%2RN2]M'BJ,XXUcgcJ"_WįdMM*<If\~U= q@fi4˥qB@ @*}W CѮmt"5U&g6y*8#[I-Z D#*$oQ` &崗1XIJCw >uSӞ ҹ!uiqws#I$OQoc9hzm!tt˘cD,+Z-=^o!3s;H(8* Oz+.]xA<^-į R3뎀cZռQhwP_lyd`;@N8<㱭zu z~gqemEaB*rzmA B\QI,-JA\n3P \걵ۄeI4E5=#Ih BGQ]g`/Kj /((2N([hw+k{2QAՈ@He;įi{}vZA0 mT*9$PfXmsخRIolg^As:eCZ~:ƚ׉x:/yi~*NP;A|TùAcYWzsZzotmZHyB$0{s\g{K7{"}߀7m;U=^Hn>#jdUGʫ+c^q@6O뺏~ϐ'(%}9s"/"Ɗ+` ry'$(Ɵ# mZg"i">`ۏա*'(Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@bxD}{-n`ۏk-+o 597젲fTEtoK8LmmGX۽ 02ꣵr:c{@Ю-M. 9o#SMrԞ }{./f8h-㟧_𽮾v.^ق# ޫi^[M]5ST1-UHT؊ ?Կ)t5Y[_bKkJ7 _oL}9hƌ7B bg`˹Xխw°kWvWvjԀO0 ^> 棦Xi; v-J1rTcF~Ԋ}{G&siu((Ke, z8Nm^P5IQU*Zu4?9']^[FXykc9;'>ht^_0G}e_L<}c:mwu]WRiZmR_2Q!cj` Uqk3\5ֽ.veb2{=ZF[>n灠H?q'<殭oPV']2/A( s)#Һox~Əy,pTB@a dxD]j$lMjU`{6> t;Ivt1~tFTs2:dqOz|q>CL;7E ,26 8\.ukLחv d-Zkɋf…U00;u~ .4A .i) ؂(dMO[ŶH%~0\2$қ^]w}! Hd :ºt,mCUe`RL.dǿ~hl!mB]R3ٜ'P1@oTGI|`"ƢC p}I'8t]VWXH6*8k*—^}7Oֵ۹T@@Q@,G޽NI.qwC ,l6;4KgcXY<7i -nAA"n\+)t}KDTI+c.iDNAe]moGK2i*ĊFN3pG.FkH6 |e&>Wg3oдGZO O({U(o[_-''h ?vs:J+W I4kx>>]Β-e;"B편5jۤm 0rqqɵv%buU5 ^/2%(8eM?ל[Mm*o+"?6 -.d\qn3,teu8wf=z( ( CҖ1n|'᧽}NF&G\bO~5śAM Bm19'RktXhh}/^Oo< i*3RO%̀#(O*(1TѼk9m-`xH_(rnn 88[I<JȠAidKdXJOk>4:φΤ-wjeJ,[wdw=oj~ 5;+Si:",b@YrAOQPp,-?>'7yݷ=qqUt%VV̌mn0_xƚNae{iWVg-wQ1p JOX5{wYZC3 $ ?uvg4S[7#b8"5+=4^J%p[9~i φ|Grbm^7E7^'K񷈧# i˗qPv%i:u|=ekYG,UT>?v:Wcu?Gx(M'WyxgD֧I=*Xj`:>kR> wfZt* #8t;ehP,n+N=sF74[Nji Tzgڤ42.fDqB `wHϥ_)ZNZR25RYXi8 #8ǭhQ@em) .ԍ*t1|i">`ۏա*'+?Ɵ# mZg"-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEV'?G׿qڶƟ# m@="ޗ^qԯ4p!rfo`Rz -+B8O x]>"]XjX7r1(b s1y=p֟\/5k4-%y7i-S%¶6/[n\GnU 隙n#W2gfXz{㟈OdR¡rKwkomJi(O,H3zD卣]5"`q!={ӯ5{ K[޹KxKH@z q|'n?pomgm9ܛK l1ǷltȞ4{!H>xº.Ua>bqZwagkys}[^:G_ץyY]M+5$o7obM'ID8x,޽G4o%md#e>`3We=3A'IFԧ-DF vH?CQEQG" FCS<o$P?;8umh(Υ` PdgpsWGhk6Ma32 2r:cs T0U:߈v ~8[KmSd*5dT3@zt\ӴJ;2"sc?0g#qܷ$4D;GRWᣊ&–XGBvVtE.^duXz{'z+\Q.d S2紶?p[n8][ Byn-={ [cl&{J%A݇*os@嶡iݤ<6 =Amƣ2mnszROw$ ?П&Tz1bk7~(CjZ5I;w`v#9xPkiqmi-6mDf N2[s=:WpN+<7fuo gam⺏Isurt1s@Z /V PJ Xs9;/Y Q>Y0<0Nu'=kPOWc٦DHVxMP%tpbD+ۨ'8'8[xþ$XtI.%wgⷅN&;,#7p ײ_jxSuɾjzj"o:V?_@hҥfK(08iU^2s] źF;GQ;Xz^K7H𮛦궖Z֚]#f\HocݵK}bDl-ɴ1{E%-QEs>:na/Ҋu 7_9kQEQEQEQE^RK 'Xvw@gF6mul_}皩\cᾩA¹M?֕kT.j1VH(Ƞ(KEy|7|)mOy4FhXć-r9ZLޯn| mɆe(;G~rx5A'WiDm&88]2R Gq@ceo|&K<+#-g{ X>kHuzw]V%jVyo&m<&#Ҏ:b<Znt&Cnt *;}#-\jS\Gl}#g"bCII|z[j1:!2d2"*2pی _l=ܶ؆|9S:ΕnWEɑmѸ `}*vgW:]M2y$6V;TGȥȠK_xCF֟Oz7]Icv.RX*X6Zutm . $Arz 3FEsWDڹ %f3j~w3K0òD,ӓ sHWk=OiR'h,s=+jakXOcy op$F~6|E{X/|`ۏշX4^mj@YoK8UU?yR39+anP;E&ۥ61Ө}OG?b6݄zg$\Olo|XxWb̗A #nC^:PEiYjlZ,Ho-vn+·4dbvr9\ii]*;+gz3q:W7Yť\u)SYq AM`8hӭ,khⵎ?-b U4t[+KOnNgkrhRkem 4zuM>Kj rJA̽(DJpy( 9#8h{\IxŮ( ]A= zZtۄ&*В$Qj~0U/6(-]eI(Wc4 Śg&D3]BK= S3zgE:M?S[y9*ĂA+'O.cAK=qkA* $hI+ MAf[D G5xMjG񎙭\\Ey۴SOQӧ{JkGV̳YVxRAz`Pnt  dsb`X6o 3נCT^Ii9/&;UQ>4dH51!?g6rF=r1VtƠryg~}ݡ8>;Z>Ūۤ~2<0lgybwtzZX$O+C1oO_zŹCqumn6rw<ӆf\8ⴠVq0!fppAc$EMhV>Nӣhљ9c , wv%0[I-(I鱈l]YhW0..oRYL:Chݞecj(Qʼn ΋"e 0AVV}/_- sf)`$g:zp}+&OZFQsH}F+ pp~|r3@ ? >b7`}X}Όs*gzx+I,mKEgsmp î@krX2 #uFAQR9emTՔ\ͨ".øc2q%-,2;O3qq %*c?łz}I@z4[E M M9Ӵ{ o/~XiTvx+v((|u 7_9kxAo,rJ(h((((+$SzvWo; ~0k|/iw^=^l%v9 x:i0rZ3ơ!YqSƚU42 8ycO5=Z-^WHPڽ* JZ$D_&FR@ppz`'zQκ玵=[E5-1a@#ngpd\ V֧7xv4 7<r9=-OSOɬh5kKGY`ӊ}{k:iE7=ba efpI'zWeglVpXj\OsXv>vkuDԎ<搌dce8 y'{5F >q$MDn^^,> v~uSt5f%i7wp?vbbM2URj9v3"}l+KF-t8$KFMspX +[sZ_?~"PbVʮBsrjh%"u?ͳe@ h) ӹ7 R NPK-* GVu Nuw2Znf.СW=06G]*ZʩYc\.exOznv>Ycz$[xtGė-_.w*j"8v\(b/t~I^MV>(7:vzN-')?dw^t,|]>=oNi[lV9.2kEg;V-k­:v>E"ȲFNv7 3h]^ eԴ [͈*0O;J9֒LГ\/[YWꤸg(S6S麥yq\yvQϹTmPd zTԾSi׊o#R"!h˜zsgFA/ĭbRbѫ?͵}7ZZX'&PK16Z;9j9%={%`ۏա*'+?Ɵ# mZg"-QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEV'?G׿qڶƟ# m@="ޗ^q zzD+$1p^V=GrM;-)5KZjuH%T.ˆx#4=淬QNd1)=&nͮ",y_]q\Y0AUo`zۆO&I3 -=y\VF)1]ng>:OlbdkKZH*yu߂|9;tBT4_ W9r%kKc#ph' : (/s0 =+"Ҭծ58 yrKUǵ%coj[UIrFa@z >Y\K$*ϻFw9#>ڌv ̗cOrkjF@ ey#z<|#>u t;v2Y>MIT+j]hr #z{_H> k弹ul Nykʳ6Jum`]QP o*KR튪Mnv:b:& m݈m:G -WPFeys^! R ylg M!x5uE[T%NI]/ jv^iK"B@Y1R=V hMwv Z W{c<@~ «90ذR8S޳/~=$6'0cֺ χu%˿,Fdk\Z>mpaIrF'$c@ȯ9q]N{[LG&y22W'諵9P}"f0,ێB1uWKCx`ۏշX4^mj@u]KDG[ UNwG~b,tcM@At][-̉3F3+o==Pw~>m+ɛRb-o!]QCmn^lUøsU}q"-6M6s*>VCCtun[NJK1@ r@e9S[mMWh7lY+1\ ^ρ4HX l=瘡a;c.-+IӠ$i B!@?yſ>)ä.wa)lK|$&8^xҴ]KW wRYƥ"ab70Y 5S_i6چy9Y\)lzq@ 3&"QKAR6 ;z Bזp&èJZ]ġV*o"jD$[@p?I?Jmg: 6v,|UD+N0;z/|nNkYKUǪfa+>%}n\@43,2,a;YjzkCKOۼ1[Ddp̮s8}3\sC?_Kou%Rkq'ޕKņ<HҀ=<kU6Ze} +)@@[֟s_\O.`y6132} * ѴǦ$W=99{ޟ&-޽Z@quQEQEQEQEQEs>:fa/Ҋu 7_9kQEQEQEQEQEWo +7ރG@A{}kZIw{q UQMO\tKkI:t1\c}ٴҦs'y%K ߅oW$thYѭH $=31[x@Ю-%3+J"@2I=2^$Ѵ}VQK m+#(%WGxtگ5w\O6s۔0ƊmsĺƩ>I59 46O9Ԟ:VT>;*Mnxvo\H`*czuV쥽K{xWs!QUZ-wBaRw RG##3ք~uKFᵅ>f,J.s@ii+ֵ%K'#!m$FujheC\iyo4 'iH$sӎRS񦇠auJ24ql(99 lQm8NkXN}2*qw";W36 u+8ɼK_CӖ)O;fHhn zgXTT,70#;)w!T N^éK~H/KgňH;$/Gs'1kp8<[PpF zE.#q~f JP.sHZZV>e-ƥ‚ўvЬ*X;qzqh(mjQAouD]]w:sҀ:+>[jC6"o2mps8'_5A%ZO(ٳsPGEp6~1as-]Ԥ0ڒɂW*xcT|Cs]k7 VK8oH:;76=TW[Ksq I֧Wi֫kH1D#-I{N9YŮ-c&py B@d,r<0z; [/mbedFє? TnNi i-$8U es9|j@@Z}%x #9'W-*T7:yaa`;sW+]E4fEEK, Ϝq'NzU_4{NOvCndҮX{:mt} Nqkq.`GLswW7=6ܛf{iE.! ƺJ((n?[V ?ȏ6Ehi EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPX4^mj۬Oȏ6EZz_y $i4M2@@>дˏi5#̂zҭ 6[洀ݢykpc`NCuǵX ( Ym: S#zO֋{K3+ZCC$4 ds՛O槢2ʶ2Z>}e{H.o.xîGCjZN .̅1q U^(((((g_ 1eQ\׎bG-t(((((M?a\&z^{z Xevܩdp?Cg#$8 ]) ),-8noF+1f)yq]IEn҈Hv10;O<]ŴGc/W % '3wI:-rۛa.Wvgy3@ԼU>d6(Fsb_ f#xnGA֪/dgG<2Jᶶp} gizZ$.M"wcٗw(<3|uR[;aI|; sd#.R~64x ^bBnǽvyy4/#(p(jƺVi}k+3m oct崷knXRq(@$B3,8 S(Z:'ao۪5YU *ml|A难&gfy$];x }㯎hMH/S{x>N"\@Waz^m^-Fc zN,j]1As>w dPc;xWN'?Y>UBy' vkI)c^w$wSFAcQ8FiGDiY cJΊ 2I8P^t _^%.cz YX`i\߭ΜEtegL),8U=x$"G 2 HDe1,\ =q@~Nx~pڈӠ(&F]*oUTK3P2I8z=STLѮF̰rZe|!6ūXKep//)]l[A$sjZhݶJ298+[6Y6;r3֬Pv4ҵ >k#cSI[| a[H𭶕˩yy_H=z;+[-Ih6ۿ.$. k95aO3 ;$ gWgx>WVu .tTUQ8^xe`H/Ueмk7G.G/Er ltxfQxpItI:C$yrNsOG-c%R[,q2FEkl=<⺱KI5 -FU/o,f40rB {ga|b..˻#(6|2W=9!_/1UcCApYj TЖ_%g:pyfڭKM5jk8 /͟lٿ~q'ր<('<[]Olm`$%QýK\2FtHTkM>dW!΄g81һMG׺ֺLe*/ެ qT_HָQ>ќP?᳦)5u}NH.pǔ.qԞi|Zkrs-;Yjz]{*7TG,Sl0]8W4 ivڭg{FќKy¼n$h4wO_T[F;cfK63 w5k{(/m'u+}⁇ `*8ivΧ3YUjI/-Gj]v}B]rD T"; 0}ViZ?-v̈́˛"BfU\WSsKGVts%W acܩ=ς4t6O(g=e?{{i7G4ߴ>v "g{W[y4"O5H<֓3'qtWi{V5IsTÝ?a.OF-0?.⣌݅g\m{e{Vmљ pn4[/$vgBV2aى\ cj5퇉N_!g#fg9>]>Kry Etf1#y <-eia>+;xѭcPPI5Y|w~G;8(((((Ɵ# mZg"i">`ۏա*'(Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@bxD}{-n`ۏk-+F="ޗ^qh(((((((((((((((((((((4 Y宔W5i]((((((?}O?|uW_I>:((((((((()-Z(((((((((( _ȏ6Ehi n?[V ? TQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEO\趭}eaqct้A#*2:ph[?/Vs1M5-K\D@UuYP:7Si(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 64 Y宔tm| ծ~2Lq"oS%K`:PEQEQEQEQEW`ᾩ>:jk\nIm>7Sx \ m?G m?@% aA]wT aA]wTQ\ m?G m?@% aA]wT aA]wTQ\ m?G m?@% aA]wT aA]wTQ\ m?G m?@% aA]wT aA]wTQ\ m?G m?@% aA]wT aA]wTf; NJ/ԵahJ$$~gݒ9=kg[ 6yY1Βi?ii?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6i?i(o[ 6[ 6 ^3^mji\A74^ nXR2 Ki Kcj }Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ƛ%X1)]=soct]עXQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEiPu1A? WOZz/ΞՅQYQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ƛ%X1)]=soct]עXQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEgZ柤9gzM&ݐKVdiPu c=&Zxc) .x{NUEHQ$}@FIEӒwW[+P(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((iXѥT;~##zdFHʨ,pŦj[[Yns$G=OcӬbtl&?RyG<8|o=rȐ\es$%mH# bzCtk[%\lZ((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((({_ɤVmr[C>4xOI{#4[BoIy"#е?̷^(eV V |9洴O [W]\I.&qA4eT41˛8edl :;c遊:߂2\kz |ﻳ^a'9?0 WcI@^[K6;w{yWk|(}&ە5GPW6}*>a֥ѼV:izŒYXz'st4RREPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPT]^D{J;ktz@:&%>luMa~XW+c9zWGxu=UGLAiH{vX:P?#[K[C'gKyt|ǜ,4M.;;x]kY ( ( t-;_.Aaё*V WWq֓SԐ.f#s]e7[KʡH2=EHFz'sMC H}Ƒ)"&3,f:+B5eUfH ٠(((((((((((((((((((((((((((((((((((((((((((((((<▲u+mD/,I@,r9 oxB}bm*h->-$qkmhmodEuTQEQEQEQEQEQEQEQEQEQXC/5 cn7K)\?JԺ{s#UGWFKј Y)ч~-ouۄ|\ͱQx8 C /iбwbKi׾-Ppr>` v4U];Rլbce$_vTQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQERR(rW -^vʍAԿ`aZ.NFk/e~ >? ߿f_!3g3(/e~ =e|ɝ6hs?`aG? ߿f_!s3g3(/e~ =e|gM3\? ߿f_ gM3\;gۭfA%&帀H6AO4VN y뱟hh:DtαnI?%ͯlݢ"Z j䋏-!T=8y j~UI.l#|==}kK~]r >.; _/x#uFjY"Ӿ_tme g#wm}ӕ(ݓI=8 ͼ0iQ7JӃ|>}hd^;8k&)*PE:z\b:j]m;uia:kwzkZNl/63 ky∨EBj`2}<'%F X~ޥs:n$У1_#6?*ZB1L)IAEU YKxZ4Xż6d}l9Zp=U'^ϪGlq$&8=8:wuӧv5řo )yzO]dFNTy`cуӚQ蹴B|u62ֱo Sۻal{M4w5)U$#uJ>F, Z^c>lo6]|0[[aY&D-iFu$ץtA=:OЀ@xQ21w82+omL^Ka{[xuW\ G& Q܀ pyzob Kh87*\]Ķg%''JZ+k?ou,R]?2 `c=N~5G[}N!6Ġz(_G4g+AI`A1Y> ) jP$nkpO!{ctme]Tx÷>|X|3sv]tZCe m }3J>*'\ 8:%^(4Qӭ<0,R3|OSў6-6M{^͒]1Wh,) r2=+*גMyz۫(`h]*$Y[,,l \?dD$8Eе_:x}N -'t3p8yK K򵧄hɘ м7aE'ٕ帜pޮǯӠ+Nc(8Q`(I@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@!4=?/kkKYQ+]-kWu#:{0+#@(((((((((((((((((((((((9Kr}.᫈RL69Ĩ;k >⨯IKgs>j~'"zr0r8 Oŵ;ȧl820Xz@LsF=h`b`&(Z_jWqsh8cPMWm/b%g#>r>EqU|sƄqh-.wx#9k=*++hH\}h+CU72j[7cqd}yoQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE7(/GgEt]עŠ((((((((((((((((((((((((((*; PF}Vo1c?ϷxLf1YkXIm}osep&ч5X,.rd-;fgʜY&'OxH5xy`Y9pk- nK{e4yX ˟ė!M?!X7[s#=>QO5xfCfC%ocV 0(. _xxT;"lz!O9QK@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@!4=?/kkKYQ+]-kWu#:{0+#@((((((((((((((((((((((((((((XkVX6P}"7[W[Wo_A>`3P-ߋ+]-X1Mm>IӷG,Fxɦ4;t)$Q|C;(ͨ[o$l,Gl-DۯgUѭT}|G,x~KfJ r|̤d7گAO6\T*K(n;d`/cxf4`RKx<(Tm@|8/m谺\w61N1箯n;'NWKW~o/Zkw67GjC!Kd䁁T.)tnL--$%#|3 JOZjxf8dXg)qoتT>Y+Cb(#[o8R2?&oac-ԱX<{ɮ^{[JHRNzt*tK]3H!8RDz8NmJR5(s-b1.,2F+9hxǘ8+F 2AkKu+&1L7nH6QXAy|D 23ִdӿ¼JQJE(`(((F_KoV#/%7(((((((((((((((((((4(:qAJ?+jgOgŠ((1Z1ޡ{{{l#W)asՁk HI1S:^siql0{ *; hk]Y,cOAqzyh.|[s^Z]$Nͧ Ov0AZRiIY8%Z5.!Kun>njVl;6s98㟭uTqe*Z&s*–k&'dL[U-5\YaՈ].B"ٜƿ};Op0 { cG>֗48N7c mi kjUڟE8S6 Ԕ *Š(((tգiRd@;P1ːpq]5׎,WKҮ-gGX9- Gn4XTE U Ūj+SشQ\'PQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEWZ$ua\zh҃@xzgtXnQDU6U DsJ(a;x\_"6V<sy?Er:!x͋1K˕q#޹hMCÿ?"4HL!m{{z=ey_i=ci\ep{EgailƢ,.A(':C+ ^/H^O#* `=WO k$O˜ \8d5 .uP3Z:-̼99uǪy[ť&Tsy[->wFɒHN?SҀ9/zv ֮nֹ&z[+1Cɴ z׮Q@$7ǚ.Ϧh4"K$F$78&eq/.Fͧw^Ep*G6%5`[$W?%[ĚGyIwi= '8`Fpzv[9Om\{c쓨4y ۜ桖)?r/?]>LcEyVecZ kN9o,b#y`3̶v#ºΧiqyu#B=T9BMjH;p+m]#>@._iOJo3B+w>XVuIn0 Acmwi-X[ҵ T,KI"Jת-'UlE(ӕb4x'.Z5יtm# (,OekM1Γ=WV\H`K;3eZ0nNpGs޽NZ.vqq.Aػ'6Ai;h̏d 0gx-WKݬc4W9v=Hkcvy1Dp2~ TUEݩ>IV~!l il.OOPh. Z44WjwSrD o)*#v4Q@Q@Q@Q@Q@`?0xX+zt5@?aCm 6hk6?aCm 濱aCm 6hk6?aCm aCm 69i( (r@sFh (ri+8G}5x\̡^O쁒Okp=*??m@2(k??m@cO9]&hg7m?P?0WI3@??m@cO9]%cO9G??m@@??m@cO9]-cO9G??m@@??m@㔚%ֳotmWQc9c,cq5W7o%26j((((((((((((((((((+_-غPk=IbA¼{oAh+ٕZi5vr˸_Dw=.-]G@sZ᧋pI:WM{Vkmp8l b'V/i="c|Mv+8NVoxR֬+r#,$ )|/j:▇_mק1-(Krm?mSZmNMP)Vm2[5 <]iTܬWK 7c N8*xF&15cLԙ^Ieq".Ց7#3%׋ V-Gk5nŜ 6$09[}/DeV]JUn.@ ,1*Czq-u9̶bS2g! Ӄ@|]^,֗R[}1 \a=sUuMgƃözm6j/#3TV`v9J}^˨#K,‚3uTh7z-=o*hn+`{Vyo fڌW_jYiw2$T(V+]O;SM_rׯuK[`@?9f^iWVn^.FppFv㷭rq=W:dմSݛX$"pb(ȍs,|+um_BkLk wmw4=ֽmh>,}~'Xh)$ Ēp}xҏS Z.ul$33Bpz煮|<"m9 syˍ^OwU-/ތd:s|Exw[7˫hɉTOw( Ϛw4=ZAqyyqus!m$)㠭{7/"Tԯ⼺ck)[>K:mVs_-ВD,>U`^H#p:_XI]jzvfF[HeU OM΃ĺtk{kI$y70!Tڲ5Yk^#_ԐZ[Xo(]wg8_Z<-ke%©d]+T@5 .w[3^l`S$oA#y}ΛZ_* I7;X)#h޳wza [@|-I'`s Ȑf@ X}ӑm^xCJua$h@积zж׆n˭NZ#gf&U@_> cBfrpI'CZ}l--4 +bPq0w?i%GxML` 9FW4BK j$:n[,;!blɯhR_~KDUː2FH==Es>K%ƝV8nP Hf=RiCU!ɂvmwdsx/h~%geq/jOXSV:]ēF@fMAld/73Ҁ=Jlu6-GM\Z͟.@ TpzW*qaubih'8#sV((;_R|k&5%'ƿ[h(((YYOw AH'Wh^pϬk;ZRC \d9s^Z}Lݷ[73 YxrE-b7! ۀy`W5[9-<ʜ>->kyoVH|#z<2ޥ^O R췶qr1#'xw%/rf< {Ƕ3ְ|#At-s6LdmӜ\o򯳩{kM޹Y! 錌z^2Ӿ  ZKXc9խz&4)Z{{g/=>SE=4#6[?\|5ku߇Vf{-űnxI?gv}fl?avm9w;3H|owלڋ_G'd{ןv~01۱hs>7=/w;1v5|AG|ݿitݷ=s@U%r7Ǟ|-:mӾ;f|~_V,~xskڀ:+f(ϵ_y{0qs}oo7?h}lo^@U]r?y^ZnvAv{c5)>8:ʚ>Լwm3@%7d~6'߻ic8oJxsw<߹~Gۻ9ǽu4W/xSw{{~m~1Ԏ?<95.qߞ@MN?gÆbݸfqo^E|@,c{|Iq3h݌1(rCル~44r7g6qڛh9: /S;:u۟ltW/l?+8áO9LnӞ7~s'~ٹ>Č1kv4>^ c)fo<73fzuz)+o6K8m1jKラto\^q. 8(vټju.B14vvs?El|؞o'y8쏻8:+W>zxw_'<:3Ӧ;I97/;b:+Aϴ>qn}sjKRs>n9ہq9u4W5v9Śhc?؞ ?1#|UI J[v{(rt5@Q@Q@^:|A&k}**w6T1B[Bhat;-g;RYIۜxBj;Jy麃+^[\ /u4}%"$ kk\:5KPN Wۭ/4jYI~g]om"xc5葠U4@( Ή_L+.4}ut]KZ1"rǮFЧ)7}KUvPɻuąuOAQ{*sEgagad<0Tb_?h۷7w\W>"j^\xf{HQ33c8CLJGo{65Rc6ԟ”jz!ʍH6t;Fv +>&)';%@5ZGԯ? \\1f|}qlxƑk:iV3i e=q@98JZrv]BT*]=#MӜkl`PR Cx/>@ǝ>^@wv^4LА 3xuYtCK.e\gp8IUU+ܓBJGbn=I8ի{[{Hh#>#@Mz/_~i "߷{88'x_1KbE亹I"߻i9Aϖn sU5ƙg,HIE6ivQH*n V|&aɓ4~gtXn?k'_^ ;{. )eI09<]iW̆v+ϦGE_i\v2_Mݶs=zv9#Q%VndHZVÞBy*Ԅ4tT3)kC6s:tR۹_.]Ŝ``INՌ>!j3DVTu<)ւ݂Qc~Vkvx߆CZujJQqv{ESW7o%26j+`5tQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEǯ?]_(5WZ$uaIK\O>(i>M>H&e@{ON}2Y65=5,Q@êgAElP *]A0ʜQ^a=.>(xXͪ麅Դ|"_1\p{dwѯC6Lv,F_z#զ$q)y"W7'ԭkMѵ;yG]UW;B[MP*ȴNtcQBy*H`z9OHvMmպ BHJ౰>(Yb;dKIN ~pvO6w)"EI#D(Iz湮xgU)^[8SA8 I8kXI /Bp-5fСbR7^x?^x;$dІVrW/F@K4eʈ+`> g9*|@n;^Ë帽1S wmg8 {;\x× `K}a5ŭT…P(8$>?kڦ&UZ2Y/98wW61}CP[ڳ$ga |9Qz3]Nyu+Encc捿 s>$ڡvƼz# 5qqWDIE@}_ t_t4UsCr˹]G%Wa5G4? K]G%Wa5G4? K]G%Wa5G4? K]G%Wa5G4?Yw9K>h/ ?ƺ(!.= t_E@}_CE_-.= t_E@}_CE_-.= t_E@}_CE_-.= t_E@}_CE_9e.0h,%Wa5S]KR-ENyרW+o ]G*CCnNrx[PN3V2 s|qi4l8]o a'Nɓkȭ#f2a-? lI:s~T8yQ\EPkSjVHF\r{My5?iѴ<*$pX.Iv=FEu#AAmvdW}*ƭiW2G@yې}q:S#Zm3&|GN"7_f_(M'\{fm^&s |۶s֩k7Vvqfđ97zU 3i)gA9FT⮶빓I5~'ɥCbSvz4OxXZ[[FKdqEq˹|ymha(INq)6S"<§_]g\:ٱ3;Y?_wx/Y*gI|I&ya!pch2zUwjw].mc{-!V >2l9? vF5P̌FI*79 sRW/]ѧ%>`ׯ=iFWA%dc:׋t*a nXFO8 {?u{+?YX,*9ǫ/[/je}-ܛ y'“>[lYwVA;G$?3OJ\ZW)]cc=wk׮OZZ̐BXH#xN5]bg̎8f 7(z3Z=pz#_nV:Kc'y??N1C]X(IEfWfq٨$![GVl@^@U4[]{K:W'qeki} "Hq؊xM׹QMFjx|^4.A#! ?"5o [f!73[tb 2+N-QZsvS/of)ѳPIEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP\zh҃]q%OWJ v>"[ѥFUgWAQ2c#۾xJ>x>OxpN\)f;A zskl4>$xS{Y"F!ml[+;;Xm܆0?К<5{Y =д_)C.8'>O>zkN 6Gh!<8&S>I?I$wP.f0rH$p3Ft>Y\*rrLM )#H$t% k?HJJ!L|AbpzUWE;MWzeos ܺy(>bV" a^LQq ,5]iv$0y,k2XEsۥnv$Piڹ$GyYxR/~p{V47FѮ> u~~㙧c빺~o!-GbI5搑P)kY4{my69csy犩GO-"#3<ڍ_1^Y ~d/-ඉNQp9<Y^EXA*57 0tAbXƭ,,ݭN¯Q3sj__iw/"fe=ܲٸBUZNǸ@(?<_u-os/&VBMOCfim|=u\,&L@luZ഍>-S%-\3D@9RxGOS5Ŝ]Hʹ,H9qfy{0gE)Io cVM.dm`f/2Aj2X:Mma0nN!sVΑ]OSm*}>My Jjt%J223n Pog^i׵&G,bX @m6%/燯{iQiIbcKS6TK$ïBhoh Uе*v .QdߵL90@ E%RU;-cMf嵐1Kt.卤Pc\NeHzttW;o{?Ml-gg@v#G^Oͷ s'R|A+K`톺]s\+Q:LT56+)`z{}I``?PQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@%-kJO~?$c\wcMv4QEQE%æi^i8"5I[͚Ӧ^F,WTӵMc@7>TͿ`r?~*_okk ᓫ>n0:df뫴V6{K_;Xuq^yrj7Vk%̣t>cx_u?6zxh ~7RZ%RnǠ#.qּwBZTVPjI=r*Ĩk-+WYJt-t{Rϕ}]9pkQ+¶ }|$̤$mz޴|M<P&Dwc L$Gj[['gNzѸtyߍi&f]y*\+O&zpBk~ܙvӏ ϐAJgSik%%'^F-zU9Rv 0)h ĥ(+`5tLE:J( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( KD.+_-غPh#/_G~!w6~`p `ws+OG>o"F6}W9z> _ _6Dzό.u+ 6ӱ1ة G[1_fNX *so ^m|%Y44[J,;#R0MN9kf |إiŷn=}(k1v(ּ&kKC ю\ 6p2 xNk]X˩-niS#'#w.C nDw] &,2ן׎j/< ]Uk.8ˌ<Ќ K˹Xmgi2@+-S@9MRS5?Sυ-'$mDT Ns5Xxf]pZ 67,9Ϸo4&] L*C6h^Á۠ kDŽ즾ћQ{ݢp## Vudӵ{-+P^$pZf;6lJ<`p8E.2VAl͸=xsU<3x[5;Xiu ݩwF0]Ht6 S4..4.,$=Jt=Aҵ4iw 3p0S*ڵ< qooHn}~ 3BF[#>nOZx+X:^^WEZ|Q@6MPnG[{1q(mI ;e8rRt#S+R'k}1o.7<nqө%_Mvh&YK# 8y{ wz N K{[sQ 38j"+ _N&er62N7ր&;𾙭[oruĐ0b#Jgi'8gN{hⲄ^4PWz8='Bѭ|?VAɵKrXI?Zo K(3iwm ! GEc6ΙPWuA@ZEҦLG9gh}IImr-lmr6%RG@'kgR9g{] 4Q[EPEP\ݿ[٫nJe-lQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEWZ$ua\zh҃@P'ETmSRϔ&uz^[Q(㷐Șݸ@os qm4s"I#`k7j_zr\d#$1Ǿ{@kZNJe߇[(V]BEhs= $~{iq.e,մ񤑫ퟨo[x_~5y z(%Z$і<?r3K%ޟ \HdVHvP8: }z/ve ®.r'}kӚ%Oci3Gju/_*%H:JvK ٦UY`ekgiY.(jwj#:Tqd#j݊ćgv GX1|^VYř~2غpHŷ:%ejok+1y0;H’3@Okc wR3\p7qy6K+L,J#GѝTdxhf<''XX|if1\{Vq~u5 7V!"`F1S&{}pN@.eMr[`hѼE)d%ʅY2znVpqy_\j~,lֺ$:; ͊9KȀ2`ۃ9G {vSM4G=D AҀ:sY]FP}##D8Gfҵn~F'y_ MsQmU&mNG1ȱ9gnxyZVxvW6"K+0p@~t߈0մ].=s5jȀCnmߑ霚<݈ d{ )sOx\Դ -*/m$p 5X8@<1O^ ZC&@%'H6<ֵ I4W[J Ѳ6B ]]* `K)bKa >i!FyֵmnČkq*p<{כǾG'ٱ 2<> FPX"Tclj%cW* 㹺6&\2"ivPɾ"J8nXFu.\R;%Fx;fyELR2@bG8'!^8q}bX?obw= mrўzAQxL44$LJ0s:/5>E{reZ`nh@]MTLX\h}D'XoDx72ؚ{Ɍ}pJ7{LTsP}GYcgdm$g8]Ur׽EPEPEPEPEPEPX:' ެF_KoQEQEQEQEQEQEQEQEQEQEQEQEW)>5]s9jSj7{=D%ı02(oVl?G+o 6_ [xOl]'@6.:+m?t¶eh[/  goVl?G+o 6_ [xOl]'@6.:+m?t¶eh[/  goVl?G+o 6_ [xOl]'@6.:+m?t¶eh[/  goVl?G+o 6_ [xOl]'@6.:_"FQ¶e|-xzi,/:3H |@QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEǯ?]_(5WZ$uaI▒KIFhe[{8.$+GC1Tt x{FOhvq*B77P=Z)ekԗQD@OSՙ3 +0ɂ;c=kg4f(!4{\Fz;S4m8iٲ6=A\`'>o4f34 hz,6ZK&wn>n|ֽRHuKAiaoun0V)c @ y/EX ]mc :]b4f"{kx`asAR ڌњVދhG 3oam 1S]w}c=:gjOv-ĊRMFhl,uô(Vlu'5 &>lm 4+實w4P +Bt8Z/NF aKN4 f1 lTFmB[]!K;X$(U@OSzTPI(hJ(hRfIE-`?0xX+zt2ǥu9-ra%-edD s<o·e,bmxdy#OK8P;E+ kGj` W ExYe)]BN}?]Em2ZB>(ڛ>? <yp8yQ#7%*(E7eP? 2+;nQCtl8 ԓPh{Qm (}i?ݻלcYJxD(Q-Xƺ֌eh"FQySK&|}>dSǥ d0ȒHhd vxߝu9dP, 16 Rh`wgQ??\m 0hc1B>(ڥǟZk<@2w.Wn~9g]|2u5ƌqGʊG T¦omkd@>w'۷cv:b<ё@O}Gͱw%<:awV#gH#FQy3Jw&lrrx"/_Ca=z8[{G>/ɻi:Fg`mDD; s<_ʺ3@ <smmm6+D1¿hlRO> |:0v$O%DP8n]NE“ki!|7>pr7cw;KFI|?|n cƺ\(i%[} (Dr KoGdiϗ)ֺ|њOGfIZeOKÐ9ݞ?*&iKkYt`چ%C4dP-uO4`DK  S\=>r79P`v w:֯ohZseFch.4O7ϐ͝Ojᧃ|h> C'DrdrºbG 9>)ߴyݑMga>e}_#׭Y[ɣٝOKwd? <xq[h%Sqlp]FA9^s.@@$qBQSf?;Iw=9[O^iFbx\Sapjxf[Nʛ\3EI``?PQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@q%OWJ vǯ?]_(4W_-<^Msakm2CaG8N=s^X?↉5.^.M N: fdihv4H'ԍkvgc%+#`=ޭP@RG$|DCipvqk.;Lčy7{_s4kreG>߸}9ϛ{ӏzuቧ=mq4)smH#:P3.wOKi敼H>~\Gۦst;ė:"VIhRqצiЯyIpq);#Y FmR5ΔXcQ2x p Qux&m}4g7=S2$ٓ`}ҡfӤt욅fFoU' 8$iֶڕ՜z#a&ߙH*I_L Aiڍڥޫ\&Wjxh%̱uo#;L\ݒB<7Go޵, N}mBKUmp2o%δH% лni5x ho 52* vy'95z1Λ-؞y k I ˿Z^x<$SbaF LuZH=CMYٚhq%JMZ\wqs7ق\&eXGXKɭ Hy4h]Qu?JɪݷCNuȪ;o5K"[#erK|;Zufmal`bz*X5h3TJƲ[vF:uNU6e۽Z V aqc"k r~V֓Z}bU#p!lնa뚾,]ū]w2"6s vyί=uY${-oN4]T<\s=z=ŵ^C$p (+^0i>%Ӵ۹I܂xF2Q]&[:mh bwހ-EQEV#/%A@QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEǯ?]_(5WYyaEPEPEPEPEPREQEQEQEQI@ Iѐz(hJ-QE(((((+A[ՃI` ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( |%ޱ-嫙]H\uEq @?Sx+u@w*o"o.T D]v4P _77]¦7W&MoMcEq @?Sx+u@w*o"o.T D]v4P _77]¦7W&MoMcEq @?Sx+u@w*o"o.T D]v4<>>efE6Cdַ*o"o.i=?/kjgOfq @?Sx+uYw*o"o.T D]v4P _77]¦7W&MoMcEq @?Sx+u@w*o"o.T D]v4P _77]¦7W&MoMcEq @?Sx+u@w*o"o./i>{MZ$F@bX Ӣ ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( CKHh{_ K\֗#޳\VZ֮~FtaEVFEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPHii sz_zrAZk{_ KZz/Ξ(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((() -!oKYQ+]-sZ_zrAZkZEمQYQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@!4=?/kkKYQ+]-kWu#:{0+#@(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((49/GgEti=?/kjgOfQEdhQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE#Xڛ̻uqeNEq_u<%\ZB~bqߏ°>$ Ś5|`;m=4X̦ ]FJ):/]ciFBK3It?đ=ޕ6h=rAJ]B;[iR*oY=Tvt$mn4Դ,FqpynyKYmª[v@G>^Diκ*CJF8'$(q2IREQEQEQEG41DȌ0UA:q67Ŝ LP!+XdY#qt9 =A*oʼn 3 lHCא:9RZ,8hOz{q,I֖ ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (;EQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE%-2Ic6WTDfc7j,bLǩHVRK*_"R5W=|*@-X%<1?tMȡ kN''<ԔPEPEPEPEPEPEP+@rI Ǹ$ MEg[(' =(#5C +BԐ6<8 Tp+4O>A ( ( ( ( ( ( ( ( ( ( ( ( ( ( J3T[1؅![;PzNF-v:w\{rN$d-e=uI㠠 r=j]KzLv$yY힀V_onqulqlG-HT~)e HJmk./#r}I8 ڀs\&> jz>FҭlTY6K~@-q#X֭x*$9 R=r{c+^mS/sErXVr<޻XpT;zJV㿲o.v9FLx`nzfhnK-",@ucA\⚾t.( ( ( ( ( ( ( ( ( ( ( (-Cqu [}8K@$ [kTJ.3\7;JiHs:qׁHE\_/O qԐp/**(U(t-QEQEUIYa&OU?^"A|vJ}'M]IMG"+ 2#Њu-gӔ.mT奏v?73q)Ԓ2ppGF=J( ( ( ( ( ( ( ( ( ( ( ( ( |@'n KzZcojyU.3\c:k!|J29!G$fMQp=I?I@+|kY⡫Ǫ)6F2y^-4k4Ҷ>ӥ("if#FY݀{r(?y~+q _S|+sOD͐xceu Xdr+onfPLp:z( HnɫyjD':Nw><}^|4t- Hf1[GM(\(vl?xWk&? v+}`DEsh+kO\ʰ `^FmQ┻c4Yy_.|,o6n϶kqŧOYg V\`u?1XZ[Os QqΑh=8 \ZtIc&gRw1kF~+xVEUNGVͯ|15`Ep:uGiciבėp=ڀ^sFRmıdzfu>K*HLS wFu ܀F+j6idK$0%A4%t.? ^xfPPlk}vucy9$^q"7 nD_zW[t=X@@⟩wF^7[ǏiV zd:so]Oo $yU =4={DP,)*8%YQŸƺ (P(UPtW5M/Wh.vћן+eT~b`@Vky/AYb50;faYDgn}zvn.fF;!coD8#5d\AX11YO|5g 4/O'N :~ik"F}Dxn.aigT2US Bkӣ/"[BvQ:q^w_ޛ䜙dVf=Hz4M,# 킵ڈlր9X]^mZWiLH82GMG}KP+Դ}^L}B+hNB7JKC=j:V}R ='zf4 aogY`&d3Tx,Jor=U(O#U?7zqQ,T7p܄扷Fr Yn_. qߡ#BQEQEdz\KVId/ifp28Gwiki']x[KoT '{[8Ӵ&ͮhOǞ721ڻX/=8<EEq_{;}Z6=ǔ&̝v^qu-Q@Q@Q@UKD(g O@qXD2ʪK jtImfI` ^eɤn/XK*h ,9}N8y局qV28c1hWQRQLhD5fvM>Ε$4*Τ\i᷈<cg`gɠ (( 5WLN\>axgREF&9 :C?B22EZma:nSA:9[θog>rl?C_G,k$nVSGEPEPEPEPEQ\5Y هg~tr?p?J~;:v\\ vMwbA=>bފZz45ʗbbIQXgB|eM?0rk)`H@mK@Q@Q@Q@W_OjW_OhQEQX᰷aRy~ݪe%vTa)Dߢ7->NMJ3ë\:Zn5kR~ߝlqԪ{2JqѭEVaEg\W0kv ,g\숌xajZ{Tn;SؾIZ^ Smb_vp8ޭq&Qqv{QLAEQEQEgjZ͍݌0i]s.e8d|ғi+۲4hb ( DOZ(((((()2=h7nU܊1o@:rp9PܷNc QXUHygNܼ_sO:EJ0w^R$ϗُGӀ9KEr~=ke  >s_x^9F3dpJ\[E,m *Tխ?NҬb-]ƃh>q>+kN@ڷfb_N0Ӯ3|Seuufh-;kyl2}95?ºդLJ2^O/2nb$m8s0@5W6Jm=.]$1@[-Wt^k7ZemξD⸈oB@# &S|Gt6O=@ՆN:m0jύz-4M`WMP\ ~Zauvx^EDݸ/eS|7'+>n弈F۞b~(ֆ&`s[9e31Ppq eؚE5YJ*lf|rd?,,X0Ff05h.g]tV )`YAFkZ^j|N[ *vJ^T|A}z|Kik>g6I5%) W88aĞ3]KmͰ{ &x 3q\](ZKYtq]Ak{I s?@j>:v@Ӓe4^Oנ-p:l7$vU_ 3 x&6\qL՘t;Ox'rCغ\I'O5 i/IO!VOtFz\sIz,۪1탟Or/-=[YIluW cR$eJP|Mj:%dȲYrNp87|Cu^iVfz,R$TwvGXŞ.LbA#qޮPoX&+G dFG^~j|]H;{{G2E*\G9#zQ1ZFgg6$4-X'=rߝ.mKWĚ5펞K%{SyqXnY|8,uO 6eMhas]4jHqg%Ӣ?vC2`۸ceMo Q<1ܳ] #nW+YeeZ}ceq"+$= `oLva@ae$*yf=Mufg~c{\-/FSP|C]iv2XN5!~*xN\ޟ!'.MH+En L*񍣾xnk L2Ogye I|09v/hY 2)*~~X5T06]/ñC>m#inK,y<Ĝf <'1 lޛO0Wٶ26@8`AO}OU.l@VP3:9ğa ,>X&$WV> DCqqxɼX;3h+v1.c0-N̮ߖ*TyS)h((I$ z77m w8HezZKy&^SxAibp$gwykW~inba#[F  \LlDҧ$Ջ88Q[]jmPK;`:^Mv:YAqxr$VH&XO \k[R-WC8mOq$.Bʌy$5wDeVK#kv?@Im5|Sβ^$X;$%8 ۋuzpDI1 EChGg \&cQ$vlrq'MEQEQEQEUu[7tVUu[7tVEPkOwVG5&k-vHZImo!QE5ڌX{AY4\|{r:qڹ&T-Yͺ"iX+SFmi\I;GN:󌎽x^\K$e#8M;u c:qM&O9HUռ0#Spg'?_nk=Ҭ^hb̾S`GU}hu92@XN2?ka}~Xk vBa4g]禱IχtWȊ@7ICjtkXUӧd SW[ww =eu0=睊IJk6ke?$9䟭_jIۯc?oo8ohVڏu;ۉ Z(Bcv; _^MHk hH_0 ]K]'A"߹r8T*_ fq rɁO5 l0s}oK=m˻TTL֢Bus4&8ȸ3G{$HBۀ~5k[[xBvZ73skJpMyq-yc&'$_ϞU|!bɤ$2K i2y(w;vO׽N9p>%VSNeVtc> gzƽ$5Bˏ]x]Y2B"h@yȣK ҵ=F)w$ITڒZ.>K5h9?ii>ր'(((((uxM ,ą$ALd nnb̙¯@0K1prO&mC?lC-w;hヒKod{<|Ҹ ?p=I[U QQ@Q@%-qnKgkqg{d-*Lrq?vՃXx:Bt_-VrÌU~\~i"n`T# ?)a* Z\$}]#FRv#l.<7 }sk~ Xk~t7Ra [7ʨc@kǘR"C {9]+51CpJmFitfPle^ {_m֖ڵ DY9Q0N ɗPZZ귓#kZ]M13c^Cր=.)D$JPX`{O3yzJ:Ρidt;iXKT2z6yx_I5$fx%a3m/<$!xܫό9? KĒ,2J"Q;"Bpø=O#֩Yڕ +8O^0x:m]t^%{{mHmVs#?(kD{[u$r,$.~`L PQJgqU֊EKB& `dqd񇌴dյ-*ñjC dzM-q:e>WW`]B[ZWDmK7Sִ oz4qH$rsEE Rh((93IL5Ξ@}V7icqp3%!,s“E"et`C2=>ZKI=U"<~C` ʟE̖y$LQp Tc)i'$::+CG'zcSItW3 ^O?~{Κ($Ms_hߛ9w<@߷֏cS{Hw:$Etudae9R׏iz档m. rbnQèEŶya O kZYj^2fu9R^vfʵ8tXc zO88%jqQqD@UFMmvg WfO$ɫ4Q@&GUsp^DtC!T!' !ߌ1ڀ=#֌ךƧ{xwͪuDf'RxK3~01 sޛy.}jQ]x^ocHYà0xXO\Pdz^[e{-g᷇O ԣe:0 z{:]nOuXT[6$m1Y# 9(H{eAai]65`'u]Ikދ+ia+HVL8 N:2z2=k4%u OSVK{eeG[n݌t Y_]j^Ҹm47q *m>{%RҴch"7 |\DžMPokI ,pz0Cј_+#[u;Ķڍ0[)U#EF0s׌P2=kSKJL-m%3nfR PQmVQXuKai'f6C'q=6W{sk>h.ei.՝$*D ך0W柮 }mˤlv<`Pc#4RHuԳf>V`H''^a}sփ෷֟Y|C P&02qgj|+TtRO1fx`Ƥ$@j;+6~U\<q_h@ e a{UzS5)EsLB C6 Typ}jjsbۉS$aKpzdf^H[j#p ˒8zz\I]W3 ^O?~Hw:j+CG'z=OiMEs?hߟCG!騮g߿hߛ5?=;5}~oף߿Ƨ򇴇sO?~}~oףPtW3 ^O?~{Κ>? ^cSCCT~|^/vǥsmDSOj^4^LACd0}JxyVjNbSleZt^ZQQ<Ov}W#z?u}UhΛHbQXQ@Q@ھhQG&?,IOTzOmK !C>eEdxH5McIN͚B1䏗eϮ߭P[G}of%WB?O*Jk߶΁w >vmGl-tm6_.4XCl)e3k;+NOGL$` *;ig9O ,'*;I_Mg2c*Gv{O[[^{hsޭiuo73yR ր'(((((-⺋˙.Aǡb A-ϧ疞'9Gtѕ*r=)Ig%kU.ŤӞr8999Z9P|Iç~q5b ( ( ιuL.ٗu/wFޣz[tP0 O?, RjʹG |^x;'L)x%3Ѷw1+1Ќ^0r'K_#gŷnϾ1˼Q_,cN|6zٷ\:yZP/Ç߻>?LΝkVGзWι={b*&mI#`('@U˝;GУjf9VM2c_*-ͼRDGm-8 9$q4jn?bDt!UJ(#pEvt [mCQXg#4[ nqހ$|9g~Ywܶ18 x\;ki/aH3+l0 qki#5})[eMd㓻v s8kR_6M.m W̉ w9W8ZO#A oBFe%y#7=j]mtSĩ5+=! $V:Lj\YGMe,dݍR2+DnO-Nxzր#еOEokk ѩQᔯGBy5I~h1GʺWQ]@D8'm nq[ߋt?:,bTyo?6>zYϛv21GOZ͵ޭMJ- h 1$v?1,:,>W> 6 !`rͻ) o{_. Xg_U5@MSğj4cy}yv\_# 6{7Fm;>;~@uׄucP _]nxප)˖,x<zj ^K,=+8sz]|9?󢪈jی go#Zك1x-v 8aƜ&Cg1Ʒ:m[|?mwU.$MEj]ޙ]\4EB `0 hgaepQREPEPQ\\GmV II5 M~}3僀 88&EĞ|pc ;{Iq#Osp c Hwxq"HQUTmUAO_MEaGGKt~T( !GGQ&yTTǵME-cvC2 R`2^ {GQ-U{Ho]NRE8d>z+#BC؝1n!n@}tӎE-sZ-5o~"b Dds Z(|!=KItoSj[ڐ{u䱍Np?iSL[-/IJYW<S4AYRRx%I@eNXkS[i3-؄lu;V᛻MzMsVտc)n (n ($HMhxk/ jVi#qX! b t-$kwL2sx7ⅹ[s6jX[w{VmuM{[:![ lq9[zfqܲ5>M/4R8ϵ;Ni׉{bpq@G#Ou h1u9:HXK~)Fp[sh4(ĖD@H<}-Mu_8i) N~7lt@CyYG4y A}|5o˻رJD :5c /QFotNO=PI H##OXgY>`e-ynfTmgo=(VAzJ-dSRsxoS{u7<ݟMk·z4X&;giڅN85}koq 1G4wp;-a{jZƧSF>V[xڹhS'ĐiM4w0'r${Jw o4[XEL_X:u|6m1̓Gc?lEi#)I݅QTHQER'|?-"QEQEQEQEQEQEQEWKG*XtϧA8[-,/ !<GNr$kȅR0T= :#t3KOQ=88jŵ7p6oQpAЃҀ&((((QA,ѴEpY222;f IٵJvrǧvܜ^1z5e4֚%23ܖ 1*4j_^Lեhm؈c qbbT>dc#fFtkkfk tLJL ?`簳-ۈ^0Pm P%G|[IjdK#!g q{qxK6\6|=GZ|GN|M8la]Hel9~XiխMRs$chU (h)o54m.Ჽ qg 4 h5\EI2G 3akEPEPEPEPE^;UVV x/&198<9  OATߐ-!i~g =Dr kKtVVʡs< .FM+XPO'Ory55PEPEPEPEPEPEPj٥u=21 09f$]l~0MZ5@A0pFyWkK‰eXy(czPKugx/4WN)BmB8C0/C[TH& lP08`;3YZs ܶ=Ÿo&V@^= qր (n.bPҰPu,pNs@UV dPA6V݂9A: 3/*P0=CmgXVI+༘Sb(((((((((((oXo:((( rTiWQL;SO<;O1n= s]s>үsv(.Ł޻Qְy[G2|AZ]j sJ9m}8;~4_ i7QLP\Hq s)vZM?ųx.r-t 2O^kƏĚ]$ӂ]F_I+8@gU"Rd?_|G˽4zLH 9ʏ;g֖k f, s>;梾ܖׇƗh~b?y?r{ՙm-6q٘]Æsv)7 rwУ|E=LJՌj%Lßv_QϡqdckvVsdPYUB;Yx)yXiqVHdLt<7j2K4w6}Szbh^ֺ~J巎k9NU Gĺ%:gk1%dy̅$Nq#ijv^&҄0K)кXL~ojײo,3ǷjOKO$ӄuv^׭1S8Ͻ]KQa;h ]'8cV ү%ΨYIh#Yw[cڹ{Hy|vt{y[jGqpOwn<߈npW]IS}G{^_hw\NBOlV"U k++3N)()>֖?hz( ( ( ( ( ( ( ( qfZSso'qJsG8#'6 <8TE[-˙.r;>A#Uxy2: \ Qn xQ,}$nL*A`75q{/OMW7d( ;bYSU%@zp ld4dRj{#LwS>4eqesYw~F;<7MUY IVS -: &6 Lpp2OsүxF1SK%CWv,T}2UgowN"tT iYd*@}/E%u B,I*Ϳ~=T~!Cg?ͥŌJ8`8ˑ"t u㸸&nfVa"O.'rq qK~M+Y6"䓌OO ^ִ{ Hx$0q޵zgKH,7+|~Ls8i:χռ>.nn/.eW̲Uz0OW:va_4T+$d8G.oGDKKc6'{J`G}㻋? W6q3hڙTq"wCPxSolHC)"`qsiS-W Yn 28Mn^xZNaGMUV1]+O8C?gg e7~ &|35II3(ȍ|>L-}Oayv>_3ݷ>:( ( *)#+\ܓ$z#9}ItwHh^<*RCgӏstfkk4nie`& =qdTDƱƪ*@)QEQEQEQEQEQEQEQEQETsC/ Ѥ6:==jJ(=Ձܻʓ#ǫqXZsČe\cp@.QU-D yȸ>Y9 ROq3V((((hieuDQf8{MΠF2Ԃ>Pv_@$Im#L ÞGA[{_>g3`1?xu8$AB(P"((((((((((((ٿʵbٿʴ( ( ( ( ( ( ( ( <)Osg yλK?J٢7vRI (((OZZD 袊(((((((() -Eo2ŕ9i!oGNyFNDܨZ9@ çQ8Vj՚\)zg2AX-["f~SǮF 99(MfZ.}4_MkƓ41d~\tn6ג[ 'vg :W$Ps8E/4}GYˬ-/,臅ʌtև4ȴ_I/+&[b1=;ڡkv\AƱ\nC%r"#MPׯu;&-vo7RrNI`{V66_GO L ̱/g ?Ƈkt/# e8 ɭ*Cws<'o̱q%ؚ5r@!$ny沴#=_Tu }Rno.9yDM(*^뺵⥷%I\K+idr_`;A< К+KixJ55"'Q|p6Ac:a{x~(ɭ6]`JI;'gf8hOԺfcsu55k(f}hAPEFOAր\_l"݀8('> q\ͨ!`Ӳyx "յvP$f>I<+!}O:`r,\c ;wPEPEPEPEPEPEPEPEPEPEPEPEP76]Ge;T#y9t-gp>e8zJHe@A uQ{9-bʣ,nF県[ -w@9)xgv## EPEfެ"Dib1uoE}02p ]Hɲݓ"`w0' XDwz8$I'Z'Tq$ɒϠq\mEQEQEQEQEQEQEQEQEQEQEQEQEQEUu[7tVVesureT=]55i(?lէ Z++PWVb C_Zբ55i(?lէ Z++PWVb C_Zբ55i(?lէ Z++PWVb C_Zբ55i(?lէ Z++PWVb C_Zբ55i(?lէ Z++PWVb C_Zբ55i(?lէ Z++PWVb C_ZդOZ?lէv=O v}<^@袊((((((((((dr*8* T\X1h[F͗C<-_"+u=pGbR9쉘H VAÿׂ1mD yɹ>Y9 R#dd u>Kji1h>bJ~AWC= [ ak)=۴޴!BŠ0p'IOQK@w~pCi<$с#?gGJ_xK{Dۥ"kHA;?uP+qB VAQypTLd@OҡxGu9vnov27Vy]Z7R}{Mֵs4Z-BI`RON]ĒivqqY+}F$'.< Ad% 7Fsx鉟w6Zwv4 ۴䂠@x7SoYLnL |i!uqsUcy~Zms׵l@50.| FkmcsuJ-HXpϧx?225v al`Xypp +"fĔyC# p䜓?mm/ #7LZ 1*F*tEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPE&h-W3?t>t_OZѝO(KH:RFEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP{4!1L13ׯp89J;ǂEB1¤S2~S}x']KMG"+2#Њp9)rS%w3gxđ8e'@3 &1@s9o0/9[`rб#(+kXm"LK12I:jj(((((((((((((((((#⍃zncI> $maGuzŶWӦ GgGu*943iqgCs6X 'GW_nvU Qqpxܬ(j΋ {I.络ETTbz` zk]峒`vݲE8l 8Y3Xu-_Lm^ti:G$2FAJr*BURk",ǻ2p9'@>t_O]5s>/ִ~4gSgJ:RQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE&y((((((((((((L@ EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPUI ͫ&b Y ;cnRNjXm:DWrG q9ƅ@!fY$$vz $i`yu/kTZdD]Š(,((((((((((((((((())h+|ηa{9c+) ^Qk: ԍ%2Q{WVʬzK\5}Q滽y-Hs=a*C\W (((((((((((((((ۍ/OK kV hUAHɭ*f*G?i G#O(;Q@m?S+F{C6=OT Ѣ3 *h?´h G?i G#O(;Q@m?S+F{C6=OT Ѣ3 *h?´h G?i G#O(;Q@m?S+F{C6=OT Ѣ3 *h?´h G?i V,l,.Yl>a Jx=MYOZ(((((((((((((((5(_=QEQEQEQEW/oZNtk; m*d9z_iV>t2+ k\]Lo#?Qf^>nN~ݽ-dp>WY^Zn^7YXn ±Nvëbשrp[ $cܬ2>(((((((*з@wlin>O (Q]1Yw\\+r̗FUl̓Nʷ7@3FjUɿ?MPњo=.2o*wTs4fe[K *z]dU\V&ʷ7@3FjUɿ?MPÂ+ϼoH5h.c,/XFNko=.2o*=cs]6ӑNޭiTẗ՘'OJ D>u'\Sʷ7GUɿͶIYX3TMQo=.2o*˙5O*z]dUV&hSʷ7GUɿ3TMQo=.2o*.f?wTe[K e[K lʍ+F瀻$' rB@sK@Q@Q@Q@+veKMD>_?L1#'w im3Mͫm r{ۢq8FBPҢ]‚p 8ɠIZ((*V*@((kWhw06aѰ) \5t8Kmz 3BVrcXRr5;+Ze$R(zmgieR}ϚH4ڶBMoNVM*K # ګtT[7-NU md x⫞=c^si֚ZjwKT`c=*GĚFS_^,"e܊Q P =EdhgL:V#{UCZӴ8nDPQH$`O@hpbGPX]U66=p }k?_j%3!@PAVwu"Fm7:J+mR췆jo"V&S v=Zu KuKV *lz1N١TPt\٢Yk:v`qg| sSv}QI&'J2>玚]66h(?ii>ր'(((((((((((((((49/GgEti=?/kjgOfQEdhQEQEQESM,>+ Ђ#BzԚEdmK [I2pztL b'>4Y4#GE 䐾ZPEPEPEPEPEPEPEdHci$uD@YԓPn'KxZG$$'zfDKOs o/'R6 }?}2ٹ@RI㶹g2cCC_%XBD2$%Qԁh~!T+Vvan$UprZ[tKNɗe"6oy@F[;# Pldw9O\iMkjK&+olI;y9VotF[j CKN$]w#2 }AqO*n:<..ǧBc(#fWw/;tZ׈9Ka{a-0Y! ylƊ4wŚe=4r4(#c #_m} I-UiEVk1vbS0ݎzg8OJּU>Yd,L%WPpJv 6G~Ni5^jWZl}%e5˺9Zk~)Ѽ!Z4\V-NE$u <QyZEA:$Hlz4o ПJix?AfꭤyKQ8b7NQx7VZe{h'X|[FTϸsPY6weqd0enq'k' W4 x 7gpĸ`>Sә~6?ܓF=ubh)QdVF S 0O[e1b1uBFM=*ED@P8Ҩàh" .9GXTgVOĦIP/c(.qs$c#T|ON)Koԯ{tNs@aڔy8qI2J=X%Դ&xf!‚;wVKmDAHJFx8Uim}j^Wۯ.2I>9SnI}T'wcY5i!| `|* О: ~Tz֋smq[G$)x]jaE~#zƛ`,~+)|^~^Vk'Vo97r_:xed5wqʺ1-i6 ?t 丆曙$DzƟw oE'U01SLth[Xbh [@/Xʏd9g5_ meG}~/Xʏ6?>uMEs?mleK&T{'}λ?hk2M>/ʏd9g5_ meG}~/XʏV?>uMI\|e@Q&T{'}λ?u]8e.'W;N ;U[{kihۣ!zm:lMh$S5zڝ6Iv8 $^ '5>d e_V٪ $XtouG)9ֳkQ.k 0vѾXNO\m:jJwWҖ) ))hc:EkOM]0idVX@Q-?}5Khd] X Cr7#4df8%f_š\[nӵ/X*Fr3_+tY#da`A-p\>1ֆ|3cكtVzcX1%]\qg|7{[Oԭ$ hH'WmEy׆5Pأn{r9*Uq7TK~/XʏV?O]tW3&T}_ _xs:j+oc?*>/ʏd9g-}_ '|e@Qu:㦢6?2UOÝvqQ\|e@Q*T{'}λ?.n>NI'N{o|e@W#u9(NmFՉ ִ)̊yctQT!l^YnEd$Í}>}kxb)nQz'kܪu9Ū(5 ( (2X~u 2 ~ic ;'ЪOLUb[K-yⷐG#.JeNq\ .O1O sRS:J4^;-;%!ѮU2/':wZ%d>kmE^~k找jQ~{Uk_en[--sQ%9}PVz>*kW yYI\Ă?ƵiGڡ%]Ȟ`ˏP;ך(͏\ 7cMt{=7ZVngbI;$n`⟵~Ϟ ;VCwmrΰ\E+Fp7 %Qss w}3\NY{4~Kܓ#6p7} 5XQnv_)y O—mm}-]z iksր'(((((((((((((((((Z((Z()h (Z((Z(( ( JZ(+^` h] `}}7GҢ<}OZIU.^[O*tY2R2vlK9eg w9n9OrCԎ#&Csm [r=AG z;kI*.rS׎ zQEV~bh7کp4^3+ZxXֺ?M3Ư#qգ54mG:k%k;p ~cNkMH<9a_Ra9mc\4mم$I9g^iu{n XڂB^Xr2Q ' um]|@š>,7T ,Y纼X_dg䁒u^>ӘuYdF[bcw4:捤5X%ј!H/IxV[9o a_JGq/ 6bk~Ե6[H,ZR90UO5 ֠v>xu)\yg,If.''zP5 6 g˟3Qk^oq-ݹF9C"ܻ##'Sx[!bGDw+NGVƯ˪xHtR(bb%.QxHzJ<1eڶ'dqt ,{)!yBۥ̈́Q'# ^4}#ǚgM!,-ldBA zw zյ+2XovTnFb!9R!(_Z__vn&./=[֓;AQw3܌W7F*KQ25荆&Y@9#hڵrhiq-c=_hހZk>m>Rw:]D, 1Y/t[F2yEux°ç^N5@YUXp :`~yER-|b Yv~A^Łhn=%y1lf]$i$v 6`jbƺhԁRUR|y+6}wlWY/gU*fP67G{;{ iֶ[ab1wrhZ((KhLՉ$bv 2V 'wK_SkjqpU$뷢ʾIC9W$2kJ=Yڌ6?c^{7.*N.-Z yRIѽ@;kN׌R],4<$о>KP񭕖qe ڮgkh,~9Vk:tWo)B0{;Qdk'YZrN iV ,Q2̟1ǎIRkOt[}"d6|A'i nn2#67Ns'jU(藑U~fmgjwӉ --ҹ v)![59u #ƨ3Tո_?+e 4niEQ?+e 4niEP?+e 4niIVi8HKd>e&?€ p\D{GO~:REPEPEPEPEPEPEPEPUleZUleZuQ@Q@Q@5M: _N.A}+i5KXP* 0vaP>}B^^6cOJp%ޝKBQos?:Zivq(Ps:O#Ei)Ipx {~q+uZ/KrAU?ÝDӮ&RQXM(= ੨Wymd[u%g:,oQ?J<]i_]YY2o|oG]ׇ~=[M&/#;RC׹ -n$Ln;=3OΧ.uis&ޗ*xhR9 S֨5sƺ{kkWHrI\ o^Z~kOe(|x=+R@^"5qsw==*%)]/BzM^y"gӖ41܇lXlTĺ~ɧ)y CvsFM&Yo-׋rr<'LwWIy;X[흟i m~Qt[i BZOn[3$qŋOQ]Y{ww ((?ii>ր'((((((((((((((((((((((((((((((R@ E-R@ E-R@ E-x>t_M\ϋEuYҖ4Z((Z((Z(()h(((((((((ٿʵbٿʴ( ( ( ( ( ( ( (2 $qGF:((()>֖?hz( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( |_:/󮚹΋_Z?3)iJZ(((((((((((((((*s,*ՊqX]\["V8._=#V_G@/O X>CUY:zG?€-`0} U?ea t h5WHUQ*(_=#V_G@/O X>CUY:zG?€-`0} U?ea t h5WHUQ*(_=#V_G@/O X>CUY:zG?€-`0} U?ea t h5WHUQ*(|?W?e=ckk \q@(((((((((((((((((((((((((((((((((()JZJηs]hq]ZFK RR:tȩ?쿷?|߳}qۭۜy档^Oe5zJ '|Mc뎔Ukw MfH𔳘XᕒbYЂMO-? ^Og"F-3hB\)8P@áP|κj|_:/hhΧΔt)k#@(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((2,41c [V:=hW9< xQS;Fd>y&(=W7Z EBش$tR *0:qkP\ϋEuW3?kGFu>t- KYQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@U)oֶ̖"Z[C!ZEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5GuoTEgV/ 5SZw$VWʘɟ\WZ(((((((((((((((((((((((((((((((((((((g:髙|ε: :QҖt(((((((((((((((ٿʵbٿʴ( ( ( ( ( ( ( ( ( ( ( ( DOZ(((((((((((((((((((((((((((((((((((((΋_릮g:֏ƌ|,GJZAҖ4 ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( f*Պf*++ #!>\OG 97S+*qѵ)̙uy`k^7\ux5ףPC2 _uOKw\LjsMЦ4-IO4sԹ:{i[sK(xF$X4n͸F1{c/]ovujKxꎺZ{=.UluIJNA]6bĻk`,lTgڡWN߉o ^Q^o :ƷOrt)l&``PQ׵ Orguqdq{{g{}.o wh߉٢: ,}"dUGf"|yN?ƒ?KmsL[]^Fn;_n38u1é-կgɮlh8/sӵKe<60\M I#VxXHOӥp nmH|.\xs4IMY7cF]?ӻ5AIY>_DzOdg]Jwپ›7sTth:bLi<9{>2s9k8Hח6Kvɛ\ygNU$(Ҍ=.X|eLҡ%Yn&ӯ}˓[MKK v$j8膒ա3.~:w^ЭZi㑉0ie XIխO1B8 dsV|3N;d[qnwA" 7OKK;mLymà\ۻjW*ܵEV!H?@EQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW3?t>t_OZѝO(KM\FI3@ E&h-4RfI3@ E&h-4RfI3@ E&h-4RfI3@ E&h-%K%еRI`xCwOߔB)PkRҴ]U1@)ic?g h09jNwc.CK[|'%Ư}ڨL}0Itp+"Úë(oMJsTxOk%}j R9p=ZFz&Aյ\\&6 gt\{J1_F4nV;) #@h b:=RIk ִ起ad08<<zm]jQ Z{!\k8_dm9SRkVZOc_joYߩ.>$sW-xgRYWŲ(W<ߏM$w9+8P+S(OZZD 袊(M֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=h=j*(]֍֢%=ij!TQEQEQEQEUu[7tVUu[7tVEPEPEPUo4|ۘHA>=MXCOE,OQ<}37֔POgsD|ngӎtkۈ-<Cb)5nŒTi!oN m΁ēدOz:wQBTR AܒNyCZ*m%XTo7(()>֖?hz( (0ZO ZƘ]IÒykMWVh@w(;X=xm,J]('9_54y-m{߈5?:>n!p% '-=36{j ە眒8J<[#燿_ Ri:e|O![;q$v،QIz4';':(s5/v7PY۵̩ ); .Զdqzd`U?șGVPI ڋݱF7~ǵiRs*Tc8﫱Zi(P6v<=SUt[RбŸBNϭrחVZO}6ym;`zꎃ rX6Hl#udZFΊya4$ɁUqֶFmcjw-(oF+W=F;W nkXmy˻随UxV0-/ϐ_i8~;ji$t ]jx2ߍU ɪ[6 <8[]YKVkVZ 1=IZc7=B[Hd XJ7)Q_'v:- ;E[\n~3xG!'U)UƼTO2eu |wۥz][%if"[p>A6*NRVR}6[)/c$I* Onm:;{c Ǟ?yƶiڶr#.C[-6)KH Ea$y} J걷5G#7E)y?u;cy{O u׊'S\~çPf)wu7)e^p~g6[^|:Ho5)~ʥߺp$%wxHդ1X_4g \qZ@Oj +ZtM8,:9q v:ս{qu M wħ9Z¥eV,R(|U]-Rݥ$7pNqjƥiB+jUA0ףc{lMvk0;5_-k"& "ύzY*6 [ ;R70oj&cw1i|QB!2jO#$ddOWfKgy_e̗gn8LLOދX̏Po 8UJ6Mw@ԆډǗzgۭ@.?*kS}fm;ZYx_vp 43O~kr?+RחUY7g~${v74;xDj \6HxTfI.uR;.Ǥj:晤`j@P$q֡su @F@ L'1 3q7Jm?ViyA#^y5uMYOmH g#$`Nש 9T.t0ZU!n8ޟ 'TಿiS9Ec⡤ۿیEf,-4ɐ?):|LkKE,<5w;{FAqۡH79*[IXoۢ3drAkt-K"+ U%@n'{mNj<@ z<Ձ `ݹUk۩*/kzK_Z-!m7\lǮ[\/m b2@>ǑV"-n\Bq~=:Z.M;-lÛ?yL i8itAI_]VL*a6j(8#ZWJlu(s=?Ii@i.on=?>p…Ss "K_y .a0rsǩzlɷ!m}C\L4mm(Э.q[6Kgi$p?qXZ>}yH9$zEyKPt0ޖ< ֬>uG Æ\ǐ}}دGM\a6'$T.*(45dgNO:M>=vg`>ZkVJ_E; 8Oºm1]\ O!X`@u0m>9~&YE1I cЬjvS?9Ujv(QRqMm#,P3 w d`sUOxHЗPx.cuHP;7*^ȁ@F =9=+Ɏ_+3F$Wd# @Hlnoͣn//5y'JOt`oLu5KRaNRNJ ,> ޡrJzn/SH *"TǎtDJU 4{t~խ Lecr7wz=`Gyrs 7C+/ 6ϙqT&- )abג gl/_>}Wz5tNf\Hoy]q8a])&iI\(nayCh/&Sx뎽Ri [Tx-DH𫪌HDG+'zufZnJW-vNERQHf[Z!I;ϱê[Ā~Пrw>˝h97w5zx5<I|B?0wgo?o%B7m߶;ѵ9VU,'ۿO[z_O|GVf΍543tAy T?L5^e]*֑<G3YTdޔRm?/ĚRqkB|:ν`iZL ^3u_AeplOi^F%譪P7H';U SYf_<,氍J:eNV_Iu (lPBzMִ]XO<EyL|!E&/w䈷y]߆koJǖ6[iA!Vg8=G{Umi"Xh-]=ԫ1sh;_Ko6P  !sӜ*Q?5KRaXa4ˑx=UqJ\Tc8﫱7ƛ"  #J/"=2=IOu'+|1ogIw0Wc}GJ9lKohԋ|uJ\"ִ+1Pj}:4VBKԪAs\W>[\i<];,Q~5z֝>xZȬ+9as+b{HftK|l h.+im$69ߠJho[:I^}N9tcY#o4oBuXo LrHx[qAr&NkG]?syuh0$PJPnW=OER죺cxeGVAbuũ[LZFbLٲ{A]m>uWgp>N|ѻ8䕖ŁT*Z((((*V*@((([ZN%A[FaݤH;G]M.pwG-#SQn] -FItQIt(|V\maHQ5ܿm.u>3&Rt)m̑] &m6.9VUѬA(|r8_EnK~Jkz#UHT zz~'+O#DNDi\<<z^+Ѩt#mX^]?u9.<&kiȂ_ݐ=zU\YYܗػCҺ*lrUy]>O>_XXV7hԌʤ``'kt[# H4𞊚~ɺg$q[4MOTN0](((?ii>ր'(((*\6^\,ۜ!SǦũKGnw2AY.zdҲ|ֹOWVʪw0=OzWt4t~j䜍@;Iz蕕CA`$t3-TcʌON$rI<+A cO)&{k($ +ӧ^ 9ԁԒ#>X'V2omsm 97 u<`UK9mP8%x[l-wn>\cW.g dBs(YSMag 'Io<[}t6 Nz2j >H?CN*-&KI=JJK3$m< u=ի;;}>;KHPF0 8=m9I-Q.Rj͔lnuu SODzM:vs.הua   @<Ӳ3ҴC]̫ h4d%8c*H *+ ,/"2 q=:vy|dإAY~xmGewC6w{it:|qK%X~,Q *+"eaSd(V 20$Rf$~ QIPn,OI­zGzN#)bC94C\iH5WAqPO⃦xf=[WWrfSd:C_n]úEHXC Iee}]ϭ89bd.qiVZ#k% 8L ~ ,u/l2oU5mWUl`GOeI İ8oZ~_j6O6!Q6?#No54%,,mfHH1#?_úLdzkFm"rNs_s֖7 hgUb⫖;+~+Zu(eʰ8,};O{;[8C`=x㚹dR+Zv^.`"ǜKqi4 hMɹnp,F}7´ѳciKJ]=uz;Kx9i#=3Uu? hĢmB9oOԩkHeOz\3M-Y)I;V̱6|n3^~B h6Ѭqi(Y3sO2 hq NkffIt7JlA/኱j+nlt2M-YY|v}9E]=ⴶJ$1_s!`ұ'%CXnnlm d!$ϰ$MB]< uWTL (7{t'* m/6, >ZElsRcz/-ؒpr$> I?1j? 88޽މyi{c1b<۸$'k H15:WwI4 +Ar33rxWCQ:d/pqcW>MngH*[6V4amgI me5V, ~BP@,==h*a]L hӢc.3ՋmN 8 ZXbF6pAڂ@$;\畭s&º&y=:(sqTJV]VK4k#0 80AFݷ#83.XZi6sn(!㞸CAxOMI>^Nx ФfUf9,5#nkT%;})-4+ku[3Iv9OVz7=jwSSl5oK K4PD2w`OS4ճ|+CRԵ a ݙ7f=lp'OZ#˪]\ͽ34 L{>89X\N? Uާ==EJ˒GB@88 FFqO6;m4+%XLA?9t kyp8 ͏LN8Z!ՆUёO;\W2L[ƮIުHi9kǵ U\Y}n4Xю[nIo<Ɩ=&-NMJ;d[kDqRCGQJUc>i]dԣԞZ$ؒW?MC&q:)f=\HZ4:3 @=(qd 56}$ gCA=.--tҶYFX-^MΥvn?N RmvNO2Sz>*˨X40%[R vul-O>k+i G񓝄GjP4c{՛ІQ{[Vh$n#ZA-'H-!E7@̭}jV'p}GVhΟe 3Y$ڴhʯ{4kc\G@7鐴ۉ>AE]Ҭ続{twmY?*E79>)t/P2ɒ .1J?&-I{H8XjdlFSqt-/K,aَ93w6of;a}ZE6d>{fҕWVVN/E_,--n9 [~w}#EaE-2Ƚ7cyŋB#G 'tEui-&C:}*k=b v,ֲlmiM/7jr&~'c?YG.m_)vӯ'] . nZKq#?Rk=~iJbUIsۃ:RteW71%5W+.p^s‘y.K:cz5K!0c۱~O}-2O %Hk}HO9+ֺfڃ][_A94)'Klr ,ƅj,\Ɠ:uYڅHh,W2F'frF?"?X\]oyz]2:4~'Ai'kxغHY|ۉq#J^\F_a~tM/T𝕜^\^X3"&[⦋ +NWMm!x^Pe\=),egj0<̙|TifӶ[5m=<]8.6[RdR:k.G*][~_wv-"g2I <$[Q$%w tRv.K^=CϺv d̼tm Ut=+ݍIzٳ(xDl793+,gO_o mۿׯlz봟 Xbfv-IOV+(bjb7szғ5kmŚ62x~Q4F8짮3ۭSդ׵K8FQ(1e 9z+$$UUuO jZ^^]ZK+ISVVmc|1-x`W=fx7F֡yF+ ǘ QT m] ӭuhX`\1]9=j}C–:i5СFV]jCY{ rMk֣xkZ y^\;XIgsۥfkkM$c*#\r uu]JyfIl|kXr=bj e!bSg.'׊E|xZxPac1X.$ -lm=+#Œ lu[ŞLL0& y끎euxGO@mImҼL7$nMn*iCi&1 0 SKO/{x{{O%7W$D xsM,Υz+˃wWgm[[x[I%7Q G޲d{"g%sb#cSt}hZm} :C yw_jU*kjږ%\JI4(`xCqAM)u :L5vAT>7 w} WO{h3߽7}?+[W|Q-oq5ޑ;I`mt17X9@ dwhKi۹l' 93fҿ :j^1'Yi6HN9?tº+iLig}2S$/,į#VLjגaqmPNTOIrߣ7ڧzK睼+m1<밚8+J$zzW_٦aqe+2qFO Ge-:Bd3y`H=r;UU);ߩj )w`i:-͗ZiZ= ݼ#J7OjқAcȶKG''~+)ejPkۭkw/S<-[DpF#8cr3V~\hFijZsY9O="$ ##$ҥ𯌴tm-;|-[*em~W(ӿU(^>;|-[*em~W(ӿU(^>;|-[*em~W(ӿU(^>;|-[*em~W(ӿU(^>;|-[*em~W(ӿU(^>;|-[*em~W(ӿU(^>¥ر"Lh?MEQEQECE-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-R@ E-Z ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (?ٸ$$If!vh555#v#v#v:V l40*,555af4ytuK$$If!vh5>5h5N55#v>#vh#vN#v#v:V l 2&&&&&0+5>5h5N55ap2&&&&&yt0c$$If!vh5+#v+:V l4  0+,5+af4p yt0c$$If!vh5+#v+:V l40+,5+af4yt0c$$If!vh5>5h5Z55#v>#vh#vZ#v#v:V l4c0+++,5>5h5Z55af4yt0c$$If!vh5>5h5?#v>#vh#v?:V l40+++5>5h5?af4yt0c$$If!vh5>5h55p5#v>#vh#v#vp#v:V l4v0+5>5h55p5af4yt0c$$If!vh5>5h55p5#v>#vh#v#vp#v:V l40+5>5h55p5af4yt0c$$If!vh5>5h55p5#v>#vh#v#vp#v:V l40+5>5h55p5af4yt0cK$$If!vh55 5553#v#v #v#v#v3:V l 2&&&&&01+55 5553ap2&&&&&ytG:$$If!vh51+#v1+:V l4  &01+,51+af4p &ytG:$$If!vh55 5553#v#v #v#v#v3:V l401+55 5553af4ytG:$$If!vh51+#v1+:V l401+,51+af4ytG:K$$If!vh55 5553#v#v #v#v#v3:V l 2&&&&&01+55 5553ap2&&&&&ytG:$$If!vh51+#v1+:V l4  &01+,51+af4p &ytG:$$If!vh55 5553#v#v #v#v#v3:V l01+55 5553aytG:$$If!vh55T"#v#vT":V l401+55T"af4ytG:$$If!vh55 5553#v#v #v#v#v3:V l401+,55 5553af4ytG:K$$If!vh55 55O5n#v#v #v#vO#vn:V l 2&&&&&0<*55 55O5nap2&&&&&yt5H$$If!vh5<*#v<*:V l4  &0<*,5<*af4p &yt5H$$If!vh55.##v#v.#:V lI0<*55.#ayt5H$$If!vh55 55O5n#v#v #v#vO#vn:V l0<*55 55O5nayt5H$$If!vh55 55O5n#v#v #v#vO#vn:V ly0<*55 55O5nayt5H$$If!vh55 55O5n#v#v #v#vO#vn:V l0<*55 55O5nayt5H$$If!vh55 55O5n#v#v #v#vO#vn:V l40<*55 55O5naf4yt5H$$If!vh55 55O5n#v#v #v#vO#vn:V l4A0<*55 55O5naf4yt5H$$If!vh5*#v*:V l4  &0*,5*af4p &yt)$$If!vh55u55| #v#vu#v#v| :V l4 (0*55u55| af4p(yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4T0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4_0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4F0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4R0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4B0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4.0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4g0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt)$$If!vh55u55| #v#vu#v#v| :V l4 (0*55u55| af4p(yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4B0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l40*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4z0*,55u55| af4yt$$If!vh55u55| #v#vu#v#v| :V l4_0*,55u55| af4yt)$$If!vh55u55| #v#vu#v#v| :V l4 (0*55u55| af4p(yt$$If!vh55u55m5#v#vu#v#vm#v:V l40*55u55m5af4yt$$If!vh55u55m5#v#vu#v#vm#v:V l40*55u55m5af4yt$$If!vh55u55m5#v#vu#v#vm#v:V l40*,55u55m5af4yt$$If!vh55u55m5#v#vu#v#vm#v:V l40*55u55m5af4yt$$If!vh55u55m5#v#vu#v#vm#v:V l40*55u55m5af4yt$$If!vh55$#v#v$:V l4 0*55$af4yt$$If!vh55u55O5#v#vu#v#vO#v:V l4 0*55u55O5af4yt$$If!vh5*#v*:V l4  &0*,5*af4p &yt$$If!vh55]55G5!#v#v]#v#vG#v!:V l40*55]55G5!af4ytB 9777777777wwwwwwwww777777?77777777777777777777777777777777777777777777777779I777777777777777777777777777777777777777777777777777777777777777777F@F Normal7$8$CJ_HaJmH sH tH N@N 0 Heading 1$@&5CJOJQJ\^JaJ:: 0 Heading 2$@&5\X@X 0 Heading 3 $@&a$ 56CJOJQJ\]^JaJ:: 0 Heading 4$@&6]BB 0 Heading 5$@&6CJ]aJB@B 0 Heading 6$@&5CJ\aJ>@> 0 Heading 7 $@&a$5\R@R 0 Heading 8$@&59B*OJQJ\^JphB @B 0 Heading 9 $@&6CJ]aJDA@D Default Paragraph FontRi@R 0 Table Normal4 l4a (k( 0No List RR 0 Char Char16"5CJ KH OJQJ\^JaJ tH TT 0 Char Char15$56CJOJQJ\]^JaJtH NN 0 Char Char145CJOJQJ\^JaJtH N!N 0 Char Char135CJOJQJ\^JaJtH T1T 0 Char Char12$56CJOJQJ\]^JaJtH FAF 0 Char Char115OJQJ\^JtH HQH 0 Char Char10CJOJQJ^JaJtH LaL 0 Char Char96CJOJQJ]^JaJtH >q>  0 Char Char8OJQJ^JtH RR 0 Balloon Text7$8$CJOJQJ^JaJtH FF 0 Char Char7CJOJQJ^JaJtH 4@4 0Header !FOF 0 Char Char6CJ^JaJmH sH tH 4 @4 0Footer !>> 0 Char Char5CJ^JaJtH 2B2 0 Body Texta$>> 0 Char Char4CJ^JaJtH :P@: !0 Body Text 2 CJaJ>>  0 Char Char3CJ^JaJtH :)@!: 0 Page Number OJQJ^JBU@1B 0 Hyperlink>*B*OJQJ^JphRVAR 0FollowedHyperlink>*B* OJQJ^JphNOQNL0 EmailStyle37B*CJOJQJ^JaJph6W@a6 0Strong5OJQJ\^JVrV 0Default '7$8$H$!B*CJ_HaJmH phsH tH   0ti^JF'F 0Comment Reference CJ^JaJ<< +0 Comment Text*CJaJ>> *0 Char Char2CJ^JaJtH @j@ -0Comment Subject,5\44 ,0 Char Char15\*O* 0ti2 CJ^JaJNNL0 EmailStyle47B*CJOJQJ^JaJphjj 0 listbullet20<<7$8$]^!B*CJOJQJ^JaJphtH $$ 0b 5\^JLqrL 0Pa192d!B*OJ QJ ^J mH phsH tH <1< 0 hyperlink1^Jr@POBP 70Style Header + 10 pt4xCJaJRORR 60Style Header + 10 pt15xCJaJLaL 50Style Header + 10 pt1 CharJOqJ 40Style Header + 10 pt CharNNL0 EmailStyle56B*CJOJQJ^JaJphNNL0 EmailStyle57B*CJOJQJ^JaJph<O< 0List Paragraph:^4^4 0 Normal (Web);PPL0 EmailStyle601B*CJOJQJ^JaJphDD0Revision=CJ_HaJmH sH tH $O$ src1^J$O$ jrnl^JDC@D A0Body Text Indent @x^<< @0 Char CharCJ^JaJtH *O2d 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6| YDz"*0;:COf݁+gG fP1  Q2I|SEytuv}e f G h r -<=Istu 7iIUder    }$%yz{|&' $%34>?IJKLXtu ,CMNbijqry-AHOPQXYyz|NCDQ]{~'YZz.HI`ast~   Q       ) * + , 6 \ ] ^ _ ` p q !!(!5!6!D!P!Q!b!c!d!w!x!!!!!!!!!!&"6"7"A"B"_"k"w"x""""""""""T######$$x$$$$$$$$$$$$d%t%u%v%%%%%%%%%%%%& &I&l&&&&& '''#'0'1'3'4'7'8'B'C'I'J'K'L'r's'{''''''(n())!)")#)$))*2*_*************++++%,&,',s,,,,,,,,,,,,,,,,-----)-*-2-3-J-------- .... .2.3.Z......./////;/4H4x44445515?5[5555553646@6[6\66666668808>8`889999999::;:@:A:S:b:k:l:::: ; ;o;p;;;;;;0<1<><L<[<<<<?=@=A=B=`=n==>>>>>?/?w?x??????n@o@x@@@@@A.A/AAA6BXBsBtB;C ""'#(#=#>#$$$')k*v*w*..5.6.D.E... 0 00 0235577_9`9O:P:d:e:+<,<>>@@xByB D D DDDEEgGhG"JpLqLLL4Q5QSSKVLV3Z4ZE\F\G\Y\Z\1`2`bbbbbcc f fgg0j1j#l$l-l.lnnppvv)x*xyyzzD|E|~~}~,-.FGՈֈuv<=FGOPVW89uv '(56fgrsPQ]^12'(7 * *V *V *V *V * *V *V *V *V *V *V *V *V *V *V *V *V *G( ?"5 m$m$m$m$m$m$m$m$[m$m$m$m$m$rr       p{           Ao        [Q           V    xqxqf v>5 + + + +ffff         .. gggff f   ......ff f   .....`ff  ...k( [         []Y*Y*5( [ V     [[[[V[[Ȫ|!|!|!k  [[EQ(6 w56V"P66    wVwwwwwwwf6  www 66  wwwV 66   wwwwww 66    wwwZ6 (00  v:50   0   Ӄ 0  ]A0    0  k0  y 0  f<0  0   0  ]0  W 00  v:50    0  c 0   0  0  I0   0    0  0  0    0   00  v:50000000000000         7777777]00   7 00    77q00     7777777]0000000    77777774 0#50 w#500    ooIIIq( ( ( ( ( ( (((( ( ( (((((( ( ( ( ((((( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (  ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (r( ( (][ ( (I (*( (4( (I ( (*( ( ( (>( (>( (S| ( ( ( (S| ( (4( (!( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (  ( ( ( ( ( ( ( ( ( (  ( ( ( ( ( ( ( ( ( ( ( ( ( (  ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (  ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (  ( (  ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (| ( (x ( (x ( (d( (Y!( (n( (n( (n( (n( (x ( (d( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ()(^SEyuv''@0@ 0@ 0@ 0@0@0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0Z00@0@ Z00yP@3 0( ` DZ00yP@0SEytuv{}e f G h r -<=Istu 7iIUder    }$%yz{|&' $%34>?IJKLMpqWXtu ,CMNbijqry-AHOPQXYyz|NCDQ]{~'YZz.HI`ast~   Q       ) * + , 6 \ ] ^ _ ` p q !!(!5!6!D!P!Q!b!c!d!w!x!!!!!!!!!!&"6"7"A"B"_"k"w"x"y""""""""""""T######$$x$$$$$$$$$$$$d%t%u%v%%%%%%%%%%%%%%& &I&l&&&&& '''#'0'1'3'4'7'8'B'C'I'J'K'L'r's'{''''''(n())!)")#)$))*2*_****************++++%,&,',s,,,,,,,,,,,,,,,,-----)-*-2-3-J-------- .... .2.3.Z......./////;/4H4x44445515?5[5555553646@6[6\66666668808>8`889999999::;:@:A:S:b:k:l:::: ; ;o;p;;;;;;0<1<><L<[<<<<?=@=A=B=`=n==>>>>>?/?w?x??????n@o@x@@@@@A.A/AAA6BXBsBtB;C ""'#(#=#>#$$$')k*v*w*..5.6.D.E... 0 00 0235577_9`9O:P:d:e:+<,<>>@@xByB D D DDDEEgGhG"JpLqLLL4Q5QSSKVLV3Z4ZE\F\G\Y\Z\1`2`bbbbbcc f fgg0j1j#l$l-l.lnnppvv)x*xyyzzD|E|~~}~,-.FGՈֈuv<=FGOPVW89uv '(56fgrsPQ]^12'()+,./124567Bw0 0 0 000 0 0 0 0 0 0 0 0 0 0  0  0 0 0 000 0 0 0 0 0 0 0 00 0000 0 000 000000000 0 000 0001 0! 0! 0 0000000 000000000 000000 0 0000000 00000 00000000 0000000000 000 0 00000000000 0000000 00000000000 00000000000 00000000000 0 0 0 00 000000 000000 0000 00 0 0 0 0 0 00 000 0000 000 000 0 000 00 00000 000000 00000 0 00 0 0 0 00 0 0 0 0 0 0 0 0000 0 0000 000000000 0000 000 00 0 0 0 0 00 0 000 000 000000000 000000000 000000 0 000 000 00000 000000 00000 0 00 00 00 00 000 0 000 0 0 0 0 0 0 0 0 00 00000000 00 0000000 0 0 00 0 00 0 0 0 0 0 0 @0 0@0@ 0@ 0@ 0@ 0@ 0 @0@0@0@0 @0@0@0@0@0@0@0@0 @0@0@0@0@0@0@0@0@0 @0@0@0@0@0@0 @0 0 @0@0@0 @0 0@0@0@0 @0 @0@0 @0@0 @0@0 @0 000 0 0 0 0 0 0 0 0 0 0 00 0000 00000000 00000000 0000000 0 0 00 0 0 0 000 000 0 00 00 0 0 0 000 000 0 00 000 0000 000000 0000 0 00 000 000 000 000 0 000 0 00 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 00 0 0 0 0 0000000000000 00 0000000 00 0 0 00 0000000000 0000000 0 00 00 000 0 0 0 0 0 0 0 0000 00 00 00 0 0 0 00000 0000 0000000 0000000 0 0000000 000 0000 0000000 0000000 0 0 0 0 0 0 0 0 0 0 0 0 00 000 000 0 0 000 0 0000" 0000* 0* 0* 0000+ 0+ 0+ 0+ 0+ 00000) 0) 0) 0) 0000$ 00$ 00$ 0000% 00% 00% 00% 00% 00% 00% 00% 00% 00% 0 000000000& 00& 00& 00& 00& 00& 00& 00& 00& 00& 0 0& 0 000' 00' 00' 00' 0000( 00( 00( 00( 00( 00( 00( 00( 00( 00( 0 :0:0:000:000# 000, 00, 0, 00, 00, 00, 0000. 00. 0:0. 0000- 00- 00- 000000 0 000000 4040 4040 40000 4040 40:0 4040 40:0 40:0 40:0 40:0 40:0 40:0 40 :0 40 :0 40 40:0 40 :0 40 :0 4040 4040404040404040404000 4040 40 4040 4040 4040 4000 0 0:000 00 0:0 000050 5050 50:0 50:0 50:0 5050 50:0 5050 50:0 50:0 50 000 0@0 50 50 5000 40400000 00 0000 00 0:0 0:0 0:0 0:000 00 0:0 0:0 0:0 00000 00 0:0 0 0000 00 0:0 0:0 0:0 0:0000 00 0000000 00 0:0 0:0 0000 00 0:0 0:0 00 0000 00 0:0 0000 00 00000 00 0:0 0:0 0:0 0:0 0:0 0000 00 0:0 0000 00 0:0 00 00000 00 0:0 0:0 0:0 0:0 0000/ 00/ 0:0/ 00/ 00/ 00/ 00/ 0:0/ 0:0/ 0:0/ 0 :0/ 0 000 00 0:0 00 0000000 00 0:0 0:0 0:0 0:0 000@0X00@0X00@0X00@0X00@0@00@0@0@0@0@0@0@0@0@0@0@0@0X0sSEytuv{}e f G h r -<=Istu 7iIUder    }$%yz{|&' $%34>?IJKLMpqWXtu ,CMNbijqry-AHOPQXYyz|NCDQ]{~'YZz.HI`ast~   Q       ) * + , 6 \ ] ^ _ ` p q !!(!5!6!D!P!Q!b!c!d!w!x!!!!!!!!!!&"6"7"A"B"_"k"w"x"y""""""""""""T######$x$$$$$$$$$$$$d%t%u%v%%%%%%%%%%%%%%& &I&l&&&&& '''#'0'1'3'4'7'8'B'C'I'J'K'L'r's'{''''''(n())!)")#)$))*2*_****************++++%,&,',s,,,,,,,,,,,,,,,,-----)-*-2-3-J-------- .... .2.3.Z......./////;/4H4x44445515?5[5555553646@6[6\66666668808>8`889999999::;:@:A:S:b:k:l:::: ; ;o;p;;;;;;0<1<><L<[<<<<?=@=A=B=`=n==>>>>>?/?w?x??????n@o@x@@@@@A.A/AAA6BXBsBtB;C ""'#(#=#>#$$$')k*v*w*..5.6.D.E... 0 00 0235577_9`9O:P:d:e:+<,<>>@@xByB D D DDDEEgGhG"JpLqLLL4Q5QSSKVLV3Z4ZE\F\G\Y\Z\1`2`bbbbbcc f fgg0j1j#l$l-l.lnnppvv)x*xyyzzD|E|~~}~,-.FGՈֈuv<=FGOPVW89uv '(56fgrsPQ]^12'()+.14Bw0 0 0 0@0@0 0 0 0 0 0 0 0 0 0 0 0  0 @0@0 @0@0@0@0@0@0@0@0 @0@0 @0@0 @0@0@0@0@0 0@0@0 @00@0@00000@0 @00@0@0 0@0@01 0! 0@0@00@0@0@0@0@0@00@0@0@0@0@0@0@0@0@0@0@0@0@0@0 0@0@0@0@0@0@0@000@0@0 @0@0@0@0@0@0@0@0 @0@0@0@0@0@0@0@0@0@0@0@0@0@0 @00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 @0@0 @0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 @0@0 @0@0 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 @00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0  0@0@0@0@0 @00@0@0@0@0@0 0@0 0000@0 0@00@0 @0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 `0`0 0 0@0@0 0@0@0@0@0@0 @0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@00@0@0@0@0@0@0 0@0@0 @0@0@0 @0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 0@0@0@0@0@0@0@0@0@0@0@0 000@0@0@0@0@0 0@0 Z0d1@ 0@0000@0@0000@0@0X0q1X0q1X0q1X0q1@0@00@0 @0@0@0 00@0@0@00@0 @0@0 @0@0@ 0@ 0@ 0@ 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 @0@0@0@0@0 @0@0@0@0@0@0@0@0@0@0@0@0 000@0@0@000 0@0 0@0@0 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 00@0 0@ 0@ 00@0@00@0@000@0@0@0@0@ 0@ 0@0@0@0@0@0@0@0  0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 0@0@ 0@0@0@0@0@0@0@0@0@0@0@0@0 0@0@0 @0 @0@0 @0 @ 0 @0 @0D 0 @0 @ 0 @0 @0@0 @0@0@ 0@0 @0@0 @0@ 0@ 0@0 @00 @0 @ 0@ 0@0@0 @0@0 @0 @ 0@ 0@ 0@0 @0@0 @0 @ 0@0 @0@0 @0 @ 0@0 @0@0 @0 @ 0 @0 @0@0 @0@0 @ 0 @0@0@0 @0 @ 0@ 0 @0@0@0 @0 @ 0@ 0@ 0@0 @0@0@0 @0 @ 0 @0 @0D 0 @0@0@0 @ 0 @0@00 @0 @ 0@ 0@ 0@0 @0@0 @0 @ 0 @0 @0@0 @0 @ 0 @0 @00 @0 @ 0 @0 @0@0 @0@0@ 0@ 0@0 @00 @0@0@0@ 0 @0@0@0@0@ 0@0@0 @0@0@ 0@0@0 @0@0@0@ 0@0@0 @0@0@ 0@0@0 @0@0 @0 @ 0 @0 @0D 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@ 0@0@0@0@0@0@0 @ 0@0@ 0@ 0@ 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 0@0@0@0@0@0@0@ 0@ 0@ 0@0@0@0@ 0@0@0@0@0@0@0@0@0@0@0@0 0@ 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@00@0@0@0@0@0@0@0@0@0@00@0@0@0@0@0@0@0@ 0@ 0@0@0@0@0@0@0@0@0" 0000* 0* 0* 0000+ 0+ 0+ 0+ 0+ 00000) 0) 0) 0) 0000$ 00$ 00$ 0000% 00% 00% 00% 00% 00% 00% 00% 00% 00% 0 000000000& 00& 00& 00& 00& 00& 00& 00& 00& 00& 0 0& 0 000' 00' 00' 00' 0000( 00( 00( 00( 00( 00( 00( 00( 00( 00( 0 :0:0:000:000# 000, 00, 0, 00, 00, 00, 0000. 00. 0:0. 0000- 00- 00- 000000 0 000000 4040 4040 40000 4040 40:0 4040 40:0 40:0 40:0 40:0 40:0 40:0 40 :0 40 :0 40 40:0 40 :0 40 :0 4040 4040404040404040404000 4040 40 4040 4040 4040 4000 0b 0b:000 00 0:0 000050 5050 50:0 50:0 50:0 5050 50:0 5050 50:0 50:0 50 000 0@0 50 50 5000 40400000 00 0000 00 0:0 0:0 0:0 0:000 00 0:0 0:0 0:0 00000 00 0:0 0 0000 00 0:0 0:0 0:0 0:0000 00 000000@0 0@0 0@:0 0@:0 0000 00 0:0 0:0 00 00@0@0 0@0 0@:0 00#0#0# 0#0# 0#0#0#0#0# 0#0# 0#:0# 0#:0# 0#:0# 0#:0# 0#:0# 0#0#0#0# 0#0# 0#:0# 0#0#0#0# 0#0# 0#:0# 0#0# 0#0#0#0#0# 0#0# 0#:0# 0#:0# 0#:0# 0#:0# 0#0#0#0#/ 0#0#/ 0#:0#/ 0#0#/ 0#0#/ 0#0#/ 0#0#/ 0#:0#/ 0#:0#/ 0#:0#/ 0 #:0#/ 0 #0#0#0# 0#0# 0#:0# 0#0# 0#0#0#0#0#0#0# 0#0# 0#:0# 0#:0# 0#:0# 0#:0# 0#0# 00Z00Z00Z00Z00Z00@1%0cZ00r: prZ v\p6pXRK !"_###=$%R))*v+a,,,./1C2z346Q7?8j9;,<==]>??]@ASABCPEGJKMQ TUfV8WXCZ@[\ ]]^%h2lw}:Ӕ]eb@ n*p56;=iBGOMX_CnEuyv~BǒҭƽjHN    $&')+-/02469=?AEGJLPSUWY[^acfilosw{~up7Zl !!###$$$%>) **:,,(-/0111134z555R677\9::;;+<<{= >h>?c??K@@8ALA}AACCDPEE|FF_HIJJJKLMNOPQFRSST3T!V|V-WtWkXXvY6[u[ ]]]]7__dkj}[F]6A]*b;CJ^QuԐ   !"#%(*,.13578:;<>@BCDFHIKMNOQRTVXZ\]_`bdeghjkmnpqrtuvxyz|},"Q#R#SXXXBYY ZGægLAcH;nWzmXb% m  6b$$$)))***+l...///1u11j333+666<&={=2AUAeAB(CQCDDD!FDFTFJK\KMMMQQR5TTUWMRQ0V(ޛd1mɡ*x]`c4AN9XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX!  ?$R$8J+Jq2M0-_RR$,`{RQm8# @ 8(  6  "?  c A2. UTI assessment communityAT`TAT`T"`B S  ?(    c A6. Antibiotic Committee Logo2%T`T%T`T"`Fw5&3@9t5mKtq.lr.ms.Lt.Tu.\v.,w.,Mx.dPy.Tz.}{.T|.D}.L~....L.....t.l..4 .%.4.6.4=.P.W.$Y.[.o.T..,.l..\.D..4g.tg.l.,m.|..4.t.e.?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~M%!!!!5?@ABo\\\r_r_qbqbbbcc m m mfnfnwowoNrrr}}~~00SWbxx!$ssT"T"I#I##)**++.3.3@@EELLL"P"PPPiSiSc\c\ggjj0x0xyy,y,yxyxy|||  ffiiYaa  !"#$%&'()*+,-.0/123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~ >*urn:schemas-microsoft-com:office:smarttags PersonName9*urn:schemas-microsoft-com:office:smarttagsplaceB|*urn:schemas-microsoft-com:office:smarttagscountry-region;g*urn:schemas-microsoft-com:office:smarttagsaddress8y*urn:schemas-microsoft-com:office:smarttagsCity:f*urn:schemas-microsoft-com:office:smarttagsStreet=U*urn:schemas-microsoft-com:office:smarttags PlaceType=W*urn:schemas-microsoft-com:office:smarttags PlaceName9o*urn:schemas-microsoft-com:office:smarttagsState ||y|||yo||||gf|yoy|yyoWUUWUyo|||||yoyyyy||||WU||||y|y||||UWyoyygfWUWUyo|fo K V  7r|49:>?DEICHIMNST^_a(*   $ % ) , 1 2 5 ""))++4+P,\,s,,,,,,,,,,,,,,-----.........////// 00g0r0:1B1C1J1>4G4m4v455[5546>699AAB B_BlBfQfXfff g#ggggggggggggggggh,h.h i"ioiwiiiiiij3l>  (#=#$$$% %%(())++$,.,0,:,,,{----./I/M///00 0'0+030J0R0W0_0o0{0|000000^2j244(5155555!7*7G7O7d7o78829>9B9L999991:=:D:M:e:l:q:w:::::;;*;.;W;b;;;;<9<E<====>>>>>>c?g?o?r?{??AACC DDNDYDZDcDTEbEEEFFkGrGGG$H.HBHKHlHzHHHHHHHIIII"J'J+J5JUJcJKKRN]NNNOOnRwRRR%S/SSS(X1XXXYY+Y4Y:YDYjYsYZZ&[.[M\X\\\\\]]&^1^^^$`/`2`<`>`E`bbAbCbEbNbhhphthiiiiiijjjjjj$k'k5k>kl!lp4q\r`rrr>sBsttuuxvvvvvvLxSxcxkxlxux0y:y;yDyzzz$z,<Đϐ!*mw?IǙΙݙɚ 6@JTbiȜ̜ȝϝ#=FKRV\ΤФ:DUYCN]gCM۩# XenvgimrvzЬլ٭,9Ubs{ɰ)/9R^>@ Yefsַ߷%*9B;Dֺߺ !<E(0Ze*0<]d6=OZu_ks~s|EOW`IQ.7bjp{ (0z}15r{2=~ }2w ^m;CXg())++,,./12457A 64=?HCLNaz|    ( , 5 ########$$s,,,,,,,,,,....[5577R9X9`EmEFFJKKKK"KLLLLLLFMRMLRQR|RRETJTVVX#Y\\____bbee]fafggRhVh|mmmmmmop$p+pqrgsosuuxz|zY|b|~~:̀ԀEy‚̓҃G yjrß9AAF3AKTioö}S\cmqUY?BPBIbe`h#+d13= A }/7,6%,>  (#<###\$b$%%:;w?z?HHbbbbufwfjjllp4qIyPyVy[y*3{ AG͸%jr&*2w{())++,,./12457A::::::::::::::::::::::::::::::3333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333}} ##$$$$$$$$$$$$$$$$$$$$%%'%8%%%%&&&**WW())++,,./1247Bbgqw())++,,./12452r>PS&zJ+ {R&^ /Z'(fq *{Z; n|K56S"xe : "z rXk"ʞx$Hd'4gtu*S(e8e)Lq;*JNfL.D.ꛊ}k29޷^24 w7ø kjTc> j?ݰ26}@ҚcG@P*.B6 wEV[QF* FB""YDzGaU*8dcX&Y~y[v*B6\4,_o]:W4la. &#cp/e[VTi^Ro@]t YupGP1flv2 Fw&x|z’ ~W~j TT^T`6^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. 8^8`OJQJo( ^`OJ QJ o(o  ^ `OJ QJ o(  ^ `OJQJo( x^x`OJ QJ o(o H^H`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o ^`OJ QJ o(TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.hh^h`B*OJPJQJ^Jph.88^8`^J.L^`L^J.  ^ `^J.  ^ `^J.xLx^x`L^J.HH^H`^J.^`^J.L^`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.)hh^h`567CJOJQJS*\]^JaJo(.^`^J.pL^p`L^J.@ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PL^P`L^J.h^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJ QJ o(hH^`^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.2hh^h`567B*CJOJQJS*\]^JaJo(ph.^`^J.pL^p`L^J.@ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PL^P`L^J. hh^h`6]^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`56^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`6]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.hh^h`6B*]^Jo(ph.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`6]^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`OJQJo( p^p`OJ QJ o(o @ ^@ `OJ QJ o( ^`OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( P^P`OJ QJ o(o  ^ `OJ QJ o( ^`OJQJo( ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( 8^8`OJQJo( ^`OJ QJ o(o  ^ `OJ QJ o(  ^ `OJQJo( x^x`OJ QJ o(o H^H`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o ^`OJ QJ o(TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`B*^Jo(ph.^`^J.pLp^p`L^J.@ @ ^@ `B*^Jo(ph.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. hh^h`6]^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.$TT^T`56B*OJQJ\]^Jo(ph.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.hh^h`CJOJ QJ o(q2hh^h`567B*CJOJQJS*\]^JaJo(ph.^`^J.pL^p`L^J.@ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PL^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. hh^h`6]^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`6]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.2hh^h`567B*CJOJQJS*\]^JaJo(ph.TT^T`56\]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`6]^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.hh^h`6B*]^Jo(ph.88^8`^J.L^`L^J.  ^ `^J.  ^ `^J.xLx^x`L^J.HH^H`^J.^`^J.L^`L^J.^`56CJ^JaJo(.^`^J.pL^p`L^J.@ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PL^P`L^J.2hh^h`567B*CJOJQJS*\]^JaJo(ph.^`^J.pL^p`L^J.@ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PL^P`L^J.TT^T`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. hh^h`6]^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. hh^h`6]^J.88^8`^J.L^`L^J.  ^ `^J.  ^ `^J.xLx^x`L^J.HH^H`^J.^`^J.L^`L^J.$TT^T`56B*OJQJ\]^Jo(ph.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.2cX/eoW~YDzGaU~y[Ti Fj?G@k2 n;*4la#c'(56S6}@+ w7*S(^2V[QF *^ ]t.BFwr>B6\k" E> ~xe x|wEd'_o]NfL.>& kj<1flv&Yx$ Yu8e)"z .22p                  (Y        `$(        NL{        (Y         X        (Y        R                          v*        :        (Y        x        $*        ޏ                  (Y                 7t                                   (Y        (Y        (Y        :       :        R        (Y        (Y                 P2TE        (Y        (Y        :        ݚ                 (Y        W                @^        @~O        :[        :        :                't%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^t%^}|fcp~Ehh ph|wuy=/ |*(a,Kd-_.X/Wr/d0*a033fU7~:=lZ=>? @<1Aa:B5H M$}NKU'V_WXEZ:[w^zai1bOb>cpc6kdVQfKLi{jl+pprsK"s^s% u&u#zK/z>}$%r1TTc kG:bm)QJ7pQyF/NmcI& |&"\eITQY0c7, `HXg$J0#T: s8eQ;N[5 c{|kHKF+ tuv} =7Iy'4JLMpqWXuCbqrAXYz|CD~.a~  6 p q !P!x!!!!&"7"B"w"x""""""""""T#x$$$$$t%u%v%%%%%%%%% &&3'L''''))$))2**************+++s,,-2-3-J--- .. .3...///4H4x445515?5[5555553646@6[6\6666668808>8899999::;:A:S:b:k:l:: ; ;o;p;;;;0<1<><L<[<<<<?=@=A=B=`=n==>>>>/?w?x????n@o@x@@@@@A.A/AAA6BsBtB;C?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~' !"#$%&Root Entry F0nnData T2o1TableWordDocumentSummaryInformation(DocumentSummaryInformation8-CompObjqMsoDataStore0nn0nn   FMicrosoft Office Word Document MSWordDocWord.Document.89q ds:itemID="{7EC8B59E-E831-47F7-A3A6-EB5DC61C983A}" xmlAXRB0UGSITQ==2 0nn0nnItem  PropertiesXI5H43YO==2 0nn0nnItem  Properties NELHOGXNR4S0Q==20nn0nnItem "PropertiesDocumentLibraryFormDocumentLibraryFormDocumentLibraryForm This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision.